

# Interventions for prodromal stage of psychosis

---

**Bošnjak Kuharić, Dina; Kekin, Ivana; Hew, Joanne; Rojnić Kuzman, Martina; Puljak, Livia**

Source / Izvornik: **Cochrane Database of Systematic Reviews, 2019, 11**

**Journal article, Published version**

**Rad u časopisu, Objavljena verzija rada (izdavačev PDF)**

<https://doi.org/10.1002/14651858.CD012236.pub2>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:105:579518>

Rights / Prava: [In copyright](#)/[Zaštićeno autorskim pravom.](#)

Download date / Datum preuzimanja: **2024-08-19**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine Digital Repository](#)





**Cochrane**  
**Library**

Cochrane Database of Systematic Reviews

## Interventions for prodromal stage of psychosis (Review)

Bosnjak Kuharic D, Kekin I, Hew J, Rojnic Kuzman M, Puljak L

Bosnjak Kuharic D, Kekin I, Hew J, Rojnic Kuzman M, Puljak L.  
Interventions for prodromal stage of psychosis.  
*Cochrane Database of Systematic Reviews* 2019, Issue 11. Art. No.: CD012236.  
DOI: [10.1002/14651858.CD012236.pub2](https://doi.org/10.1002/14651858.CD012236.pub2).

[www.cochranelibrary.com](http://www.cochranelibrary.com)

**TABLE OF CONTENTS**

HEADER .....	1
ABSTRACT .....	1
PLAIN LANGUAGE SUMMARY .....	2
SUMMARY OF FINDINGS .....	4
BACKGROUND .....	24
OBJECTIVES .....	25
METHODS .....	25
Figure 1. ....	28
Figure 2. ....	29
RESULTS .....	32
Figure 3. ....	33
DISCUSSION .....	57
AUTHORS' CONCLUSIONS .....	65
ACKNOWLEDGEMENTS .....	65
REFERENCES .....	67
CHARACTERISTICS OF STUDIES .....	89
DATA AND ANALYSES .....	144
Analysis 1.1. Comparison 1 Group A: amino acids vs placebo, Outcome 1 Prodromal symptoms: transition to psychosis, endpoint data. ....	147
Analysis 1.2. Comparison 1 Group A: amino acids vs placebo, Outcome 2 Mental state 1: specific, psychosis risk symptoms, average total score, short-term (at 8 weeks), SOPS (higher score = worse). ....	147
Analysis 1.3. Comparison 1 Group A: amino acids vs placebo, Outcome 3 Mental state 2 specific: depression, average total score, short-term (at 8 weeks), MADRS (higher score = worse), skewed data. ....	148
Analysis 1.4. Comparison 1 Group A: amino acids vs placebo, Outcome 4 Mental state 3a specific: cognitive symptoms, average total score, short-term (at 12 weeks), various tests (higher score = better). ....	148
Analysis 1.5. Comparison 1 Group A: amino acids vs placebo, Outcome 5 Mental state 3b specific: cognitive symptoms, average total score, short-term (at 12 weeks), various tests (higher score = worse). ....	149
Analysis 1.6. Comparison 1 Group A: amino acids vs placebo, Outcome 6 Adverse effects 1 specific: treatment-emergent adverse effects, short-term (by 8 weeks). ....	149
Analysis 1.7. Comparison 1 Group A: amino acids vs placebo, Outcome 7 Adverse effects 2 specific: cardiovascular, average total score, short-term (by 8 weeks), blood pressure and pulse rate (higher score = worse). ....	151
Analysis 1.8. Comparison 1 Group A: amino acids vs placebo, Outcome 8 Adverse effects 3 specific: weight, average total change score, short-term (by 8 weeks), kg gained (higher score = worse). ....	151
Analysis 1.9. Comparison 1 Group A: amino acids vs placebo, Outcome 9 Adverse effects 4 specific: suicidal thoughts, short-term (by 16 weeks). ....	151
Analysis 1.10. Comparison 1 Group A: amino acids vs placebo, Outcome 10 Satisfaction with treatment: leaving the study early - end point data. ....	152
Analysis 2.1. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 1 Prodromal symptoms: transition to psychosis. ....	155
Analysis 2.2. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 2 Global state: antipsychotic prescription, long-term (at 7 years' follow-up). ....	155
Analysis 2.3. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 3 Mental state 1a specific: psychotic symptoms, average total score, PANSS (higher score = worse). ....	156
Analysis 2.4. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 4 Mental state 1b specific: negative symptoms, average total score, medium-term (at 12 months), SANS (higher score = worse). ....	157
Analysis 2.5. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 5 Mental state 2 specific: depression, average total score, medium-term (at 12 months), MADRS (higher score = worse), skewed data. ....	157
Analysis 2.6. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 6 Mental state 3 specific: mania, average total score, medium-term (at 12 months), YMS (higher score = worse). ....	157
Analysis 2.7. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 7 Mental state 4 specific: average total scores, various scales (higher score = worse), skewed data. ....	158
Analysis 2.8. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 8 Functioning 1 global: average total score, GAF (higher score = better). ....	158
Analysis 2.9. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 9 Functioning 2 specific: role functioning, average total score, medium-term (at 12 months), GFR (higher score = better). ....	159

Analysis 2.10. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 10 Functioning 3a specific: social functioning, average total score, medium-term (at 12 months), GFS (higher score = better). .....	159
Analysis 2.11. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 11 Functioning 3b specific: social functioning, average total score, medium-term (at 12 months), SOFAS (higher score = better). .....	159
Analysis 2.12. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 12 Adverse effects, specific: medium-term (by 12 months), UKU checklist. ....	159
Analysis 2.13. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 13 Satisfaction with treatment: leaving the study early. ....	163
Analysis 3.1. Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs-focused intervention (NFI) vs NFI, Outcome 1 Mental state, specific: average endpoint scores, short-term (at 12 weeks), various scales (higher score = worse), skewed data. .	165
Analysis 3.2. Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs-focused intervention (NFI) vs NFI, Outcome 2 Functioning, global: average endpoint score, short-term (at 12 weeks), GAF (higher score = better). ....	166
Analysis 3.3. Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs-focused intervention (NFI) vs NFI, Outcome 3 Adverse effects 1a specific: akathisia, short-term (at 12 weeks), ESRS. ....	166
Analysis 3.4. Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs-focused intervention (NFI) vs NFI, Outcome 4 Adverse effects 1b specific: akathisia (average endpoint score), short-term (at 12 weeks), ESRS (higher score = worse), skewed data. ....	166
Analysis 3.5. Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs-focused intervention (NFI) vs NFI, Outcome 5 Adverse effects 2 specific: increased prolactin levels, short-term (at 12 weeks). ....	166
Analysis 3.6. Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs-focused intervention (NFI) vs NFI, Outcome 6 Adverse effects 3 specific: severity of at least moderate and a frequency of at least 5%, short-term (at 12 weeks), UKU. ....	167
Analysis 3.7. Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs-focused intervention (NFI) vs NFI, Outcome 7 Adverse effects 4 specific: suicidal thoughts. ....	170
Analysis 3.8. Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs-focused intervention (NFI) vs NFI, Outcome 8 Satisfaction with treatment: leaving the study early, end point data. ....	170
Analysis 4.1. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 1 Prodromal symptoms: transition to psychosis, endpoint data, medium-term (by 12 months). ....	173
Analysis 4.2. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 2 Global state, global: illness severity, average total score, medium-term (at 12 months), CGI (higher score = worse). ....	173
Analysis 4.3. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 3 Mental state specific: average total scores, medium-term (at 12 months), various scales (higher score = worse), skewed data. ....	174
Analysis 4.4. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 4 Functioning, global: average total score, medium-term (at 12 months), GAF (higher score = better). ..	175
Analysis 4.5. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 5 Adverse effects 1 specific: average total score, short-term (at 8 weeks), various scales (higher score = worse), skewed data. ....	175
Analysis 4.6. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 6 Adverse effects 2a specific: cardiovascular, average total change score, short-term (at 8 weeks), blood pressure and pulse rate (higher score = worse). ....	175
Analysis 4.7. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 7 Adverse effects 2b specific: cardiovascular, average total score, medium-term (at 12 months), pulse rate (higher score = worse). ....	176
Analysis 4.8. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 8 Adverse effects 3 specific: treatment-emergent adverse effects, short-term (at 8 weeks). ....	177
Analysis 4.9. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 9 Adverse effects 4a specific: weight, average total weight change, kg gained (higher scores = worse). ..	178
Analysis 4.10. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 10 Adverse effects 4b specific: weight gain, medium-term (at 12 months). ....	179
Analysis 4.11. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 11 Adverse effects 5 specific: fatigue, medium-term (at 12 months). ....	179
Analysis 4.12. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 12 Satisfaction with treatment: leaving the study early, endpoint data, medium-term (by 12 months). .	179
Analysis 5.1. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 1 Prodromal symptoms: transition to psychosis. ....	182

Analysis 5.2. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 2 Global state specific: personal beliefs, average scores, long-term (at 18 months), PBIQ- R (higher score = worse). ...	183
Analysis 5.3. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 3 Mental state 1 specific: social anxiety, average total score, long-term (at 18 months), SAS (higher score = worse). ...	184
Analysis 5.4. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 4 Mental state 2 specific: average scores, various scales, higher score = worse, skewed data). .....	184
Analysis 5.5. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 5 Functioning 1 global: average total score, GAF, (higher score = better). .....	185
Analysis 5.6. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 6 Functioning 2.a specific: social functioning, average total score, medium-term (at 12 months), SAS II (higher score = worse). .....	185
Analysis 5.7. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 7 Functioning 2.b.i. specific: social functioning, average total score, long-term (at 18 months), SFS (higher score = better). .....	186
Analysis 5.8. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 8 Functioning 2.b.ii. specific: social functioning, average total score, medium-term (at 18 months), SOFAS (higher score = better). .....	186
Analysis 5.9. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 9 Quality of life: average total score, long-term (at 18 months), MANSA (higher score = better). .....	186
Analysis 5.10. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 10 Cost: cumulative, USD, skewed data. .....	186
Analysis 5.11. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 11 Satisfaction with treatment: leaving the study early, end point data. .....	187
Analysis 6.1. Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 1 Prodromal symptoms: transition to psychosis, end point data. .....	188
Analysis 6.2. Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 2 Mental state specific: average end point scores, medium-term (at 12 months), various scales (higher score = worse), skewed data. ....	189
Analysis 6.3. Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 3 Functioning global: average end point score, medium-term (at 12 months), GAF (higher score = better). .....	189
Analysis 6.4. Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 4 Adverse effects 1 specific: doctors' assessment of adverse effects, medium-term (at 12 months), UKU. .....	189
Analysis 6.5. Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 5 Adverse effects 2 specific: adverse effects reported by participants, medium-term (at 12 months), UKU. .....	190
Analysis 6.6. Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 6 Quality of life: average end point score, medium-term (at 12 months), QLS (higher score = better). .....	190
Analysis 6.7. Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 7 Satisfaction with treatment: leaving the study early, end point data. .....	190
Analysis 7.1. Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs-based intervention (NBI) + risperidone vs NBI, Outcome 1 Prodromal symptoms: transition to psychosis, end point data. ....	193
Analysis 7.2. Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs-based intervention (NBI) + risperidone vs NBI, Outcome 2 Mental state specific: average end point scores, various scales (high score = worse), skewed data. .....	193
Analysis 7.3. Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs-based intervention (NBI) + risperidone vs NBI, Outcome 3 Functioning global: average end point score, GAF (higher score = better). .....	195
Analysis 7.4. Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs-based intervention (NBI) + risperidone vs NBI, Outcome 4 Quality of life: average end point score, QLS (higher score = better). ..	195
Analysis 7.5. Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs-based intervention (NBI) + risperidone vs NBI, Outcome 5 Cost: average cost of treatment, AUD, skewed data. ....	196
Analysis 7.6. Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs-based intervention (NBI) + risperidone vs NBI, Outcome 6 Satisfaction with treatment: leaving the study early. ....	196
Analysis 8.1. Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 1 Prodromal symptoms: transition to psychosis, end point data. ....	198
Analysis 8.2. Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 2 Mental state specific: average end point scores, medium-term (at 12 months), various scales (higher score = worse), skewed data. ....	198

Analysis 8.3. Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 3 Functioning global: average end point scores, medium-term (at 12 months), GAF (higher score = better). .....	198
Analysis 8.4. Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 4 Adverse effects 1 specific: doctors' assessment of adverse effects, medium-term (at 12 months), UKU. ....	199
Analysis 8.5. Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 5 Adverse effects 2 specific: adverse effects reported by participants, medium-term (at 12 months), UKU. ....	199
Analysis 8.6. Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 6 Quality of life: average end point scores, medium-term (at 12 months), QLS (higher score = better). ....	199
Analysis 8.7. Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 7 Satisfaction with treatment: leaving the study early, end point data. ....	200
Analysis 9.1. Comparison 9 Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non-directive reflective listening + supportive intervention, Outcome 1 Prodromal symptoms: transition to psychosis, end point data. ....	200
Analysis 9.2. Comparison 9 Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non-directive reflective listening + supportive intervention, Outcome 2 Functioning 1 global: average total score, short-term (at 6 months), GAF (higher score = better). ....	201
Analysis 9.3. Comparison 9 Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non-directive reflective listening + supportive intervention, Outcome 3 Functioning 2 specific: social functioning, average total score, short-term (at 6 months), SOFAS (higher score = better). ....	201
Analysis 9.4. Comparison 9 Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non-directive reflective listening + supportive intervention, Outcome 4 Satisfaction with treatment: leaving the study early, end point data. .	201
Analysis 10.1. Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 1 Prodromal symptoms: transition to psychosis, end point data. ....	202
Analysis 10.2. Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 2 Mental state specific: average end point scores, medium-term (at 12 months), various scales (higher score = worse), skewed data. ....	203
Analysis 10.3. Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 3 Functioning global: average end point score, medium-term (at 12 months), GAF (higher score = better). ....	203
Analysis 10.4. Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 4 Adverse effects 1 specific: doctors' assessment of adverse effects, medium-term (at 12 months), UKU. ....	203
Analysis 10.5. Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 5 Adverse effects 2 specific: adverse effects reported by participants, medium-term (at 12 months), UKU. ....	204
Analysis 10.6. Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 6 Quality of life: average end point scores, medium-term (at 12 months), QLS (higher score = better). ....	204
Analysis 10.7. Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 7 Satisfaction with treatment: leaving the study early, end point data. ....	204
Analysis 11.1. Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 1 Mental state 1 specific: average total scores, various scales (higher score = worse), skewed data. ....	206
Analysis 11.2. Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 2 Mental state 2 specific: depression, average end point score, short-term (at 4 months), BDI-II (higher score = worse). ....	207
Analysis 11.3. Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 3 Mental state 3.a specific: cognitive, average end point score, short-term (at 4 months). ....	207
Analysis 11.4. Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 4 Mental state 3.b specific: cognitive, average total score (presented as LSM = least square means estimated by the generalised linear mixed models), short-term (at 3 months), MATRICS, higher score = better). ....	208
Analysis 11.5. Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 5 Functioning 1 global: average total score, long-term (at 24 months), GAF (higher score = better). ....	209
Analysis 11.6. Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 6 Functioning 2 specific: role functioning, GFR (higher score = better). ....	209
Analysis 11.7. Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 7 Functioning 3.a specific: social functioning, GFS (higher score = better). ....	209
Analysis 11.8. Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 8 Functioning 3.b specific: social functioning, average end point score, short-term (at 4 months), SAS-SR (higher score = worse). ....	210
Analysis 11.9. Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 9 Satisfaction with treatment: leaving the study early, end point data. ....	210
Analysis 12.1. Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 1 Prodromal symptoms: transition to psychosis. ....	212

Analysis 12.2. Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 2 Global state: antipsychotic prescription, short-term (by 6 months). .....	212
Analysis 12.3. Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 3 Mental state specific: psychosis risk positive symptoms, average total score, short-term (at 6 months), SOPS positive (higher score = worse). .....	212
Analysis 12.4. Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 4 Functioning global: average total score, long-term (at 24 months), GAF (higher score = better). .....	213
Analysis 12.5. Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 5 Adverse events 1.a specific: suicide, long-term (by 24 months), events. .....	213
Analysis 12.6. Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 6 Adverse events 1.b specific: suicide, long-term (by 24 months), participants affected/at risk. .....	213
Analysis 12.7. Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 7 Satisfaction with treatment: leaving the study early. .....	214
Analysis 13.1. Comparison 13 Group C: other, integrated treatment vs standard treatment, Outcome 1 Prodromal symptoms: transition to psychosis, end point data, long-term (by 2 years). .....	215
Analysis 13.2. Comparison 13 Group C: other, integrated treatment vs standard treatment, Outcome 2 Mental state specific: average total score, long-term (at 2 years), various scales (higher score = worse), skewed data. .....	215
Analysis 13.3. Comparison 13 Group C: other, integrated treatment vs standard treatment, Outcome 3 Satisfaction with treatment: leaving the study early, end point data. .....	215
ADDITIONAL TABLES .....	215
APPENDICES .....	218
CONTRIBUTIONS OF AUTHORS .....	224
DECLARATIONS OF INTEREST .....	224
SOURCES OF SUPPORT .....	224
DIFFERENCES BETWEEN PROTOCOL AND REVIEW .....	224

[Intervention Review]

# Interventions for prodromal stage of psychosis

Dina Bosnjak Kuharic<sup>1</sup>, Ivana Kekin<sup>2</sup>, Joanne Hew<sup>3</sup>, Martina Rojnic Kuzman<sup>2</sup>, Livia Puljak<sup>4</sup><sup>1</sup>University Psychiatric Hospital Vrapče, Zagreb, Croatia. <sup>2</sup>Department of Psychiatry, Clinical Hospital Centre Zagreb, Zagreb, Croatia.<sup>3</sup>Department of Acute Care Psychiatry, South London and Maudsley NHS Foundation Trust, London, UK. <sup>4</sup>Center for Evidence-Based Medicine and Health Care, Catholic University of Croatia, Zagreb, Croatia**Contact address:** Dina Bosnjak Kuharic, University Psychiatric Hospital Vrapče, Bolnicka cesta 32, Zagreb, Grad Zagreb, 10000, Croatia. [dina.bosnjak@gmail.com](mailto:dina.bosnjak@gmail.com).**Editorial group:** Cochrane Schizophrenia Group.**Publication status and date:** New, published in Issue 11, 2019.**Citation:** Bosnjak Kuharic D, Kekin I, Hew J, Rojnic Kuzman M, Puljak L. Interventions for prodromal stage of psychosis. *Cochrane Database of Systematic Reviews* 2019, Issue 11. Art. No.: CD012236. DOI: [10.1002/14651858.CD012236.pub2](https://doi.org/10.1002/14651858.CD012236.pub2).

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.

## ABSTRACT

### Background

Psychosis is a serious mental condition characterised by a loss of contact with reality. There may be a prodromal period or stage of psychosis, where early signs of symptoms indicating onset of first episode psychosis (FEP) occur. A number of services, incorporating multimodal treatment approaches (pharmacotherapy, psychotherapy and psychosocial interventions), developed worldwide, now focus on this prodromal period with the aim of preventing psychosis in people at risk of developing FEP.

### Objectives

The primary objective is to assess the safety and efficacy of early interventions for people in the prodromal stage of psychosis.

The secondary objective is, if possible, to compare the effectiveness of the various different interventions.

### Search methods

We searched Cochrane Schizophrenia's study-based Register of studies (including trials registers) on 8 June 2016 and 4 August 2017.

### Selection criteria

All randomised controlled trials (RCTs) evaluating interventions for participants older than 12 years, who had developed a prodromal stage of psychosis.

### Data collection and analysis

Review authors independently inspected citations, selected studies, extracted data, and assessed study quality.

### Main results

We included 20 studies with 2151 participants. The studies analysed 13 different comparisons. Group A comparisons explored the absolute effects of the experimental intervention. Group B were comparisons within which we could not be clear whether differential interactive effects were also ongoing. Group C comparisons explored differential effects between clearly distinct treatments.

A key outcome for this review was 'transition to psychosis'. For details of other main outcomes please see 'Summary of findings' tables.

In Group A (comparisons of absolute effects) we found no clear difference between amino acids and placebo (risk ratio (RR) 0.48 95% confidence interval (CI) 0.08 to 2.98; 2 RCTs, 52 participants; very low-quality evidence). When omega-3 fatty acids were compared to



placebo, fewer participants given the omega-3 (10%) transitioned to psychosis compared to the placebo group (33%) during long-term follow-up of seven years (RR 0.24 95% CI 0.09 to 0.67; 1 RCT, 81 participants; low-quality evidence).

In Group B (comparisons where complex interactions are probable) and in the subgroup focusing on antipsychotic drugs added to specific care packages, the amisulpiride + needs-focused intervention (NFI) compared to NFI comparison (no reporting of transition to psychosis; 1 RCT, 102 participants; very low-quality evidence) and the olanzapine + supportive intervention compared to supportive intervention alone comparison (RR 0.58 95% CI 0.28 to 1.18; 1 RCT, 60 participants; very low-quality evidence) showed no clear differences between groups.

In the second Group B subgroup (cognitive behavioural therapies (CBT)), when CBT + supportive therapy was compared with supportive therapy alone around 8% of participants allocated to the combination of CBT and supportive therapy group transitioned to psychosis during follow-up by 18 months, compared with double that percentage in the supportive therapy alone group (RR 0.45 95% CI 0.23 to 0.89; 2 RCTs, 252 participants; very low-quality evidence). The CBT + risperidone versus CBT + placebo comparison identified no clear difference between treatments (RR 1.02 95% CI 0.39 to 2.67; 1 RCT, 87 participants; very low-quality evidence) and this also applies to the CBT + needs-based intervention (NBI) + risperidone versus NBI comparison (RR 0.75 95% CI 0.39 to 1.46; 1 RCT, 59 participants; very low-quality evidence).

Group C (differential effects) also involved six comparisons. The first compared CBT with supportive therapy. No clear difference was found for the 'transition to psychosis' outcome (RR 0.74 95% CI 0.28 to 1.98; 1 RCT, 72 participants; very low-quality evidence). The second subgroup compared CBT + supportive intervention was compared with a NBI + supportive intervention, again, data were equivocal, few and of very low quality (RR 6.32 95% CI 0.34 to 117.09; 1 RCT, 57 participants). In the CBT + risperidone versus supportive therapy comparison, again there was no clear difference between groups (RR 0.76 95% CI 0.28 to 2.03; 1 RCT, 71 participants; very low-quality evidence).

The three other comparisons in Group C demonstrated no clear differences between treatment groups. When cognitive training was compared to active control (tablet games) (no reporting of transition to psychosis; 1 RCT, 62 participants; very low quality data), family treatment compared with enhanced care comparison (RR 0.54 95% CI 0.18 to 1.59; 2 RCTs, 229 participants; very low-quality evidence) and integrated treatment compared to standard treatment comparison (RR 0.57 95% CI 0.28 to 1.15; 1 RCT, 79 participants; very low-quality evidence) no effects of any of these approaches was evident.

### Authors' conclusions

There has been considerable research effort in this area and several interventions have been trialled. The evidence available suggests that omega-3 fatty acids may prevent transition to psychosis but this evidence is low quality and more research is needed to confirm this finding. Other comparisons did not show any clear differences in effect for preventing transition to psychosis but again, the quality of this evidence is very low or low and not strong enough to make firm conclusions.

## PLAIN LANGUAGE SUMMARY

### Early interventions for people at risk of developing psychosis

#### Review question

Is there high-quality evidence indicating that interventions for people at risk of developing psychosis are effective?

#### Background

Psychoses are serious mental conditions characterised by a loss of contact with reality. The first clear episode of psychosis can be preceded by a 'prodromal' period of at least six months, where a person experiences gradual non-specific changes in thoughts, perceptions, behaviours and functioning. Although an individual is experiencing changes, they have not yet started to experience the more obvious psychotic symptoms such as delusions (fixed false beliefs) or hallucinations (perceptions without a cause). A number of services with treatment approaches that combine pharmacotherapy, psychotherapy and psychosocial treatments, developed worldwide, are now focusing on prevention of psychosis in people at risk by giving treatments during this prodromal period. This review assesses the evidence available concerning the effects of different treatment approaches for people not yet diagnosed with a non affective psychosis but who are in the prodromal stage of psychosis.

#### Searching for evidence

On 8 June 2016 and 4 August 2017 we ran electronic searches of the Cochrane Schizophrenia's specialised register of studies in order to find clinical studies that randomly allocated individuals at risk of developing psychosis to receive various treatments for preventing development of psychosis.

#### Evidence found

We were able to include 20 studies with 2151 participants. These studies analysed a wide range of treatments. All the review findings are of, at very best, low quality. There is some suggestion from one small study that people at risk of psychosis may benefit from taking omega-3 fatty acids in terms of reduced transition to psychosis. Other studies found adding antipsychotic drugs to supportive-care packages did

not seem to make much difference in terms of transition to full illness. When cognitive behavioural therapy (CBT) + supportive therapy was compared with supportive therapy alone around 8% of participants treated allocated to the combination of CBT and supportive therapy transitioned to psychosis during follow-up by 18 months, compared with double that percentage in people who just received supportive therapy. This could be important but these data are of very low quality. All other testing of CBT and other packages of care found no clear difference between treatments for transition to psychosis.

### **Conclusions**

There has been considerable effort and expense invested testing treatment approaches for prevention of the first episode of schizophrenia. Currently, there is some low-quality evidence suggesting that omega-3 fatty acids may be effective, but there is no high-quality evidence to suggest that any type of treatment is effective, and no firm conclusions can be made.

## SUMMARY OF FINDINGS

### Summary of findings for the main comparison. Group A: amino acids compared to placebo for prodromal stage of psychosis

#### Amino acids compared to placebo for prodromal stage of psychosis

**Patient or population:** people in the prodromal stage of psychosis

**Setting:** outpatient

**Intervention:** amino acids

**Comparison:** placebo

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	N° of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with placebo	Risk with amino acids				
<b>Prodromal symptoms: transition to psychosis</b>	Study population		RR 0.48 (0.08 to 2.98)	52 (2 RCTs)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
Endpoint data (events)	107 per 1000	51 per 1000 (9 to 319)				
<b>Global state: clinically important change in global state</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Mental state: psychosis risk symptoms</b>	The mean mental state: psychosis risk symptoms was 42.0 points		-	8 (1 RCT)	⊕⊕⊕⊕ Very low <sup>3,4</sup>	Data for our pre-defined outcome of interest 'Clinically important change in mental state' were not reported by the studies.
Average total score (SOPS total score; higher score = worse, scale from: 0-114)  Short-term Follow-up: 8 weeks		MD 10 points lower (22.38 lower to 2.38 higher)				
<b>Behaviour: clinically important change in behaviour</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Adverse effects: suicidal thoughts</b>	Study population		RR 3.57 (0.15 to 83.14)	44 (1 RCT)	⊕⊕⊕⊕ Very low <sup>4,5</sup>	
Short-term (events) Follow-up: by 16 weeks	0 per 1000	0 per 1000 (0 to 0)				
<b>Quality of life: clinically important change in quality of life</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome

Satisfaction with treatment: leaving the study early Endpoint data (events)	Study population		RR 0.96 (0.55 to 1.69)	52 (2 RCTs)	⊕⊕⊕⊕ Very low <sup>1,2</sup>
	464 per 1000	446 per 1000 (255 to 785)			

\***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** confidence interval; **MD:** mean difference; **RCT:** randomised controlled trial; **RR:** risk ratio; **SOPS:** Scale of Psychotic Symptoms

#### GRADE Working Group grades of evidence

**High quality:** further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** we are very uncertain about the estimate.

<sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, high attrition, blinding of outcome assessors not described, unclear risk of selective reporting bias.

<sup>2</sup>Imprecision: rated 'very serious'; evidence from two small studies.

<sup>3</sup>Risk of bias: rated 'very serious'; 1 randomisation method not described, allocation concealment method not described, blinding of outcome assessors not described, unclear risk of selective reporting bias.

<sup>4</sup>Imprecision: rated 'very serious'; evidence from one small study.

<sup>5</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, high attrition.

## Summary of findings 2. Group A: omega-3 fatty acids compared to placebo for prodromal stage of psychosis

### Omega-3 fatty acids compared to placebo for prodromal stage of psychosis

**Patient or population:** people in the prodromal stage of psychosis

**Setting:** outpatient

**Intervention:** omega-3 fatty acids

**Comparison:** placebo

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with placebo	Risk with omega-3 fatty acids				
<b>Prodromal symptoms: transition to psychosis</b>	Study population		RR 0.24 (0.09 to 0.67)	81 (1 RCT)	⊕⊕⊕⊕ Low <sup>1</sup>	
Long-term (events) Follow-up: 7 years	400 per 1000	96 per 1000				

	(36 to 268)						
<b>Global state: antipsychotic prescription</b>	Study population		RR 0.54 (0.30 to 0.99)	69 (1 RCT)	⊕⊕○○ Low <sup>1</sup>		
Long-term (events) Follow-up: 7 years	543 per 1000	293 per 1000 (163 to 537)					
<b>Mental state: psychotic symptoms</b>	The mean mental state: psychotic symptoms was 57.4 points		MD 11.40 points lower (20.55 lower to 2.25 lower)	-	81 (1 RCT)	⊕⊕○○ Low <sup>1</sup>	Data for our pre-defined outcome of interest 'Clinically important change in mental state' were not reported by the studies.
Average total score (PANSS, higher score = worse, scale from 30-210)  Long-term (up to 7 years)							
<b>Behaviour: clinically important change in behaviour</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome	
<b>Adverse effects: neurological, extrapyramidal</b>	Study population		RR 2.57 (0.94 to 7.02)	304 (1 RCT)	⊕⊕○○ Low <sup>1</sup>		
UKU (events)  Medium-term Follow-up: by 12 months	33 per 1000	85 per 1000 (31 to 232)					
<b>Quality of life: clinically important change in quality of life</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome	
<b>Satisfaction with treatment: leaving the study early</b>	Study population		RR 1.46 (0.45 to 4.80)	81 (1 RCT)	⊕⊕○○ Low <sup>1</sup>		
Long-term (events) Follow-up: 7 years	100 per 1000	146 per 1000 (45 to 480)					

\***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** confidence interval; **MD:** mean difference; **PANSS:** Positive and Negative Syndrome Scale; **RCT:** randomised controlled trial; **RR:** risk ratio; **UKU:** Udvalg for Kliniske Undersøgelser Adverse Effects Scale

#### GRADE Working Group grades of evidence

**High quality:** further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** we are very uncertain about the estimate.

<sup>1</sup>Imprecision: rated 'very serious'; evidence from one small study.

### Summary of findings 3. Group B antipsychotic drugs: amisulpiride + needs-focused intervention compared to needs-focused intervention for prodromal stage of psychosis

#### Amisulpiride + needs-focused intervention compared to needs-focused intervention for prodromal stage of psychosis

**Patient or population:** people in the prodromal stage of psychosis

**Setting:** outpatient

**Intervention:** amisulpiride + needs-focused intervention (NFI)

**Comparison:** needs-focused intervention (NFI)

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with NFI	Risk with amisulpiride + NFI				
<b>Prodromal symptoms: transition to psychosis</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Global state: clinically important change in global state</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Mental state: clinically important change in mental state</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Behaviour: clinically important change in behaviour</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Adverse effects: suicidal thoughts</b> (events)	Study population		RR 0.25 (0.01 to 6.10)	102 (1 RCT)	⊕○○○ Very low <sup>1,2</sup>	
	23 per 1000	6 per 1000 (0 to 127)				
<b>Quality of life: clinically important change in quality of life</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Satisfaction with treatment: leaving the study early</b>	Study population		RR 0.59 (0.38 to 0.94)	124 (1 RCT)	⊕○○○ Very low <sup>1,2</sup>	
	492 per 1000	290 per 1000				

Endpoint data (events) (187 to 462)

\***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** confidence interval; **MD:** mean difference; **NFI:** needs-focused intervention; **RCT:** randomised controlled trial; **RR:** risk ratio

**GRADE Working Group grades of evidence**

**High quality:** further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** we are very uncertain about the estimate.

<sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, participants not blinded, outcome assessors not blinded, high attrition, unclear risk of selective reporting bias.

<sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study.

**Summary of findings 4. Group B antipsychotic drugs: olanzapine + supportive intervention compared to placebo + supportive intervention for prodromal stage of psychosis**

**Olanzapine + supportive intervention compared to placebo + supportive intervention for prodromal stage of psychosis**

**Patient or population:** people in the prodromal stage of psychosis

**Setting:** outpatient

**Intervention:** olanzapine + supportive intervention

**Comparison:** placebo + supportive intervention

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	N° of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with placebo + supportive intervention	Risk with olanzapine + supportive intervention				
<b>Prodromal symptoms: transition to psychosis</b>	Study population		RR 0.58 (0.28 to 1.18)	60 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
Endpoint data, (events)	448 per 1000	260 per 1000 (126 to 529)				
Medium-term Follow-up: by 12 months						
<b>Global state: global illness severity</b>	The mean global state: global illness severity was 3.86 points		-	59 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
Average total score, CGI (higher score = worse, scale from: 2-14)	MD 0.23 points lower (0.82 lower to 0.36 higher)					



Medium-term Follow-up: 12 months						
<b>Mental state: psychosis risk symptoms</b> SOPS total (higher score = worse, scale from: 0-114) Follow-up: 12 months	The mean mental state: psychosis risk symptoms was 36.56 points	The mean mental state: psychosis risk symptoms was 33.8  See comment	-	59 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	Data for this outcome were skewed, and therefore we did not present summary estimates
<b>Behaviour: clinically important change in behaviour</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Adverse effects: average weight gain change</b> kg gained (higher scores = worse)  Medium-term Follow-up: 12 months	The mean adverse effects: average weight gain change was 0.32 kg	MD 8.49 kg higher (4.90 higher to 12.08 higher)	-	59 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
<b>Quality of life: clinically important change in quality of life</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Satisfaction with treatment: leaving the study early</b>  Endpoint data (events) Medium-term  Follow-up: by 12 months	Study population  345 per 1000	  548 per 1000 (303 to 993)	RR 1.59 (0.88 to 2.88)	60 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	

\***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CGI:** Clinical Global Impression-Severity of Illness Scale; **CI:** Confidence interval; **MD:** mean difference; **RCT:** randomised controlled trial; **RR:** Risk ratio; **SOPS:** Scale of Prodromal Symptoms

**GRADE Working Group grades of evidence**

**High quality:** further research is very unlikely to change our confidence in the estimate of effect.



**Moderate quality:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  
**Low quality:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  
**Very low quality:** we are very uncertain about the estimate.

<sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, high attrition, unclear risk of selective reporting bias.

<sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study.

### Summary of findings 5. Group B cognitive behavioural therapy: cognitive behavioural therapy + supportive therapy compared to supportive therapy for prodromal stage of psychosis

#### Cognitive behavioural therapy + supportive therapy compared to supportive therapy for prodromal stage of psychosis

**Patient or population:** people in the prodromal stage of psychosis  
**Setting:** outpatient  
**Intervention:** cognitive behavioural therapy (CBT) + supportive therapy  
**Comparison:** supportive therapy

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with supportive therapy	Risk with CBT + supportive therapy				
<b>Prodromal symptoms: transition to psychosis</b>	Study population		RR 0.45 (0.23 to 0.89)	252 (2 RCTs)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
Long-term (events) Follow-up: by 18 months	195 per 1000	88 per 1000 (45 to 174)				
<b>Global state: clinically important change in global state</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Mental state</b>	The mean mental state was 39.1 points		-	68 (1 RCT)	⊕⊕⊕⊕ Very low <sup>3,4</sup>	Data for this outcome were skewed, and therefore we did not present summary estimates
PANSS total (higher score = worse, scale from: 30-210) Follow-up: 12 months	The mean mental state was 39.4 points See comment	See comment				
<b>Behaviour: clinically important change in behaviour</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Adverse effects: at least one serious adverse event</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome

<b>Quality of life</b>	The mean quality of life was 55.5 points	MD 1.50 points higher (2.93 lower to 5.93 higher)	-	140 (1 RCT)	⊕⊕⊕⊕ Very low <sup>4,5</sup>	Data for clinically important change in quality of life not available.
Average total score, MANSA (higher score = better, scale from: 16-112)						
Long-term Follow-up: 18 months						
<b>Satisfaction with treatment: leaving the study early</b>	Study population			RR 0.96 (0.74 to 1.24)	261 (2 RCTs)	⊕⊕⊕⊕ Very low <sup>2,6</sup>
Endpoint data (events)	468 per 1000	450 per 1000 (347 to 581)				
Additional follow-up: by between > 2 years to 4 years						

\***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CBT:** cognitive behavioural therapy; **CI:** confidence interval; **MANSA:** Montgomery–Asberg Depression Rating Scale; **MD:** mean difference; **PANSS:** Positive and Negative Syndrome Scale; **RCT:** randomised controlled trial; **RR:** risk ratio; **SOPS:** Scale of Prodromal Symptoms

#### GRADE Working Group grades of evidence

**High quality:** further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** we are very uncertain about the estimate.

<sup>1</sup>Risk of bias: rated 'very serious'; allocation concealment not described, participants not blinded, high attrition, unclear risk of selective reporting bias.

<sup>2</sup>Imprecision: rated 'very serious'; evidence from two small studies.

<sup>3</sup>Risk of bias: rated 'very serious'; allocation concealment not described, participants not blinded, outcome assessors not blinded, high attrition.

<sup>4</sup>Imprecision: rated 'very serious'; evidence from one small study.

<sup>5</sup>Risk of bias: rated 'very serious'; allocation concealment not described, participants not blinded, unclear risk of selective reporting bias.

<sup>6</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, participants not blinded, outcome assessors not blinded, high attrition.

### Summary of findings 6. Group B cognitive behavioural therapy: cognitive behavioural therapy + risperidone compared to cognitive behavioural therapy + placebo for prodromal stage of psychosis

#### Cognitive behavioural therapy + risperidone compared to cognitive behavioural therapy + placebo for prodromal stage of psychosis

**Patient or population:** people in the prodromal stage of psychosis

**Setting:** outpatient

**Intervention:** cognitive behavioural therapy (CBT) + risperidone

**Comparison:** cognitive behavioural therapy (CBT) + placebo

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with CBT + placebo	Risk with CBT + risperidone				
<b>Prodromal symptoms: transition to psychosis</b>	Study population		RR 1.02 (0.39 to 2.67)	87 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
Endpoint data (events)	159 per 1000	162 per 1000 (62 to 425)				
<b>Global state: clinically important change in global state</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Mental state: psychopathology</b>	The mean mental state: psychopathology was 16.5 points		-	51 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	Data for this outcome were skewed, and therefore we did not present summary estimates
Total endpoint data, BPRS (higher score = worse, scale from 0-126) Follow-up: 12 months		See comment				
<b>Behaviour: clinically important change in behaviour</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Adverse effects: specific - doctors' assessment of adverse effects</b>	Study population		RR 1.03 (0.55 to 1.91)	65 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
UKU (events) Medium-term Follow-up: 12 months	379 per 1000	391 per 1000 (209 to 724)				
<b>Quality of life</b>	The mean quality of life was 0		-	51 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	Data for clinically important change in quality of life were not available
Average endpoint score, QLS (higher score = better, scale from: 0-126) Medium-term Follow-up: 12 months		MD 5.70 higher (7.86 lower to 19.26 higher)				
<b>Satisfaction with treatment: leaving the study early</b>	Study population		RR 1.09 (0.62 to 1.92)	87 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
Endpoint data (events)	341 per 1000	372 per 1000 (211 to 655)				

\*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**BPRS:** Brief Psychiatric Rating Scale; **CBT:** cognitive behavioural therapy; **CI:** confidence interval; **MD:** mean difference; **QLS:** Quality of Life Scale; **RCT:** randomised controlled trial; **RR:** risk ratio; **UKU:** Udvalg for Kliniske Undersøgelser Adverse Effects Scale

**GRADE Working Group grades of evidence**

**High quality:** further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** we are very uncertain about the estimate.

<sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, high attrition.

<sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study.

**Summary of findings 7. Group B cognitive behavioural therapy: cognitive behavioural therapy (specific preventive intervention) + needs-based intervention + risperidone compared to needs-based intervention for prodromal stage of psychosis**

**Cognitive behavioural therapy (specific preventive intervention) + needs-based intervention + risperidone compared to needs-based intervention for prodromal stage of psychosis**

**Patient or population:** people in the prodromal stage of psychosis

**Setting:** outpatient

**Intervention:** cognitive behavioural therapy (specific preventive intervention) (CBT(SPI)) + needs-based intervention (NBI) + risperidone

**Comparison:** needs-based intervention (NBI)

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with NBI	Risk with CBT(SPI) + NBI + risperidone				
<b>Prodromal symptoms: transition to psychosis</b>	Study population		RR 0.75 (0.39 to 1.46)	59 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
Endpoint data (events)	429 per 1000	321 per 1000 (167 to 626)				
Long-term Follow-up: up to 4 years						
<b>Global state: clinically important change in global state</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Mental state: psychopathology</b>	The mean mental state: psychopathology was 22.47		-	40 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	Data for this outcome were skewed, and therefore we did not present summary estimates
Total endpoint data, BPRS (higher score = worse, scale from: 0-126)	The mean mental state: psychopathology was 26.33					

Follow-up: 4 years	See comment					
<b>Behaviour: clinically important change in behaviour</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Adverse effects: at least one serious adverse event</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Quality of life</b> Average endpoint score, QLS (higher score = better, scale from: 0-126) Long-term Follow-up: up to 4 years	The mean quality of life was 80.53 points	MD 2.03 points lower (16.90 lower to 12.84 higher)	-	40 (1 RCT)	⊕○○○ Very low <sup>1,2</sup>	Data for clinically important change in quality of life were not available
<b>Satisfaction with treatment: leaving the study early</b> (events) Long-term Follow-up: up to 4 years	Study population 393 per 1000	224 per 1000 (102 to 503)	RR 0.57 (0.26 to 1.28)	59 (1 RCT)	⊕○○○ Very low <sup>1,2</sup>	

\***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**BPRS:** Brief Psychiatric Rating Scale; **CBT(SPI):** cognitive behavioural therapy (specific preventive intervention); **CI:** confidence interval; **MD:** mean difference; **QLS:** Quality of Life Scale; **RCT:** randomised controlled trial; **RR:** risk ratio

#### GRADE Working Group grades of evidence

**High quality:** further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** we are very uncertain about the estimate.

<sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment not described, participants not blinded, outcome assessors not blinded.

<sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study.

### Summary of findings 8. Group C cognitive behavioural therapy: cognitive behavioural therapy + placebo compared to supportive therapy + placebo for prodromal stage of psychosis

#### Cognitive behavioural therapy + placebo compared to supportive therapy + placebo for prodromal stage of psychosis

**Patient or population:** people in the prodromal stage of psychosis

**Setting:** outpatient  
**Intervention:** cognitive behavioural therapy (CBT) + placebo  
**Comparison:** supportive therapy + placebo

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with supportive therapy + placebo	Risk with CBT + placebo				
<b>Prodromal symptoms: transition to psychosis</b>	Study population		RR 0.74 (0.28 to 1.98)	72 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
Endpoint data (events)	214 per 1000	159 per 1000 (60 to 424)				
<b>Global state: clinically important change in global state</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Mental state: psychopathology</b>	The mean mental state: psychopathology: was 15.3 points		-	45 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	Data for this outcome were skewed, and therefore we did not present summary estimates
Total endpoint data, BPRS (higher score = worse, scale from 0-126) Follow-up: 12 months		The mean mental state: psychopathology: was 16.5 points See comment				
<b>Behaviour: clinically important change in behaviour</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported data we could use for this outcome
<b>Adverse effects: specific - doctors' assessment of adverse effects</b>	Study population		RR 1.39 (0.61 to 3.18)	51 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
UKU (events) Medium-term Follow-up: 12 months	273 per 1000	379 per 1000 (166 to 867)				
<b>Quality of life</b>	The mean quality of life was 84.4 points		-	44 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	Data for clinically important change in quality of life were not available.
Average endpoint scores, QLS (higher score = better, scale from 0-126) Medium-term Follow-up: 12 months		MD 3.30 points lower (18.76 lower to 12.16 higher)				
<b>Satisfaction with treatment: leaving the study early</b>	Study population		RR 1.06	72 (1 RCT)	⊕⊕⊕⊕	

Endpoint data (events)	321 per 1000	341 per 1000 (174 to 672)	(0.54 to 2.09)	Very low <sup>1,2</sup>
------------------------	--------------	------------------------------	----------------	-------------------------

\***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**BPRS:** Brief Psychiatric Rating Scale; **CBT:** cognitive behavioural therapy; **CI:** confidence interval; **MD:** mean difference; **QLS:** Quality of Life Scale; **RCT:** randomised controlled trial; **RR:** risk ratio; **UKU:** Udvalg for Kliniske Undersøgelser Adverse Effects Scale

#### GRADE Working Group grades of evidence

**High quality:** further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** we are very uncertain about the estimate.

<sup>1</sup>Risk of bias: rated 'serious'; randomisation process unclear, method of allocation concealment unclear, large attrition of participants.

<sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study.

### Summary of findings 9. Group C cognitive behavioural therapy: cognitive behavioural therapy + supportive intervention compared to non-directive reflective listening + supportive intervention for prodromal stage of psychosis

#### Cognitive behavioural therapy + supportive intervention compared to non-directive reflective listening + supportive intervention for prodromal stage of psychosis

**Patient or population:** people in the prodromal stage of psychosis

**Setting:** outpatient

**Intervention:** cognitive behavioural therapy (CBT) + supportive intervention

**Comparison:** non-directive reflective listening (NDRL) + supportive intervention

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Certainty of the evidence (GRADE)	Comments
	Risk with NDRL + supportive intervention	Risk with CBT + supportive intervention				
<b>Prodromal symptoms: transition to psychosis</b>	Study population		RR 6.32 (0.34 to 117.09)	57 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
Endpoint data (events)	0 per 1000	0 per 1000 (0 to 0)				
<b>Global state: clinically important change in global state</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome

<b>Mental state: clinically important change in mental state</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Behaviour: clinically important change in behaviour</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Adverse effects: at least one serious adverse event</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Quality of life: clinically important change in quality of life</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Satisfaction with treatment: leaving the study early</b>	Study population		RR 1.35 (0.81 to 2.25)	57 (1 RCT)	⊕○○○ Very low <sup>1,2</sup>	
Endpoint data (events)	444 per 1000	600 per 1000 (360 to 1000)				

\***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CBT:** cognitive behavioural therapy; **CI:** confidence interval; **NDRL:** non-directive reflective listening; **RCT:** randomised controlled trial; **RR:** risk ratio

#### GRADE Working Group grades of evidence

**High quality:** further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** we are very uncertain about the estimate.

<sup>1</sup>Risk of bias: rated 'very serious'; allocation concealment method unclear; participants not blinded; high attrition.

<sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study.

### Summary of findings 10. Group C cognitive behavioural therapy: cognitive behavioural therapy + risperidone compared to supportive therapy + placebo for prodromal stage of psychosis

#### Cognitive behavioural therapy + risperidone compared to supportive therapy + placebo for prodromal stage of psychosis

**Patient or population:** people in the prodromal stage of psychosis

**Setting:** outpatient

**Intervention:** cognitive behavioural therapy (CBT) + risperidone

**Comparison:** supportive therapy + placebo

Outcomes	Anticipated absolute effects* (95% CI)	Relative effect	Comments
----------	--	-----------------	----------



	Risk with support- ive therapy + place- bo	Risk with CBT + risperi- done	(95% CI)	Nº of parti- cants (stud- ies)	Quality of the evi- dence (GRADE)	
<b>Prodromal symptoms: transition to psychosis</b>	Study population					
Endpoint data (events)	214 per 1000	163 per 1000 (60 to 435)	RR 0.76 (0.28 to 2.03)	71 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
<b>Global state: clinically important change in global state</b>	See comment	See comment	Not es- timable	0 (0)	See com- ment	No study reported this outcome
<b>Mental state: psychopathology</b>	The mean mental state: psychopathol- ogy was 15.3 points	The mean mental state: psychopathology was 14 points	-	42 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	Data for this out- come were skewed, and therefore we did not present summary esti- mates
Total endpoint data, BPRS (higher score = worse, scale from: 0-126) Follow-up: 12 months		See comment				
<b>Behaviour: clinically important change in behaviour</b>	See comment	See comment	Not es- timable	0 (0)	See com- ment	No study reported this outcome
<b>Adverse effects: doctors' assessment of adverse ef- fects</b>	Study population					
UKU (events) Medium-term Follow-up: 12 months	273 per 1000	390 per 1000 (175 to 862)	RR 1.43 (0.64 to 3.16)	58 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
<b>Quality of life</b>	The mean quality of life was 84.4 points	MD 2.40 points higher (9.91 lower to 14.71 high- er)	-	43 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	Data for clinically important change in quality of life were not available.
Average endpoint scores, QLS (higher score = better, scale from: 0-126) Medium-term Follow-up: 12 months						
<b>Satisfaction with treatment: leaving the study early</b>	Study population					
Endpoint data (events)	321 per 1000	373 per 1000 (193 to 723)	RR 1.16 (0.60 to 2.25)	71 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	

\***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**BPRS:** Brief Psychiatric Rating Scale; **CI:** confidence interval; **QLS:** Quality of Life Scale; **RR:** risk ratio; **UKU:** Udvalg for Kliniske Undersøgelser Adverse Effects Scale

#### GRADE Working Group grades of evidence

**High quality:** further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** we are very uncertain about the estimate.

<sup>1</sup> Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, high attrition

<sup>2</sup> Imprecision: rated 'very serious'; evidence from one small study

### Summary of findings 11. Group C other: cognitive training compared to active control (tablet games) for prodromal stage of psychosis

#### Cognitive training compared to active control (tablet games) for prodromal stage of psychosis

**Patient or population:** people in the prodromal stage of psychosis

**Setting:** outpatient

**Intervention:** cognitive training

**Comparison:** active control (tablet games)

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with active control (tablet games)	Risk with cognitive training				
<b>Prodromal symptoms: transition to psychosis</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Global state: clinically important change in global state</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Mental state: psychosis risk symptoms</b> SOPS total (higher score = worse, scale from: 0-114) Follow-up: 24 months	The mean mental state: psychosis risk symptoms was 25.49 points	The mean mental state: psychosis risk symptoms was 33.9 points  See comment	-	62 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	Data for this outcome were skewed, and therefore we did not present summary estimates

<b>Behaviour: clinically important change in behaviour</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Adverse effects: at least one serious adverse event</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Quality of life: clinically important change in quality of life</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Satisfaction with treatment: leaving the study early</b>	Study population		RR 0.78 (0.48 to 1.29)	83 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
Endpoint data (events)	485 per 1000	378 per 1000 (233 to 625)				
Long-term Follow-up: by 24 months						

\***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** confidence interval; **RR:** risk ratio; **SOPS:** Scale of Prodromal Symptoms

#### GRADE Working Group grades of evidence

**High quality:** further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** we are very uncertain about the estimate.

<sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, high attrition.

<sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study.

## Summary of findings 12. Group C other: family treatment compared to enhanced care for prodromal stage of psychosis

### Family treatment compared to enhanced care for prodromal stage of psychosis

**Patient or population:** people in the prodromal stage of psychosis

**Setting:** outpatient

**Intervention:** family treatment

**Comparison:** enhanced care

Outcomes	Anticipated absolute effects <sup>†</sup> (95% CI)	Relative effect (95% CI)	Nº of participants	Quality of the evidence	Comments
----------	--	--------------------------	--------------------	-------------------------	----------

	Risk with enhanced care	Risk with family treatment	(studies)	(GRADE)		
<b>Prodromal symptoms: transition to psychosis</b>	Study population		RR 0.71 (0.35 to 1.45)	100 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
FACT	280 per 1000	199 per 1000 (98 to 406)				
Long-term Follow-up: 24 months						
<b>Global state: antipsychotic prescriptions</b>	Study population		RR 1.18 (0.69 to 2.02)	129 (1 RCT)	⊕⊕⊕⊕ Very low <sup>2,3</sup>	
(events) Follow-up: 24 months	270 per 1000	318 per 1000 (186 to 545)				
<b>Mental state: specific - psychosis risk, positive symptoms</b>	The mean mental state: specific - psychosis risk, positive symptoms was 9.84 points	MD 2.01 points lower (3.87 lower to 0.15 lower)	-	102 (1 RCT)	⊕⊕⊕⊕ Very low <sup>2,3</sup>	Data for our pre-defined outcome of interest 'Clinically important change in mental state' were not reported by the studies.
Average total score, SOPS positive (higher score = worse, scale from 0-30)						
Short-term Follow-up: 6 months						
<b>Behaviour: clinically important change in behaviour</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Adverse events: suicide</b>	Study population		RR 1.00 (0.06 to 15.55)	100 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
(events)	20 per 1000	20 per 1000 (1 to 311)				
Long-term (by 24 months) Follow-up: 24 months						
<b>Quality of life: clinically important change in quality of life</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Satisfaction with treatment: leaving the study early</b>	Study population		RR 0.94 (0.52 to 1.68)	100 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
FACT	320 per 1000	301 per 1000 (166 to 538)				
Long-term Follow-up: 24 months						

\*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** confidence interval; **FACT:** Family-aided Assertive Community Treatment; **MD:** mean difference; **RCT:** randomised controlled trial; **RR:** risk ratio; **SOPS:** Scale for Prodromal Symptoms

**GRADE Working Group grades of evidence**

**High quality:** further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** we are very uncertain about the estimate.

<sup>1</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, participants not blinded, high attrition, unclear risk of selective reporting bias.

<sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study.

<sup>3</sup>Risk of bias: rated 'very serious'; randomisation method not described, allocation concealment method not described, participants not blinded, outcome assessors not blinded, unclear risk of selective reporting bias.

**Summary of findings 13. Group C other: integrated treatment compared to standard treatment for prodromal stage of psychosis**

**Integrated treatment compared to standard treatment for prodromal stage of psychosis**

**Patient or population:** people in the prodromal stage of psychosis

**Setting:** outpatient

**Intervention:** integrated treatment

**Comparison:** standard treatment

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with standard treatment	Risk with integrated treatment				
<b>Prodromal symptoms: transition to psychosis</b>	Study population		RR 0.57 (0.28 to 1.15)	79 (1 RCT)	⊕○○○ Very low <sup>1,2</sup>	
Endpoint data (events) Long-term Follow-up: by 2 years	378 per 1000	216 per 1000 (106 to 435)				
<b>Global state: clinically important change in global state</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Mental state</b> SANS total (higher score = worse, scale from 0-130)	The mean mental state was 1.7 points	The mean mental state was 1.34 points	-	57 (1 RCT)	⊕○○○ Very low <sup>1,2</sup>	Data for this outcome were skewed, and therefore we did not

Follow-up: 2 years	See comment					present summary estimates
<b>Behaviour: clinically important change in behaviour</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Adverse effects: at least one serious adverse event</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Quality of life: clinically important change in quality of life</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome
<b>Satisfaction with treatment: leaving the study early</b>	Study population		RR 0.66 (0.25 to 1.73)	79 (1 RCT)	⊕⊕⊕⊕ Very low <sup>1,2</sup>	
Endpoint data (events)	216 per 1000	143 per 1000 (54 to 374)				

\***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** Confidence interval; **MD:** mean difference; **RCT:** randomised controlled trial; **RR:** Risk ratio; **SANS:** Scale for Assessment of Negative Symptoms

#### GRADE Working Group grades of evidence

**High quality:** further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** we are very uncertain about the estimate.

<sup>1</sup>Risk of bias: rated 'very serious'; allocation concealment method not described, participants not blinded, outcome assessors not blinded, moderate attrition, unclear risk of selective reporting bias.

<sup>2</sup>Imprecision: rated 'very serious'; evidence from one small study.

## BACKGROUND

### Description of the condition

Schizophrenia is a chronic, recurrent illness that usually starts with a prodromal phase, eventually followed by the first acute phase. It continues with periods of remission and acute psychosis. With each episode of psychosis, mental state will usually deteriorate, finally reaching a state of chronicity. People with schizophrenia usually have more than three psychotic episodes, with only partial remission from each episode over the course of their illness (Wiersma 1998), and decline in functional status is linked to the progression of neurobiological damage over time (Andreassen 2013).

Schizophrenia has a prevalence of 1% worldwide, affecting a substantial number of people each year (Wittchen 2011). Treatment of schizophrenia is complex, costly, and offers only partial, limited improvement in two-thirds of sufferers. Treatment response is best for first-episode psychoses, but unfortunately, due to treatment non-adherence, the majority of patients relapse within a few years. With every new relapse, treatment resistance increases (Emsley 2013). Over its course, schizophrenia still remains a disorder with low functional recovery rates (Jaaskelainen 2013; Wunderink 2013), and remains among the leading causes of disability (Wittchen 2011).

A number of early intervention services, developed over the last 20 years worldwide, have shifted attention to the treatment of the early course of schizophrenia, including the prevention of schizophrenia in people at risk. Specialised teams have established a set of clinical criteria for identifying people at risk of developing schizophrenia, this includes the clinical high risk (CHR) criteria (comprising the 'at-risk mental state' (ARMS) or prodromal syndrome); the ultra high risk (UHR) criteria (comprising the attenuated psychotic syndrome (APS)); the 'Brief Limited Intermittent Psychotic Syndrome' (BLIPS); and genetic risk combined with functional decline (Cornblatt 2002; Miller 2003; Yung 2004; Broome 2005; Yung 2005; Cannon 2008). Another approach has been researched - the Basic Symptom approach. This includes the cognitive-perceptive (COPER) basic symptoms; and Cognitive Disturbances (COGDIS; Schultze-Lutter 2009). The use of psychometric prognostic interviews for CHR have been reviewed by Fusar-Poli, and their use as clinical tools for high risk services worldwide has been supported (Fusar-Poli 2016).

People with CHR criteria have been found to have neurocognitive impairments, and corresponding neurotransmitter and structural changes have been identified. These include hyperdopaminergia in the striatum and hippocampal glutamate alterations (Stone 2010; Allen 2012; Howes 2012), thalamic disconnectivity (Anticevic 2015), as well as reductions in grey matter in the left parahippocampal and fusiform gyri (Job 2006), and temporal lobe volume reduction (Chung 2015).

### Description of the intervention

There are a number of early intervention services that focus on treating early phases or prodromal stage of schizophrenia and preventing development of psychoses in CHR/UHR groups.

### 1. Pharmacotherapy treatment

Pharmacotherapy includes antipsychotics, mood stabilisers and antidepressant treatment.

Antipsychotic treatment is a well-established treatment for first episode psychosis. However, due to a number of potential side effects as well as the lack of firm evidence that it is effective for prevention of psychosis, antipsychotic treatment is currently suggested in the prodromal phase of the illness only for more complex cases and only with a few atypical antipsychotics (Schmidt 2015). Treatment with antidepressants is not suggested for the treatment of acute-episode psychosis, as evidence suggests that antidepressants may be associated with the risk of worsening psychosis. However, it has been suggested that treating prodromal depressive syndromes may actually delay the onset of psychosis (Cornblatt 2007a; Fusar-Poli 2007). Mood stabilisers are used as first- or second-line treatment for bipolar disorders, which sometimes present as affective psychoses. Their use in the prodromal stage may potentially be useful (Berger 2012). Anxiolytics are used for the short-term reduction of anxiety in first-episode psychosis. It has been suggested that reducing anxiety in the prodromal phase of the illness may postpone psychosis (McAusland 2015).

### 2. The use of nutritives/supplements and alternative medication

This category includes omega-3, glycine, D-serine, B vitamins, folic acid, and immune response modulators.

Based on the hypothesis of the alteration of metabolism of lipids, homocysteine levels and neuroinflammation in schizophrenia, a number of studies examined the influence of different supplements aimed at restoring lipid metabolism or low levels of vitamins in UHR people (Amminger 2010; Woods-1-USA; Sommer 2014; Kantrowitz 2015; Xu 2015).

### 3. Psychotherapy or psychosocial interventions

Psychotherapy and psychosocial interventions include psychoeducation, social skills training, metacognitive training, cognitive remediation, family therapy, individual psychotherapy, and combined multiple approaches.

Most early intervention services focus on psychosocial methods, offered for a variable duration of time, and suggested psychosocial interventions as the first-line treatment for the prodromal stage. Studies showed variable and generally modest effectiveness of a variety of psychosocial methods for people with schizophrenia, especially over a longer assessment period (Falloon 1985; Hogarty 1991; Dolder 2003; Durham 2005; Velligan 2008; Jauhar 2014; Anderson 2015; Cai 2015; Ruggeri 2015).

### How the intervention might work

There are a variety of treatment options, and each of them may work differently:

Pharmacotherapy based on antipsychotics has documented efficacy for psychotic symptoms, based on their blockade/agonism of multireceptor sites. In particular, cortical dopamine transmission via D1 receptors may play a role in impaired working memory and negative symptoms, whereas striatal dopamine activity

via D2 receptors may modulate response inhibition, temporal organisation, and motor performance (Abi-Dargham 2004).

Mood stabilisers may act as modulators of glutamate neurotransmission, counteracting the effect of the excessive glutamate transmission. Anxiolytics may increase GABA neurotransmission, subsequently decreasing excessive glutamate transmission. Both of these support the glutamate hypothesis of schizophrenia. Antidepressants may increase serotonergic, noradrenergic or dopaminergic neurotransmission in the prefrontal cortex, subsequently affecting cognitive and depressive symptoms in the prodromal stage.

Nutritives/supplements and alternative medication (omega-3, glycine, D-serine, B vitamins, folic acid) act as glutamatergic modulators (glycine, D-serine), suppressing the increased immune response (acetylsalicylate and others) or counteracting the altered phospholipid metabolism observed in some people with schizophrenia (Amminger 2010; Woods-1-USA; Sommer 2014; Kantrowitz 2015; Xu 2015).

Psychosocial interventions may enhance self-confidence and self-esteem, cognitive abilities, social skills, social network and support, all contributing to increased coping mechanisms and decreased anxiety and vulnerability to stressors, and subsequently to psychosis.

### Why it is important to do this review

Psychosis has a large impact on an individual's life, causing long-term health, economic and social problems. Identifying and treating people in the prodromal stage of psychosis may prevent full transition to schizophrenia and in turn negate some of the ill effects brought about by psychosis. Since firm evidence of the efficacy and safety of different treatment approaches in this vulnerable group is lacking, a systematic review can help inform decisions of healthcare workers, researchers, politicians and other public health decision makers.

## OBJECTIVES

The primary objective is to assess the safety and efficacy of early interventions for people in the prodromal stage of psychosis.

The secondary objective is, if possible, to compare the effectiveness of the various different interventions.

## METHODS

### Criteria for considering studies for this review

#### Types of studies

All relevant randomised controlled studies. If a study had been described as 'double-blind' but implied randomisation, we would have included such studies in a sensitivity analysis (see [Sensitivity analysis](#)). We excluded quasi-randomised studies, such as those allocating by alternate days of the week.

#### Types of participants

We included participants older than 12 years, who had developed a prodromal stage of psychosis, including people that met at least one of the following criteria:

1. positive psychiatric heredity (relatives that suffer from schizophrenia spectrum disorders and non-organic psychosis) combined with functional decline over the last 12 months;
2. experienced Brief Limited Intermittent Psychotic Symptoms combined with functional decline over the last 12 months;
3. experienced Attenuated Psychosis Syndrome combined with functional decline over the last 12 months.

Exclusion criteria were mental illness in childhood that can present with psychosis (such as autism); organic conditions that can present with psychosis; neurological disorders; mental retardation; comorbid alcoholism or abuse of opiates and other substance disorders (excluding marijuana); pregnancy and lactation; and the use of medications that can produce psychotic reactions.

Studies had to use internationally recognised criteria for diagnosis (such as Diagnostic and Statistical Manual of Mental Disorders V (DSM-5) or previous editions of DSM (APA 2013); and the International Classification of Diseases 10 (ICD-10) or previous editions of ICD (WHO 2010)). For studies that included only a subset of relevant participants, we only included the study if data for the population of interest were reported separately.

### Types of interventions

1. Pharmacotherapy: any oral antipsychotics
2. Alternative medication (e.g. omega-3, B12 vitamins, folic acid, B6 vitamins)
3. Psychotherapies: including psychodynamically oriented individual psychotherapy, cognitive behavioural psychotherapy, group therapy (psychodynamically oriented), systemic therapy, interpersonal therapy, integrative therapy, family therapy
4. Psychosocial interventions: including psychoeducation (individual, group and family), metacognitive training (individual and group), cognitive remediation training, social skills training
5. Combined pharmacotherapy and psychotherapy or psychosocial interventions, or psychosocial interventions including a combination of at least two approaches, one of which is pharmacotherapy and one psychotherapy or psychosocial intervention
6. Placebo
7. No therapy or treatment, or treatment as usual (TAU) (e.g. brief outpatients' consultations less than once every three months).

### Types of outcome measures

We divided all outcomes into short-term (less than six months), medium-term (7 to 12 months) and long-term (over one year) outcomes.

#### Primary outcomes

##### 1. Prodromal symptoms

- 1.1. Transition to psychosis during follow-up period
- 1.2. Clinically important change of severity of prodromal symptoms
- 1.3. Any change in prodromal symptoms
- 1.4. Remission of prodromal symptoms

##### 2. Global state

- 2.1. Clinically important change in global state



### 3. Adverse effects

#### 3.1. Clinically important general adverse effects

#### *Secondary outcomes*

##### **1. General overall functioning (social functioning, relationship status, employment status, academic status)**

- 1.1. Clinically important change in overall functioning, as defined by each of the studies
- 1.2. Average endpoint/change score in overall functioning scales
- 1.3. Clinically important change in social functioning, as defined by each of the studies
- 1.4. Average endpoint/change score in social functioning scales
- 1.5. Change in the relationship status, as defined by each of the studies
- 1.6. Change in the employment status, as defined by each of the studies
- 1.7. Change in the academic status, as defined by each of the studies

##### **2. Global state**

- 2.1. Any change in global state
- 2.2. Average endpoint/change score in global state scales

##### **3. Mental state: general symptoms; specific psychotic symptoms (positive symptoms (delusions, hallucinations, disordered thinking); negative symptoms (avolition, poor self-care, blunted affect)); mood; psychomotor; cognitive**

- 3.1. Clinically important change in mental state, as defined by each of the studies
- 3.2. Average endpoint/change score in mental state scales
- 3.3. Clinically important change in positive symptoms, as defined by each of the studies
- 3.4. Average endpoint/change score in positive symptoms scales
- 3.5. Clinically important change in negative symptoms, as defined by each of the studies
- 3.6. Average endpoint/change score in negative symptoms scales
- 3.7. Clinically important change in affective/mood symptoms, as defined by each of the studies
- 3.8. Average endpoint/change score in affective/mood symptoms scales
- 3.9. Clinically important change in psychomotor symptoms, as defined by each of the studies
- 3.10. Average endpoint/change score in psychomotor symptoms scales
- 3.11. Clinically important change in cognitive symptoms, as defined by each of the studies
- 3.12. Average endpoint/change score in cognitive symptoms scales

##### **4. Behaviour: general behaviour, specific behaviours (for example, aggressive or violent behaviour); occurrence of violent incidents (to self, others or property)**

- 4.1. Clinically important change in overall behaviour, as defined by each of the studies
- 4.2. Average endpoint/change score in overall behaviour scales
- 4.3. Clinically important change in specific behaviour, as defined by each of the studies
- 4.4. Average endpoint/change score in specific behaviour scales
- 4.5. Occurrence of violent incidents

### 5. Adverse effects

- 5.1. Average endpoint/change score in general adverse effect scores
- 5.2. Clinically important specific adverse effects
- 5.3. Average endpoint/change score in specific adverse effect scores
- 5.4. Various adverse effects: specific movement disorders (extrapyramidal side effects, specifically tardive dyskinesia and neuroleptic malignant syndrome); sedation; dry mouth; weight gain; sleepiness; dizziness; palpitations; muscle rigidity; hypersalivation; blurred vision; dysuria; nausea; nocturnal enuresis; thirst; polyuria; prolactinaemia side-effects (swollen nipples, galactorrhoea, loss of sexual pleasure, erectile dysfunction)

### 6. Death by suicide or by natural causes

### 7. Quality of life

- 7.1. Any change in quality of life, as defined by each of the studies
- 7.2. Average endpoint/change score in quality-of-life scales

### 8. Satisfaction with treatment (participant/carer)

- 8.1. Leaving the study early
- 8.2. Participant/carer not satisfied with treatment
- 8.3. Participant/carer average satisfaction score
- 8.4. Participant/carer change in the satisfaction scores

### 9. Service outcomes

- 9.1. Hospital admission
- 9.2. Duration of hospital stay

### 10. Economic outcomes

- 10.1. Cost of care

#### **'Summary of findings' table**

We used the GRADE approach to interpret findings (Schünemann 2017); and GRADEpro GDT to import data from Review Manager 5 (RevMan 5) to create 'Summary of findings' tables (Review Manager 2014). These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table:

1. Prodromal symptoms: transition to psychosis
2. Global state: clinically important change in global state
3. Mental state: clinically important change in mental state
4. Behaviour: clinically important change in behaviour
5. Adverse effects: at least one serious adverse event
6. Quality of life: clinically important change in quality of life
7. Satisfaction with treatment: leaving the study early

### Search methods for identification of studies

#### Electronic searches

##### **Cochrane Schizophrenia's Register of studies**

On 8 June 2016 and 4 August 2017, the Information Specialist searched Cochrane Schizophrenia's study-based Register of studies using the following search strategy, which has been developed

based on literature review and consulting with the authors of the review:

(\*At Risk\* OR \*At-Risk\* OR \*Attenuat\* Psycho\* Syndrome\* OR \*Brief Limited Intermittent Psycho\* Symptom\* OR \*Brief Limited Intermittent Psycho\* Syndrome\* OR \*Brief Self Limited Psycho\* Syndrome\* OR \*Brief Self-Limited Psycho\* Syndrome\* OR \*Cognit\* Disturbance\* OR \*Cognit\* Percept\* Basic Symptom\* OR \*Cognitive-Percept\* Basic Symptom\* OR \*Conver\* OR \*Elevated Clinical Risk\* OR \*Family History\* OR \*Genetic\* Risk\* OR \*Heredity\* OR \*High Clinical Risk\* OR \*High Genetic Risk\* OR \*High Risk\* OR \*High-Risk\* OR \*Inherit\* OR \*Onset\* OR \*Pre Delusion\* OR \*Pre Psycho\* OR \*Predelusion\* OR \*Pre-Delusion\* OR \*Prepsycho\* OR \*Pre-Psycho\* OR \*Prodrom\* OR \*Relative\* OR \*Risk\* Syndrome\* OR \*Sub Psycho\* OR \*Subpsycho\* OR \*Sub-Psycho\* OR \*Transition\* OR \*Vulnerable\*) in Title OR Abstract of REFERENCE OR (\*At Risk of Psychosis\* OR \*Prodromal Illness\* OR \*Family History of Psychosis\* OR \*Early Onset\*) in Healthcare Condition of STUDY

In study-based registers, searching the major concept retrieves all the synonym keywords and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics.

Cochrane Schizophrenia's Register of studies is compiled by systematic searches of major resources (including AMED, BIOSIS CINAHL, EMBASE, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings (see [Cochrane Schizophrenia Register of trials](#)). There are no language, date, document type, or publication status limitations for inclusion of records into the register.

## Searching other resources

### 1. Reference searching

We inspected references of all included studies for further relevant studies.

### 2. Personal contact

We contacted the first author of each included study for information regarding unpublished studies. We noted the outcome of this contact in the sections '[Characteristics of included studies](#)' or '[Characteristics of studies awaiting classification](#)'.

## Data collection and analysis

### Selection of studies

DB and IK independently inspected citations from the searches and identified relevant abstracts. JH re-inspected a random 20% sample to ensure reliability. In the case of disputes, we acquired the full report for more detailed scrutiny. We obtained full reports of the abstracts meeting the review criteria and DB and IK inspected these. Again, JH re-inspected a random 20% of the full reports in order to ensure reliable selection. Where it was not possible to resolve disagreement by discussion, we attempted to contact the authors of the study for clarification.

## Data extraction and management

### 1. Extraction

Review authors DB and IK extracted data from all included studies. In addition, to ensure reliability, JH independently extracted data from a random sample of these studies, comprising 10% of the total. Again, we discussed any disagreement, documented decisions and, if necessary, contacted authors of studies for clarification. With remaining problems MRK helped to clarify issues and we documented these final decisions. We extracted data presented only in graphs and figures whenever possible, but only included them if two review authors independently had the same result. We attempted to contact study authors through an open-ended request in order to obtain missing information or for clarification whenever necessary. If studies were multicentre, where possible we extracted data relevant to each component centre separately.

### 2. Management

#### 2.1 Forms

We extracted data onto standard, simple forms.

#### 2.2 Scale-derived data

We included continuous data from rating scales only if:

- the psychometric properties of the measuring instrument had been described in a peer-reviewed journal ([Marshall 2000](#)); and
- the measuring instrument had not been written or modified by one of the trialists for that particular study.

Ideally the measuring instrument should either be i. a self-report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; in '[Description of studies](#)' we noted if this is the case or not.

#### 2.3 Endpoint versus change data

There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. On the other hand calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult-to-measure conditions such as schizophrenia. We decided to primarily use endpoint data, and only use change data if the former are not available and used mean differences (MD) rather than standardised mean differences throughout ([Deeks 2017](#)).

#### 2.4 Skewed data

Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we applied the following standards to all data before inclusion.

#### Endpoint data (more than 200 participants)

We entered data from studies of at least 200 participants in analyses, irrespective of the following rules, because skewed data pose less of a problem in large studies.

#### Change data

We also entered change data as when continuous data are presented on a scale that includes a possibility of negative values

(such as change data), it is difficult to tell whether data are skewed or not. We presented and entered change data into statistical analyses where possible.

**Endpoint data (fewer than 200 participants)**

a) when a scale starts from the finite number zero, we subtracted the lowest possible value from the mean, and divided this by the standard deviation. If this value was lower than 1, it strongly suggests a skew and we excluded these data. If this ratio was higher than 1 but below 2, there is suggestion of skew. We entered these data and tested whether their inclusion or exclusion would change the results substantially. Finally, if the ratio was larger than 2 we included such data because skew is less likely (Altman 1996; Deeks 2017).

b) if a scale starts from a positive value (such as the Positive and Negative Syndrome Scale (PANSS, Kay 1986), which can have values from 30 to 210), we modified the calculation described to take the scale starting point into account. In these cases skew is present if  $2\text{ SD} > (S - S_{\text{min}})$ , where S is the mean score and 'S min' is the minimum score.

**2.5 Common measure**

To facilitate comparison between studies, we converted variables that could be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month).

**2.6 Conversion of continuous to binary**

Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, Overall 1962), or the PANSS (Kay 1987), this could be considered as a clinically significant response

(Leucht 2005a; Leucht 2005b). If data based on these thresholds were not available, we used the primary cut-off presented by the original study authors.

**2.7 Direction of graphs**

Where possible, we entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome for early intervention. Where keeping to this made it impossible to avoid outcome titles with clumsy double-negatives (e.g. 'Not unimproved') we reported data where the left of the line indicated an unfavourable outcome and made a note in the relevant graphs.


**Assessment of risk of bias in included studies**

Review authors DB and LP worked independently to assess risk of bias by using criteria described in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2017). This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting.

For attrition bias, we used the following assessment criteria: we judged as low risk of bias studies where attrition was under 30%, unclear risk of bias if attrition was between 30% and 50%, and high risk of bias if total attrition rate, or attrition in any of the groups, was higher than 50%. If attrition was under 30%, but reasons for attrition were unclear, we judged the study as unclear risk of attrition bias.

If the raters disagreed, we made the final rating by consensus. Where inadequate details of randomisation and other characteristics of studies were provided, we contacted authors of the studies in order to obtain further information. We have noted the level of risk of bias in both the text of the review and in Figure 1; Figure 2

**Figure 1. 'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies**



**Figure 2. 'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study**

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
ADAPT-Canada	+	?	-	+	?	?	+
Amminger-Austria	+	?	+	+	+	+	+
Choi-USA	?	?	+	+	?	?	+
DEPTH-Australia	+	?	-	+	-	+	+
EDIE-2-UK	+	?	-	?	-	?	+
EDIE-NL	+	?	-	+	+	?	+
EDIE-UK	?	?	-	-	-	+	+
EDIP-USA	?	?	-	+	?	?	+
EIPS-Germany	+	?	-	-	?	+	+
Kantrowitz-USA	?	+	+	?	-	+	+
LIPS-Germany	?	?	-	-	?	?	+
Miklowitz-USA	?	?	-	-	+	?	+
NEURAPRO-AAE	+	?	+	+	+	+	+
Nordentoft-Denmark	+	?	-	-	?	?	+
PACE-Australia	?	?	-	-	+	+	+
Piskulic-Canada	?	?	-	+	-	+	+
PRIME-USA	?	?	+	+	-	?	+
Vinogradov-USA	?	?	+	+	?	+	+
Woods-1-USA	?	?	+	?	+	?	+
Yung-Australia	-	?	+	+	?	+	+

**Figure 2. (Continued)**



**Measures of treatment effect**

**1. Binary data**

For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive than odds ratios (Boissel 1999); and that odds ratios tend to be interpreted as RR by clinicians (Deeks 2000).

**2. Continuous data**

For continuous outcomes we aimed to estimate mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference (SMD)). However, if scales of very considerable similarity were used, we presumed there was a small difference in measurement, and calculated effect size and transformed the effect back to the units of one or more of the specific instruments.

**Unit of analysis issues**

**1. Cluster trials**

Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra-class correlation in clustered trials, leading to a 'unit of analysis' error whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated (Divine 1992). This causes type I errors (Bland 1997; Gulliford 1999).

Where clustering is not accounted for in primary studies, we presented data in a table, with a (\*) symbol to indicate the presence of a probable unit-of-analysis error. We aimed to contact first authors of studies to obtain intra-class correlation coefficients for their clustered data and to adjust for this by using accepted methods (Gulliford 1999). Where primary studies incorporated clustering into their analysis, we presented these data as if from a non-cluster randomised trial, but adjusted for the clustering effect.

We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra-class correlation coefficient (ICC): [Design effect = 1 + (m - 1) \* ICC] (Donner 2002). If the ICC was not reported we assumed it was 0.1 (Ukoumunne 1999).

If cluster trials have been appropriately analysed taking into account intra-class correlation coefficients and relevant data documented in the report, synthesis with other studies is possible using the generic inverse variance technique.

**2. Cross-over trials**

A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if

the condition of interest is unstable (Elbourne 2002). As both effects are very likely in severe mental illness, we only used data of the first phase of cross-over trials.

**3. Studies with multiple treatment groups**

Where a study involved more than two treatment arms we, if relevant, presented the additional treatment arms in comparisons. If data were binary we simply added these and combined within the two-by-two table. If data were continuous we combined data following the formula in section 7.7.3.8 (Combining groups) of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011a). Where the additional treatment arms were not relevant, we did not reproduce these data.

**Dealing with missing data**

**1. Overall loss of credibility**

At some degree of loss of follow-up, data must lose credibility (Xia 2009). We chose that, for any particular outcome, when more than 50% of data was unaccounted for, we did not reproduce these data or used them within analyses. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we addressed this within the 'Summary of findings' tables by downgrading quality. Finally, we also downgraded quality within the 'Summary of findings' tables when loss was 25% to 50% in total.

**2. Binary**

In the case where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we presented data on a 'once-randomised-always-analyse' basis (an intention-to-treat analysis). Those leaving the study early were all assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death and adverse effects. For these outcomes we used the rate of those who stayed in the study - in that particular arm of the study - for those who did not. We undertook a sensitivity analysis testing how prone the primary outcomes were to change when data only from people who completed the study to that point were compared to the intention-to-treat analysis using the above assumptions.

**3. Continuous**

**3.1 Attrition**

In the case where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported, we reproduced these.

**3.2 Standard deviations**

If standard deviations (SDs) were not reported, we first tried to obtain the missing values from the study authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error and confidence intervals available for group means, and either P value or T value available for differences in mean, we calculated them according to the rules described in the *Cochrane Handbook for Systemic Reviews of Interventions*. When studies only reported the standard error (SE),

we calculated SDs by the formula  $SD = SE * \sqrt{n}$ . Chapters 7.7.3 (Higgins 2011a), and 16.1.3 (Higgins 2011b), of the *Cochrane Handbook for Systemic Reviews of Interventions* present detailed formulae for estimating SDs from P values, T or F values, confidence intervals, ranges or other statistics. If these formulae did not apply, we calculated the SDs according to a validated imputation method that is based on the SDs of the other included studies (Furukawa 2006). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study's outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values.

### 3.3 Assumptions about participants who left the studies early or were lost to follow-up

Various methods were available to account for participants who left the studies early or were lost to follow-up. Some studies just presented the results of study completers, others used the method of last observation carried forward (LOCF), while more recently, methods such as multiple imputation or mixed-effects models for repeated measurements (MMRM) have become more of a standard. While the latter methods seem somewhat better than LOCF (Leon 2006), we feel that the high percentage of participants leaving the studies early and differences in the reasons for leaving the studies early between groups is often the core problem in randomised schizophrenia studies. We therefore did not exclude studies based on the statistical approach used. However, we preferably used the more sophisticated approaches. For example, we preferred to use MMRM or multiple-imputation to LOCF and completer analyses only if some kind of ITT data were not available at all. Moreover, we addressed this issue in the item 'incomplete outcome data' of the 'Risk of bias' tool.

## Assessment of heterogeneity

### 1. Clinical heterogeneity

We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations that we had not predicted would arise and if such situations or participant groups arose, we fully discussed them.

### 2. Methodological heterogeneity

We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods that we had not predicted would arise and if such situations or participant groups arose, we fully discussed them.

### 3. Statistical heterogeneity

#### 3.1 Visual inspection

We visually inspected graphs to investigate the possibility of statistical heterogeneity.

#### 3.2 Employing the $I^2$ statistic

We investigated heterogeneity between studies by considering the  $I^2$  method alongside the  $\text{Chi}^2$  P value. The  $I^2$  statistic provides an estimate of the percentage of inconsistency thought to be due to chance (Higgins 2003). The importance of the observed value of the  $I^2$  statistic depends on i) the magnitude and direction of effects and ii) strength of evidence for heterogeneity (e.g. P

value from  $\text{Chi}^2$  test, or a confidence interval for  $I^2$  statistic). We interpreted an  $I^2$  statistic estimate greater than 50% accompanied by a statistically significant  $\text{Chi}^2$  statistic as evidence of substantial levels of heterogeneity (Deeks 2017). When we found substantial levels of heterogeneity in the primary outcome, we explored reasons for heterogeneity ([Subgroup analysis and investigation of heterogeneity](#)).

## Assessment of reporting biases

Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (Egger 1997). These are described in Section 10 of the *Cochrane Handbook for Systemic Reviews of Interventions* (Sterne 2017). We were aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar size. In cases where funnel plots were possible, we looked for statistical advice in their interpretation.

## Data synthesis

We understand that there is no closed argument for preference for use of fixed-effect or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random-effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random-effects model: it puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect these studies can either inflate or deflate the effect size. We chose to use random-effects or fixed-effect models for all analyses after the selection of studies.

## Subgroup analysis and investigation of heterogeneity

### 1. Subgroup analyses

#### 1.1 Primary outcomes

If data were available, then for primary outcomes we investigated whether continuous treatment over a longer period (> 6 months) was more effective than structured short-duration treatments of any kind.

#### 1.2 Clinical state, stage or problem

We proposed to undertake this review and provide an overview of the various interventions available for people in the prodromal stage of psychosis. In addition, however, we reported any available data on subgroups of people in the same clinical state, stage and with similar problems.

### 2. Investigation of heterogeneity

We reported if inconsistency was high. First we investigated whether data had been entered correctly. Second, if data were correct, we visually inspected the graph and successively removed studies from the analysis to see if homogeneity was restored. For this review we decided that when this occurred with data contributing to the summary finding of no more than 10% of the total weighting, we would present the data. If not, we did not pool data, but discussed these issues. We know of no supporting

research for this 10% cut-off but are investigating use of prediction intervals as an alternative to this unsatisfactory state.

When unanticipated clinical or methodological heterogeneity were obvious we simply stated hypotheses regarding these for future reviews or versions of this review. We did not undertake analyses relating to these.

## Sensitivity analysis

### 1. Implication of randomisation

We aimed to include studies in a sensitivity analysis if they were described in some way as to imply randomisation. We included these studies for the primary outcomes, and if their inclusion did not result in a substantive difference, they remained in the analyses. If their inclusion did result in significant differences, we did not add the data from these lower-quality studies to the results of the better studies, but presented such data within a subcategory.

### 2. Assumptions for lost binary data

Where assumptions had to be made regarding people lost to follow-up (see [Dealing with missing data](#)), we compared the findings of the primary outcomes when we used our assumption compared with completer data only. If there was a substantial difference, we reported results and discussed them but continued to employ our assumption.

Where assumptions had to be made regarding missing SD data (see [Dealing with missing data](#)), we compared the findings on primary outcomes when we used our assumption compared with completer data only. We undertook a sensitivity analysis testing how prone results were to change when 'completer' data only were compared to the imputed data using the above assumption. If there was a substantial difference, we reported results and discussed them but continued to employ our assumption.

### 3. Risk of bias

For primary outcomes, we analysed the effects of excluding studies that we judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available, allocation concealment, blinding and outcome reporting). If the exclusion of studies at high risk of bias did not substantially alter the direction of effect or the precision of the

effect estimates, then we included relevant data from these studies in the analysis.

### 4. Imputed values

We also undertook a sensitivity analysis to assess the effects of including data from studies where we used imputed values for ICC in calculating the design effect in cluster-randomised studies.

If we noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded studies with the other studies contributing to the outcome, but presented them separately.

### 5. Fixed and random effects

If we synthesised data using a fixed-effect model, we also synthesised data for the primary outcome using a random-effects model to evaluate whether this alters the significance of the results. If we synthesised data using a random-effects model we also synthesised data for the primary outcome using a fixed-effect model to evaluate whether this alters the significance of the results.

## RESULTS


### Description of studies

For substantive descriptions of studies, please see [Characteristics of included studies](#); [Characteristics of excluded studies](#); [Characteristics of ongoing studies](#).

### Results of the search

The original search (8 June 2016) identified 4852 abstracts to be screened. In addition, after screening the references of the studies, we identified three additional potentially eligible studies. After screening, we identified 70 potentially eligible unique studies, which were reported in 337 manuscripts ([Figure 3](#)). Out of these 70, 19 were finished studies that met our inclusion criteria. [RAP-USA](#) and [NEURAPRO-Q-Australia](#) also met the inclusion criteria, but these studies terminated early in the recruitment phase so we excluded them from the analysis. Overall, we excluded 51 studies from the analysis (25 that did not meet the inclusion criteria, two that met the inclusion criteria but were terminated early, 16 that we classified as ongoing studies and eight that we classified as awaiting assessment due to insufficient data).

**Figure 3. Study flow diagram**





The update search (4 August 2017), found a further 84 new references. Among them, there were 37 potentially eligible manuscripts; some of which described studies that we had already found in the initial search. Out of these, we identified three potentially eligible unique studies; of those three studies, we were able to include one additional study ([Piskulic-Canada](#)). Two other studies met the inclusion criteria but we did not include them as one was terminated ([Heresco-Levy-Israel](#)), and one was ongoing ([NCT02047539](#)). One study, that we had previously categorised as awaiting assessment, we excluded after publication of the results.

Therefore, in total, we analysed 73 unique studies (reported in 374 manuscripts), of which we included 20 studies; we excluded 29 studies because they did not meet the inclusion criteria or were terminated early, 17 were still ongoing and seven are currently awaiting classification (three of which published data that are not usable for analysis and four of which require further clarification).

For substantive descriptions of studies, please see the [Characteristics of included studies](#), [Characteristics of ongoing studies](#), [Characteristics of studies awaiting classification](#) and [Characteristics of excluded studies](#).

## Included studies

We included 20 studies with 2016 participants ([ADAPT-Canada](#); [Amminger-Austria](#); [Choi-USA](#); [DEPTH-Australia](#); [EDIE-2-UK](#); [EDIE-NL](#); [EDIE-UK](#); [EDIP-USA](#); [EIPS-Germany](#); [Kantrowitz-USA](#); [LIPS-Germany](#); [Miklowitz-USA](#); [NEURAPRO-AAE](#); [Nordentoft-Denmark](#); [PACE-Australia](#); [Piskulic-Canada](#); [PRIME-USA](#); [Vinogradov-USA](#); [Woods-1-USA](#); [Yung-Australia](#)).

### 1. Methods

All the included studies stated that they were randomised. For further description of study methods, please see [Characteristics of included studies](#) and [Risk of bias in included studies](#).

### 2. Participants and setting

#### 2.1 Within the cognitive behavioural therapy (CBT) and supportive therapy versus supportive therapy alone comparison

There are five included studies ([ADAPT-Canada](#); [EDIE-UK](#); [EDIE-2-UK](#); [EDIE-NL](#); [EIPS-Germany](#)). These studies included participants between the ages of 14 and 36 years old (mean ages ranged from 20.6 to 26). The studies were conducted in different locations around the world: [ADAPT-Canada](#) was conducted in Toronto, Canada; [EDIE-UK](#) and [EDIE-2-UK](#) were conducted in multiple locations in the UK; [EDIE-NL](#) in The Hague, Rivierduinen and Friesland, Netherlands; and lastly, [EIPS-Germany](#) in Cologne, Bonn, Dusseldorf, and Munich. The method of recruitment varied. [ADAPT-Canada](#) recruited participants via advertisement on radio, public transit and local newspaper. [EDIE-UK](#) recruited participants from community settings. The participants from [EIPS-Germany](#) and [EDIE-2-UK](#) were help-seeking. Different assessment criteria were used, ranging from Criteria of Prodromal States (COPS) in [ADAPT-Canada](#), CAARMS criteria ([Yung 2005](#)), in [EDIE-2-UK](#) and [EDIE-NL](#), adapted criteria ([Yung 1998](#)), in [EDIE-UK](#) and criteria for the Early Initial Prodrome State in [EIPS-Germany](#).

#### 2.2 Within the CBT versus different pharmacological or other interventions comparison

There are three included studies ([DEPTH-Australia](#); [PACE-Australia](#); [Yung-Australia](#)). These studies were conducted in Australia, apart

from [DEPTH-Australia](#), which also included participants from Newcastle, UK. The age of participants was between 14 to 30 years, and they were recruited from clinical settings. All of these studies defined UHR using CAARMS criteria ([Yung 2005](#)).

#### 2.3 Within the cognitive training versus active control group comparison

There are three included studies ([Choi-USA](#); [Piskulic-Canada](#); [Vinogradov-USA](#)). Ages of participants from these studies ranged between 12 to 35 years, and were recruited from North America (USA or Canada). All three studies made diagnosis using SIPS criteria. [Choi-USA](#) and [Piskulic-Canada](#) recruited participants who had been enrolled in other related research and [Vinogradov-USA](#) recruited participants from community settings.

#### 2.4 Within the family treatment versus enhanced treatment comparison

There are two included studies: ([EDIP-USA](#); [Miklowitz-USA](#)). [EDIP-USA](#) took place in Portland, USA and [Miklowitz-USA](#) undertook research in multiple states in the USA and Canada. Participants were aged between 12 to 35 years, and SIPS criteria was used to define CHR. Both studies recruited participants who had been enrolled in previous related studies.

#### 2.5 Within the integrated treatment versus standard treatment comparison

There is one study included in this comparison. [Nordentoft-Denmark](#) was conducted in inpatient and outpatient mental health services in Copenhagen and Aarhus County, Denmark. Participants met criteria for schizotypal disorder (ICD-10) and had a mean age of 24.9 years.

#### 2.6 Within the antipsychotic drugs comparison

There are two included studies ([LIPS-Germany](#); [PRIME-USA](#)). [LIPS-Germany](#) recruited participants in community settings in Cologne, Bonn, Dusseldorf and Munich, whilst [PRIME-USA](#) recruited treatment-seeking patients in an outpatient setting in New Haven and North Carolina (USA) and Calgary and Toronto (Canada). The age range of participants was 18 to 36 years for [LIPS-Germany](#) and 12 to 45 years for [PRIME-USA](#). The participants for [LIPS-Germany](#) fulfilled the Basic Symptom criteria for either the Early Initial Prodrome State or Late Initial Prodrome State. The participants for [PRIME-USA](#) fulfilled SIPS criteria.

#### 2.7 Within the different nutritives/supplements versus alternative medication comparison

There are four included studies ([Amminger-Austria](#); [Kantrowitz-USA](#); [NEURAPRO-AAE](#); [Woods-1-USA](#)). [Amminger-Austria](#) took place in Vienna, Austria; [Kantrowitz-USA](#) and [Woods-1-USA](#) took place in the USA; and [NEURAPRO-AAE](#) is a multicentre study that took place in Australia, Switzerland, Denmark, Austria, Hong Kong, Singapore, Germany and the Netherlands. Participants were aged between 13 to 40 years. [Amminger-Austria](#) used Yung's criteria for the 'ultra high risk' mental state. [Kantrowitz-USA](#) and [Woods-1-USA](#) used the SOPS criteria, whilst [NEURAPRO-AAE](#) included participants who met the criteria for "at risk" groups, as measured by Trait and State Risk Factor, Attenuated Psychotic Symptoms (APS) or Brief Limited Intermittent Psychotic Symptoms (BLIPS).

### 3. Study size

The size of studies ranged from eight participants to 304 participants.

Study	Number
<a href="#">NEURAPRO-AAE</a>	304
<a href="#">EDIE-2-UK</a>	288
<a href="#">EDIE-NL</a>	201
<a href="#">Yung-Australia</a>	115
<a href="#">EIPS-Germany</a>	128
<a href="#">Miklowitz-USA</a>	102
<a href="#">LIPS-Germany</a>	102
<a href="#">EDIP-USA</a>	100
<a href="#">Vinogradov-USA</a>	83
<a href="#">Amminger-Austria</a>	81
<a href="#">Nordentoft-Denmark</a>	79
<a href="#">Choi-USA</a>	62
<a href="#">PACE-Australia</a>	59
<a href="#">EDIE-UK</a>	60
<a href="#">PRIME-USA</a>	60
<a href="#">DEPTH-Australia</a>	57
<a href="#">ADAPT-Canada</a>	51
<a href="#">Kantrowitz-USA</a>	44
<a href="#">Piskulic-Canada</a>	32
<a href="#">Woods-1-USA</a>	8

### 4. Length of studies

The length of intervention ranged from eight weeks to 24 months. The overall length of the studies (including intervention and follow-up) ranged from three months to 84 months. Three studies were specific as they had additional follow-up longer than it was planned

in their protocols. These were [Amminger-Austria](#) (1 year according to the protocol, but 7 years with the additional follow-up), [EDIE-NL](#) (1.5 years planned, but 4 years with the additional follow-up) and [PACE-Australia](#) (1 year planned, but 4 years with additional follow-up).

Study	Months
-------	--------

LIPS-Germany	3
Kantrowitz-USA	4
Choi-USA	4
Woods-1-USA	5.5
Piskulic-Canada	9
	<b>Years</b>
ADAPT-Canada; DEPTH-Australia	1.5
EDIE-2-UK; EDIP-USA; Miklowitz-USA; NEURAPRO-AAE; Nordentoft-Denmark; PRIME-USA; Vinogradov-USA; Yung-Australia	2
EDIE-UK; EIPS-Germany	3
EDIE-NL; PACE-Australia	4
Amminger-Austria	7

## 5. Interventions

Within this review, we aim to summarise best evidence of the effects of a series of treatments for people with prodromal illness. In doing so it was always likely that we would identify several treatments that have been used for these people but we did not pre-state within our protocol groupings for the treatments. In order to make presentation of the results and discussion less of a list and more of a logical categorisation we have grouped treatments into three.

The first group (A) is where researchers seem to have been investigating the absolute effects of the experimental intervention, comparing these treatments with – essentially – placebo. The two comparisons in question happened within the context of ongoing standard care but we could see no reason why meaningful interaction with the standard care would occur.

The second group (B) is a series of five comparisons where the experimental treatment is either a package of care or is given as an adjunct to a form of care that is not standard and even where the underlying treatment is thought of as a relatively simple approach. Differential interaction could have happened enhancing the effects of, for example, CBT or undermining its effects. Such interaction was not discussed in the papers so does not leave us reassured – hence this second grouping.

The final group (C) is a series of six comparisons where differential effects seem to be being explored. These comparisons are comparing two different approaches.

### 5.1 Group A: absolute effects

#### 5.1.1 Different nutrients/supplements versus alternative medication

Four studies assessed effectiveness of different nutrients/supplements and alternative medication. Two of them involved amino-acids, D-serine ([Kantrowitz-USA](#)), and glycine ([Woods-1-](#)

[USA](#)), and the other two involved omega-3 fatty acids ([Amminger-Austria](#); [NEURAPRO-AAE](#)).

#### a. Different nutrients/supplements

[Kantrowitz-USA](#) assessed effects of orally administered D-serine on negative symptoms in participants at high risk for developing psychosis according to SOPS criteria.

The intervention arm of [Woods-1-USA](#) received glycine. The doses were 0.2 g/kg during the first seven days, followed by 0.4 g/kg until the end of the study.

Participants in [Amminger-Austria](#) received omega-3 fatty acids (daily dose of capsules containing 700 mg of eicosapentaenoic acid and 500 mg of docosahexaenoic acid) as an active intervention. These were offered over a period of three months.

The active intervention for [NEURAPRO-AAE](#) was combined omega-3 fatty acids (2.8 g of marine fish oil containing approximately 1.4 g eicosapentaenoic acid/docosahexaenoic acid in 4 x 0.700 g capsules daily with cognitive behavioural case management (sessions of 30 to 60 minutes' duration). Omega-3 fatty acids and up to 20 sessions of cognitive behavioural case management were administered over the first six months. During the follow-up period, further sessions of case management were available on a needs-basis for up to 12 months from study entry.

#### b. Alternative medication

[Kantrowitz-USA](#) gave matched placebo to the control group. Some of the participants continued taking medication that had been prescribed to them prior to the study (antidepressants, anxiolytics), but the majority (over 60%) did not receive any other psychotropic medication.

The control group in [Woods-1-USA](#) received placebo. After 12 weeks, all participants from both groups could choose to use open-label glycine for another 12 weeks.

Control participants in [Amminger-Austria](#) received placebo (coconut oil capsules). Antipsychotic medication and mood stabilisers were not permitted, but participants could receive antidepressants for moderate to severe levels of depression (MADRS score of 21) and benzodiazepines for any one or a combination of anxiety, agitation or insomnia. Also, all participants were offered nine sessions of needs-based psychological and psychosocial interventions with the research follow-up interviews.

[NEURAPRO-AAE](#) provided control group participants with placebo capsules (paraffin/coconut oil, tocopherols, a small amount of fish oil) with cognitive behavioural case management in the same amount as in the intervention group. During the first 12 months of the study, antidepressants (selective serotonin reuptake inhibitors (SSRI)) were allowed for moderate to severe depression (MADRS score 21 or above for at least two consecutive weeks; [Montgomery 1979](#)) and benzodiazepines for anxiety. Antipsychotics and mood stabilisers were not allowed during the study period (unless the participant was withdrawn).

## 5.2 Group B: comparisons in which interaction is probable

### 5.2.1 Antipsychotic drugs

Two included studies assessed efficacy of antipsychotics, alone or in combination with another type of treatment: amisulpiride ([LIPS-Germany](#)), and olanzapine ([PRIME-USA](#)).

[LIPS-Germany](#) used needs-focused intervention (NFI) with amisulpiride (mean dose 118 mg/day) in the intervention group and NFI only in the control group for prevention of psychosis in the late initial prodromas state that is defined by the presence of attenuated positive symptoms or brief limited intermittent positive symptoms, or both, within the three months preceding the study using Early Recognition Inventory (ERIRAOS) questionnaire ([Maurer 2004](#)). NFI included psychoeducation, crisis intervention, family counselling and assistance with education or work-related difficulties, according to participants' needs.

The Prevention through Risk Identification Management and Education study ([PRIME-USA](#)) compared olanzapine (5 mg/day to 15 mg/day, mean 8 mg/day) with placebo. During the one-year treatment period, individual and family psychosocial interventions were available for both groups. In case of agitation or insomnia, or both, lorazepam (max 8 mg/day), diazepam (max 40 mg/day) and chloral hydrate (max 100 mg/day) were allowed. Benzotropine mesylate or biperiden (max 6 mg/day) were used to treat extrapyramidal symptoms and nizatidine (300 mg/day to 600 mg/day) for weight gain. Antidepressants were allowed at the time of admission (with a tendency to cut them off), but once a patient was randomised, the initiation of antidepressants was not allowed.

### 5.2.2 Cognitive behavioural therapy (CBT)

#### a. CBT plus supportive therapy versus supportive therapy alone

Five included studies are relevant ([ADAPT-Canada](#); [EDIE-2-UK](#); [EDIE-NL](#) [EDIE-UK](#); [EIPS-Germany](#)).

##### i. Cognitive behavioural therapy (CBT)

CBT sessions were manualised and time limited, ranging from 20 sessions ([ADAPT-Canada](#)), to 30 sessions ([EIPS-Germany](#)). The sessions were individual therapy sessions. The CBT sessions focused on a combination of psychoeducation, symptom, stress and crisis management, as well as any anxiety, depression, family or occupational problems.

##### ii. Supportive therapy

Supportive therapy varied between studies. [ADAPT-Canada](#) provided active supportive psychological therapy during the six-month treatment period. [EIPS-Germany](#) also provided supportive counselling to control participants.

The control group in [EDIE-2-UK](#) had treatment as usual plus regular monitoring. This provided warm, empathic and non-judgemental face-to-face contact, supportive listening and signposting to appropriate local services for unmet needs and crisis management when required. [EDIE-NL](#) provided the control group with treatment as usual for the mental problems that they were seeking help for (e.g. depression, attention deficit hyperactivity disorder (ADHD) or anxiety disorder). [EDIE-UK](#) monitored the control group without any active psychological intervention. However participants were provided with elements of case management for resolving crises with social issues and mental health risk.

#### b. CBT plus risperidone versus CBT plus placebo

One study is relevant to this comparison ([Yung-Australia](#)).

##### i. Cognitive behavioural therapy (CBT)

CBT sessions were manualised and time limited. These sessions were tailored to meet the individual's needs, to help them to understand and cope with experienced symptoms, enhancing the control of them and reducing associated distress.

##### ii. Risperidone

The risperidone that was given with the CBT was at a low dose (0.5 mg/day to 2.0 mg/day).

#### c. CBT (specific preventive intervention) plus needs-based intervention versus needs-based intervention

[PACE-Australia](#) randomised patients into two groups: needs-based intervention (NBI) and specific preventive intervention (SPI).

##### i. Specific preventive intervention

SPI included manualised CBT and low doses of risperidone (mean dosage 1.3mg/day), along with all elements of NBI.

##### ii. Needs-based intervention

NBI comprised supportive psychotherapy primarily focusing on pertinent issues such as social relationships and vocational and family issues. Both groups received case management from a PACE (Playfulness, Acceptance, Curiosity and Empathy) therapist.

## 5.3 Group C: differential effects

### 5.3.1 Cognitive behavioural therapy (CBT)

#### a. CBT versus supportive therapy

One study is relevant to this comparison ([Yung-Australia](#)).

i. Cognitive behavioural therapy (CBT)

CBT sessions were manualised and time limited. These sessions were tailored to meet the individual's needs, to help them to understand and cope with experienced symptoms, enhancing the control of them and reducing associated distress.

ii. Supportive therapy

This therapy was delivered by the same psychologists who delivered the CBT. The aim of this was to provide the participant with emotional and social support, as well as basic problem solving, stress management, and psychoeducation.

*b. CBT plus supportive intervention versus non-directive reflective listening plus supportive intervention*

[DEPTH-Australia](#) compared CBT with non-directive reflective listening (NDRL).

i. Cognitive behavioural therapy (CBT)

CBT sessions were manualised and time limited. These sessions were tailored to meet the individual's needs, to help them to understand and cope with experienced symptoms, enhancing the control of them and reducing associated distress.

ii. Supportive therapy

This therapy was delivered by the same psychologists who delivered the CBT. The aim of this was to provide the participant with emotional and social support, as well as basic problem solving, stress management, and psychoeducation.

iii. Non-directive reflective listening

This is a form of person-centred counselling in which participants could discuss topics that they chose, while the therapist offered empathic reflections and positive regard. All participants were offered casework (help with accommodation, education and employment) and non-structured family intervention (brief education and support).

*c. CBT plus risperidone versus supportive therapy*

One study is relevant to this comparison ([Yung-Australia](#)).

i. Cognitive behavioural therapy (CBT)

CBT sessions were manualised and time limited. These sessions were tailored to meet the individual's needs, to help them to understand and cope with experienced symptoms, enhancing the control of them and reducing associated distress.

ii. Supportive therapy

This therapy was delivered by the same psychologists who delivered the CBT. The aim of this was to provide the participant with emotional and social support, as well as basic problem solving, stress management, and psychoeducation.

iii. Risperidone

The risperidone that was given with the CBT was at a low dose (0.5 mg/day to 2.0 mg/day).

**5.3.2 Cognitive training versus active control**

Three included studies compared cognitive training with active control ([Choi-USA](#); [Piskulic-Canada](#); [Vinogradov-USA](#)).

*a. Cognitive training*

[Choi-USA](#) used processing speed training (PST) as the intervention. PST is delivered on tablets and it consists of exercises centred on pupillometric cognitive load, working memory theory, and motivational psychology. During each PST session, participants worked in groups of two or three on tablets for approximately 30 hours over the course of two months (about 3.5 to 4.0 hours per week).

The participants in [Piskulic-Canada](#) took part in Posit Science Brain Fitness Training (PSBFT), a cognitive remediation therapy that involves auditory training exercises. This was delivered online, and activity was monitored via an online monitoring system.

The participants in the intervention group of [Vinogradov-USA](#) were enrolled in an Auditory Training Program (AT). AT consisted of computer exercises for improving speed and accuracy of auditory information processing that were continuously adjusted at adequate difficulty level, with rewards (points and animations) for correct studies. During each session, the participant had four of six exercises (15 minutes per exercise). Compliance was monitored by electronic data upload. Participants were asked to complete 20 to 40 hours of training.

*b. Active control*

The control group for [Choi-USA](#) participated in active control training (commercial tablet games) in the same dose and duration as the intervention participants.

The control group for [Piskulic-Canada](#) played commercial games (CG). The activity for this was monitored online.

The control group for [Vinogradov-USA](#) participated in a series of available games. During the study, participants received different types of treatment from therapists who were not involved in the study (psychoeducation, psychotherapy, pharmacotherapy if clinically indicated).

**5.3.3 Family treatment versus enhanced treatment**

Two included studies are relevant ([EDIP-USA](#) and [Miklowitz-USA](#)).

*a. Family treatment*

[EDIP-USA](#) used family-aided assertive community treatment (FACT) as the active intervention. FACT was a combination of multifamily psychoeducational group therapy, assertive community treatment, supported education/employment and psychotropic medication.

The active intervention for [Miklowitz-USA](#) was family-focused treatment (FFT). FFT was an 18-session training consisting of psychoeducation, communication enhancement, and problem-solving skills training over six months, focusing on skills for coping with symptoms and improving family communication and problem-solving.

### b. Enhanced treatment

Control participants in [EDIP-USA](#) received enhanced standard treatment (EST). This comprised psychotropic drugs, individual case management, family education and crisis intervention.

Control participants in [Miklowitz-USA](#) had three sessions of psychoeducational treatment for assisting participants and their families in coping with early signs of psychosis. Additional medication was allowed for both participant groups (antipsychotics, antidepressants, mood stabilisers, anxiolytics, psychostimulants).

#### 5.3.4 Integrated treatment versus standard treatment

There is one included study in this comparison ([Nordentoft-Denmark](#)).

#### a. Integrated treatment

This consisted of Assertive Community Treatment, social skills training (individual or group) and group psychoeducation for patients and their family members.

#### b. Standard treatment

Standard treatment was treatment as usual within standard mental health services in Copenhagen and Aarhus. Participants were usually offered treatment at a community mental health centre, and were in contact with a physician, community mental health nurse and in some cases a social worker. Visits usually took place once a month. In a small proportion of cases, the standard treatment included psychosocial interventions such as training in social skills or daily living activities, or supportive contacts with the family.

For description of adherence to treatment, see additional [Table 1](#).

## 6. Outcomes

### 6.1 Non-scale data

We were able to report dichotomous data on leaving the study early, transition to psychosis and adverse effects.

### 6.2 Scale-derived data

We have only shown details of the outcome scales that provided usable data below and we have given reasons for exclusions of data under 'Outcomes' in [Characteristics of included studies](#).

#### 6.2.1 Global state

##### a. Clinical Global Impression (CGI; [Guy 1976](#))

The CGI is a brief observer-rated scale consisting of Severity scale (CGI-S) and Improvement scale (CGI-I). Both CGI-S and CGI-I are seven-point scales rating the severity or improvement of the patient's illness at the time of assessment. Higher scores represent higher severity and worsening of the illness (1: normal or very much improved; 7: among the most severely ill or very much worse since the initiation of treatment). Scores range from 2 to 14. [PRIME-USA](#) reported data from this scale.

##### b. Personal Beliefs about Illness Questionnaire (PBIQ; [Birchwood 1993](#))

PBIQ is a 16-item scale originally developed to assess five constructs related to people's appraisals of their psychotic illness: control over illness, self as illness, illness as an impediment to the attainment of goals, humiliation and guilt, and need for social containment. Personal Beliefs about Illness Questionnaire - Revised (PBIQ-R; [Birchwood 2012](#)), is a 29-item scale, designed to measure five different categories of emotion/appraisal following a psychotic illness: shame (six items); loss (seven items); entrapment (six items); control over illness (five items), and social marginalisation/group fit (five items). The scale was designed to measure both stigma- and social rank-based variables. [EDIE-NL](#) reported data from this scale. An adapted version of PBIQ, Personal Beliefs about Experiences Questionnaire (PBEQ; [Pyle 2015](#)) is a 13-item, self-report questionnaire. Each item reflects social and cultural beliefs/stereotypes about psychosis. Participants rate the degree to which they endorse statements to be true about themselves on a four-point scale. [EDIE-2-UK](#) reported data from PBEQ (please see [Appendix 1](#)).

#### 6.2.2 Mental state

##### a. Brief Psychopathological Rating Scale (BPRS; [Overall 1962](#))

The BPRS is a scale used for assessment of positive symptoms, general psychopathology and affective symptoms. The original scale has 16 items, but a revised scale consisting of 18 items is commonly used. Each item is rated from 0 (not present) to 7 (extremely severe), with total scores ranging from 0 to 126 (higher scores meaning more severe symptoms). [PACE-Australia](#) and [Yung-Australia](#) reported data from this scale, while [NEURAPRO-AAE](#) reported data for psychotic subscale (please see [Appendix 1](#)).

##### b. Positive and Negative Symptom Scale (PANSS; [Kay 1987](#))

The PANSS is used for evaluation of positive, negative and other symptom dimensions in schizophrenia. The scale consists of 30 items divided into three subscales: positive (PANSS P), negative (PANSS N) and general (PANSS G) symptoms. Each item is rated on a seven-point scoring system, higher levels meaning more severity of symptoms. Scores range from 30 to 210. [Amminger-Austria](#), [EIPS-Germany](#), [LIPS-Germany](#) and [PRIME-USA](#) reported data from the PANSS.

##### c. Scale for the Assessment of Negative Symptoms (SANS; [Andreasen 1983](#))

SANS is an observer-rated, 26-item scale for measuring the severity of negative symptoms of schizophrenia across five domains (alogia, affective blunting, avolition-apathy, anhedonia-asociality, attention impairment). Items are rated on a six-point scale from 0 to 5, with higher scores indicating more severe symptoms. [NEURAPRO-AAE](#), [Nordentoft-Denmark](#), [PACE-Australia](#) and [Yung-Australia](#) reported data from this scale (please see [Appendix 1](#)).

##### d. Comprehensive Assessment of At-Risk Mental States (CAARMS; [Yung 2005](#))

This is a semi-structured interview designed to identify people who meet criteria for at-risk mental state. Rater assesses symptoms, frequency and distress under these categories: disorders of thought content; perceptual abnormalities; conceptual disorganisation; motor changes; concentration and attention; emotion and affect; subjectively impaired energy; and impaired tolerance to normal

stress. [DEPTh-Australia](#), [EDIE-2-UK](#) and [EDIE-NL](#) reported data for this scale (please see [Appendix 1](#)).

e. Scale of Psychotic Symptoms (SOPS; [Miller 1999](#))

The SOPS is a 19-item scale designed according to the PANSS scale to measure the severity of prodromal symptoms. It consists of five positive symptom items (unusual thought content/delusional ideas, suspiciousness/persecutory ideas, grandiosity, perceptual abnormalities/hallucinations, disorganised communication), six negative symptom items (social anhedonia, avolition, expression of emotion, experience of emotions and self, ideational richness, occupational functioning), four disorganizational symptoms items (odd behavior and appearance, bizarre thinking, trouble with focus and attention, personal hygiene) and four general symptom items (sleep disturbance, dysphoric mood, motor disturbances, impaired tolerance to normal stress). Each item is rated on a seven-point scale from 0 (never, absent) to 6 (severe/extreme - and psychotic for the positive items), total scores ranging from 0 to 114. [ADAPT-Canada](#), [PRIME-USA](#), [Vinogradov-USA](#) and [Woods-1-USA](#) reported data from SOPS, while [Miklowitz-USA](#) reported data for SOPS positive symptoms.

f. Hamilton Rating Scale for Anxiety (HRSA; [Hamilton 1959](#))

Hamilton Rating Scale for Anxiety (HRSA) is one of the first rating scales developed to quantify the severity of anxiety symptoms. HAMA consists of 14 items, each defined by a series of symptoms. The 14 items consist of: anxious mood; tension; fears; insomnia; intellectual; depressed mood; somatic complaints (muscular); somatic complaints (sensory); cardiovascular symptoms; respiratory symptoms; gastrointestinal symptoms; genitourinary symptoms; autonomic symptoms and behaviour at Interview. Each item is rated on a five-point scale, from 0 (not present) to 4 (severe). Total score range is between 0 and 56, with higher score indicating more severe symptoms. [PACE-Australia](#) reported data from this scale.

g. Hamilton Rating Scale for Depression (HRSD; [Hamilton 1960](#))

This is an observer-rated scale, designed to rate the severity of depression by probing mood, feelings of guilt, suicide ideation, insomnia, interest, agitation or retardation, anxiety (psychic and somatic), weight loss, somatic symptoms and insight. It consists of 17 variables measured on either a three-point or a five-point rating scale. A score of 0 to 7 is considered to be normal, higher scores indicate depression (mild, moderate, severe, very severe). [PACE-Australia](#) reported data from this scale.

h. Calgary Depression Scale for Schizophrenia (CDSS; [Addington 1990](#))

The CDSS is a nine-item scale (0 = absent; 1 = mild; 2 = moderate; 3 = severe) that was specifically developed for assessment of depression in people with schizophrenia, independent of the negative symptoms. It has been evaluated in both relapsed and remitted patients, and is provided as a semi-structured interview. High scores indicate worse outcome. [ADAPT-Canada](#) and [EDIE-NL](#) reported data from this scale.

i. Montgomery Asberg Depression Rating Scale (MADRS; [Montgomery 1979](#))

MADRS is a scale designed for assessment of depressive symptoms through 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts). Each item is rated on a seven-point scale from 0 to 6. Higher scores indicate more severe symptoms. Total scores range from 0 to 60, results from 0 to 6 are considered as normal/symptom absent. [Amminger-Austria](#), [EIPS-Germany](#), [LIPS-Germany](#), [NEURAPRO-AAE](#), [PRIME-USA](#) and [Woods-1-USA](#) used this scale.

j. Beck Depression Inventory (BDI; [Beck 1961](#))

This is a 21-item self-rating scale for assessment of presence and severity of depressive symptoms over the last week. Each item comprises four statements (rated 0 to 4). The score ranges from 0 to 63, higher scores meaning more severe depression. [Choi-USA](#) used a revised version of BDI, BDI-II ([Beck 1996](#)), while [EDIE-NL](#) used the Dutch translation of the Beck Depression Inventory second edition, BDI-II-NL ([Van der Does 2002](#)). A shorter version of BDI, BDI-PC ([Winter 1999](#)), is comprised of seven items that are related to depressive symptoms, each rated on a four-point scale (0 to 3). The BDI-PC is scored by adding the ratings for each item to produce a total score, with a range of 0 to 21. [EDIE-2-UK](#) reported data from this scale.

k. Young Mania Scale (YMS; [Young 1978](#))

YMS is an interviewer-rated, 11-item scale designed for assessment of symptoms of mania. Seven items are graded on a 0 to 4 scale, but four items are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behaviour). Higher scores indicate more severe manic symptoms. [NEURAPRO-AAE](#), [PACE-Australia](#) and [PRIME-USA](#) reported data from this scale.

l. Social Interaction and Anxiety Scale (SIAS; [Mattick 1998](#))

The SIAS is a 20-item questionnaire designed to measure levels of fear in social interaction situations. Each item is rated on a five-point Likert scale (0 to 5). Total scores range from 0 to 80, higher scores reflecting more severe social anxiety. [ADAPT-Canada](#), [EDIE-2-UK](#) and [EDIE-NL](#) reported data from this scale.

m. The Social Phobia Scale (SPS; [Mattick 1998](#))

The SPS is a 20-item questionnaire for assessment of fear of being observed or scrutinised by others during routine activities, e.g. eating, writing, speaking in public. Each item is rated from 0 to 4 (all items are negatively worded), total scores ranging from 0 to 80. [ADAPT-Canada](#) reported data from this scale.

n. The Social Anxiety Scale for Adolescents (SAS-A; [La Greca 1993](#))

SAS-A is a clinician-rated scale for assessing social function specific to the fear of negative evaluation by peers, social avoidance, and social response to new situations. It contains 18 items rated on a five-point scale ranging from 1 (not at all) to 5 (all the time), with total scores from 18 to 90 (higher scores indicating more anxiety and poorer relations). [Choi-USA](#) reported data from this scale.

o. The Brief Symptom Inventory (BSI; [Derogatis 1995](#))

The BSI is a psychological self-report symptom scale consisting of 53 items divided into nine primary symptom dimensions:

somatisation, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism. Each item of the BSI is rated on a five-point scale of distress (0 to 4), ranging from 'not-at-all' to 'extremely'. [DEPTH-Australia](#) reported data from this scale (please see [Appendix 1](#)).

p. The Scale for the Assessment of Positive Symptoms (SAPS; [Andreasen 1984](#))

The SAPS is a rating scale developed for the assessment of positive symptoms in schizophrenia. It consists of four domains: hallucinations; delusion; bizarre behaviour; and positive formal thought disorder. Within each domain, symptoms are rated from 0 (absent) to 5 (severe). [Nordentoft-Denmark](#) reported data from this scale (please see [Appendix 1](#)).

q. The Early Recognition Inventory (ERIRAOS; [Maurer 2004](#))

The ERIRAOS is a comprehensive early-recognition inventory developed on an empirical basis as an extension of the Retrospective Assessment of the Onset and course of Schizophrenia and Other Psychoses (IRAOS; [Häfner 1992](#)). The psychopathological section comprises a symptom list with 110 items structured in 12 sections. Each item score ranges from 0 to 3. [LIPS-Germany](#) used the ERIRAOS. Basic and Positive Psychotic Spectrum Symptoms score (ERI-BAPPSS score) used to assess treatment effects, was formed of the 16 items related to full-blown psychotic symptoms (including disorganised thinking and behaviour), six items assessing attenuated positive symptoms and 10 items assessing a set of basic symptoms. Data were reported for two ERI-BAPPSS subscores, ERI-PPS score (the attenuated and full-blown psychotic positive symptoms) and ERI-BS (the basic symptoms) (please see [Appendix 1](#)).

r. Cognitive tests

[Woods-1-USA](#) used various tests for neuropsychological assessment of processing speed, verbal memory, executive functioning, semantic (category) fluency, phonemic fluency, attention and working memory. Data were reported for the following tests: Trails B ([Reitan 1985](#)), Stroop Color Word Test ([Golden 1978](#)), Auditory Verbal Learning Task (AVLT; [Rey 1964](#)), Wisconsin Card Sort Test (WCS; [Heaton 1993](#)), semantic (category) fluency ([Spreeen 1998](#)), Controlled Oral Word Association (FAS) Test of phonemic fluency ([Spreeen 1969](#)), Letter-number sequencing ([Gold 1997](#)) and Trails A ([Reitan 1985](#)).

[Piskulic-Canada](#) used modified battery of MATRICS measures ([Neuchterlein 2008](#)), consisting of nine subtests for measuring neurocognitive functioning in the following domains: processing speed; attention/vigilance; working memory; verbal learning; visual learning; and reasoning and problem solving.

[Choi-USA](#) used neurocognitive tests for assessment of processing speed (Wechsler Adult Intelligence Scale-Third Edition (WAIS-III) Digit Symbol-Coding subtest ([Wechsler 1999](#)), and The Minnesota Clerical Test (MCT; [Andrew 1979](#)).

### 6.2.3 Functioning

a. Global Assessment of Functioning (GAF; [APA 1994](#))

This is an observer-rated scale for measuring social, occupational and psychological functioning (impairment). Scores range from 100

(extremely high functioning) to 1 (inadequate information). [ADAPT-Canada](#), [Amminger-Austria](#), [DEPTH-Australia](#), [EDIE-2-UK](#), [EDIP-USA](#), [LIPS-Germany](#), [Miklowitz-USA](#), [PACE-Australia](#), [PRIME-USA](#) and [Yung-Australia](#) reported data from this scale.

b. The Global Functioning: Social and Role scales ([Cornblatt 2007b](#))

The Global Functioning: Social (GFS) and Global Functioning: Role (GFR) scales were designed to distinguish social from role functioning and to detect functional changes over time, taking account the age and the phase of illness. Each scale consists of 10 items, with scores ranging between 1 (severe dysfunction) and 10 (superior functioning). Also, both scales generate three scores: lowest level of functioning in the past month (i.e. current functioning), and lowest and highest level of functioning reported over the past year. [Miklowitz-USA](#), [NEURAPRO-AAE](#), [Piskulic-Canada](#) and [Vinogradov-USA](#) reported data from these scales.

c. Social Functioning Scale-II (SAS-II; [Schooler 1979](#))

The SAS-II is an interviewer-rated scale containing 52 questions for assessment of current functioning: work role; relationship with a "principal household member"; sexual adjustment; romantic involvement; parental role; extended family relationships; social leisure activities; and personal well-being. Each item is rated from 1 to 5, with higher scores indicating worse functioning. [EIPS-Germany](#) reported data from this scale (for subscores, please see [Appendix 1](#)).

d. Social Functioning Scale-Self report (SAS-SR; [Weissman 1976](#))

SAS-SR is self-administered version of the Social Adjustment Scale (SAS; [Weissman 1976](#)), commonly used to assess social adjustment in children and adolescents. It contains 54 items that measure performance in occupational role, social and leisure activities, relationship with extended family, marital role, parental role, family unit, and economic independence. The form is scored on a five-point scale, higher scores indicating greater impairment. [Choi-USA](#) reported data from this scale.

e. Social and Occupational Functioning Assessment Scale (SOFAS; [Goldman 1992](#))

The SOFAS is an instrument for assessment of social or occupational functioning, or both, independent of the overall severity of the illness. To be counted, impairment must be a direct consequence of mental and physical health problems. The rating scores range from 0 (inadequate information) to 100 (superior functioning). [DEPTH-Australia](#), [EDIE-NL](#) and [NEURAPRO-AAE](#) reported data from this scale.

f. The Social Functioning Scale (SFS; [Birchwood 1990](#)).

Social Functioning Scale, SFS is a 79-item questionnaire, developed for assessing functioning and performance in seven areas: social engagement/withdrawal (time spent alone, initiation of conversations, social avoidance); interpersonal communication (number of friends, heterosexual contact, quality of communication); recreational activities (engagement in a range of common social activities, e.g. sport); social activities (engagement in a range of common hobbies, interests, pastimes etc.); independence competence (ability to perform skills necessary for independent living); independence performance (performance of skills necessary for independent living); and occupational



activity (engagement in productive employment or structured programme of daily activity). Total score ranges between 55 and 145 points, with higher scores indicating better functioning. [ADAPT-Canada](#) reported data from this scale.

#### 6.2.4 Adverse effects

##### a. Simpson Angus Scale (SAS; [Simpson 1970](#))

The SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal side effects. The items are gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor and salivation. The 10 items focus on rigidity rather than bradykinesia and do not assess subjective rigidity or slowness. Each item is rated on a five-point scale, from 0 (complete absence of condition) to 4 (presence of condition in extreme), higher scores indicating higher levels of side effects. [PRIME-USA](#) reported data from this scale.

##### b. Barnes Akathisia Rating Scale (BAS; [Barnes 1989](#))

BAS is a four-item scale to assess the presence and severity of drug-induced movement disorder akathisia. Items include restless movements, the subjective awareness of restlessness, distress associated with the condition, and the global severity. Three items are rated on a four-point scale and one on a six-point scale, higher scores meaning more severe-level akathisia. [PRIME-USA](#) reported data from this scale.

##### c. Abnormal Involuntary Movement Scale (AIMS; [Guy 1976b](#))

AIMS is a scale designed to assess abnormal involuntary movements associated with antipsychotic drugs, such as tardive dyskinesia and chronic akathisia, as well as 'spontaneous' motor disturbance related to the illness itself. Scoring consists of rating movement severity in the anatomical areas (facial/oral, extremities, trunk). Each item is rated on a five-point scale from 0 to 4, with higher scores indicating higher levels of abnormal movements. [PRIME-USA](#) reported data from this scale.

##### d. Extrapyramidal Symptom Rating Scale (ESRS; [Chouinard 1980](#))

The ESRS consists of four subscales (subjective examination questionnaire, examination of parkinsonism and akathisia, dystonia, dyskinesia) and four clinical global impression severity scales (tardive dyskinesia, parkinsonism, dystonia and akathisia). The subjective examination (subscale I of the ESRS) is rated on a four-point scale (higher scores meaning more severe symptoms). Tremors, rigidity dystonic and dyskinetic movements are rated for each body part as separate terms on a seven-point scale from 0 (absent) to 6 (most severe). [LIPS-Germany](#) reported data from this scale.

##### e. Side Effect Rating Scale (UKU; [Lingjærde 1987](#))

UKU is an observer-rated, semi-structured interview for assessment of side effects divided into four categories: psychic, neurologic, autonomic and other. Each of the 48 items is rated on a four-point scale, from 0 to 3, a higher score meaning more severe side effects. UKU takes into account global assessment of the interference by existing side effects with the patient's daily performance and the consequence of it, as well as possible interactions with

administered drugs. [Amminger-Austria](#), [LIPS-Germany](#) and [Yung-Australia](#) reported data from this scale.

##### f. Systematic Assessment For Treatment Emergent Adverse Events (SAFTEE; [Levine 1986](#))

The SAFTEE is designed for assessment of safety and adverse effects. The SAFTEE has two forms, a General Inquiry (GI) and a Specific Inquiry (SI) form. GI is an open-ended form about any physical or health problems and their impact on functioning. SI is a detailed and systematic inquiry including 78 adverse effects divided into 23 categories corresponding to organ systems or body parts. [Woods-1-USA](#) reported data using SAFTEE.

#### 6.2.5. Quality of life

##### a. Quality of Life Scale; (QLS; [Heinrichs 1984](#))

QLS is a semi-structured interview administered and rated by trained clinicians. The 21 items are rated on a seven-point scale based on the interviewer's judgement of patient functioning. Higher scores indicate better quality of life. Scores range from 0 to 126. [DEPTH-Australia](#), [PACE-Australia](#) and [Yung-Australia](#) reported data from this scale (please also see [Appendix 1](#)).

##### b. Manchester Short Assessment of Quality of Life; (MANSA; [Priebe 1999](#))

MANSA is a brief instrument for assessing quality of life focusing on satisfaction with life as a whole and with life domains. This self-report questionnaire contains 16 items, which are rated on a seven-point scale, higher scores meaning better quality of life. Scores range from 16 to 112. [EDIE-NL](#) reported data from this questionnaire.

#### 6.3 Redundant data

Some studies reported data only as P values or statements of significant or non-significant differences, and we could not extract other continuous data because the number of participants was missing or they had not reported standard deviations.

#### 6.4. Missing data

Ten of the included studies had missing outcomes that they had planned in the registered protocol or indicated in the methods section of the manuscript. These were: [ADAPT-Canada](#) (part of the mental state and physical questionnaires/scales, cost-effectiveness report); [Choi-USA](#) (2 specific cognitive tests); [EDIE-2-UK](#) (part of the mental state questionnaires/scales, cost-effectiveness report); [EDIE-NL](#) (a questionnaire for quality of life and cognitive test for verbal fluency); [EDIP-USA](#) (transition to psychosis after 60 months); [LIPS-Germany](#) (part of the mental state/functioning/adverse events questionnaire/scales); [Miklowitz-USA](#) (mental scale score after one year); [Nordentoft-Denmark](#) (treatment satisfaction/compliance/adherence and suicidal behaviour); [PRIME-USA](#) (quality of life questionnaire); and [Woods-1-USA](#) (multiple outcomes reported for only one participant). We did not find missing outcomes for other studies.

#### Excluded studies

There are currently 29 excluded studies. We have summarized the reasons for excluding the studies in the following table:

Totals	Randomisation	Reasons	Totals	Studies
29	Randomised	Not UHR sample	17	Berry-USA, Biagianni-USA, Capra-Australia, CHANGSHA-USA, Chien-Hong Kong, Cordes-Germany, Holzer-Switzerland, Koren-Israel, LEGS-USA, LEO CAT-UK, LEO-UK, Leweke-Germany, OPUS-Denmark, RAISE-ETP-USA, Ramsay-USA, Schmechtig-USA, Uher-Canada
		Terminated early	4	Heresco-Levy-Israel, NEURAPRO-Q-Australia, Piskulic-2-Canada, RAP-USA
		Different outcomes	1	O'Neill-UK
	Not randomised		7	Berger-Australia, EDIPP-USA, EPIP-Singapore, Keri-Hungary, Lewis-USA, Woods-2-USA, Vadhan-USA

Reasons for exclusion of each study are described in [Characteristics of excluded studies](#) tables.

### Awaiting classification

Seven studies are awaiting assessment (see descriptions in [Characteristics of studies awaiting classification](#) table). For three of them published data are not usable for analysis and the other four require further clarification. Ultimately, we will exclude studies where data are unobtainable.

### Ongoing studies

We are awaiting data from 17 studies (see descriptions in [Characteristics of ongoing studies](#) table). This is an active area for research.

### Risk of bias in included studies

Overview of risk of bias in included studies is illustrated in [Figure 1](#) and across different domains of risk of bias in [Figure 2](#).

### Allocation

The authors of all 20 included studies described them as randomised. Eight studies adequately described the process of generating a random sequence using a computer or web-based resources ([Amminger-Austria](#); [DEPTH-Australia](#); [EDIE-2-UK](#); [EDIE-NL](#); [EIPS-Germany](#); [NEURAPRO-AAE](#); [Nordentoft-Denmark](#)), or minimisation ([ADAPT-Canada](#)), so we judged it at low risk of bias. In other studies method for generating random sequence was not described, so we judged them at unclear risk of bias.

Allocation concealment was adequately described in only one study ([Kantrowitz-USA](#)), so we judged it at low risk of bias. In the remaining studies allocation concealment was either not described or only briefly commented on and we were unable to determine in these instances if concealment was adequate, so we judged them at unclear risk of bias.

### Blinding

Eight studies used the double-blind design, blinding both participants and clinicians ([Amminger-Austria](#); [Choi-USA](#); [Kantrowitz-USA](#); [NEURAPRO-AAE](#); [PRIME-USA](#); [Vinogradov-USA](#);

[Woods-1-USA](#); [Yung-Australia](#)), so we judged them at low risk of bias.

Nine studies blinded clinicians, but not participants ([ADAPT-Canada](#); [DEPTH-Australia](#); [EDIE-2-UK](#); [EDIE-NL](#); [EDIE-UK](#) (intended to be blind, but it was difficult in practice) [EDIP-USA](#); [Miklowitz-USA](#); [PACE-Australia](#); [Piskulic-Canada](#)). Two studies did not blind either participants or clinicians ([LIPS-Germany](#); [Nordentoft-Denmark](#)). One study did not provide information about blinding of participants and personnel in the manuscript ([EIPS-Germany](#)), but in the study protocol published online it was indicated that there was no masking, that the study was open-label. We judged all of these studies at high risk of bias.

In eleven studies, raters or attending psychiatrists were blind to the outcome assessments ([ADAPT-Canada](#); [Amminger-Austria](#); [Choi-USA](#); [DEPTH-Australia](#); [EDIE-NL](#); [EDIP-USA](#); [NEURAPRO-AAE](#); [Piskulic-Canada](#); [PRIME-USA](#); [Vinogradov-USA](#); [Yung-Australia](#)), so we judged them at low risk of bias.

In six studies assessors were not kept blind to outcome assessments ([EDIE-UK](#) intended the raters to be blind, but it was difficult in practice; [EIPS-Germany](#); [LIPS-Germany](#); [Miklowitz-USA](#); [Nordentoft-Denmark](#); [PACE-Australia](#)), so we judged them at high risk of bias.

In two studies the process regarding blinding of outcome assessors was unclear ([Kantrowitz-USA](#); [Woods-1-USA](#)) and in one study blinding breaks were reported in a minority of participants ([EDIE-2-UK](#)), so we judged these three studies at unclear risk of bias.

### Incomplete outcome data

We judged six studies as having low risk of attrition bias because they had attrition under 30% and clearly reported reasons for attrition ([Amminger-Austria](#); [EDIE-NL](#); [Miklowitz-USA](#); [NEURAPRO-AAE](#); [PACE-Australia](#); [Woods-1-USA](#)). We judged eight studies as having unclear risk of attrition bias; two studies had attrition under 30%, but reasons for attrition were unclear ([Choi-USA](#); [Nordentoft-Denmark](#)), and the other six studies had attrition between 30% and 50% ([ADAPT-Canada](#); [EDIP-USA](#); [EIPS-Germany](#); [LIPS-Germany](#); [Vinogradov-USA](#); [Yung-Australia](#)). We judged six studies with high risk of attrition bias because the attrition was above 50% ([DEPTH-](#)

Australia; EDIE-2-UK; EDIE-UK; Kantrowitz-USA; Piskulic-Canada; PRIME-USA).

### Selective reporting

We found selective reporting in 10 studies, as they did not report in their results all the outcomes that were planned in the registered protocol, or indicated in the methods section of the manuscript if the study protocol registration was not mentioned ([ADAPT-Canada](#); [Choi-USA](#); [EDIE-2-UK](#); [EDIE-NL](#); [EDIP-USA](#); [LIPS-Germany](#); [Miklowitz-USA](#); [Nordentoft-Denmark](#); [PRIME-USA](#); [Woods-1-USA](#)); we judged them at unclear risk of bias. We did not identify overt under-reporting of outcomes in the other included studies so we judged them at low risk of bias, although we did not have access to study protocols to check whether they had recorded other data but not reported them in the final papers.

### Other potential sources of bias

We did not find other potential sources of bias in the included studies.

### Effects of interventions

See: [Summary of findings for the main comparison Group A: amino acids compared to placebo for prodromal stage of psychosis](#); [Summary of findings 2 Group A: omega-3 fatty acids compared to placebo for prodromal stage of psychosis](#); [Summary of findings 3 Group B antipsychotic drugs: amisulpiride + needs-focused intervention compared to needs-focused intervention for prodromal stage of psychosis](#); [Summary of findings 4 Group B antipsychotic drugs: olanzapine + supportive intervention compared to placebo + supportive intervention for prodromal stage of psychosis](#); [Summary of findings 5 Group B cognitive behavioural therapy: cognitive behavioural therapy + supportive therapy compared to supportive therapy for prodromal stage of psychosis](#); [Summary of findings 6 Group B cognitive behavioural therapy: cognitive behavioural therapy + risperidone compared to cognitive behavioural therapy + placebo for prodromal stage of psychosis](#); [Summary of findings 7 Group B cognitive behavioural therapy: cognitive behavioural therapy \(specific preventive intervention\) + needs-based intervention + risperidone compared to needs-based intervention for prodromal stage of psychosis](#); [Summary of findings 8 Group C cognitive behavioural therapy: cognitive behavioural therapy + placebo compared to supportive therapy + placebo for prodromal stage of psychosis](#); [Summary of findings 9 Group C cognitive behavioural therapy: cognitive behavioural therapy + supportive intervention compared to non-directive reflective listening + supportive intervention for prodromal stage of psychosis](#); [Summary of findings 10 Group C cognitive behavioural therapy: cognitive behavioural therapy + risperidone compared to supportive therapy + placebo for prodromal stage of psychosis](#); [Summary of findings 11 Group C other: cognitive training compared to active control \(tablet games\) for prodromal stage of psychosis](#); [Summary of findings 12 Group C other: family treatment compared to enhanced care for prodromal stage of psychosis](#); [Summary of findings 13 Group C other: integrated treatment compared to standard treatment for prodromal stage of psychosis](#)

For this review we generated 13 comparisons. In total there are 20 relevant randomised studies. As stated above in [Description of studies](#), we loosely categorised comparisons into three. Group A comparisons explored the absolute effects of the experimental

intervention. Group B was a series of comparisons (further subdivided into antipsychotic and CBT) within which we could not be clear whether differential interactive effects were also ongoing in each intervention group. For example it is not clear, for Comparison 5, whether the supportive therapy's effect is changed by being accompanied by the CBT. The combination may be interactive making this comparison more like those in Group C rather than Group A. Group C comparisons explore differential effects between clearly distinct treatments. Again we have subdivided these again into CBT treatments and several others.

### Group A: absolute effects

#### 1. Comparison: amino acids versus placebo

This comparison has 10 outcomes.

##### 1.1 Prodromal symptoms: transition to psychosis, end point data

We identified two studies relevant to this outcome, the data from which we divided into two subgroups, with a total of 52 participants. There was no clear difference between amino acids and placebo (RR 0.48, 95% CI 0.08 to 2.98; [Analysis 1.1](#)).

##### 1.1.1 Short-term (16 weeks, D-serine)

We found one study to be relevant to this subgroup (44 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.60, 95% CI 0.06 to 6.14; [Analysis 1.1](#)).

##### 1.1.2 Short-term (24 weeks, glycine)

We found one study to be relevant to this subgroup (8 participants). There was no clear difference between amino acids and placebo within this subgroup (RR 0.33, 95% CI 0.02 to 6.37; [Analysis 1.1](#)).

##### 1.2 Mental state 1 specific: psychosis risk symptoms, average total score, short-term (at 8 weeks), SOPS (higher score = worse)

We identified one study relevant to this outcome and categorised data into five subgroups.

##### 1.2.1 Total score

There is a single study in this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD -10.00, 95% CI -22.38 to 2.38; [Analysis 1.2](#)).

##### 1.2.2 Positive score

There is a single study in this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD -2.50, 95% CI -7.86 to 2.86; [Analysis 1.2](#)).

##### 1.2.3 Negative score

There is a single study in this subgroup (8 participants). There was no clear difference between amino acids and placebo within this subgroup (MD -1.80, 95% CI -4.88 to 1.28; [Analysis 1.2](#)).

##### 1.2.4 Disorganisation score

There is a single study in this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD 1.00, 95% CI -1.57 to 3.57; [Analysis 1.2](#)).

### 1.2.5 General score

We found one study relevant to this subgroup (8 participants). For this outcome, within this subgroup, we did find evidence that amino acids were clearly superior compared with placebo (MD -6.80, 95% CI -9.47 to -4.13; [Analysis 1.2](#)).

### 1.3 Mental state 2, specific: depression, average total score, short-term (at 8 weeks), MADRS (higher score = worse) skewed data

These continuous data, from a single study, had such large standard deviations as to suggest that analysis within [Review Manager 2014](#) would be inadvisable (please see [Analysis 1.3](#)).

### 1.4 Mental state 3.a, specific: cognitive symptoms, average total score, short-term (at 12 weeks), various tests (higher score = better)

For this outcome we found a single study and categorised data into five subgroups.

#### 1.4.1 Immediate verbal memory (AVLT immediate studies sum)

There is a single study in this subgroup (5 participants). There was no clear difference between amino acids and placebo within this subgroup (MD 6.50, 95% CI -2.15 to 15.15; [Analysis 1.4](#)).

#### 1.4.2 Delayed verbal memory (AVLT delay trial)

We found one study to be relevant to this subgroup (5 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD 0.50, 95% CI -1.17 to 2.17; [Analysis 1.4](#)).

#### 1.4.3 Executive functioning (semantic fluency test)

We found one study to be relevant to this subgroup (4 participants). There was no clear difference between amino acids and placebo within this subgroup (MD -0.50, 95% CI -10.53 to 9.53; [Analysis 1.4](#)).

#### 1.4.4 Executive functioning (phonemic fluency test)

We found one study to be relevant to this subgroup (4 participants). There was no clear difference between amino acids and placebo within this subgroup (MD -3.00, 95% CI -20.38 to 14.38; [Analysis 1.4](#)).

#### 1.4.5 Attention and working memory (letter-number sequencing)

There is a single study in this subgroup (5 participants). For this outcome, within this subgroup, we found evidence that amino acids were clearly superior in their effects compared with placebo (MD 4.50, 95% CI 2.04 to 6.96; [Analysis 1.4](#)).

### 1.5 Mental state 3.b, specific: cognitive symptoms, average total score, short-term (at 12 weeks), various tests (higher score = worse)

For this outcome we found a single study, the data from which we divided into six subgroups.

#### 1.5.1 Processing speed (Trails A)

There is a single study in this subgroup (4 participants). There was no clear difference between amino acids and placebo within this subgroup (MD 8.80, 95% CI -8.57 to 26.17; [Analysis 1.5](#)).

#### 1.5.2 Attention and working memory (Trails B)

There is a single study in this subgroup (4 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD -2.80, 95% CI -48.7 to 43.10; [Analysis 1.5](#)).

#### 1.5.3 Processing speed (Stroop Words)

There is a single study in this subgroup (4 participants). There was no clear difference between amino acids and placebo within this subgroup (MD -11.50, 95% CI -27.49 to 4.49; [Analysis 1.5](#)).

#### 1.5.4 Processing speed (Stroop Colors)

There is a single study in this subgroup (4 participants). There was no clear difference between amino acids and placebo within this subgroup (MD -6.60, 95% CI -17.45 to 4.25; [Analysis 1.5](#)).

#### 1.5.5 Processing speed (Stroop Color-Words)

There is a single study in this subgroup (4 participants). We found evidence of a clear difference between amino acids and placebo within this subgroup, in favour of amino acids (MD -6.00, 95% CI -9.50 to -2.50; [Analysis 1.5](#)).

#### 1.5.6 Executive functioning (WCS perseverative errors)

There is a single study in this subgroup (5 participants). For this outcome, within this subgroup, we found evidence that amino acids were clearly inferior in effect compared with placebo (MD 9.70, 95% CI 4.16 to 15.24; [Analysis 1.5](#)).

### 1.6 Adverse effects 1, specific: treatment-emergent adverse effects, short-term (by 8 weeks)

We identified one study relevant to this outcome and categorised data into eight subgroups.

#### 1.6.1 Psychological: irritability

There is a single study in this subgroup (8 participants). There was no clear difference between amino acids and placebo within this subgroup (RR 0.33, 95% CI 0.02 to 6.37; [Analysis 1.6](#)).

#### 1.6.2 Psychological: mentation impaired

There is a single study in this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.33, 95% CI 0.02 to 6.37; [Analysis 1.6](#)).

#### 1.6.3 Psychological: hallucinations

We found one study to be relevant to this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.33, 95% CI 0.02 to 6.37; [Analysis 1.6](#)).

#### 1.6.4 Arousal: sedation

We found one study to be relevant to this subgroup (8 participants). There was no clear difference between amino acids and placebo within this subgroup (RR 0.20, 95% CI 0.01 to 3.20; [Analysis 1.6](#)).

#### 1.6.5 Arousal: disturbed sleep

There is a single study in this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.20, 95% CI 0.01 to 3.20; [Analysis 1.6](#)).

#### 1.6.6 Arousal: malaise

We found one study to be relevant to this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.33, 95% CI 0.02 to 6.37; [Analysis 1.6](#)).

### 1.6.7 Sexual: orgasm dysfunction

There is a single study in this subgroup (8 participants). There was no clear difference between amino acids and placebo within this subgroup (RR 3.00, 95% CI 0.16 to 57.36; [Analysis 1.6](#)).

### 1.6.8 Gastrointestinal: stomach discomfort

We found one study to be relevant to this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.33, 95% CI 0.02 to 6.37; [Analysis 1.6](#)).

### 1.7 Adverse effects 2, specific: cardiovascular, average total score, short-term (by 8 weeks), blood pressure and pulse rate (higher score = worse)

We identified one study relevant to this outcome and categorised data into three subgroups.

#### 1.7.1 Systolic blood pressure

We found one study to be relevant to this subgroup (8 participants). There was no clear difference between amino acids and placebo within this subgroup (MD 6.00, 95% CI -8.70 to 20.70; [Analysis 1.7](#)).

#### 1.7.2 Diastolic blood pressure

We found one study to be relevant to this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD 2.00, 95% CI -12.03 to 16.03; [Analysis 1.7](#)).

#### 1.7.3 Pulse

We found one study to be relevant to this subgroup (8 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD -20.0, 95% CI -41.76 to 1.76; [Analysis 1.7](#)).

### 1.8 Adverse effects 3, specific: weight, average total score, short-term (by 8 weeks), weight gain (higher score = worse)

For this outcome we found a single study (8 participants). We found evidence of a clear difference between amino acids and placebo, in favour of amino acids (MD -0.67, 95% CI -2.13 to -0.79; [Analysis 1.8](#)).

### 1.9 Adverse effects 4, specific: suicidal thoughts, short-term (by 16 weeks)

For this outcome we found a single study (44 participants). There was no clear difference between amino acids and placebo (RR 3.57, 95% CI 0.15 to 83.14; [Analysis 1.9](#)).

### 1.10 Satisfaction with treatment: leaving the study early, end point data

For this outcome we found two relevant studies and categorised data into two subgroups (total 52 participants). There was no clear difference between amino acids and placebo (RR 0.96, 95% CI 0.55 to 1.69; [Analysis 1.10](#)).

#### 1.10.1 Short-term (16 weeks, D-serine)

There is a single study in this subgroup (44 participants). There was no clear difference between amino acids and placebo within this subgroup (RR 0.92, 95% CI 0.52 to 1.64; [Analysis 1.10](#)).

#### 1.10.2 Short-term (24 weeks, glycine)

There is a single study in this subgroup (8 participants). There was no clear difference between amino acids and placebo within this subgroup (RR 3.0, 95% CI 0.16 to 57.36; [Analysis 1.10](#)).

## 2. Comparison: omega-3 fatty acids versus placebo

In this comparison, there were 13 outcomes.

### 2.1 Prodromal symptoms: transition to psychosis

We identified two studies relevant to this outcome, the data from which we divided into two subgroups.

#### 2.1.1 Medium-term (at 12 months)

We found two studies to be relevant to this subgroup (385 participants). There was no clear difference between omega-3 fatty acids and placebo within this subgroup (RR 0.50, 95% CI 0.08 to 3.08). For this outcome heterogeneity is high ( $\text{Chi}^2 = 5.36$ ;  $\text{df} = 1.0$ ;  $P = 0.02$ ;  $I^2 = 81\%$ ; [Analysis 2.1](#)).

#### 2.1.2 Long-term (at 7 years)

There is a single study in this subgroup (81 participants). We found evidence of a clear difference between omega-3 fatty acids and placebo within this subgroup, in favour of omega-3 fatty acids (RR 0.24, 95% CI 0.09 to 0.67; [Analysis 2.1](#)).

### 2.2 Global state: antipsychotic prescription, long-term (at 7 years' follow-up)

For this outcome we found a single study (69 participants). We found evidence of a clear difference between omega-3 fatty acids and placebo, in favour of omega-3 fatty acids (RR 0.54, 95% CI 0.30 to 0.99; [Analysis 2.2](#)).

### 2.3 Mental state 1.a, specific: psychotic symptoms, average total score, PANSS (higher score = worse)

We identified one study relevant to this outcome and categorised data into eight subgroups.

#### 2.3.1 General: medium-term (at 12 months)

We found one study to be relevant to this subgroup (81 participants). For this outcome, within this subgroup, we did not find evidence that omega-3 fatty acids were clearly different in effect compared with placebo (MD -3.90, 95% CI -8.06 to 0.26; [Analysis 2.3](#)).

#### 2.3.2 General: long-term (up to 7 years)

There is a single study in this subgroup (81 participants). We did not find evidence of a clear difference between omega-3 fatty acids and placebo within this subgroup (MD -4.70, 95% CI -9.69 to 0.29; [Analysis 2.3](#)).

#### 2.3.3 Negative: medium-term (at 12 months)

There is a single study in this subgroup (81 participants). We found evidence of a clear difference between omega-3 fatty acids and placebo within this subgroup in favour of omega-3 fatty acids (MD -2.60, 95% CI -5.09 to -0.11; [Analysis 2.3](#)).

#### 2.3.4 Negative: long-term (up to 7 years)

We found one study to be relevant to this subgroup (81 participants). For this outcome, within this subgroup, we found

evidence that omega-3 fatty acids were clearly superior in effect compared with placebo (MD -3.10, 95% CI -6.15 to -0.05; [Analysis 2.3](#)).

### 2.3.5 Positive: medium-term (at 12 months)

There is a single study in this subgroup (81 participants). For this outcome, within this subgroup, we found evidence that omega-3 fatty acids were clearly superior in effect compared with placebo (MD -2.10, 95% CI -4.32 to 0.12; [Analysis 2.3](#)).

### 2.3.6 Positive: long-term (up to 7 years)

We found one study to be relevant to this subgroup (81 participants). We found evidence of a clear difference between omega-3 fatty acids and placebo within this subgroup, in favour of omega-3 fatty acids (MD -3.50, 95% CI -5.99 to -1.01; [Analysis 2.3](#)).

### 2.3.7 Total: medium-term (at 12 months)

We found one study to be relevant to this subgroup (81 participants). We found evidence of a clear difference between omega-3 fatty acids and placebo within this subgroup, in favour of omega-3 fatty acids (MD -8.60, 95% CI -16.36 to -0.84; [Analysis 2.3](#)).

### 2.3.8 Total: long-term (up to 7 years)

There is a single study in this subgroup (81 participants). We found evidence of a clear difference between omega-3 fatty acids and placebo within this subgroup, in favour of omega-3 fatty acids (MD -11.40, 95% CI -20.55 to -2.25; [Analysis 2.3](#)).

### 2.4 Mental state 1.b, specific: negative symptoms, average total score, medium-term (at 12 months), SANS (higher score = worse)

We identified one study relevant to this outcome (225 participants). We did not find evidence of a clear difference between omega-3 fatty acids and placebo in this comparison (MD 0.50, 95% CI -2.56 to 3.56; [Analysis 2.4](#)).

### 2.5 Mental state 2, specific: depression, average total score, medium-term (at 12 months), MADRS (higher score = worse), skewed data

For this outcome we found a single study (225 participants). We did not find evidence of a clear difference between omega-3 fatty acids and placebo in this comparison (MD -0.3, 95% CI -2.78 to 2.18; [Analysis 2.5](#)).

### 2.6 Mental state 3, specific: mania, average total score, medium-term (at 12 months), YMS (higher score = worse)

We identified one study relevant to this outcome (225 participants). We did not find evidence of a clear difference between omega-3 fatty acids and placebo in this comparison (MD 0.4, 95% CI -0.35 to 1.15; [Analysis 2.6](#)).

### 2.7 Mental state 4, specific: average total scores, various scales (higher score = worse), skewed data

These continuous data (1 RCT) had such large standard deviations as to suggest that analysis within [Review Manager 2014](#) would be inadvisable. Therefore, we have presented them in [Analysis 2.7](#).

### 2.8 Functioning 1, global: average total score GAF (higher score = better)

For this outcome we found a single study and categorised data into two subgroups.

### 2.8.1 Medium-term (at 12 months)

There is a single study in this subgroup (81 participants). We found evidence of a clear difference between omega-3 fatty acids and placebo within this subgroup, in favour of omega-3 fatty acids (MD 11.5, 95% CI 5.12 to 17.88; [Analysis 2.8](#)).

### 2.8.2 Long-term (at up to 7 years)

We found one study to be relevant to this subgroup (81 participants). We found evidence of a clear difference between omega-3 fatty acids and placebo, in favour of omega-3 fatty acids (MD 9.50, 95% CI 2.02 to 16.98; [Analysis 2.8](#)).

### 2.9 Functioning 2, specific: role functioning, average total score, medium-term (at 12 months), GFR (higher score = better)

We identified one study relevant to this outcome (225 participants). We found no clear difference between omega-3 fatty acids and placebo (MD 0.00, 95% CI -0.49 to 0.49; [Analysis 2.9](#)).

### 2.10 Functioning 3.a, specific: social functioning, average total score, medium-term (at 12 months), GFS (higher score = better)

We identified one study relevant to this outcome (225 participants). For this outcome, we did not find evidence that omega-3 fatty acids were clearly different in effect compared with placebo (MD -0.20, 95% CI -0.59 to 0.19; [Analysis 2.10](#)).

### 2.11 Functioning 3.b, specific: social functioning, average total score, medium-term (at 12 months), SOFAS, (higher score = better)

For this outcome we found a single study (225 participants). There was no clear difference between omega-3 fatty acids and placebo (MD 0.10, 95% CI -4.60 to 4.80; [Analysis 2.11](#)).

### 2.12 Adverse effects, specific: medium-term (by 12 months), UKU checklist

We identified two studies relevant to this outcome and categorised data into 23 subgroups.

#### 2.12.1 Arousal: concentration difficulties

We found one study to be relevant to this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega-3 fatty acids and placebo (RR 0.20, 95% CI 0.02 to 1.60; [Analysis 2.12](#)).

#### 2.12.2 Arousal: increased fatigability

We found one study to be relevant to this subgroup (81 participants). There was no clear difference between omega-3 fatty acids and placebo within this subgroup (RR 1.46, 95% CI 0.26 to 8.3; [Analysis 2.12](#)).

#### 2.12.3 Arousal: sleep: reduced duration of sleep

We found one study to be relevant to this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega-3 fatty acids and placebo (RR 0.98, 95% CI 0.21 to 4.55; [Analysis 2.12](#)).

#### 2.12.4 Arousal: sleep-related: unspecified

There is a single study in this subgroup (304 participants). For this subgroup, we did not find evidence of a clear difference between omega-3 fatty acids and placebo (RR 0.83, 95% CI 0.49 to 1.42; [Analysis 2.12](#)).

### 2.12.5 Autonomic nervous system: orthostatic dizziness

We found one study to be relevant to this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega-3 fatty acids and placebo (RR 0.20, 95% CI 0.01 to 3.94; [Analysis 2.12](#)).

### 2.12.6 Autonomic nervous system: sweating increase

There is a single study in this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega-3 fatty acids and placebo (RR 0.20, 95% CI 0.01 to 3.94; [Analysis 2.12](#)).

### 2.12.7 Autonomic nervous system: unspecified

We found one study to be relevant to this subgroup (304 participants). There was no clear difference between omega-3 fatty acids and placebo within this subgroup (RR 1.56, 95% CI 0.79 to 3.11; [Analysis 2.12](#)).

### 2.12.8 Gastrointestinal: diarrhoea

We found one study to be relevant to this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega-3 fatty acids and placebo (RR 0.24, 95% CI 0.03 to 2.09; [Analysis 2.12](#)).

### 2.12.9 Gastrointestinal: nausea/vomiting

There is a single study in this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega-3 fatty acids and placebo (RR 0.98, 95% CI 0.21 to 4.55; [Analysis 2.12](#)).

### 2.12.10 Gastrointestinal: unspecified

We found one study to be relevant to this subgroup (304 participants). For this subgroup, we did not find evidence of a clear difference between omega-3 fatty acids and placebo (RR 1.28, 95% CI 0.91 to 1.79; [Analysis 2.12](#)).

### 2.12.11 Haematological: increased bleeding

There is a single study in this subgroup (304 participants). For this subgroup, we did not find evidence of a clear difference between omega-3 fatty acids and placebo (RR 0.33, 95% CI 0.01 to 8.01; [Analysis 2.12](#)).

### 2.12.12 Hormonal: unspecified

There is a single study in this subgroup (304 participants). There was no clear difference between omega-3 fatty acids and placebo within this subgroup (RR 0.61, 95% CI 0.26 to 1.42; [Analysis 2.12](#)).

### 2.12.13 Neurological: extrapyramidal

There is a single study in this subgroup (304 participants). There was no clear difference between omega-3 fatty acids and placebo within this subgroup (RR 2.57, 95% CI 0.94 to 7.02; [Analysis 2.12](#)).

### 2.12.14 Neurological: failing memory

We found one study to be relevant to this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega-3 fatty acids and placebo (RR 0.20, 95% CI 0.01 to 3.94; [Analysis 2.12](#)).

### 2.12.15 Neurological: tension headache

There is a single study in this subgroup (81 participants). There was no clear difference between omega-3 fatty acids and placebo within this subgroup (RR 0.24, 95% CI 0.03 to 2.09; [Analysis 2.12](#)).

### 2.12.16 Neurological: unspecified

There is a single study in this subgroup (304 participants). There was no clear difference between omega-3 fatty acids and placebo within this subgroup (RR 1.85, 95% CI 0.81 to 4.24; [Analysis 2.12](#)).

### 2.12.17 Psychological: depression

We found one study to be relevant to this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega-3 fatty acids and placebo (RR 0.39, 95% CI 0.08 to 1.90; [Analysis 2.12](#)).

### 2.12.18 Psychological: emotional indifference

We found one study to be relevant to this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega-3 fatty acids and placebo (RR 0.49, 95% CI 0.09 to 2.52; [Analysis 2.12](#)).

### 2.12.19 Psychological: tension/inner unrest

There is a single study in this subgroup (81 participants). There was no clear difference between omega-3 fatty acids and placebo within this subgroup (RR 0.78, 95% CI 0.23 to 2.70; [Analysis 2.12](#)).

### 2.12.20 Psychological: unspecified

We found one study to be relevant to this subgroup (304 participants). There was no clear difference between omega-3 fatty acids and placebo within this subgroup (RR 1.32, 95% CI 0.70 to 2.47; [Analysis 2.12](#)).

### 2.12.21 Sexual: unspecified

There is a single study in this subgroup (304 participants). There was no clear difference between omega-3 fatty acids and placebo within this subgroup (RR 6.91, 95% CI 0.86 to 55.48; [Analysis 2.12](#)).

### 2.12.22 Skin: unspecified

There is a single study in this subgroup (304 participants). There was no clear difference between omega-3 fatty acids and placebo within this subgroup (RR 0.70, 95% CI 0.23 to 2.17; [Analysis 2.12](#)).

### 2.12.23 Other: unspecified

We found one study to be relevant to this subgroup (304 participants). There was no clear difference between omega-3 fatty acids and placebo within this subgroup (RR 1.12, 95% CI 0.66 to 1.90; [Analysis 2.12](#)).

## 2.13 Satisfaction with treatment: leaving the study early

We identified two studies relevant to this outcome, the data from which we divided into two subgroups.

### 2.13.1 Medium-term (by 12 months, end point)

There are two relevant studies in this subgroup (385 participants). There was no clear difference between omega-3 fatty acids and placebo within this subgroup (RR 0.98, 95% CI 0.68 to 1.42; [Analysis 2.13](#)).

### 2.13.2 Long-term (by 7 years, additional follow-up)

We found one study to be relevant to this subgroup (81 participants). For this subgroup, we did not find evidence of a clear difference between omega-3 fatty acids and placebo (RR 1.46, 95% CI 0.45 to 4.80; [Analysis 2.13](#)).

## Group B: comparisons where it is unclear how interaction has affected the interventions

### B.i. Antipsychotic drugs

#### 3. Comparison: amisulpiride + needs-focused intervention versus needs-focused intervention

This comparison has seven outcomes.

##### 3.1 Mental state, specific: average end point scores, short-term (at 12 weeks), various scales (higher score = worse), skewed data

These continuous data, from a single study, had such large standard deviations as to suggest that analysis within [Review Manager 2014](#) would be inadvisable (please see [Analysis 3.1](#)).

##### 3.2 Functioning, global: average end point score, short-term (at 12 weeks), GAF (higher score = better)

For this outcome we found a single study (102 participants). We found evidence of a clear difference between amisulpiride + needs-focused intervention (NFI) and NFI alone in this comparison, in favour of amisulpiride + NFI (MD 6.10, 95% CI 0.44 to 11.76; [Analysis 3.2](#)).

##### 3.3 Adverse effects 1.a, specific: akathisia, short-term (at 12 weeks), ESRS

For this outcome we found a single study (104 participants). There was no clear difference between amisulpiride + NFI and NFI (RR 2.82, 95% CI 0.33 to 24.36; [Analysis 3.3](#)).

##### 3.4 Adverse effects 1.b, specific: akathisia, average end point score, short-term (at 12 weeks), ESRS (higher score = worse), skewed data

These continuous data (1 RCT) were too skewed to report in a graph (please see [Analysis 3.4](#)).

##### 3.5 Adverse effects 2, specific: increased prolactin levels, short-term (at 12 weeks)

For this outcome we found a single study (78 participants). We found evidence of a clear difference between amisulpiride + NFI and NFI, in favour of NFI (RR 3.97, 95% CI 2.02 to 7.80; [Analysis 3.5](#)).

##### 3.6 Adverse effects 3, specific: severity of at least moderate and a frequency of at least 5%, short-term (at 12 weeks), UKU

For this outcome we found a single study, the data from which we divided into subgroups.

##### 3.6.1 Psychological: concentration difficulties

There is a single study in this subgroup (101 participants). There was no clear difference between amisulpiride + NFI and NFI within this subgroup (RR 1.01, 95% CI 0.78 to 1.31; [Analysis 3.6](#)).

##### 3.6.2 Psychological: asthenia/lassitude/increased fatigability

There is a single study in this subgroup (101 participants). We found evidence of a clear difference between amisulpiride + NFI and NFI within this subgroup, in favour of NFI (RR 1.64, 95% CI 1.08 to 2.50; [Analysis 3.6](#)).

##### 3.6.3 Psychological: failing memory

We found one study to be relevant to this subgroup (101 participants). For this outcome, within this subgroup, we found evidence that amisulpiride + NFI was inferior compared to NFI (RR 2.19, 95% CI 1.17 to 4.10; [Analysis 3.6](#)).

##### 3.6.4 Psychological: depression

There is a single study in this subgroup (101 participants). There was no clear difference between amisulpiride + NFI and NFI within this subgroup (RR 1.10, 95% CI 0.82 to 1.48; [Analysis 3.6](#)).

##### 3.6.5 Psychological: tension

There is a single study in this subgroup (101 participants). There was no clear difference between amisulpiride + NFI and NFI within this subgroup (RR 1.17, 95% CI 0.85 to 1.61; [Analysis 3.6](#)).

##### 3.6.6 Arousal: sleepiness/sedation

There is a single study in this subgroup (101 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 1.48, 95% CI 0.49 to 4.47; [Analysis 3.6](#)).

##### 3.6.7 Arousal: increased duration of sleep

We found one study to be relevant to this subgroup (101 participants). We found evidence of a clear difference between amisulpiride + NFI and NFI within this subgroup, in favour of NFI (RR 3.28, 95% CI 1.37 to 7.85; [Analysis 3.6](#)).

##### 3.6.8 Arousal: decreased duration of sleep

We found one study to be relevant to this subgroup (101 participants). There was no clear difference between amisulpiride + NFI and NFI within this subgroup (RR 0.49, 95% CI 0.23 to 1.06; [Analysis 3.6](#)).

##### 3.6.9 Arousal: increased dream activity

We found one study to be relevant to this subgroup (101 participants). For this outcome, within this subgroup, we found evidence that amisulpiride + NFI was inferior to NFI (RR 21.82, 95% CI 1.35 to 353.77; [Analysis 3.6](#)).

##### 3.6.10 Gastrointestinal: nausea/vomiting

We found one study to be relevant to this subgroup (101 participants). There was no clear difference between amisulpiride + NFI and NFI within this subgroup (RR 9.92, 95% CI 0.58 to 169.0; [Analysis 3.6](#)).

##### 3.6.11 Autonomic nervous system: orthostatic dizziness

There is a single study in this subgroup (101 participants). There was no clear difference between amisulpiride + NFI and NFI within this subgroup (RR 5.95, 95% CI 0.33 to 107.62; [Analysis 3.6](#)).

##### 3.6.12 Autonomic nervous system: increased tendency to sweating

There is a single study in this subgroup (101 participants). For this outcome, within this subgroup, we found evidence that amisulpiride + NFI was inferior to NFI (RR 16.53, 95% CI 1.01 to 271.60). [Analysis 3.6](#).



### 3.6.13 Cardiological: palpitation/tachycardia

There is a single study in this subgroup (101 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.98, 95% CI 0.30 to 3.27; [Analysis 3.6](#)).

### 3.6.14 Neurological: headache

We found one study to be relevant to this subgroup (101 participants). There was no clear difference between amisulpiride + NFI and NFI within this subgroup (RR 1.86, 95% CI 0.8 to 4.31; [Analysis 3.6](#)).

### 3.6.15 Endocrinological: polyuria/polydipsia

We found one study to be relevant to this subgroup (101 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.98, 95% CI 0.30 to 3.27; [Analysis 3.6](#)).

### 3.6.16 Sexual: diminished sexual desire

There is a single study in this subgroup (101 participants). We found evidence of a clear difference between amisulpiride + NFI and NFI within this subgroup, in favour of NFI (RR 3.44, 95% CI 1.28 to 9.28; [Analysis 3.6](#)).

### 3.6.17 Sexual: orgasmic dysfunction

There is a single study in this subgroup (101 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 5.95, 95% CI 0.33 to 107.62; [Analysis 3.6](#)).

## 3.7 Adverse effects 4, specific: suicidal thoughts

For this important outcome we identified one small study (102 participants). We identified no clear difference between groups (RR 0.25, 95% CI 0.01 to 6.10; [Analysis 3.7](#)).

## 3.8 Satisfaction with treatment: leaving the study early, end point data

For this outcome we found a single study (124 participants). We found evidence of a clear difference between amisulpiride + NFI and NFI (RR 0.59, 95% CI 0.38 to 0.94; [Analysis 3.8](#)).

## 4. Comparison: olanzapine + supportive intervention versus placebo + supportive intervention

This comparison has 12 outcomes.

### 4.1 Prodromal symptoms: transition to psychosis, end point data, medium-term (by 12 months)

We identified one study relevant to this outcome (60 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 0.58, 95% CI 0.28 to 1.18; [Analysis 4.1](#)).

### 4.2 Global state, global: illness severity, average total score, medium-term (at 12 months), CGI (higher score = worse)

We identified one study relevant to this outcome (59 participants). For this outcome, we did not find evidence that olanzapine + supportive intervention was different in its effects compared with placebo + supportive intervention (MD -0.23, 95% CI -0.82 to 0.36; [Analysis 4.2](#)).

### 4.3 Mental state, specific: average total scores, medium-term (at 12 months), various scales (higher score = worse), skewed data

These continuous data (1 RCT) were too skewed to report in a graph (please see [Analysis 4.3](#)).

### 4.4 Functioning, global: average total score, medium-term (at 12 months), GAF (higher score = better)

We identified one study relevant to this outcome (59 participants). There was no clear difference between olanzapine + supportive intervention and placebo + supportive intervention (MD 2.43, 95% CI -4.77 to 9.63; [Analysis 4.4](#)).

### 4.5 Adverse effects 1, specific: average total score, short-term (at 8 weeks), various scales (higher score = worse), skewed data

These continuous data, from a single study, had such large standard deviations as to suggest that analysis within [Review Manager 2014](#) would be inadvisable (please see [Analysis 4.5](#)).

### 4.6 Adverse effects 2.a, specific: cardiovascular, average total score, short-term (at 8 weeks), blood pressure and pulse rate (higher score = worse)

We identified one study relevant to this outcome, the data from which we divided into six subgroups.

#### 4.6.1 Sitting systolic blood pressure

There is a single study in this subgroup (59 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD 1.00, 95% CI -4.28 to 6.28; [Analysis 4.6](#)).

#### 4.6.2 Sitting diastolic blood pressure

We found one study to be relevant to this subgroup (59 participants). There was no clear difference between olanzapine + supportive intervention and placebo + supportive intervention within this subgroup (MD 2.30, 95% CI -7.43 to 2.83; [Analysis 4.6](#)).

#### 4.6.3 Sitting pulse

We found one study to be relevant to this subgroup (59 participants). There was no clear difference between olanzapine + supportive intervention and placebo + supportive intervention within this subgroup (MD 8.20, 95% CI -0.03 to 16.37; [Analysis 4.6](#)).

#### 4.6.4 Standing systolic blood pressure

We found one study to be relevant to this subgroup (59 participants). There was no clear difference between olanzapine + supportive intervention and placebo + supportive intervention within this subgroup (MD -1.80, 95% CI -6.96 to 3.36; [Analysis 4.6](#)).

#### 4.6.5 Standing diastolic blood pressure

There is a single study in this subgroup (59 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD -1.80, 95% CI -6.96 to 3.36; [Analysis 4.6](#)).

#### 4.6.6 Standing pulse

There is a single study in this subgroup (59 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD 7.90, 95% CI -0.74 to 16.54; [Analysis 4.6](#)).

#### 4.7 Adverse effects 2.b, specific: cardiovascular, average total score, medium-term (at 12 months), pulse rate (higher score = worse)

For this outcome we found a single study and categorised data into two subgroups.

##### 4.7.1 Sitting pulse

There is a single study in this subgroup (58 participants). For this subgroup, we found evidence of a difference between the two treatments, in favour of placebo + supportive intervention (MD 9.27, 95% CI 1.49 to 17.05; [Analysis 4.7](#)).

##### 4.7.2 Standing pulse

We found one study to be relevant to this subgroup (57 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD 6.94, 95% CI -2.61 to 16.49; [Analysis 4.7](#)).

#### 4.8 Adverse effects 3, specific: treatment-emergent adverse effects, short-term (at 8 weeks)

We identified one study relevant to this outcome and categorised data into eight subgroups.

##### 4.8.1 Arousal: somnolence

We found one study to be relevant to this subgroup (60 participants). There was no clear difference between olanzapine + supportive intervention and placebo + supportive intervention within this subgroup (RR 2.25, 95% CI 0.90 to 5.59; [Analysis 4.8](#)).

##### 4.8.2 Gastrointestinal: weight gain

There is a single study in this subgroup (60 participants). For this outcome, within this subgroup, we found evidence that olanzapine + supportive intervention was clearly different in its effects compared with placebo + supportive intervention, in favour of the control group (RR 10.29, 95% CI 1.42 to 74.79; [Analysis 4.8](#)).

##### 4.8.3 Gastrointestinal: increased appetite

We found one study to be relevant to this subgroup (60 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 1.87, 95% CI 0.51 to 6.80; [Analysis 4.8](#)).

##### 4.8.4 Psychological: anxiety

There is a single study in this subgroup (60 participants). There was no clear difference between olanzapine + supportive intervention and placebo + supportive intervention within this subgroup (RR 4.68, 95% CI 0.58 to 37.68; [Analysis 4.8](#)).

##### 4.8.5 Psychological: nervousness

We found one study to be relevant to this subgroup (60 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 1.87, 95% CI 0.37 to 9.46; [Analysis 4.8](#)).

##### 4.8.6 Psychological: asthenia

We found one study to be relevant to this subgroup (60 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 3.74, 95% CI 0.44 to 31.55; [Analysis 4.8](#)).

##### 4.8.7 Psychological: abnormal thoughts

We found one study to be relevant to this subgroup (60 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 1.40, 95% CI 0.25 to 7.81; [Analysis 4.8](#)).

##### 4.8.8 Musculoskeletal: joint disorder

There is a single study in this subgroup (60 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.94, 95% CI 0.20 to 4.27; [Analysis 4.8](#)).

#### 4.9 Adverse effects 4.a, specific: weight, average total weight change, kg gained (higher scores = worse)

For this outcome we found a single study (59 participants) with both short- and medium-term data. For this outcome, we found evidence that olanzapine + supportive intervention was clearly inferior in its effects compared with placebo + supportive intervention by 12 months (MD 8.49, 95% CI 4.90 to 12.08; [Analysis 4.9](#)).

#### 4.10 Adverse effects 4.b, specific: weight gain, medium-term (at 12 months)

For this outcome we found a single study (60 participants). For this outcome, we found evidence that olanzapine + supportive intervention was clearly inferior in its effects compared with placebo + supportive intervention (RR 3.55, 95% CI 1.53 to 8.28; [Analysis 4.10](#)).

#### 4.11 Adverse effects 5, specific: fatigue, medium-term (at 12 months)

We identified one study relevant to this outcome (60 participants). We found evidence of a clear difference between olanzapine + supportive intervention and placebo + supportive intervention, in favour of the control group (RR 8.42, 95% CI 1.14 to 62.4; [Analysis 4.11](#)).

#### 4.12 Satisfaction with treatment: leaving the study early, end point data, medium-term (by 12 months)

For this outcome we found a single study involving 60 participants. We did not find evidence of a clear difference between the two treatments in this comparison (RR 1.59, 95% CI 0.88 to 2.88; [Analysis 4.12](#)).

### B.ii. Cognitive behavioural therapy

#### 5. Comparison: cognitive behavioural therapy + supportive therapy versus supportive therapy

This comparison has 11 outcomes.

##### 5.1 Prodromal symptoms: transition to psychosis

We identified five studies relevant to this outcome and categorised data into four subgroups.

###### 5.1.1 Medium-term (by 12 months)

We found five studies to be relevant to this subgroup (728 participants). We found evidence of a clear difference between cognitive behavioural therapy (CBT) + supportive therapy and supportive therapy within this subgroup, favouring a combination of CBT and supportive therapy (RR 0.47, 95% CI 0.29 to 0.76; [Analysis 5.1](#)).

### 5.1.2 Long-term (by 18 months)

We found two studies to be relevant to this subgroup (252 participants). We found evidence of a clear difference between CBT + supportive therapy and supportive therapy within this subgroup, favouring a combination of CBT and supportive therapy (RR 0.45, 95% CI 0.23 to 0.89; [Analysis 5.1](#)).

### 5.1.3 Long-term (by 24 months)

We found one study to be relevant to this subgroup (128 participants). For this outcome, within this subgroup, we found evidence that CBT + supportive therapy was superior in its effects compared with supportive therapy (RR 0.32, 95% CI 0.11 to 0.92; [Analysis 5.1](#)).

### 5.1.4 Long-term (by 4 years: additional follow-up)

There is a single study in this subgroup (201 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.58, 95% CI 0.31 to 1.12; [Analysis 5.1](#)).

## 5.2 Global state, specific: personal beliefs, average scores, long-term (at 18 months), PBIQ-R (higher score = worse)

For this outcome we found a single study, the data from which we divided into five subgroups.

### 5.2.1 Control

There is a single study in this subgroup (140 participants). We did not find a clear difference between CBT + supportive therapy and supportive therapy within this subgroup (MD -0.70, 95% CI -1.79 to 0.39; [Analysis 5.2](#)).

### 5.2.2 Entrapment

We found one study to be relevant to this subgroup (140 participants). For this outcome, within this subgroup, we did not find evidence that CBT + supportive therapy was clearly different in its effects compared with supportive therapy (MD -0.50, 95% CI -1.91 to 0.91; [Analysis 5.2](#)).

### 5.2.3 Loss

There is a single study in this subgroup (140 participants). For this outcome, within this subgroup, we did not find evidence that CBT + supportive therapy was clearly different in its effects compared with supportive therapy (MD -0.90, 95% CI -2.37 to 0.57; [Analysis 5.2](#)).

### 5.2.4 Participation

We found one study to be relevant to this subgroup (140 participants). For this outcome, within this subgroup, we did not find evidence that CBT + supportive therapy was clearly different in its effects compared with supportive therapy (MD -0.40, 95% CI -1.48 to 0.68; [Analysis 5.2](#)).

### 5.2.5 Shame

We found one study to be relevant to this subgroup (140 participants). We did not find evidence of a clear difference between CBT + supportive therapy and supportive therapy within this subgroup (MD -0.40, 95% CI -1.68 to 0.88; [Analysis 5.2](#)).

## 5.3 Mental state 1, specific: social anxiety, average total score, long-term (at 18 months), SAS (higher score = worse)

For this outcome we found a single study (28 participants). There was no clear difference between CBT + supportive therapy and supportive therapy (MD -3.60, 95% CI -12.34 to 5.14; [Analysis 5.3](#)).

## 5.4 Mental state 2, specific: average scores, various scales (higher score = worse), skewed data

These continuous data, from four studies, had such large standard deviations as to suggest that analysis within [Review Manager 2014](#) would be inadvisable (see [Analysis 5.4](#)).

## 5.5 Functioning 1, global: average total score, GAF (higher score = better)

For this outcome we found three relevant studies and categorised data into two subgroups.

### 5.5.1 Medium-term (at 12 months)

We found two studies to be relevant to this subgroup (294 participants). There was no clear difference between CBT + supportive therapy and supportive therapy within this subgroup (MD 5.97, 95% CI -1.33 to 13.27). For this outcome heterogeneity is high ( $\text{Chi}^2 = 5.54$ ;  $\text{df} = 1.0$ ;  $P = 0.02$ ;  $I^2 = 82\%$ ; [Analysis 5.5](#)).

### 5.5.2 Long-term (at 18 months)

There is a single study in this subgroup (28 participants). There was no clear difference between CBT + supportive therapy and supportive therapy within this subgroup (MD -3.20, 95% CI -14.05 to 7.65; [Analysis 5.5](#)).

## 5.6 Functioning 2.a, specific: social functioning, average total score, medium-term (at 12 months), SAS II (higher score = worse)

There is a single study in this outcome (67 participants). We did not find evidence of a clear difference between CBT + supportive therapy and supportive therapy within this outcome (MD 0.40, 95% CI -0.07 to 0.87; [Analysis 5.6](#)). The results were imprecise as the confidence interval includes both no effect and appreciable benefit.

## 5.7 Functioning 2.b.i, specific: social functioning, average total score, long-term (at 18 months), SFS (higher score = better)

We identified one study relevant to this outcome (28 participants). There was no clear difference between CBT + supportive therapy and supportive therapy (MD 9.10, 95% CI -5.65 to 23.85; [Analysis 5.7](#)).

## 5.8 Functioning 2.b.ii, specific: social functioning, average total score, medium-term (at 18 months), SOFAS (higher score = better)

For this outcome we found a single study (140 participants). There was no clear difference between CBT + supportive therapy and supportive therapy (MD 2.00, 95% CI -2.39 to 6.39; [Analysis 5.8](#)).

## 5.9 Quality of life: average total score, long-term (at 18 months), MANSAs (higher score = better)

For this outcome we found a single study (140 participants). There was no clear difference between CBT + supportive therapy and supportive therapy (MD 1.50, 95% CI -2.93 to 5.93; [Analysis 5.9](#)).

### 5.10 Cost: cumulative (USD) skewed data

These continuous data, from a single study, had such large standard deviations as to suggest that analysis within [Review Manager 2014](#) would be inadvisable (see [Analysis 5.10](#)).

### 5.11 Satisfaction with treatment: leaving the study early, end point data

For this outcome we found five relevant studies, the data from which we divided into two subgroups.

#### 5.11.1 By between 1 year to 2 years

We found four studies to be relevant to this subgroup (668 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.98, 95% CI 0.87 to 1.10; [Analysis 5.11](#)).

#### 5.11.2 By between 2 years to 4 years (additional follow-up)

We found two studies to be relevant to this subgroup (261 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.96, 95% CI 0.74 to 1.24; [Analysis 5.11](#)).

## 6. Comparison: cognitive behavioural therapy + risperidone versus cognitive behavioural therapy + placebo

This comparison has seven outcomes.

### 6.1 Prodromal symptoms: transition to psychosis, end point data

We identified one study relevant to this outcome (87 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 1.02, 95% CI 0.39 to 2.67; [Analysis 6.1](#)).

### 6.2 Mental state, specific: average end point scores, medium-term (at 12 months), various scales (higher score = worse), skewed data

These continuous data, from a single study, were too skewed to report in a graph (please see [Analysis 6.2](#)).

### 6.3 Functioning, global: average end point score, medium-term (at 12 months), GAF (higher score = better)

We identified one study relevant to this outcome (52 participants). There was no clear difference between CBT + risperidone and CBT + placebo (MD -2.00, 95% CI -6.55 to 2.55; [Analysis 6.3](#)).

### 6.4 Adverse effects 1, specific: doctors' assessment of adverse effects, medium-term (at 12 months), UKU

We identified one study relevant to this outcome (65 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 1.03, 95% CI 0.55 to 1.91; [Analysis 6.4](#)).

### 6.5 Adverse effects 2, specific: adverse effects reported by participants, medium-term (at 12 months), UKU

For this outcome we found a single study, with a total of 65 participants. There was no clear difference between CBT + risperidone and CBT + placebo (RR 2.01, 95% CI 0.9 to 4.53; [Analysis 6.5](#)).

### 6.6 Quality of life: average end point score, medium-term (at 12 months), QLS (higher score = better)

We identified one study relevant to this outcome (51 participants). We did not find evidence of a clear difference between the two treatments in this comparison (MD 5.70, 95% CI -7.86 to 19.26; [Analysis 6.6](#)).

### 6.7 Satisfaction with treatment: leaving the study early, end point data

We identified one study relevant to this outcome (87 participants). There was no clear difference between CBT + risperidone and CBT + placebo (RR 1.09, 95% CI 0.62 to 1.92; [Analysis 6.7](#)).

## 7. Comparison: cognitive behavioural therapy (specific preventive intervention) + needs-based intervention + risperidone versus needs-based intervention

This comparison has six outcomes.

### 7.1 Prodromal symptoms: transition to psychosis, end point data

We identified one study relevant to this outcome, the data from which we divided into two subgroups.

#### 7.1.1 Medium-term (at 12 months)

There is a single study in this subgroup (59 participants). There was no clear difference between CBT (specific preventive intervention (SPI)) + needs-based intervention (NBI) + risperidone and NBI within this subgroup (RR 0.54, 95% CI 0.23 to 1.30; [Analysis 7.1](#)).

#### 7.1.2 Long-term (up to 4 years)

We found one study to be relevant to this subgroup (59 participants). There was no clear difference between CBT (SPI) + NBI + risperidone and NBI within this subgroup (RR 0.75, 95% CI 0.39 to 1.46; [Analysis 7.1](#)).

### 7.2 Mental state, specific: average end point scores, various scales (high score = worse), skewed data

These continuous data, from a single study, had such large standard deviations as to suggest that analysis within [Review Manager 2014](#) would be inadvisable (please see [Analysis 7.2](#)).

### 7.3 Functioning, global: average end point score, GAF (higher score = better)

We identified one study relevant to this outcome and categorised data into two subgroups.

#### 7.3.1 Medium-term (at 12 months)

We found one study to be relevant to this subgroup (40 participants). There was no clear difference between CBT (SPI) + NBI + risperidone and NBI within this subgroup (MD -0.62, 95% CI -5.81 to 4.57; [Analysis 7.3](#)).

#### 7.3.2 Long-term (up to 4 years)

We found one study to be relevant to this subgroup (40 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD -2.40, 95% CI -12.32 to 7.52; [Analysis 7.3](#)).

### 7.4 Quality of life: average end point score, QLS (higher score = better)

For this outcome we found a single study, the data from which we divided into three subgroups.

#### 7.4.1 immediately post-treatment

We found one study to be relevant to this subgroup (40 participants). There was no clear difference between CBT (SPI) + NBI + risperidone and NBI within this subgroup (MD 2.83, 95% CI -13.07 to 18.73; [Analysis 7.4](#)).

#### 7.4.2 Medium-term (at 12 months)

We found one study to be relevant to this subgroup (40 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD -2.12, 95% CI -15.43 to 11.19; [Analysis 7.4](#)).

#### 7.4.3 Long-term (up to 4 years)

There is a single study in this subgroup (40 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD -2.03, 95% CI -16.90 to 12.84; [Analysis 7.4](#)).

#### 7.5 Cost: average cost of treatment (AUD), skewed data

These continuous data (1 RCT) had such large standard deviations as to suggest that analysis within [Review Manager 2014](#) would be inadvisable (please see [Analysis 7.5](#)).

#### 7.6 Satisfaction with treatment: leaving the study early

For this outcome we found a single study and categorised data into two subgroups (59 participants). At medium-term follow-up (12 months) there were no dropouts in either group. At long-term follow-up (up to 4 years), we did not find evidence of a clear difference between the two treatments in this comparison (RR 0.57, 95% CI 0.26 to 1.28; [Analysis 7.6](#)).

### Group C: differential effects

#### C.i Cognitive behavioural therapy

#### 8. Comparison: cognitive behavioural therapy + placebo versus supportive therapy + placebo

There are seven outcomes in this comparison.

##### 8.1 Prodromal symptoms: transition to psychosis, end point data

We found a single study relevant to this outcome (72 participants). There was no clear difference between CBT + placebo and supportive therapy + placebo (RR 0.74, 95% CI 0.28 to 1.98; [Analysis 8.1](#)).

##### 8.2 Mental state, specific: average end point scores, medium-term (at 12 months), various scales (higher score = worse), skewed data

These continuous data, from a single study, had such large standard deviations as to suggest that data were very skewed and analysis within [Review Manager 2014](#) would be inadvisable ([Analysis 8.2](#)).

##### 8.3 Functioning, global: average end point scores, medium-term (at 12 months), GAF (higher score = better)

We identified one study relevant to this outcome (45 participants). We did not find evidence of a clear difference between the two treatments (MD 2.20, 95% CI -4.59 to 8.99; [Analysis 8.3](#)).

##### 8.4 Adverse effects 1, specific: doctors' assessment of adverse effects, medium-term (at 12 months), UKU

We identified one study relevant to this outcome (51 participants). We did not find evidence of a clear difference between the two

treatments in this comparison (RR 1.39, 95% CI 0.61 to 3.18; [Analysis 8.4](#)).

##### 8.5 Adverse effects 2, specific: adverse effects reported by participants, medium-term (at 12 months), UKU

We identified one study relevant to this outcome (51 participants). There was no clear difference between CBT + placebo and supportive therapy + placebo (RR 0.91, 95% CI 0.32 to 2.60; [Analysis 8.5](#)).

##### 8.6 Quality of life: average end point scores, medium-term (at 12 months), QLS (higher score = better)

We identified one study relevant to this outcome (44 participants). There was no clear difference between CBT + placebo and supportive therapy + placebo (MD -3.30, 95% CI, -18.76 to 12.16; [Analysis 8.6](#)).

##### 8.7 Satisfaction with treatment: leaving the study early, end point data

For this outcome we found a single study involving 72 participants. We did not find evidence of a clear difference between the two treatments in this comparison (RR 1.06, 95% CI 0.54 to 2.09; [Analysis 8.7](#)).

#### 9. Comparison: cognitive behavioural therapy + supportive intervention versus non-directive reflective listening + supportive intervention

Studies reported data on four outcomes.

##### 9.1 Prodromal symptoms: transition to psychosis, end point data

We found a single study reporting this outcome (57 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 6.32, 95% CI 0.34 to 117.09; [Analysis 9.1](#)).

##### 9.2 Functioning 1, global: average total score, short-term (at 6 months), GAF (higher score = better)

We identified one study relevant to this outcome (34 participants). There was no clear difference between CBT + supportive intervention and non-directive reflective listening (NDRL) + supportive intervention (MD -4.48, 95% CI -12.81 to 3.85; [Analysis 9.2](#)).

##### 9.3 Functioning 2, specific: social functioning, average total score, short-term (at 6 months), SOFAS (higher score = better)

For this outcome we found a single study (34 participants). We did not find evidence of a clear difference between the two treatments in this comparison (MD -6.47, 95% CI -15.30 to 2.36; [Analysis 9.3](#)).

##### 9.4 Satisfaction with treatment: leaving the study early, end point data

One study was relevant (57 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 1.35, 95% CI 0.81 to 2.25; [Analysis 9.4](#)).

#### 10. Comparison: cognitive behavioural therapy + risperidone versus supportive therapy + placebo

In this comparison, there were seven outcomes.

### 10.1 Prodromal symptoms: transition to psychosis, end point data

We identified one study relevant to this outcome (71 participants). There was no clear difference between CBT + risperidone and supportive therapy + placebo (RR 0.76, 95% CI 0.28 to 2.03; [Analysis 10.1](#)).

### 10.2 Mental state, specific: average end point scores, medium-term (at 12 months), various scales (higher score = worse), skewed data

These continuous data, from a single study, were too skewed to report in a graph (please see [Analysis 10.2](#)).

### 10.3 Functioning, global: average end point score, medium-term (at 12 months), GAF (higher score = better)

We identified one study relevant to this outcome (45 participants). There was no clear difference between CBT + risperidone and supportive therapy + placebo (MD 0.20, 95% CI -6.83 to 7.23; [Analysis 10.3](#)).

### 10.4 Adverse effects 1, specific: doctors' assessment of adverse effects, medium-term (at 12 months), UKU

For this outcome we found a single study (58 participants). There was no clear difference between CBT + risperidone and supportive therapy + placebo (RR 1.43, 95% CI 0.64 to 3.16; [Analysis 10.4](#)).

### 10.5 Adverse effects 2, specific: adverse effects reported by participants, medium-term (at 12 months), UKU

For this outcome we found a single study (58 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 1.83, 95% CI 0.77 to 4.34; [Analysis 10.5](#)).

### 10.6 Quality of life: average end point scores, medium-term (at 12 months), QLS (higher score = better)

For this outcome we found a single study (43 participants). We did not find evidence of a clear difference between the two treatments in this comparison (MD 2.40, 95% CI -9.91 to 14.71; [Analysis 10.6](#)).

### 10.7 Satisfaction with treatment: leaving the study early, end point data

We identified one study relevant to this outcome (71 participants). There was no clear difference between CBT + risperidone and supportive therapy + placebo (RR 1.16, 95% CI 0.60 to 2.25; [Analysis 10.7](#)).

## C.ii Other

### 11. Comparison: cognitive training versus active control (tablet games)

This comparison has nine outcomes.

#### 11.1 Mental state 1, specific: average total scores, various scales (higher score = worse), skewed data

These continuous data, from two studies, were too skewed to report in a graph (please see [Analysis 11.1](#)).

#### 11.2 Mental state 2, specific: depression, average end point score, short-term (at 4 months), BDI-II (higher score = worse)

For this outcome we found a single study (62 participants). There was no clear difference between cognitive training and active control (tablet games) (MD 0.99, 95% CI -1.72 to 3.7; [Analysis 11.2](#)).

#### 11.3 Mental state 3.a, specific: cognitive, average end point score short-term (at 4 months)

For this outcome we found a single study, the data from which we divided into two subgroups.

##### 11.3.1 Processing speed (Minnesota Clerical Test, T score, higher score = better)

We found one study to be relevant to this subgroup (62 participants). We found evidence of a clear difference between cognitive training and active control (tablet games) within this subgroup, in favour of cognitive training (MD 6.25, 95% CI 1.70 to 10.80; [Analysis 11.3](#)).

##### 11.3.2 Processing speed (Digit Symbol Coding, higher score = better)

There is a single study in this subgroup (62 participants). There was a clear difference between cognitive training and active control (tablet games) within this subgroup, in favour of cognitive training (MD 1.69, 95% CI 0.69 to 2.69; [Analysis 11.3](#)).

#### 11.4 Mental state 3.b, specific: cognitive, average total score (presented as least square means estimated by the generalised linear mixed models), short-term (at 3 months), MATRICS (higher score = better)

For this outcome we found a single study, the data from which we divided into six subgroups.

##### 11.4.1 Attention/vigilance

There is a single study in this subgroup (25 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD -3.12, 95% CI -11.48 to 5.24; [Analysis 11.4](#)).

##### 11.4.2 Speed of processing

There is a single study in this subgroup (25 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (MD -2.58, 95% CI -9.72 to 4.56; [Analysis 11.4](#)).

##### 11.4.3 Reasoning and problem solving

There is a single study in this subgroup (25 participants). There was no clear difference between cognitive training and active control (tablet games) within this subgroup (MD -1.84, 95% CI -8.32 to 4.64; [Analysis 11.4](#)).

##### 11.4.4 Verbal learning

There is a single study in this subgroup (25 participants). There was no clear difference between cognitive training and active control (tablet games) within this subgroup (MD -0.19, 95% CI -7.00 to 6.62; [Analysis 11.4](#)).

##### 11.4.5 Visual learning

We found one study to be relevant to this subgroup (25 participants). There was no clear difference between cognitive training and active control (tablet games) within this subgroup (MD -4.39, 95% CI -11.10 to 2.32; [Analysis 11.4](#)).

##### 11.4.6 Working memory

There is a single study in this subgroup (25 participants). There was no clear difference between cognitive training and active control (tablet games) within this subgroup (MD 3.56, 95% CI -4.88 to 12.0; [Analysis 11.4](#)).

**11.5 Functioning 1, global: average total score, long-term (at 24 months), GAF (higher score = better)**

For this outcome we found a single study (83 participants). We did not find evidence of a clear difference between the two treatments in this comparison (MD 0.36, 95% CI -5.34 to 6.06; [Analysis 11.5](#)).

**11.6 Functioning 2, specific: role functioning, GFR (higher score = better)**

We identified two studies relevant to this outcome, the data from which we divided into two subgroups.

**11.6.1 Role functioning: average total score (presented as least square means estimated by the generalised linear mixed models), short-term (at 3 months)**

We found one study to be relevant to this subgroup (25 participants). We found evidence of a clear difference between cognitive training and active control (tablet games) within this subgroup, in favour of active control (tablet games) (MD -1.27, 95% CI -1.84 to -0.70; [Analysis 11.6](#)).

**11.6.2 Role functioning: average total score, long-term (at 24 months)**

We found one study to be relevant to this subgroup (83 participants). For this outcome, within this subgroup, we did not find evidence that cognitive training was clearly different in its effects compared with active control (tablet games) (MD -0.23, 95% CI -1.37 to 0.91; [Analysis 11.6](#)).

**11.7 Functioning 3.a, specific: social functioning, GFS (higher score = better)**

For this outcome we found two relevant studies, the data from which we divided into two subgroups.

**11.7.1 Social functioning: average total score (presented as least square means estimated by the generalised linear mixed models), short-term (at 3 months)**

We found one study to be relevant to this subgroup (25 participants). For this outcome, within this subgroup, we did not find evidence that cognitive training was clearly different in its effects compared with active control (tablet games) (MD -0.68, 95% CI -2.12 to 0.76; [Analysis 11.7](#)).

**11.7.2 Social functioning: average total score, long-term (at 24 months)**

There is a single study in this subgroup, which included a total of 83 participants. For this subgroup, we did not find evidence of a clear difference between the two treatments (MD 0.26, 95% CI -0.52 to 1.04; [Analysis 11.7](#)).

**11.8 Functioning 3.b, specific: social functioning, average end point score, short-term (at 4 months), SAS-SR (higher score = worse)**

We identified one study relevant to this outcome (62 participants). For this outcome, we found evidence that cognitive training was clearly different in its effects compared with active control (tablet games), in favour of cognitive training (MD -0.64, 95% CI -0.94 to -0.34; [Analysis 11.8](#)).

**11.9 Satisfaction with treatment: leaving the study early, end point data**

For this outcome we found three relevant studies and categorised data into three subgroup (177 participants). There was no clear

difference between cognitive training and active control (tablet games) (RR 0.93, 95% CI 0.82 to 1.05; [Analysis 11.9](#)).

**11.9.1 Short-term (by 2 months, PST)**

There is a single study in this subgroup (62 participants). There was no clear difference between cognitive training and active control (tablet games) within this subgroup (RR 0.93, 95% CI 0.81 to 1.06; [Analysis 11.9](#)).

**11.9.2 Medium-term (by 9 months, AT)**

We found one study to be relevant to this subgroup (32 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 1.22, 95% CI 0.64 to 2.32; [Analysis 11.9](#)).

**11.9.3 Long-term (by 24 months, AT)**

We found one study to be relevant to this subgroup, which included a total of 83 participants. For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.78, 95% CI 0.48 to 1.29; [Analysis 11.9](#)).

**12. Comparison: family treatment versus enhanced care**

This comparison has seven outcomes.

**12.1 Prodromal symptoms: transition to psychosis**

We identified two studies relevant to this outcome and categorised data into two subgroups (229 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 0.54, 95% CI 0.18 to 1.59).

**12.1.1 Short-term (6 months, FFT)**

There is a single study in this subgroup (129 participants). There was no clear difference between family treatment and enhanced care within this subgroup (RR 0.19, 95% CI 0.02 to 1.59; [Analysis 12.1](#)).

**12.1.2 Long-term (24 months, FACT)**

We found one study to be relevant to this subgroup (100 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.71, 95% CI 0.35 to 1.45; [Analysis 12.1](#)).

**12.2 Global state: antipsychotic prescription, short-term (by 6 months)**

For this outcome we found a single study (129 participants). There was no clear difference between family treatment and enhanced care (RR 1.18, 95% CI 0.69 to 2.02; [Analysis 12.2](#)).

**12.3 Mental state, specific: psychosis risk, positive symptoms, average total score, short-term (at 6 months), SOPS positive (higher score = worse)**

For this outcome we found a single study (102 participants). There was a clear difference between family treatment and enhanced care, in favour of family treatment (MD -2.01, 95% CI -3.87 to -0.15; [Analysis 12.3](#)).

**12.4 Functioning, global: average total score, long-term (at 24 months), GAF (higher score = better)**

For this outcome we found a single study (69 participants). We did not find evidence of a clear difference between the two treatments in this comparison (MD 5.15, 95% CI -1.90 to 12.20; [Analysis 12.4](#)).

### **12.5 Adverse events 1.a, specific: suicide, events, long-term (by 24 months)**

We identified one study relevant to this outcome (100 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 1.00, 95% CI 0.06 to 15.55; [Analysis 12.5](#)).

### **12.6 Adverse events 1.b, specific: suicide, participants affected/at risk, long-term (by 24 months)**

We identified one study relevant to this outcome (100 participants). There was no clear difference between family treatment and enhanced care (RR 1.00, 95% CI 0.06 to 15.55; [Analysis 12.6](#)).

### **12.7 Satisfaction with treatment: leaving the study early**

We identified two studies relevant to this outcome and categorised data into two subgroups (229 participants). There was no clear difference between family treatment and enhanced care (RR 0.81, 95% CI 0.52 to 1.26; [Analysis 12.7](#)).

#### **12.7.1 Short-term (6 months, FFT)**

There is a single study in this subgroup (129 participants). For this subgroup, we did not find evidence of a clear difference between the two treatments (RR 0.66, 95% CI 0.33 to 1.30; [Analysis 12.7](#)).

#### **12.7.2 Long-term (24 months, FACT)**

We found one study to be relevant to this subgroup (100 participants). There was no clear difference between family treatment and enhanced care within this subgroup (RR 0.94, 95% CI 0.52 to 1.68; [Analysis 12.7](#)).

## **13. Comparison: integrated treatment versus standard treatment**

There were three outcomes in this comparison.

### **13.1 Prodromal symptoms: transition to psychosis, end point data, long-term (by 2 years)**

For this outcome we found a single study (79 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 0.57, 95% CI 0.28 to 1.15; [Analysis 13.1](#)).

### **13.2 Mental state, specific: average total score, long-term (at 2 years), various scales (higher score = worse), skewed data**

These continuous data, from a single study, were too skewed to report in a graph (please see [Analysis 13.2](#)).

### **13.3 Satisfaction with treatment: leaving the study early, end point data**

We identified one study relevant to this outcome (79 participants). We did not find evidence of a clear difference between the two treatments in this comparison (RR 0.66, 95% CI 0.25 to 1.73; [Analysis 13.3](#)).

## **DISCUSSION**

There is the impression that in this whole area there is a triumph of hope over adversity. There is the repeated hope invested in another - often unique - study question and then a study of fewer than 100 participants is completed. This results in the set of comparisons reported here, all of which are too under-powered to really highlight clear differences. With more agreement, collaboration

and co-ordination across research teams in this area it might have been possible to find if, to take one example, cognitive therapy was truly more valuable than a simpler supportive approach. The diversity of underpowered testing in this area has left important questions still in doubt after well over a decade of highly-expensive, and, no doubt, career-enhancing, studies.

To summarise the main findings we used outcomes chosen at review protocol stage for presentation in the 'Summary of findings' tables. No comparison reported data on all seven outcomes and we often had to use proxy measures. No comparison, however, reported explicitly on 'behaviour'. It is possible that this is thought to be covered by reporting 'global state' or 'mental state' but we still think it is reasonable to have included it in the original list. It is not difficult to report and is of great importance to carers.



Pre-defined 'Summary of findings' table outcome	Comparison number (within clusters A-C)												
	A		B					C					
	1	2	3	4	5	6	7	8	9	10	11	12	13
Prodromal symptoms: transition to psychosis	#	#		#	#	#	#	#	#	#	#	#	#
Global state: clinically important change in global state		#				#						#	
Mental state: clinically important change in mental state	#	#		#	#	#	#	#	#	#		#	#
Behaviour: any change in behaviour													
Adverse effects: at least one serious adverse event	#	#	#		#	#		#		#		#	
Quality of life: any change in quality of life				#	#		#	#		#			
Satisfaction with treatment: leaving the study early	#	#	#	#	#	#	#	#	#	#	#	#	#

## Summary of main results

### Group A: absolute effects

Group A's interventions involved giving amino acids or omega-3 and comparing these with placebo. Both comparisons involved low numbers of studies that were likely to be of very limited power. Data quality, at best, was low. There is no suggestion that amino acids have an effect. Adding omega-3 did change both transition to psychosis and use of antipsychotic drugs in one small study but over a seven-year follow-up.

#### 1. Amino acids compared to placebo for prodromal stage of psychosis

Please see [Summary of findings for the main comparison](#).

##### 1.1 Transition to psychosis, end point data

Very low-quality evidence from two small studies (52 participants in total) failed to find a clear difference for this outcome.

##### 1.2 Psychosis risk symptoms, measured with SOPS total

Mental state was monitored using the SOPS, rating psychosis risk symptoms. No clear difference was apparent. This result is based on very low-quality evidence from one small study with data for only eight participants.

##### 1.3 Adverse events: suicidal thoughts

Suicidal thoughts were rarely experienced (one person out of 20 in the experimental versus zero out of 24 in the placebo group) and it may have not been the best effect for us to highlight in our 'Summary of findings' table. However, in a broader range of general and specific adverse effects than are reported in the other comparisons within this review there was no real indication that the use of amino acids caused problems. Results are based on very low-quality evidence from one small study with data for 44 participants.

##### 1.4 Satisfaction with treatment, measured as number of individuals leaving the study early

A little under half of the participants left early with no clear difference between groups (very low-quality evidence, 2 RCTs, 52 participants).

##### 1.5 Missing outcomes

None of the studies reported usable data on global state, behaviour or quality of life.

#### 2. Omega-3 fatty acids compared to placebo for prodromal stage of psychosis

Please see [Summary of findings 2](#).

##### 2.1 Transition to psychosis

A lower number of participants in the intervention group treated with omega-3 fatty acids transitioned to psychosis during long-term follow-up of seven years, compared to the placebo group (~10% versus ~33%, RR 0.24, 95% CI 0.09 to 0.67, low-quality evidence, 1 RCT, 81 participants). If this outcome was an isolated positive finding there would be the strong suspicion that it was the result of the play of chance. However this is not necessarily the case with other outcomes also favouring the omega-3 group (see below). All outcomes are low quality. All are from small studies undertaken by those probably who are prone to favour the omega-3

group and biases can always creep in. However, these are rare positive findings, and have some limited consistency and may well be worthy of further investigation.

##### 2.2 Global state, measured with number of antipsychotic prescriptions

A significantly lower number of participants allocated to omega-3 fatty acids had antipsychotic prescriptions during follow-up of seven years, compared to those allocated to the placebo group (RR 0.54, 95% CI 0.30 to 0.99, low-quality evidence, 1 RCT, 69 participants).

##### 2.3 Mental state, measured with PANSS total

Participants in the intervention group had significantly lower mean scores for psychotic symptoms (measured by PANSS total, scale from 30 to 210, MD 11.4 points lower, 95% CI 20.55 points lower to 2.25 lower, low-quality evidence, 1 RCT, 81 participants).

##### 2.4 Adverse effects, neurological extrapyramidal symptoms measured with UKU Side Effect Rating Scale

Although more participants in the intervention group treated with omega-3 fatty acids developed neurological extrapyramidal symptoms in follow-up by 12 months compared to the placebo group, the results did not reach conventional levels of statistical significance (RR 2.57, 95% CI 0.94 to 7.02, low-quality evidence, 1 RCT, 304 participants).

##### 2.5 Satisfaction with treatment, measured as number of individuals leaving the study early

About 25% of each group left the study early with no clear difference between groups (1 RCT, 81 participants).

##### 2.6 Missing outcomes

No study reported usable data on behaviour or quality of life.

### Group B: comparisons where it is unclear how interaction has affected the interventions

#### B.i Antipsychotic drugs

We were unclear if amisulpiride could interact with the needs-focused intervention (NFI) or olanzapine with supportive therapy. In any event, data for the amisulpiride-NFI comparison are so few and poor that no conclusion is warranted and those for the addition of olanzapine to supportive therapy are also limited in size and quality, so as to make firm conclusions impossible. There is no hint of an underlying effect.

#### 3. Amisulpiride + needs-focused intervention compared to needs-focused intervention for prodromal stage of psychosis

Please see [Summary of findings 3](#).

##### 3.1 Adverse events: suicidal thoughts

There was no difference between groups for a series of adverse events, including suicidal thoughts, and very few events in each group (very low-quality evidence, 1 RCT, 102 participants).

##### 3.2 Satisfaction with treatment, measured as number of individuals leaving the study early

Fewer participants (around 30%) left the group assigned to also take amisulpiride, compared with those needs-focused intervention (NFI only group (nearly 60% loss to follow-up, RR

0.59, 95% CI 0.38 to 0.94, very low-quality evidence, 1 RCT, 124 participants). Of course 'leaving early' is difficult to interpret and it is hard to be confident that this truly represents satisfaction. This could be a chance finding in many, but could also be a real expression of something. Most negatively it could be seen as a function of inertia facilitated by use of an antipsychotic - but on the other hand it could represent a real expression of satisfaction mediated by some sort of improvement caused by use of the drug.

### 3.3 Missing outcomes

There are particularly few usable data for this comparison. No study reported usable data on transition to psychosis, global state, mental state, behaviour or quality of life.

## 4. Olanzapine + supportive intervention compared to placebo + supportive intervention for prodromal stage of psychosis

Please see [Summary of findings 4](#).

### 4.1 Transition to psychosis

Although a lower number of participants in the intervention group treated with a combination of olanzapine and supportive intervention transitioned to psychosis during follow-up of 12 months, compared to control group treated with a combination of placebo and supportive intervention (~25% versus ~40%), these results were imprecise and do not meet conventional levels of statistical significance (RR 0.58, 95% CI 0.28 to 1.18, 1 RCT, 60 participants; very low-quality evidence).

### 4.2 Global illness severity, measured by CGI

Nor was there a clear difference between groups for a continuous measure of global severity of illness (very low-quality evidence, 1 RCT, 59 participants).

### 4.3 Psychosis risk symptoms, measured with SOPS total

For mental state, again, there was no clear difference between groups when a specific scale was employed to identify 'psychosis risk symptoms'. This result is based on very low-quality evidence from one small study with data for 59 participants.

### 4.4 Adverse effects: average weight gain in kg

Unsurprisingly, for those who are familiar with use of and evidence around olanzapine, significantly - statistically and clinically - higher weight gain was observed in the intervention group. The average weight gain in the intervention group was approaching 5 kg (95% CI 2 kg to 7 kg higher). This is an important and well-recognised adverse effect of this particular compound. In itself this could be enough to discourage use of olanzapine for this group of participants but as there are no clear effects - or suggestion of effects - in other outcomes, embarking on use of olanzapine in this group would seem very ill-advised.

### 4.5 Satisfaction with treatment, measured as number of individuals leaving the study early

There was no difference between the participants treated with a combination of olanzapine and supportive intervention and those treated with a combination of placebo and supportive intervention in terms of number of participants leaving the study early in a follow-up by 12 months. Around half left the single study (60 participants).

### 4.6 Missing outcomes

No study reported usable data on behaviour or quality of life.

## B.ii Cognitive behavioural therapy

All findings within the CBT subgroup are equivocal except for outcome 5.1 (see below) where CBT added to supportive therapy did better for 'transition to psychosis' than supportive therapy alone (at 18 months). This is one finding out of many and is not of high quality. Several complex packages have been tested involving variations of treatments using a CBT ethos but all effects of these considerable complex and skilled efforts are unconvincing as to there being true benefit.

## 5. Cognitive behavioural therapy + supportive therapy versus supportive therapy

Please see [Summary of findings 5](#).

### 5.1 Transition to psychosis

Around 8% of participants treated allocated to the combination of CBT and supportive therapy transitioned to psychosis during follow-up by 18 months, compared with double that percentage in the supportive therapy alone group (RR 0.45, 95% CI 0.23 to 0.89; 2 RCTs, 252 participants; very low-quality evidence). The finding chosen for the summary table was the medium-term outcome but this finding is consistent - and encouraging across all time periods ([Analysis 5.1](#)). Crudely calculated using the shorter-term data, the number of participants needed to treat for around one year to avoid one transition in that time period is 13. It is difficult to know if this investment would be cost effective. The skilled therapists in these studies are not universal and biases in the studies would likely favour the CBT group. In addition, what data there are in [Analysis 5.1](#) suggests some diminution of effect across time. Transition may be postponed rather than avoided. If this is not the result of the play of chance, any effect for transition to psychosis is likely to be modest in everyday clinical life.

### 5.2 Mental state, measured with SAS

Very low-quality evidence from one study (28 participants) finds no clear difference between groups.

### 5.3 Quality of life measured with MANSAS

More evidence that we had to judge as being of very low quality (1 RCT, 140 participants) failed to highlight any differences between groups.

### 5.4 Satisfaction with treatment, measured as number of individuals leaving the study early

This also applied to the outcome of satisfaction with care, with around half leaving their group of allocation early ([Analysis 5.11](#)).

### 5.5 Missing outcomes

None of the studies reported usable data on global state, behaviour or adverse effects. Other, not dissimilar studies have, and more consistency in outcome reporting would have helped us compare across comparisons.

## 6. Cognitive behavioural therapy + risperidone versus cognitive behavioural therapy + placebo

Please see [Summary of findings 6](#).

### 6.1 Transition to psychosis, end point data

There is no evidence that adding risperidone to CBT does anything for any outcome including transition to psychosis (1 RCT, 87 participants; very low-quality evidence).

### 6.2 Mental state: psychopathology measured with BPRS

Imprecise, very low-quality evidence found no difference between groups in terms of a mental state measure (1 RCT, 52 participants).

### 6.3 Doctors' assessment of adverse effects measured with UKU Side Effect Rating Scale

Although there were more adverse effects in the risperidone group, the difference did not reach conventional levels of statistical significance (1 RCT, 65 participants; very low-quality evidence).

### 6.4 Quality of life measured with QLS

One small study (51 participants) reports evidence that we had to rate as being of very low-quality evidence with no difference between groups.

### 6.5 Satisfaction with treatment, measured as number of individuals leaving the study early

All continuous data for the single relevant study ([Yung-Australia](#)), were completer data and there is a danger that randomisation was compromised by this. Leaving the study early is, however, reported for everyone and there was no difference between groups, with around 30% of both groups leaving early (87 participants). Again, this is hard to interpret with no additional information but it is encouraging that the addition of risperidone did not clearly increase the considerable attrition.

### 6.6 Missing outcomes

None of the studies reported usable data on global state or behaviour. It could be interpreted that outcomes already there covered these and further recording was unnecessary. We feel, however, that more explicit recording would not have complicated the study and would have been of interest to many.

## 7. Cognitive behavioural therapy (specific preventive intervention) + needs-based intervention + risperidone compared to needs-based intervention for prodromal stage of psychosis

Please see [Summary of findings 7](#).

### 7.1 Transition to psychosis

We found no clear difference between the two complex packages of care for this important outcome. This result is based on very low-quality evidence from one small study (59 participants).

### 7.2 Mental state: psychopathology measured with BPRS

The continuous mental state measure (BPRS) highlighted no difference between groups and, again, we had to grade these data as being of very low quality (1 RCT, 40 participants).

### 7.3 Quality of life measured with QLS

Exactly the same applied to the QLS score.

### 7.4 Satisfaction with treatment, measured as number of individuals leaving the study early

There was no difference between the intervention group, treated with a combination of SPI, CBT, NBI and risperidone and the control group in terms of number of participants leaving the study early in a follow-up of up to four years. Overall there were impressively low numbers of participants lost to follow-up with none at 12 months, rising to around 20% by four years. This result is based on evidence that we had to rate as being of very low quality (1 RCT, 59 participants).

### 7.5 Missing outcomes

None of the studies reported usable data on global state, behaviour or adverse effects and several of the findings that had to be used were proxies for simpler and, we argue, more useful outcomes.

## Group C: differential effects

### C.i. Cognitive behavioural therapy

When CBT is directly compared with another treatment, for the broad prespecified 'Summary of findings' outcomes, much of the evidence was of very low quality and none showed a suggestion of clear differences between interventions.

## 8. Cognitive behavioural therapy + placebo versus supportive therapy + placebo

Please see [Summary of findings 8](#).

### 8.1 Transition to psychosis, end point data

In a small study (72 participants) there was no clear difference between those allocated to CBT and those receiving a low grade, supportive therapy (RR 0.74, 95% CI 0.28 to 1.98). It is possible that this very low-quality evidence hides a real effect but impossible to know at this point.

### 8.2 Mental state: psychopathology measured with BPRS

The continuous proxy measure we had to use (BPRS) indicated that the CBT group was not better than the control group (45 participants; very low-quality evidence). The finding that the CBT group was 2.2 points higher (worse) was compatible with also being 5 points lower to 9 points higher compared with the control group and we found no clear clinical explanation of these findings.

### 8.3 Doctors' assessment of adverse effects measured with UKU

There was no clear difference in adverse effects between groups at 12 months (51 participants; very low-quality evidence). It is good to see how the possibility of adverse effects of talking approaches is being considered in studies.

### 8.4 Quality of life measured with QLS

There was no difference between the mean QLS score (a proxy for what was prestipulated in the review's protocol) at 12 months' follow-up in the CBT and control group. The score for the intervention group was 3.3 points lower but 95% CI indicated that the result could be 19 points lower to 12 points higher compared to the control group on a scale from 0 to 126. That the finding is equivocal is helpful as we are unclear of the meaning of the range of figures and have found no explanation of these. In any event, this result is based on very low-quality evidence from one small study with data for 44 participants.

### 8.5 Satisfaction with treatment, measured as number of individuals leaving the study early

Approaching 30% of each group left the groups early. It is hard to know what this means. This level of attrition could be expected from the client group, or could reflect badly on either the intervention or study design (72 participants).

### 8.6 Missing outcomes

None of the studies reported usable data on global state or behaviour. It could be that these outcomes are covered by what has been reported but it would be better to have been certain of the effects of these interventions on simple outcomes clearly falling into these categories.

## 9. Cognitive behavioural therapy + supportive intervention versus non-directive reflective listening + supportive intervention

Please see [Summary of findings 9](#).

### 9.1 Transition to psychosis, end point data

In a group treated with a combination of CBT and supportive therapy, three participants transitioned to psychosis (out of 30), while in the control group none of the 27 analysed participants transitioned to psychosis. As the study was small, results were imprecise and we remain unclear if one or other intervention approach remains a risk. This result is based on very low-quality evidence.

### 9.2 Satisfaction with treatment, measured as number of individuals leaving the study early

There was no difference between groups in terms of number of participants leaving the study early (1 RCT, 57 participants) but over half left the CBT + supportive therapy group.

### 9.3 Missing outcomes

None of the studies reported usable data on global or mental state, behaviour, adverse effects, or quality of life. Other, not dissimilar studies have, and more consistency in outcome reporting would have helped us compare across comparisons.

## 10. Cognitive behavioural therapy + risperidone compared to supportive therapy + placebo for prodromal stage of psychosis

Please see [Summary of findings 10](#).

### 10.1 Transition to psychosis, end point data

We found no clear difference between those allocated to a combination of CBT and risperidone compared to a combination of supportive therapy and placebo but data were of very low quality (1 RCT, 71 participants).

### 10.2 Mental state: psychopathology measured with BPRS

Few, very low-quality data (1 RCT, 45 participants) reported on a mental state outcome with no clear difference between groups.

### 10.3 Doctors' assessment of adverse effects measured with UKU Side Effect Rating Scale

Although more adverse effects were apparent in the risperidone group, there was no clear, statistically significant or clinically important difference (very low-quality, 1 RCT, 58 participants).

### 10.4 Quality of life measured with QLS

The continuous score used to measure quality of life was also equivocal (very low-quality evidence, 1 RCT, 43 participants).

### 10.5 Satisfaction with treatment, measured as number of individuals leaving the study early

Finally, about 30% of participants left each group before study completion. There was no difference between groups (1 RCT, 71 participants; very low-quality evidence).

### 10.6 Missing outcomes

None of the studies reported usable data on global state or behaviour. As for many of the other comparisons, there are so few data for other outcomes - all provided by one pioneering but single study ([Yung-Australia](#)), that we are left partially reassured that conducting evaluative studies in this area is possible but also thinking that clinicians, policy makers and above all those with prodromal signs of schizophrenia have been let down by the research fraternity and the latter's lack of co-ordination and collaboration.

### C.ii Other

Finally, in the last three comparisons, for the key outcomes of interest, there was no suggestion of any of the approaches having a clear effect.

## 11. Cognitive training compared to active control (tablet games) for prodromal stage of psychosis

Please see [Summary of findings 11](#).

### 11.1 Psychosis risk symptoms, measured with SOPS total

The equivocal result is based on use of a proxy measure and we had to grade this evidence as being of very low quality (1 RCT, 62 participants).

### 11.2 Satisfaction with treatment, measured as number of individuals leaving the study early

Overall, over half of all participants left the studies before completion (~24 months). There was no difference between groups (3 RCTs, 177 participants). It is difficult to say if this is more to do with study design than the true acceptability of the approaches.

### 11.3 Missing outcomes

There are particularly few usable data for this comparison. No studies reported on global state, mental state, behaviour, adverse effects or quality of life.

## 12. Family treatment compared to enhanced care for prodromal stage of psychosis

Please see [Summary of findings 12](#).

### 12.1 Transition to psychosis

There was no clear difference found between the packages of care for this important outcome. This result is based on very low-quality evidence from one small study (100 participants).

### 12.2 Global state, measured with number of antipsychotic prescriptions

We found no clear difference for this proxy measure of global state (very low-quality evidence, 1 RCT, 129 participants).

### 12.3 Psychosis risk, positive symptoms, measured with SOPS positive scale

In the group treated with family treatment, the mean SOPS positive score was 2.01 points lower than in the enhanced care control group (95% CI 3.87 points lower to 0.15 lower) on a scale from 0 to 30 at six months. Participants in the intervention group experienced improvement but we are unclear of the clinical meaning of these data and have not found them explained in the study (1 RCT, 102 participants; very low-quality evidence).

### 12.4 Adverse events: suicide

There was one suicide in each group of 50 participants by around two years - indicating the vulnerability of this young cohort.

### 12.5 Satisfaction with treatment, measured as number of individuals leaving the study early

Overall, 20% to 30% of participants in both groups left the studies early - with no clear difference between treatments. It is unclear how valuable this outcome is for approximating satisfaction with treatment, so we have to grade the finding as being of very low quality.

### 12.6 Missing outcomes

There are no usable data on mental state, behaviour or quality of life.

## 13. Integrated treatment compared to standard treatment for prodromal stage of psychosis

Please see [Summary of findings 13](#).

### 13.1 Transition to psychosis, end point data

We found - again - no clear difference between the treatment and control groups (RR 0.57, 95% CI 0.28 to 1.15, very low-quality evidence) and - again - one small study with data (79 participants).

### 13.2 Mental state: negative symptoms, measured with SANS

In this case, the SANS reported data did not highlight any difference between the groups but this result is based on very low-quality evidence from one small study with data for only 57 participants. Although fine-grain measures such as SANS may not require the numbers of more clinically interpretable binary outcomes to achieve adequate levels of power to have a likely chance of highlighting a difference between groups, studies with recruitment only in the 50s are really unlikely to be able to show anything with confidence.

### 13.3 Satisfaction with treatment, measured as number of individuals leaving the study early

Around 10% left the treatment arm early. Approximately 30% were lost from the control arm. Such was the power of the study that this did not represent a clear difference between the group receiving integrated treatment and the standard treatment (1 RCT, 79 participants; very low-quality evidence).

### 13.4 Missing outcomes

There are few usable data for this comparison. No studies reported on global state, behaviour, adverse effects or quality of life.

## Overall completeness and applicability of evidence

### 1. Completeness

All studies addressing the 13 comparisons had important outcomes missing. All of the data we do have is underpowered and of limited quality so just because we are able to report something does not all mean data are complete. While all comparisons had data about number of participants leaving the study early and the majority reported transition to psychosis and some mental state indicators, virtually none of the comparisons addressed behavioral outcomes, that is, any change in behaviour; only two reported outcomes regarding participants' global state and four reported data for adverse effects. Only four comparisons had data on patient satisfaction and quality of life.

### 2. Applicability

Although all studies included participants with clinical high risk for psychosis, criteria used to identify participants at risk were not uniform across the studies. However, this was foreseen and defined in the protocol for this review (Bošnjak 2016). Nevertheless, differences in tools that were used for recognition of individuals at risk may have contributed to some differences in populations studied.

The main problem is that it was difficult to interpret the results. The majority of different included studies allowed additional types of interventions. For example, studies that compared different psychosocial approaches allowed the use of concomitant medications, such as antidepressants, anxiolytics or even antipsychotics that were not controlled for, but made part of the standard control treatment. Also, all studies that compared add-on pharmacotherapy or the use of amino-acids and omega-3, also allowed psychosocial approaches as part of the control group. Comparisons that include different psychosocial approaches are very difficult, for at least several reasons: 1) comparison between different psychotherapies is not reliable if the compare different numbers and durations of sessions; 2) the definition of a standard control treatment may vary significantly from site to site due to the basic psychotherapy training of the psychiatrists in a respective country; 3) supportive therapy may incorporate elements from different psychotherapy approaches, and this may interfere with other approaches included in the 'intervention group' as well as intervention psychotherapy, as, for example, CBT also includes elements of supportive psychotherapy.

Results for omega-3 studies should be interpreted with caution as the results are based on the results from one study, and the follow-up of seven years (6 years after the intervention was finished), without the estimation of other treatment methods on the studied outcomes that the participants received over the studied period. In summary, all studies analysed complex multimodal treatment, with different designs. Therefore, it is possible that different approaches are quite effective to a similar degree in the treatment of prodromes, rather than being ineffective.

### 3. Potential harms of tested interventions

One study indicated significantly higher weight gain for the combination of olanzapine and supportive intervention compared to the control group, which received a combination of placebo and supportive intervention. There were no other clear differences in serious adverse events between interventions in either of the analysed studies. Therefore, none of the interventions analysed in the studies included in this systematic review were associated with significant harmful effects.

#### Quality of the evidence

The majority of included studies were influenced by different domains of risk of bias at some level. Fifteen studies had one or more domains that we graded as high risk of bias, while all of them had one or more with an unclear risk of bias (Figure 1; Figure 2). GRADE assessment of evidence within the 'Summary of findings' tables indicated that key outcomes presented in these are based on very low- or low-quality evidence. These limitations in study design, selective reporting and imprecision often can be avoided while conducting studies. Overall, this review included 20 studies with a total sample size of 2151 participants. One large study with a sample size of 1000 would have answered many of the questions that continue to linger with really poor levels of data. Although it is often difficult to achieve compliance in a vulnerable population like young people with prodromal symptoms of psychosis, it is needed for reliable results and adequate assessment of an intervention. Researchers should consider different options that could help to improve compliance (e.g. more frequent check-ups), as well as to assure better reporting standards. Both compliance and higher reporting standards would help to improve study quality (see [Implications for research](#)).

#### Potential biases in the review process

There are many ways in which bias could have been introduced into this review but we have made a great effort to use adequate methodological approaches and included co-authors without conflicts of interest.

#### 1. Study selection and data extraction

Searches predominantly used English terms and studies only undertaken and reported in the non-English speaking world could have been missed. The Cochrane Schizophrenia Group's register of studies is compiled from multilingual searches in many different databases but indexing is in English - so that English language searches should have identified the study if relevant. We think it unlikely that large important studies have been missed.

To reduce the possibility of mistakes during study selections, two review authors independently screened all bibliographic records obtained by the search, and we used the same method for screening full texts, extracting data, assessing risk of bias and grading the quality of evidence.

It is likely we have made mistakes in data extraction. This has been painstaking work and it is more than probable that some numbers are not fully accurate. We welcome any comments to help improve this review. We do not think that our mistakes are anything but random - more the function of exhaustion rather than systematic bias.

### 2. Review author conflict of interest

Authors of this review have no conflicts of interest to declare.

#### Agreements and disagreements with other studies or reviews

A number of other reviews on this topic were published recently.

The 2015 European Psychiatric Association (EPA) guidance formulated seven evidence-based recommendations for early intervention in people at high risk of psychosis, but they emphasised that more studies are needed to investigate the specificity of treatment effects and potential age effects in order to tailor interventions to the individual's treatment needs and risk status (Schmidt 2015). The 2017 Canadian treatment guidelines for people at clinical high risk of psychosis used a systematic search for evidence (Addington 2017). Their conclusion is that a staged approach with psychological treatments should be the first-line treatment and that pharmacotherapy should be reserved for adults, people who did not respond to psychological interventions and those who had more severe symptoms. These guidelines include nine recommendations about diagnosis and treatment, with various strength of evidence (Addington 2017).

Two network meta-analyses were published in 2018 on this subject (Davies 2018a; Davies 2018b). The first one (Davies 2018a), analyzed efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinically high risk of psychosis, and looked only into follow-up of six and 12 months. In our review, we looked into longer follow-up times. The authors concluded that there was no robust evidence to favour any specific intervention for improving attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis. The second network meta-analysis (Davies 2018b), about preventive interventions in psychosis, also concluded that there was no evidence that any specific intervention is particularly effective over any other intervention in preventing transition to psychosis. Results of both of those network meta-analyses are in line with our conclusion that there was no convincing, unbiased, high-quality evidence to suggest that any type of intervention is of value for people at prodromal stage of psychosis in terms of preventing development of psychosis. Compared to these reviews, our review included longer follow-up times and more studies.

Devoe and colleagues used systematic review and network meta-analysis to analyse efficacy and safety of negative symptom interventions in young people at risk of psychosis. They included both observational studies and those with experimental treatments. They found that no treatments significantly reduced negative symptoms and in the network meta-analysis all confidence intervals overlapped the null line. Additionally, the authors warned that many relevant studies had small samples and the majority of studies was not designed to target negative symptoms (Devoe 2018a). A second systematic review and meta-analysis from this group found that no treatment significantly improved social functioning in young people at risk of psychosis (Devoe 2018b). A third study from this group analysed attenuated psychotic symptom (APS) interventions in young people at risk of psychosis and found that, although participants treated with CBT demonstrated a slight trend in reducing APS by long-term follow-up compared to participants from control groups, no interventions were significantly more effective at reducing APS compared to all

other interventions in network meta-analysis - again in line with the findings of this review (Devoe 2018c). We think networking of the data in this area has been ill-advised. Nikolakopoulou found network analyses are not indicated when data are few, there are few common comparisons, there are no differences in the pair-wise comparisons and networks are insufficiently connected (Bergman 2017), and all these indicators would apply to our findings.

## AUTHORS' CONCLUSIONS

### Implications for practice

#### 1. For participants in prodromal stage of psychosis

There is no convincing, unbiased, high-quality evidence to suggest that any type of intervention for preventing the development of illness in at-risk individuals in the prodromal stage of psychosis is superior to the comparators. There is a lot of very low-quality evidence but nothing that supports, or refutes the use of any or no treatment approach. The low-quality evidence regarding some benefit from taking omega-3 fatty acids in terms of reduced transitions to psychosis could be used to support longer-term use of this as omega-3 did not seem to do any harm. Even this evidence was not very convincing and serves to 'medialise' the issue for many young people. However, the latter may be less of a danger than suggesting therapy is helpful when it is not clearly the case.

#### 2. For physicians

Various interventions have been tested for treatment of individuals with prodromal symptoms of psychosis, with no or very little difference among them. There is limited evidence that several interventions may be beneficial but those data are based on low, or very low-quality evidence that require unbiased replication. Olanzapine is probably ill-advised because of the early weight gain. The current level of evidence is insufficient to recommend routine use of any of the interventions - all must be seen as experimental.

#### 3. For policymakers

Those who make policy have little to guide them from studies. Any policy, therefore, will be founded on opinion and evidence from potentially less rigorous evaluations.

### Implications for research

#### 1. Current reporting

If all studies had complied with good reporting standards (CONSORT), or, even better, made all data available, as is encouraged by the AllTrials initiative, we would know more from already existing data. Selective and poor reporting of data resulted in loss of information which would never have been what people entering the study would have agreed to. This represents waste of opportunity, resource, evidence and trust (Glasziou 2018).

#### 2. Future studies

This is an area of research where new, large, methodologically rigorous studies are necessary, that will yield high-quality evidence about the benefits and harms of interventions used for treatment of individuals at risk of developing psychosis. The majority of currently available studies were small, with fewer than 50 participants per arm, and they suffered from a number of methodological shortcomings, and selective reporting. These problems can be avoided with adequate study design planning,

and inclusion of larger numbers of participants. Available studies have analysed a limited number of clinically relevant outcomes, which should be rectified in future studies. The major obstacle in analysing the results of this review is the difficulty in interpreting results on key outcomes in a pragmatic way, as described in the section Applicability (Overall completeness and applicability of evidence). Thus, in future studies focusing on comparing the efficacy and effectiveness of different psychosocial approaches, especially in combination with pharmacotherapy, a clearer delineation of intervention and control treatment is necessary. Study design should incorporate measurements that could objectify as much as possible the effect of each intervention specifically. Control conditions should be kept as neutral as possible. The inclusion of interventions as part of standard treatment (such as medication or counselling or psychoeducation etc.) imports a bias from the beginning of the study, as the intervention is not compared to a neutral (non-treatment condition or placebo) control, but to an active control, which in many case may already be quite effective for the treatment of the prodromes.

It is particularly important to conduct long-term studies for proper assessment of those interventions.

As can be seen from this review, many things have been tested for people with prodromal illnesses. We do realise that it takes great time and effort to draw up a protocol for a new study, but we have given this some thought and seen and thought about all existing studies. Considering the fact that there is no gold standard for the treatment of prodromal psychosis, and that all available treatments are actually new and unproven, it is difficult to suggest what a new intervention should be compared against. On the other hand, comparison to a placebo group or people on a waiting list for treatment over a period of adequate study duration (for example six months) is not feasible as it requires denying any treatment to people at risk. Moreover, considering that people at risk do not hold 'firm' psychiatric diagnosis, the principle of 'first do no harm' is even more important. Thus, we suggest a two-stage research approach: first, to compare low-dose, antipsychotics versus any psychosocial programme available in the setting (defined as treatment as usual). In the second step, different components of the psychosocial programme should be compared against each other, but should follow similar rules in the duration, frequency and number of sessions. We sketch an outline for such a study in Table 2, emphasising the relevance of choosing adequate interventions and comparators, as well as the need for longer follow-up of participants.

It is clear that greater collaboration in the conduct of studies in this area would greatly enhance the existing evidence-base. There are now many examples of collaboration between trialists, clinicians and patients on deciding what to measure as outcomes, and how and when to measure these outcomes (COMET). We see no reason why this subgroup of subspecialists should be exempt from working together to get compromise and larger sets of high-quality data.

## ACKNOWLEDGEMENTS

The Cochrane Schizophrenia Editorial Base in Nottingham produces and maintains standard text for use in the Methods section of their reviews. We have used this text as the basis of what appears here and adapted it as required.



We would like to thank Mahmoud Alkhatib and Mariam A Khokhar for peer reviewing the protocol; and Elizabeth Royle and her CES team for copy-editing.

We would also like to thank Genevieve Gariepy for peer reviewing the review.

Parts of this review were generated using Review Manager (RevMan) HAL v 4.2. You can find more information about RevMan HAL [here](#).

## REFERENCES

### References to studies included in this review

#### ADAPT-Canada {published data only}

\* Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB. A randomised controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. *Schizophrenia Research* 2011;**125**(1):54-61. [CSzG: Ref21945]

Addington J, Zipursky R, Epstein I. ADAPT (Access, Detection and Psychological Treatments). *Schizophrenia Research* 2006;**86**(Suppl 1):S6. [CSzG: Ref13364]

NCT00260273. Access, detection and psychological treatments. [www.ClinicalTrials.gov/ct/show/](http://www.ClinicalTrials.gov/ct/show/) 2005. [CSzG: Ref14638]

#### Amminger-Austria {published data only}

Amminger G. Ethyl eicosapentanoic acid for prodromal psychosis. Stanley Foundation Research Programs 2009. [CSzG: Ref17423]

Amminger G, Schafer M, Papageorgiou K, Cotton S, Harrigan S, Mackinnon A, et al. Indicated prevention with long-chain omega-3 fatty acids in adolescents at ultra-high-risk for psychosis: a randomised, placebo-controlled trial. *Early Intervention in Psychiatry* 2008;**2**(Suppl 1):A29. [CSzG: Ref19107]

Amminger GP, Chanen AM, Ohmann S, Klier CM, Mossaheb N, Bechdolf A, et al. Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomised controlled trial. *Canadian Journal of Psychiatry* 2013;**58**(7):402-8. [CSzG: Ref28534]

Amminger GP, Harris MS, McGorry PD, Henry LP. Omega-3 fatty acids for indicated prevention: treatment results and pathomechanisms. *European Archives of Psychiatry and Clinical Neuroscience* 2013;**263**(Suppl. 1):S44-5. [CSzG: Ref28434]

Amminger GP, Leicester S, Yung AR, Yuen HP, McGorry PD. Age predicts transition to psychosis in an ultra-high risk sample. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25-28; Copenhagen, Denmark. 2002:61.

Amminger GP, McGorry PD. Update on omega-3 polyunsaturated fatty acids in early -stage psychotic disorders. *Neuropsychopharmacology* 2012;**37**(1):309-10. [CSzG: Ref23726]

Amminger GP, Mechelli A, Rice S, Kim SW, Klier CM, McNamara RK, et al. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids. *Translational Psychiatry* 2015;**5**:e495. [CSzG: Ref29299]

Amminger GP, Schafer MR. Indicated prevention with omega-3 fatty acids in adolescents at ultra-high risk for psychosis - rationale, methods, and 3-months outcome. *Schizophrenia Research* 2006;**86**(Suppl 1):S97-8. [CSzG: Ref13367]

Amminger GP, Schafer MR. Is it feasible to conduct a RCT in ultra-high risk individuals at a child and adolescent psychiatric

service?. *Schizophrenia Research* 2006;**86**(Suppl 1):S98. [CSzG: Ref13368]

Amminger GP, Schafer MR, Klier CM, Papageorgiou K, Slavik J, Holzer I, et al. Indicated prevention with long-chain omega-3 fatty acids in young people at ultra-high risk for psychosis: a randomised, placebo-controlled trial. *Early Intervention in Psychiatry* 2010;**4**(Suppl 1):7. [CSzG: Ref23467]

Amminger GP, Schafer MR, Schlogelhofer M, Klier CM, McGorry PD. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. *Nature Communications* 2015;**6**:7934. [CSzG: Ref33023]

Amminger GP, Schlogelhofer M, Klier C, McGorry P, Schafer M. Longer-term follow-up in the Vienna omega-3 psychosis prevention trial. *Early Intervention in Psychiatry* 2014;**8**:41. [CSzG: Ref29378]

Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo-controlled trial. *Archives of General Psychiatry* 2010;**67**(2):146-54. [CSzG: Ref20680; DOI: [10.1001/archgenpsychiatry.2009.192](https://doi.org/10.1001/archgenpsychiatry.2009.192).]

Amminger P, Mossaheb N, Schlogelhofer M, Schafer M. Fatty acid metabolism and the onset of psychotic disorder. *European Psychiatry* 2011;**26**(Suppl 1):2089. [CSzG: Ref22967]

Anonymous. Fish oil may help ward off psychosis. *Journal of Psychosocial Nursing and Mental Health Services* 2010;**48**(5):55. [CSzG: Ref20739]

Berger G, Amminger P, McGorry P. Stage dependant effect of omega-3 fatty acids in emerging psychosis. *European Psychiatry* 2011;**26**(Suppl 1):1347. [CSzG: Ref22966]

Berger GE, Proffitt TM, McConchie M, Yuen H, Wood SJ, Amminger GP, et al. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomised, placebo-controlled trial. *Journal of Clinical Psychiatry* 2007;**68**(12):1867-75. [CSzG: Ref15561; ISSN: 1555-2101]

Ehrlich A. Evidence-based medicine. Omega-3 supplementation delays transition to psychotic disorder in ultra-high-risk adolescents and young adults. *Clinical Advisor for Nurse Practitioners* 2010;**13**(5):79-80. [CSzG: Ref21562]

Föcking M, Dicker P, Lopez LM, Cannon M, Schäfer MR, McGorry PD, et al. Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder?. *BMC Psychiatry* 2016;**16**(1):326. [DOI: [10.1186/s12888-016-1039-7](https://doi.org/10.1186/s12888-016-1039-7)]

Klier C, Hollmann M, Schlogelhofer M, Mossaheb N, Friedrich M, Amminger PG. Indicated prevention with omega-3 fatty acids (EPA/DHA) in adolescents with "at-risk-mental-state" for psychosis. 8th World Congress of Psychiatry; 2005 Sep 10-15; Cairo, Egypt. 2005. [CSzG: Ref12438]

Lavoie S, Benninger F, Feucht M, Klier CM, Schaefer MR, Amminger GP. Correlates of EEG resting states with erythrocyte membrane omega-3 fatty acid levels and psychopathological symptoms in individuals at ultra-high risk for psychosis. *Early Intervention in Psychiatry* 2014;**8**:137. [CSzG: Ref29516]

Lavoie S, Schafer MR, Whitford TJ, Benninger F, Feucht M, Klier CM, et al. Frontal delta power associated with negative symptoms in ultra-high risk individuals who transitioned to psychosis. *Schizophrenia Research* 2012;**138**(2-3):206-11. [CSzG: Ref24256]

Lavoie S, Schafer MR, Whitford TJ, Benninger F, Feucht M, Klier CM, et al. Frontal delta power associated with negative symptoms in ultrahigh risk individuals who transitioned to psychosis. *Early Intervention in Psychiatry* 2012;**6**:38. [CSzG: Ref24960]

Mossaheb N, Papageorgiou K, Schafer MR, Becker J, Schloegelhofer M, Amminger GP. Changes in triglyceride levels in ultra-high risk for psychosis individuals treated with omega-3 fatty acids. *Early Intervention in Psychiatry* 2018; Vol. 12, issue 1:30-36. [DOI: [10.1111/eip.12275](https://doi.org/10.1111/eip.12275)]

Mossaheb N, Schafer MR, Schloegelhofer M, Klier CM, Cotton SM, McGorry PD, et al. Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. *Schizophrenia Research* 2013;**148**(1-3):163-7. [CSzG: Ref28649]

NCT00396643. Indicated prevention with omega-3 fatty acids in adolescents with 'at-risk-mental-state' for psychosis: a randomised, double blind, placebo-controlled treatment trial. [www.ClinicalTrials.gov/ct/show/](http://www.ClinicalTrials.gov/ct/show/) 2006. [CSzG: Ref14873]

Papageorgiou K, Schafer MR, Schloegelhofer M, Mossaheb N, Amminger GP. Indicated prevention with omega-3 fatty acids in young people with 'at-risk-mental-state' for psychosis: design of a 5-year follow-up. *European Archives of Psychiatry and Clinical Neuroscience* 2011;**261**:S55. [CSzG: Ref23749]

Schafer MR, Klier CM, Papageorgiou K, Friedrich MH, Amminger GP. Early detection of psychotic disorders. *Neuropsychiatrie* 2007;**21**(1):37-44. [CSzG: Ref15290]

Smesny S, Milleit B, Hipler UC, Milleit C, Schafer MR, Klier CM, et al. Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. *Molecular Psychiatry* 2013;**19**(3):317-24. [CSzG: Ref28243]

Smesny S, Milleit B, Schaefer MR, Hesse J, Schlögelhofer M, Langbein K, et al. Effects of omega-3 PUFA on immune markers in adolescent individuals at ultra-high risk for psychosis - results of the randomised controlled Vienna omega-3 study. *Schizophrenia Research* 2017;**S0920-9964**(17):30039-7. [DOI: [10.1016/j.schres.2017.01.026](https://doi.org/10.1016/j.schres.2017.01.026)]

#### **Choi-USA** {published data only}

Choi J, Corcoran C, Dixon L, Fiszdon J, Javitt D. Processing speed training and social functioning in young adults at clinical high risk for psychosis: a pilot study. *Early Intervention in Psychiatry* 2014;**8**:109. [CSzG: Ref29417]

Choi J, Corcoran C, Dixon L, Javitt DC. Processing speed training and social functioning in teenagers and young adults at clinical high risk for psychosis. *Schizophrenia Bulletin* 2015;**41**:S41. [CSzG: Ref29418]

Choi J, Corcoran CM, Fiszdon JM, Stevens M, Javitt DC, Deasy M, et al. Pupillometer-based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. *Psychiatric Rehabilitation Journal* 2017;**40**(1):33-42. [CSzG: Ref35317]

#### **DEPTH-Australia** {published data only}

Crittenden K, Fleming J, Startup M, Carr V, Baker A, Schall U, et al. Recruitment and engagement of youth in an ultra high risk treatment study. *Early Intervention in Psychiatry* 2008;**2**(Suppl 1):A127. [CSzG: Ref19115]

Stain H, Bucci S, Halperin S, Emsley R, Shall U, Lewin T, et al. DEPTH: randomised controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis. *Early Intervention in Psychiatry* 2014;**8**:15. [CSzG: Ref29673]

Stain HJ, Bucci S, Baker A, Carr V, Emsley R, Halpin S, et al. A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPTH) trial. *European Archives of Psychiatry and Clinical Neuroscience* 2015;**1**:S8-9. [CSzG: Ref33810]

Stain HJ, Bucci S, Baker AL, Carr V, Emsley R, Halpin S, et al. A randomised controlled trial of cognitive behaviour therapy versus non-directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTH) trial. *Schizophrenia Research* 2016;**176**(2-3):212-9. [CSzG: Ref35298]

Stain HJ, Crittenden K, Startup M, Carr V, Baker A, Schall U, et al. Rural and urban youth at ultra high risk for psychosis: baseline characteristics from the DEPTH randomised controlled trial of cognitive behavior therapy. *Schizophrenia Bulletin* 2011;**37**:322. [CSzG: Ref22815]

Stain HJ, Crittenden K, Startup M, Carr V, Baker A, Schall U, et al. The DEPTH randomised controlled trial of cognitive behaviour therapy for youth at ultra high risk for psychosis: baseline characteristics for rural and urban youth. *Australian and New Zealand Journal of Psychiatry* 2010:25-6. [CSzG: Ref21845]

Stain HJ, Crittenden K, Startup M, Carr V, Baker A, Schall U, et al. The DEPTH randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth. *Early Intervention in Psychiatry* 2010;**4**(Suppl 1):113. [CSzG: Ref23498]

Stain HJ, Startup M, Carr V, Baker A, Schall U. The DEPTH project: a multisite RCT for youths at risk for psychosis. *Schizophrenia Research* 2006;**86**(Suppl 1):S51-2. [CSzG: Ref13401]

Startup M. The DEPTH project: detection, evaluation, and psychological therapy for health. *Australian New Zealand Clinical Trials Registry* 2006. [CSzG: Ref18442]

**EDIE-2-UK** {published data only}

Byrne RE, Morrison AP. Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. *Psychology and Psychotherapy* 2014;**87**(3):357-71. [CSzG: Ref29312]

Flach C, French P, Dunn G, Fowler D, Gumley AI, Birchwood M, et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE-2 trial. *British Journal of Psychiatry* 2015;**207**(2):123-9. [CSzG: Ref33109]

Morrison A. Early detection and intervention evaluation for individuals at high risk of psychosis 2. <http://www.controlled-trials.com> 2008. [CSzG: Ref18285]

Morrison A. Early detection and intervention evaluation for people at risk of psychosis (edie-2): A multisite randomised controlled trial of cognitive therapy for at-risk mental states. *Early Intervention in Psychiatry* 2012;**6**:11. [CSzG: Ref24968]

Morrison A, French P, Bentall R, Lewis S, Birchwood M, Fowler D, et al. Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. *Early Intervention in Psychiatry* 2008;**2**(Suppl 1):A15. [CSzG: Ref19128]

Morrison AP. EDIE-2: early detection and psychological intervention for individuals at high risk of psychosis (2). [www.controlled-trials.com](http://www.controlled-trials.com) 2007. [CSzG: Ref15381]

Morrison AP, Birchwood M, Pyle M, Flach C, Stewart SL, Byrne R, et al. Impact of cognitive therapy on internalised stigma in people with at-risk mental states. *British Journal of Psychiatry* 2013;**203**(2):140-5. [CSzG: Ref28630]

Morrison AP, French P, Stewart SL, Birchwood M, Fowler D, Gumley AI, et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. *BMJ* 2012;**344**(7852):e2233. [CSzG: Ref24208]

Morrison AP, French P, Stewart SL, Birchwood M, Fowler D, Gumley AI, et al. Early detection and intervention evaluation for people at-risk of psychosis. *Schizophrenia Research* 2012;**136**:S17. [CSzG: Ref29554]

Morrison AP, Pyle M, Stewart SL, French P, Byrne R, Flach C, et al. Internalised stigma in young people at high risk of developing psychosis: findings from a cognitive therapy trial. *Schizophrenia Research* 2014;**153**:S42. [CSzG: Ref29555]

Morrison AP, Stewart SL, French P, Bentall RP, Birchwood M, Byrne R, et al. Early detection and intervention evaluation for people at high-risk of psychosis-2 (EDIE-2): trial rationale, design and baseline characteristics. *Early Intervention in Psychiatry* 2011;**5**(1):24-32. [CSzG: Ref22695]

Morrison T. Early detection and psychological intervention for individuals at high risk of psychosis. EDIE-2. Data on File 2006. [CSzG: Ref13874]

Pelosi AJ. Rational policy making for early psychosis might yet become possible. *BMJ* 2012;**344**(7856):e3137. [CSzG: Ref24326]

Pyle M, Stewart SL, French P, Byrne R, Patterson P, Gumley A, et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. *Early Intervention in Psychiatry* 2015;**9**(2):133-40. [CSzG: Ref29813]

**EDIE-NL** {published data only}

Dragt S, Van der Gaag M. Prevention of psychosis with a cognitive behavioural intervention in help-seeking young people with an at risk mental state for developing psychosis. [www.trialregister.nl/trialreg/index.asp](http://www.trialregister.nl/trialreg/index.asp) 2007. [CSzG: Ref19655]

Ising HK, Kraan TC, Rietdijk J, Dragt S, Klaassen RM, Boonstra N, et al. Four-year follow-up of cognitive behavioral therapy in persons at ultra-high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE-NL) trial. *Schizophrenia Bulletin* 2016;**42**(5):1243-52. [CSzG: Ref35214]

Ising HK, Lokkerbol J, Rietdijk J, Dragt S, Klaassen RM, Kraan T, et al. Four-year cost-effectiveness of cognitive behavior therapy for preventing first-episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE-NL) trial. *Schizophrenia Bulletin* 2017;**43**(2):365-74. [CSzG: Ref35824]

Ising HK, Smit F, Veling W, Rietdijk J, Dragt S, Klaassen RM, et al. Cost-effectiveness of preventing first-episode psychosis in ultra-high-risk subjects: multi-centre randomised controlled trial. *Psychological Medicine* 2015;**45**(7):1435-46. [CSzG: Ref27798]

Kraan TC, Ising HK, Fokkema M, Velthorst E, Van den Berg DP, Kerkhoven M, et al. The effect of childhood adversity on 4-year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial. *Psychiatry Research* 2017;**247**:55-62. [CSzG: Ref35559]

Nieman DH, Ruhrmann S, Rietdijk J, Dragt S, Ising H, Klaassen R, et al. Preventive psychotherapy. *Schizophrenia Research* 2014;**153**:S42-3. [CSzG: Ref29601]

Rietdijk J, Dragt S, Klaassen R, Ising H, Nieman D, Wunderink L, et al. A single blind randomised controlled trial of cognitive behavioural therapy in a help-seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial. *Trials* 2010;**11**:30. [CSzG: Ref20654]

Van Der Gaag M. The effects of CBT in persons with ultra high risk: the Dutch EDIE trial. *European Archives of Psychiatry and Clinical Neuroscience* 2011;**261**:S18. [CSzG: Ref23756]

Van Der Gaag M, Nieman D, Wunderink L, Klaassen R, Rietdijk J, Dragt S, et al. The results of a specific CBT intervention in young help-seeking patients with social decline and an ultra-high risk for developing a first-episode of psychosis. *Early Intervention in Psychiatry* 2012;**6**:12. [CSzG: Ref24985]

Van Der Gaag M, Nieman DH, Rietdijk J, Dragt S, Ising HK, Klaassen RMC, et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomised controlled clinical trial. *Schizophrenia Bulletin* 2012;**38**(6):1180-8. [CSzG: Ref24935]

Van Der Gaag M, Nieman DH, Rietdijk J, Dragt S, Ising HK, Klaassen RMC, et al. The effects of cognitive behavioural

therapy for subjects at ultra-high risk for developing psychosis. *Schizophrenia Bulletin* 2013;**39**:S356. [CSzG: Ref28121]

Van der Gaag M. The prevention of psychosis in at risk mental state. [www.controlled-trials.com](http://www.controlled-trials.com) 2008. [CSzG: Ref17488]

Van der Gaag M, Nieman D, Van den Berg D. CBT for those at risk of a first episode psychosis: Evidence-based psychotherapy for people with an 'at risk mental state'. 1st Edition. Hove, UK: Routledge, 2013.

Van der Gaag M, Nieman D, Wunderink L, Klaassen R, Rietdijk J, Dragt S, et al. The results of a specific CBT intervention in young help-seeking patients with social decline and an ultra-high risk for developing a first episode of psychosis. *Schizophrenia Research* 2012;**136**:S17. [CSzG: Ref29692]

#### EDIE-UK {published data only}

French P, Shryane N, Bentall RP, Lewis SW, Morrison AP. Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. *British Journal of Psychiatry. Supplements* 2007;**191**(Suppl 51):s82-7. [CSzG: Ref16121]

Lewis S. EDIE - Early detection and intervention for psychosis. National Research Register 2001; Vol. 3. [CSzG: Ref13023]

Lewis S. EDIE - early detection and intervention for psychosis (in primary care). National Research Register 2002; Vol. 1. [CSzG: Ref9342]

Morrison A. Early detection and intervention for psychosis in primary care. National Research Register 2003. [CSzG: Ref15485]

Morrison A. Findings from a randomised controlled trial and clinical service delivering cognitive therapy to people at ultra-high risk of developing psychosis. *Schizophrenia Research* 2004;**70**(1):43-4. [CSzG: Ref11526]

Morrison A. Follow-up of prodromal symptoms. National Research Register 2004; Vol. 3. [CSzG: Ref13036]

Morrison A, Bentall R, French P, Kilcommons A, Lewis SW. Very early intervention in prodromal psychosis: a randomised trial. *Schizophrenia Research* 2002;**53**(3 Suppl 1):42. [CSzG: Ref8096]

Morrison A, French P, Walford L, Lewis S, Kilcommons A, Green J, et al. A randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra-high risk. *Schizophrenia Research* 2004;**67**(1):7. [CSzG: Ref11324]

Morrison A, French P, Watford L, Lewis S, Kilcommons A, Green J, et al. Randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra-high risk. *Schizophrenia Research* 2004;**70**(1):63. [CSzG: Ref11527]

Morrison AP. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: results of a randomised controlled trial. *Schizophrenia Research* 2006;**86**(Suppl 1):S59. [CSzG: Ref13388]

Morrison AP, Bentall RP, French P, Kilcommons A, Green J, Walford L, et al. Cognitive therapy in ultra high risk individuals

for psychosis: randomised controlled trial. *Schizophrenia Research* 2003;**60**:326. [CSzG: Ref9726]

Morrison AP, Bentall RP, French P, Walford L, Kilcommons A, Knight A, et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals. Study design and interim analysis of transition rate and psychological risk factors. *British Journal of Psychiatry. Supplements* 2002;**181**(43):s78-84. [CSzG: Ref8737]

Morrison AP, Bentall RP, French P, Walford L, Kilcommons A, Lewis S. Early detection and intervention for psychosis in primary care. 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002. [CSzG: Ref8932]

Morrison AP, French P, Parker S, Roberts M, Stevens H, Bentall RP, et al. Three-year follow-up of a randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. *Schizophrenia Bulletin* 2007;**33**(3):682-7. [CSzG: Ref15288]

Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. *British Journal of Psychiatry* 2004;**185**:291-7. [CSzG: Ref11450]

Morrison T. Early detection and intervention for psychosis in primary care. National Research Register 2001; Vol. 1. [CSzG: Ref13037]

Morrison T, Bentall R, French P, Kilcommons A, Green J, Lewis S. Early detection and intervention for psychosis in primary care. 3rd International Conference on Early Psychosis; 2002 Sep 25-28; Copenhagen, Denmark. 2002:44. [CSzG: Ref8932]

Renton J, Morrison A. Effectiveness of cognitive therapy for psychosis and implications for early intervention. *Schizophrenia Research* 2004;**70**(1):142. [CSzG: Ref11536]

#### EDIP-USA {unpublished data only}

McFarlane WR, Cook WL, Woodberry KA. A randomised clinical trial of familyaided assertive community treatment for young persons at high risk for onset of an initial psychosis. *Schizophrenia Bulletin* 2011;**37**:314. [CSzG: Ref22796]

\* NCT01597141. Psychosis: early detection, intervention and prevention. [ClinicalTrials.gov/show/NCT01597141](http://ClinicalTrials.gov/show/NCT01597141) 2012. [CSzG: Ref24315]

#### EIPS-Germany {published data only}

Bechdolf A. Preventing progression to first-episode psychosis in people in the early initial prodromal state. *Early Intervention in Psychiatry* 2012;**6**:11. [CSzG: 24944]

Bechdolf A, Buhler B, Berning J, Wagner M, Stamm E, Streit M. Cognitive behavioural therapy in the early initial prodromal state of psychosis: first results. *Schizophrenia Research* 2004;**67**(1):202. [CSzG: Ref11285]

Bechdolf A, Klosterkötter J. Cognitive-behavioural treatment (CBT) in the early initial prodromal state of psychosis: concept and practical approach. *Schizophrenia Research* 2004;**70**(1):52. [CSzG: Ref11506]

Bechdorf A, Ruhrmann S, Janssen B, Bottlender R, Wagner M, Maurer K, et al. Early recognition and intervention for people at risk of schizophrenia [Früherkennung und intervention bei personen mit erhöhtem psychoserisiko]. *Psychoneuroendocrinology* 2004;**30**(11):606-14. [CSzG: Ref11376]

Bechdorf A, Ruhrmann S, Wagner M, Kuhn KU, Janssen B, Bottlender R, et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. *British Journal of Psychiatry. Supplements* 2005;**187**(Suppl 48):s45-8. [CSzG: Ref12511]

Bechdorf A, Veith V, Berning J, Stamm E, Decker P, Janssen B, et al. Cognitive behavioral therapy (CBT) in the early initial prodromal state of psychosis: first results of a randomised trial. *Schizophrenia Research* 2004;**70**(1):62-3. [CSzG: Ref11507]

Bechdorf A, Wagner M, Ruhrmann S, Harrigan S, Putzfeld V, Pukrop R, et al. Preventing progression to first-episode psychosis in early initial prodromal states. *British Journal of Psychiatry* 2012;**200**(1):22-9. [CSzG: Ref24206]

Bechdorf A, Wagner M, Ruhrmann S, Harrigan S, Veith V, Pukrop R, et al. CBT for prevention of first episode psychosis in people in an putative early initial prodromal state. *Early Intervention in Psychiatry* 2008;**2**(Suppl 1):A16. [CSzG: 19109]

Bechdorf A, Wagner M, Veith V, Pukrop R, Berning J, Stamm E, et al. A randomised controlled trial of cognitive-behavioral therapy in the early initial prodromal state of psychosis. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:22-3. [CSzG: 20193]

Bechdorf A, Wagner M, Veith V, Ruhrmann R, Janssen B, Bottlender R, et al. A randomised controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. *Schizophrenia Research* 2006;**86**(Suppl 1):S8. [CSzG: 13369]

Bechdorf A, Wagner M, Veith V, Ruhrmann S, Pukrop R, Brockhaus-Dumke A, et al. Randomised controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. *Early Intervention in Psychiatry* 2007;**1**(1):71-8. [CSzG: 16450]

Bechdorf A, Wessels H, Wagner M, Kuhr K, Berning J, Putzfeld V, et al. Predictors of treatment response to psychosocial interventions in people at risk. *European Archives of Psychiatry and Clinical Neuroscience* 2015;**1**:S9. [CSzG: 33601]

Hafner H, Maurer K, Ruhrmann S, Bechdorf A, Klosterkotter J, Wagner M, et al. Early detection and secondary prevention of psychosis: facts and visions. *European Archives of Psychiatry and Clinical Neuroscience* 2004;**254**(2):117-28. [CSzG: 18539]

Komescher M, Wagner M, Putzfeld V, Berning J, Janssen B, Decker P, et al. Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. *Early Intervention in Psychiatry* 2016;**10**(1):17-27. [CSzG: 32187]

NCT00204087. Psychological intervention for persons at risk of psychosis in the early initial prodromal state. [www.ClinicalTrials.gov/ct/show/](http://www.ClinicalTrials.gov/ct/show/) 2005. [CSzG: 14890]

Wessels H, Wagner M, Frommann I, Berning J, Putzfeld V, Janssen B, et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. *Psychiatrische Praxis* 2015;**42**(6):313-9. [CSzG: 33130]

Zarafonitis S, Wagner M, Putzfeld V, Berning J, Janssen B, Decker P, et al. Psychoeducation for persons at risk of psychosis. *Psychotherapeut* 2012;**57**(4):326-34. [CSzG: 24807]

#### **Kantrowitz-USA** {published data only}

Kantrowitz JT, Woods SW, Petkova E, Cornblatt B, Corcoran CM, Chen H, et al. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. *Lancet Psychiatry* 2015;**2**(5):403-12. [CSzG: 29487]

NCT00826202. D-serine for the schizophrenia prodrome. [www.ClinicalTrials.gov/ct/show/](http://www.ClinicalTrials.gov/ct/show/) 2009. [CSzG: 17391]

#### **LIPS-Germany** {published data only}

Bechdorf A, Ruhrmann S, Wagner M, Kuhn KU, Janssen B, Bottlender R, et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. *British Journal of Psychiatry. Supplements* 2005;**187**(Suppl 48):s45-8. [CSzG: 12511]

Hafner H, Maurer K, Ruhrmann S, Bechdorf A, Klosterkotter J, Wagner M, et al. Early detection and secondary prevention of psychosis: facts and visions. *European Archives of Psychiatry and Clinical Neuroscience* 2004;**254**(2):117-28. [CSzG: 18539]

Ruhrmann S, Bechdorf A, Kuhn KU, Wagner M, Schultze-Lutter F, Janssen B, et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. *British Journal of Psychiatry. Supplements* 2007;**51**:s88-95. [CSzG: 16127]

Ruhrmann S, Hoppmann B, Theysohn S, Picker H, Kuhn K-U, Schultze-Lutter F, et al. Acute symptomatic treatment effects in persons clinically at risk for psychosis. *Schizophrenia Research* 2006;**86**(Suppl 1):S8. [CSzG: 13397]

Ruhrmann S, Hoppmann B, Theysohn S, Picker H, Kuhn K-U, Schultze-Lutter F, et al. Intervention in the late initial prodromal state (LIPS) of psychosis. *Schizophrenia Research* 2006;**86**(Suppl 1):S96. [CSzG: 13398]

#### **Miklowitz-USA** {published data only}

Marvin SE, Miklowitz DJ, O'Brien MP, Cannon TD. Family-focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomised trial. *Early Intervention in Psychiatry* 2016;**10**(2):137-43. [CSzG: 29018]

Marvin SE, Miklowitz DJ, O'Brien MP, Cannon TD. Treatment fidelity and differentiation in a randomised controlled trial of family-focused therapy for youth at clinical high risk of

psychosis. *Early Intervention in Psychiatry* 2012;**6**:95. [CSzG: 24965]

Miklowitz DJ, O'Brien MP, Schlosser DA, Addington J, Candan KA, Marshall C, et al. Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomised trial. *Journal of the American Academy of Child and Adolescent Psychiatry* 2014;**53**(8):848-58. [CSzG: 29019]

NCT01907282. Prevention trial of family focused treatment in youth at risk for psychosis. [Clinicaltrials.gov/show/NCT01907282](http://Clinicaltrials.gov/show/NCT01907282) 2010. [CSzG: 27965]

O'Brien MP, Miklowitz DJ, Candan KA, Marshall C, Domingues I, Walsh BC, et al. A randomised trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. *Journal of Consulting and Clinical Psychology* 2013;**82**(1):90-101. [CSzG: 28565]

O'Brien MP, Miklowitz DJ, Cannon TD. Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomised trial of family-focused therapy for individuals at clinical high risk for psychosis. *Journal of Family Psychology* 2015;**29**(6):945-951.. [CSzG: 32212]

Schlosser DA, Miklowitz DJ, O'Brien MP, De Silva SD, Zinberg JL, Cannon TD. A randomised trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. *Early Intervention in Psychiatry* 2012;**6**(3):283-91. [CSzG: 24491]

#### **NEURAPRO-AAE** {published data only}

ACTRN12608000475347. A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry 2009. [CSzG: 18420]

HKCTR-1438. The NEURAPRO-E (North America, EUROpe, Australia PROdrome) Study: a multicenter RCT of omega-3 fatty acids and cognitive-behavioural case management for symptomatic patients at ultra-high risk for early progression to schizophrenia and other psychotic disorders. [www.hkClinicaltrials.com/trial\\_details.aspx?trialID=d09bd177-b9fd-4162-b04f-3ebfed49baa3](http://www.hkClinicaltrials.com/trial_details.aspx?trialID=d09bd177-b9fd-4162-b04f-3ebfed49baa3) 2011. [CSzG: 29270]

McGorry P, Markulev C, Nelson B, Yuen HP, Schaefer M, Yung AR, et al. The NEURAPRO-E study: a multicenter RCT of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. *Schizophrenia Bulletin* 2015;**41**:S322-3. [CSzG: 29546]

McGorry PD, Nelson B, Markulev C, Yuen HP, Schaefer MR, Mossaheb N, et al. Effect of omega-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomised clinical trial. *JAMA psychiatry* 2017;**74**(1):19-27. [CSzG: 35590]

Nelson B, Amminger G, Markulev C, Yuen HP, Lavoie S, Schaefer M, et al. NEURAPRO: a multi-center RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders: medium-term outcome. *Schizophrenia Bulletin* 2017;**43**:S107. [CSzG: 36016]

#### **Nordentoft-Denmark** {published data only}

Nordentoft M, Jeppesen P, Petersen L, Thorup A, Ohlenschlaeger J, Christensen T, et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. *European Psychiatry* 2007;**22**:S129-S. [CSzG: 20471]

Nordentoft M, Thorup A, Petersen L, Ohlenschlaeger J, Melau M, Christensen TO, et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomised clinical trial of integrated treatment and standard treatment. *Schizophrenia Research* 2006;**83**(1):29-40. [CSzG: 13197]

Nordentoft M, Thorup A, Petersen L, Ohlenschlaeger J, Melau M, Christensen TO, et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the opus trial. A randomised clinical trial of integrated treatment and standard treatment. *Schizophrenia Research* 2006;**86**(Suppl 1):S44. [CSzG: 13393]

#### **PACE-Australia** {published data only}

McGorry P. Can the onset of schizophrenia be delayed or prevented?. *International Journal of Neuropsychopharmacology* 2002;**5**(Suppl 1):S26. [CSzG: 8351]

McGorry P, Adlard S, Yung A, McDonald A, Phillips L, Hearn N. Detection and intervention in pre-psychotic schizophrenia. *Current Opinion in Psychiatry* 1999;**12**(Suppl 1):S62. [CSzG: 4836]

McGorry P, Yung A, Francey S, Phillips L, Nelson B. A blinded, placebo-controlled randomised trial of low-dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample. *Acta Neuropsychiatrica* 2006;**18**(6):261. [CSzG: 35157]

McGorry PD, Hearn N, Germano D, Bravin J, Phillips LJ, Yung AR, et al. Prepsychotic intervention in schizophrenia: a stitch in time?. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington DC, USA. 1999. [CSzG: 3584]

McGorry PD, Phillips LJ, Nelson B, Leicester S, Baker K, Krstev H, et al. A double blind, placebo-controlled randomised trial of low-dose risperidone, cognitive-behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. *Schizophrenia Bulletin* 2007;**33**(2):446. [CSzG: 15203]

McGorry PD, Phillips LJ, Yung AR, Francey S, Germano D, Bravin J, et al. A randomised controlled trial of interventions in the pre psychotic phase of psychotic disorders. *Schizophrenia Research* 2000;**41**(1):9. [CSzG: 5149]

McGorry PD, Yung AR, Phillips L, Adlard S, Hallgren M, Patton G, et al. Pre-psychotic intervention in schizophrenia: a stitch in time?. *Schizophrenia Research* 1998;**29**(1-2):160. [CSzG: 3585]

McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomised controlled trial of interventions designed to reduce the risk of progression to first-episode

psychosis in a clinical sample with subthreshold symptoms. *Archives of General Psychiatry* 2002;**59**(10):921-8. [CSzG: 8576]

Philipps LJ, McGorry P, Yung A, Francey D, Germano F, Bravin J, et al. The development of preventive interventions for early psychosis: early findings and directions for the future. 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [CSzG: 7614]

Phillips L, Cotton S, Yuen HP, Mihalopoulos C, Shih S, Kelly D, et al. Cost effectiveness of a preventive intervention for young people at ultra high risk of developing psychosis. *Schizophrenia Bulletin* 2007;**33**(2):488-9. [CSzG: 15227]

Phillips LJ, Cotton S, Mihalopoulos C, Shih S, Yung AR, Carter R, et al. Cost implications of specific and non-specific treatment for young persons at ultra high risk of developing a first episode of psychosis. *Early Intervention in Psychiatry* 2009;**3**(1):28-34. [CSzG: 18308]

Phillips LJ, Leicester SB, O'Dwyer LE, Francey SM, Koutsogiannis J, Abdel-Baki A, et al. The PACE clinic: identification and management of young people at "ultra" high risk of psychosis. *Journal of Psychiatric Practice* 2002;**8**(5):255-69. [CSzG: 18235]

Phillips LJ, McGorry PD, Yuen HP, Ward J, Donovan K, Kelly D, et al. Medium term follow-up of a randomised controlled trial of interventions for young people at ultra high risk of psychosis. *Schizophrenia Research* 2007;**96**(1-3):25-33. [CSzG: 15544]

Phillips LJ, Yung AR, Yuen HP, Pantelis C, McGorry PD. Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. *American Journal of Medical Genetics* 2002;**114**(8):929-37. [CSzG: 18236]

#### **Piskulic-Canada** {published data only}

NCT01619319. Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. [ClinicalTrials.gov/show/NCT01619319](https://clinicaltrials.gov/show/NCT01619319) 2012. [CSzG: 24387]

Piskulic D, Barbato M, Addington J. Cognitive remediation in young people at clinical high risk of psychosis. *Early Intervention in Psychiatry* 2012;**6**:89. [CSzG: 24973]

Piskulic D, Barbato M, Addington J. Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. *Schizophrenia Research* 2012;**136**:S245-6. [CSzG: 29632]

Piskulic D, Barbato M, Liu L, Addington J. Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. *Schizophrenia Research* 2014;**153**(Suppl. 1):S218. [CSzG: 28827]

Piskulic D, Barbato M, Liu L, Addington J. Effects of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. *Early Intervention in Psychiatry* 2014;**8**:86. [CSzG: 29633]

#### **PRIME-USA** {published data only}

Block JJ, McGlashan TH. Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis... McGlashan TH, Zipursky RB, Perkins D, Addington

J, Miller T, Woods SW et al. Randomised, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. *Am J Psychiatry* 2006;**163**:790-9. *American Journal of Psychiatry* 2006; Vol. 163, issue 10:1838. [CSzG: 13960]

Breier AF, Zipursky RB, Perkins DO, Addington JM, Tohen MF, David SR, et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 8951]

Hawkins KA, Addington J, Keefe R, Christensen B, Woods S, Zipursky R, et al. Neuropsychological functioning in the first episode prodrome and early psychosis. *Schizophrenia Research* 2004;**70**(1):101. [CSzG: 11515]

Hawkins KA, Addington J, Keefe RS, Christensen B, Woods SW, Miller TJ, et al. Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. *Schizophrenia Research* 2004;**67**(1):205. [CSzG: Ref11301]

Hawkins KA, Addington J, Keefe RS, Christensen B, Woods SW, Zipursky RB, et al. Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland. 2004. [CSzG: 16470]

Hawkins KA, Keefe RS, Christensen BK, Addington J, Woods SW, Callahan J, et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America double blind treatment study. *Schizophrenia Research* 2008;**105**(1-3):1-9. [CSzG: 16983]

Hoffman RE, Woods S, Preda A, Tohen M, Breier A, Glist J, et al. Excessive top-down perceptual processing and reduced real-world investment exhibited by prodromal patients predict subsequent conversion to schizophrenia. *Schizophrenia Research* 2006;**86**(Suppl 1):S46. [CSzG: 13377]

Hoffman RE, Woods SW, Hawkins KA, Pittman B, Tohen M, Preda A, et al. Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in prodromal population. *British Journal of Psychiatry* 2007;**191**(2):355-6. [CSzG: 16068]

McGlashan T, Zipursky R, Perkins D, Addington J. Olanzapine for treatment of the schizophrenia prodrome: 2-year results of a randomised placebo-controlled study. *Schizophrenia Research* 2004;**67**(1):164. [CSzG: 11320]

McGlashan TH. Intervention in the prodrome to first psychosis. 2nd International Conference on Early Psychosis; 2000 Mar 31 - Apr 2; New York, New York, USA. 2000. [CSzG: 10191]

McGlashan TH. Treatment intervention in the New Haven PRIME clinic prodromal sample. *Current Opinion in Psychiatry* 1999;**12**(Suppl 1):S62. [CSzG: 4835]

McGlashan TH, Miller TJ, Woods SW. Psychosis treatment prior to psychosis onset: ethical issues. *Schizophrenia Research* 2002;**53**(3 Suppl 1):15. [CSzG: 8093]

McGlashan TH, Miller TJ, Woods SW, Rosen J, Davidson L, Preda A, et al. Ethical issues in the pre-onset treatment



- of schizophrenia. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSzG: 8018]
- McGlashan TH, Miller TJ, Woods SW, Rosen J, Davidson L, Preda A, et al. Ethical issues in the pre-onset treatment of schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9005]
- McGlashan TH, Miller TJ, Zipursky RB, Woods SW, Perkins DO, Hawkins KA, et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSzG: 9803]
- McGlashan TH, Vaglum P, Friis S, Johannessen JO, Simonsen E, Larsen TK, et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. *Schizophrenia Bulletin* 2005;**31**:496. [CSzG: 11622]
- McGlashan TH, Vaglum P, Friis S, Johannessen JO, Simonsen E, Larsen TK, et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. *Schizophrenia Bulletin* 2005;**31**:496. [CSzG: 11622]
- McGlashan TH, Vaglum P, Friis S, Johannessen JO, Simonsen E, Larsen TK, et al. Early detection and intervention in first episode psychosis: empirical update of the tips and prime projects. *Schizophrenia Bulletin* 2005;**31**:496. [CSzG: 11622]
- McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, et al. Randomised, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. *American Journal of Psychiatry* 2006;**163**(5):790-9. [CSzG: 12654]
- McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, et al. The PRIME North America randomised double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. *Schizophrenia Research* 2003;**61**(1):7-18. [CSzG: 9828]
- McGlashan TH, Zipursky RB, Perkins DO, Addington J, Woods SW, Miller TJ, et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. *Schizophrenia Research* 2003;**60**:295. [CSzG: 9722]
- McGlashan TH, Zipursky RB, Perkins DO, Addington JM, Woods SW, Lindborg S, et al. Olanzapine versus pbo for the schizophrenic prodrome: one-year results. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSzG: 9804]
- McGlashan TH, Zipursky RB, Perkins DO, Addington J, Miller TH, Woods SW, et al. A prodromal trial of olanzapine versus placebo baseline results. 3rd International Conference on Early Psychosis; 2002 Sep 25-28; Copenhagen, Denmark. 2002:42. [CSzG: 8934]
- Mcglashan T, Zipursky R, Perkins D, Addington J, Miller T, Woods S, et al. Pharmacotherapy in the prodromal phase of first psychosis: results and implications. *Schizophrenia Research* 2004;**70**(1):6. [CSzG: 11524]
- Mcglashan T, Zipursky R, Perkins D, Addington J, Woods S, Miller T, et al. Olanzapine vs. placebo for prodromal schizophrenia. *Schizophrenia Research* 2004;**67**(1):6. [CSzG: 11321]
- Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, et al. The PRIME North America randomised double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. *Schizophrenia Research* 2003;**61**(1):19-30. [CSzG: 9829]
- Rosen JL, Woods SW, Miller TJ, McGlashan TH. Prospective observations of emerging psychosis. *Journal of Nervous and Mental Disease* 2002;**190**:133-41. [CSzG: 8274]
- Taylor HE, Parker S, Mansell W, Morrison AP. Effects of appraisals of anomalous experience on distress in people at risk of psychosis. *Behavioural and Cognitive Psychotherapy* 2012;**41**(1):24-33. [CSzG: 24374]
- Woods S, Zipursky R, Perkins D, Addington J, Marquez E, Breier A, et al. Olanzapine versus placebo for prodromal symptoms. 3rd International Conference on Early Psychosis; 2002 Sep 25-28; Copenhagen, Denmark. 2002:43. [CSzG: 8933]
- Woods SW. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. *Biological Psychiatry* 2003;**54**(4):497. [CSzG: 19829]
- Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, et al. Olanzapine versus placebo for prodromal symptoms. *Schizophrenia Research*. 2003. [CSzG: 9978]
- Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, et al. Olanzapine versus placebo for prodromal symptoms. *Schizophrenia Research* 2003;**60**:306-7. [CSzG: 9752]
- Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, et al. Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. *Biological Psychiatry* 2003;**54**(4):453-64. [CSzG: 9994]
- Woods SW, McGlashan TH. Sample size planning for prodromal intervention trials. *Schizophrenia Research* 2002;**53**(3 Suppl 1):40. [CSzG: 8116]
- Woods SW, Zipursky RB, Perkins DO, Addington JM, Miller TJ, Breier AF, et al. Olanzapine versus placebo for prodromal symptoms. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [CSzG: 9053]
- Vinogradov-USA** {published data only}
- Loewy R, Fisher M, Mathalon DH, Vinogradov S. Interim analyses of a randomised controlled trial of computerised cognitive training in clinical high risk for psychosis. *Schizophrenia Bulletin* 2013;**39**:S238-9. [CSzG: 28151]
- Loewy R, Fisher M, Schlosser DA, Biagianni B, Stuart B, Mathalon DH, et al. Intensive auditory cognitive training

improves verbal memory in adolescents and young adults at clinical high risk for psychosis. *Schizophrenia Bulletin* 2016;**42**(Suppl 1):S118-26. [CSzG: 35221]

Vinogradov S, Loewy R, Fisher M, Lee A, Niendam T, Ragland JD, et al. Neuroplasticity-based cognitive training in ultra-high risk adolescents and recent onset patients with schizophrenia. *Schizophrenia Research* 2012;**136**:S30. [CSzG: 29703]

#### **Woods-1-USA** {published data only}

NCT00291226. Glycine vs Placebo for the Schizophrenia Prodrome. www.ClinicalTrials.gov/ct/show/ 2006. [CSzG: 14759]

Woods S, Walsh B, Hawkins K, Miller T, Saksa J, D'Souza D, et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. *Early Intervention in Psychiatry* 2012;**6**:29. [CSzG: 24987]

Woods SW, Kantrowitz JT, Javitt DC. NMDAR-based treatments for patients at clinical high risk for psychosis. *Biological Psychiatry* 2014;**1**:11S. [CSzG: 29041]

Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. *European Neuropsychopharmacology* 2013;**23**(8):931-40. [CSzG: 28750]

#### **Yung-Australia** {published data only}

McGorry P. Second generation intervention research in the pre-psychotic phase of illness in schizophrenia and related psychoses. Australian New Zealand Clinical Trials Registry 2000. [CSzG: 18439]

McGorry PD, Nelson B, Phillips LJ, Yuen HP, Francey S, Thampi A, et al. Randomised controlled trial of interventions for young people at ultra-high risk of psychosis: 12-month outcome. *Schizophrenia Research* 2012;**136**:S17-8. [CSzG: 29547]

McGorry PD, Nelson B, Phillips LJ, Yuen HP, Francey SM, Thampi A, et al. Randomised controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. *Journal of Clinical Psychiatry* 2013;**74**(4):349-56. [CSzG: 28737]

Nelson B, Phillips LJ, Yung AR, Francey SM, Leicester S, Baker K, et al. A double blind, placebo-controlled randomised trial of low-dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. *Schizophrenia Bulletin* 2007;**33**(2):450. [CSzG: 15212]

Phillips LJ, Nelson B, Yuen HP, Francey SM, Simmons M, Stanford C, et al. Randomised controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. *Australian and New Zealand Journal of Psychiatry* 2009;**43**(9):818-29.

Yung A, Amminger P, Berger G, Thompsom A, Phillips L, Nelson B, et al. Randomised controlled trial of antipsychotic and cognitive therapy in young people at ultra-high risk of psychosis. *Early Intervention in Psychiatry* 2012;**6**:11. [CSzG: 24989]

Yung A, Nelson B, Phillips L, Francey S, Leicester S, Yuen H, et al. A double blind, placebo-controlled randomised trial of low-dose risperidone, cognitive-behaviour therapy, and supportive therapy in young people at ultra high risk of psychotic disorder: 12 month outcome data. *Early Intervention in Psychiatry* 2008;**2**(Suppl 1):A12. [CSzG: 19138]

Yung AR, Phillips LJ, Nelson B, Francey SM, Yuen HP, Simmons MB, et al. Randomised controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. *Journal of Clinical Psychiatry* 2011;**72**(4):430-40. [CSzG: 22929]

## References to studies excluded from this review

#### **Berger-Australia** {published data only}

Berger G. Lithium in patients at ultra high risk of developing a first psychotic episode. Stanley Foundation Research Programs 2006.

Berger GE, Wood SJ, Ross M, Hamer CA, Wellard RM, Pell G, et al. Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study. *Current Pharmaceutical Design* 2012;**18**:570-5.

#### **Berry-USA** {published data only}

Berry K, Gregg L, Lobban F, Barrowclough C. Therapeutic alliance in psychological therapy for people with recent onset psychosis who use cannabis. *Comprehensive Psychiatry* 2016;**67**:73-80.

#### **Biagianni-USA** {published data only}

Biagianni B, Roach BJ, Fisher M, Loewy R, Ford JM, Vinogradov S, et al. Trait aspects of auditory mismatch negativity predict response to auditory training in individuals with early illness schizophrenia. *Neuropsychiatric Electrophysiology* 2017;**3**:2.

#### **Capra-Australia** {published data only}

ACTRN12612000963820. An evaluation of the effectiveness of an internet-based treatment program for psychotic like experiences. www.anzctr.org.au/ACTRN12612000963820.aspx 2012.

#### **CHANGSHA-USA** {published data only}

Stone WS, Hsi X, Giuliano AJ, Seidman LJ, Tsuang MT. Validation of a liability syndrome for schizophrenia ('schizotaxia') and effects of low dose risperidone on neurocognitive, clinical and social functioning: results from the Changsha study. *European Psychiatry* 2011;**26**(Suppl 1):1508.

Stone WS, Hsi X, Giuliano AJ, Tan L, Zhu S, Li L, et al. Are neurocognitive, clinical and social dysfunctions in schizotaxia reversible pharmacologically? Results from the Changsha study. *Asian Journal of Psychiatry* 2012;**5**(1):73-82.

#### **Chien-Hong Kong** {published data only}

Chien WT, Yip AL, Liu JY, McMaster TW. The effectiveness of manual-guided, problem-solving-based self-learning programme for family caregivers of people with recent-onset psychosis: a randomised controlled trial with 6-month follow-up. *International Journal of Nursing Studies* 2016;**59**:141-55.

**Cordes-Germany** {published data only}

Cordes J, Kahl K, Janner M, Muller H, Wagner M, Maier W, et al. Prevalence of the metabolic syndrome in men and women at risk of psychosis. *European Archives of Psychiatry and Clinical Neuroscience* 2011;**261**:S33.

NCT00169702. The effect of a weight management program to prevent weight gain and metabolic abnormalities during treatment with the atypical neuroleptic olanzapine: a randomised study. [www.ClinicalTrials.gov/ct/show/](http://www.ClinicalTrials.gov/ct/show/) 2005.

**EDIPP-USA** {published data only}

Anonymous. Re: McFarlane, W. R., et al: clinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial. *Schizophr Bull.* 2015 Jan;**41**(1):30-43. *Schizophrenia Bulletin* 2015;**41**(2):532.

McFarlane WR, Levin B, Travis L, Lucas FL, Lynch S, Verdi M, et al. Clinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial. *Schizophrenia Bulletin* 2015;**41**(1):30-43.

NCT00531518. Early detection and intervention for the prevention of psychosis, a multisite study. [www.ClinicalTrials.gov/ct/show/](http://www.ClinicalTrials.gov/ct/show/) 2007.

**EPIP-Singapore** {published data only}

Chong S. Translational and clinical research programme in psychosis. *Early Intervention in Psychiatry* 2008;**2**(Suppl 1):A130.

**Heresco-Levy-Israel** {published data only}

NCT00276263. Sarcosine (n-methylglycine) trial for individuals at risk for developing schizophrenia and related disorders. [www.ClinicalTrials.gov/ct/show/](http://www.ClinicalTrials.gov/ct/show/) 2006.

**Holzer-Switzerland** {published data only}

Holzer L, Urben S, Passini CM, Jaugey L, Herzog MH, Halfon O, et al. A randomised controlled trial of the effectiveness of computer-assisted cognitive remediation (CACR) in adolescents with psychosis or at high risk of psychosis. *Behavioural and Cognitive Psychotherapy* 2014;**42**(4):421-34.

Holzer L, Urben S, Pihet S, Jaugey L. A randomised controlled trial of the effectiveness of a computer-assisted cognitive remediation (CACR) program in adolescents with psychosis or at high risk of psychosis: short-term and long-term outcomes. *Neuropsychiatrie de L'Enfance et de L'Adolescence* 2012;**60**(5 Suppl):S71.

Jaugey L, Urben S, Pihet S, Halfon O, Holzer L. Short-and long-term outcomes of a randomised controlled trial of a computer-assisted cognitive remediation (CACR) program in adolescents with psychosis or at high risk of psychosis. *Biological Psychiatry* 2012;**8**(Suppl 1):84S.

Torrisi R, Holzer L, Pihet S, Suter S, Aeberhard A, Pellanda V, et al. Computer-assisted cognitive remediation program for adolescents at high risk of psychosis or with psychotic disorders: preliminary results. 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15-18; Barcelona, Spain. 2009.

Urben S, Pihet S, Jaugey L, Halfon O, Holzer L. A randomised controlled trial of the effectiveness of a computer-assisted cognitive remediation (CACR) program in adolescents with psychosis or at high risk of psychosis: short term and long term outcomes. *Early Intervention in Psychiatry* 2012;**6**:41.

Urben S, Pihet S, Jaugey L, Halfon O, Holzer L. Computer-assisted cognitive remediation in adolescents with psychosis or at risk for psychosis: a 6-month follow-up. *Acta Neuropsychiatrica* 2012;**24**(6):328-35.

**Keri-Hungary** {published data only}

Keri S, Kelemen O, Janka Z. Therapy of mental states at high risk for psychosis: preliminary results from Hungary [A psychosis szempontjából nagy kockázatú mentális állapotok és kezelésük: első hazai eredmények]. *Orvosi Hetilap* 2006;**147**(5):201-4.

**Koren-Israel** {published data only}

Koren D, Radin S, Libas Y. "Attenuated psychosis syndrome" versus "endangered realitytesting syndrome": a community-based experimental vignette study of their effect on stigma, hope and help-seeking. *Early Intervention in Psychiatry* 2014;**8**:136.

**LEGS-USA** {published data only}

ISRCTN70185866. LEGS cluster randomised trial: liaison with education and general practices to detect and refine referrals of people with at-risk-mental-states (ARMS). [isrctn.org/](http://isrctn.org/) ISRCTN70185866 2010.

Jones P. LEGS cluster randomised trial: liaison with education and general practices to detect and refine referrals of people with at-risk-mental-states (ARMS). National Institute for Health Research 2009.

Perez J, Jin H, Russo DA, Stochl J, Painter M, Shelley G, et al. Clinical effectiveness and cost-effectiveness of tailored intensive liaison between primary and secondary care to identify individuals at risk of a first psychotic illness (the LEGS study): a cluster-randomised controlled trial. *Lancet Psychiatry* 2015;**2**(1):984-93.

Perez J, Russo D, Jin H, Stochl J, Painter M, Graffy J, et al. Liaison with primary care to detect individuals at clinical high risk for psychosis: the LEGS CRCT. *Schizophrenia Bulletin* 2015;**41**:S130.

Perez J, Russo DA, Stochl J, Byford S, Zimbron J, Graffy JP, et al. Comparison of high and low intensity contact between secondary and primary care to detect people at ultra-high risk for psychosis: study protocol for a theory-based, cluster randomised controlled trial. *Trials* 2013;**14**:222.

**LEO CAT-UK** {published data only}

Power P, Craig T, Mcguire P, Iacoponi E, Garety P, Russell M. A randomised controlled trial of an early detection team in first episode psychosis: the LEO CAT trial. *Schizophrenia Research* 2004;**67**(1):36.

Power P, Iacoponi E, Russell M, Fisher H, Mcguire P, Garety P, et al. A randomised controlled trial of an early detection team in first-episode psychosis: provisional findings of the LEO CAT study. *Schizophrenia Research* 2004;**70**(1):131.

Power P, Monteiro E, Pobee I, Burnside A, Pugh C, Reynolds N, et al. 18 months outcome of first episode psychosis patients attending the LEO service in south London. *Early Intervention in Psychiatry* 2008;**2**(Suppl 1):A6.

**LEO-UK** {published data only}

Craig T, Garety P, Power P, Rahaman N, Colbert S, Fornells-Ambrojo M. Lambeth early onset service: a randomised controlled trial. *Schizophrenia Research* 2004;**70**(1):145-6.

Craig TK. Brixton early psychosis project. National Research Register 2000.

Craig TK, Garety P, Power P, Rahaman N, Colbert S, Fornells-Ambrojo M, et al. The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. *BMJ* 2004;**329**(7474):1067-70.

Garety PA, Craig TK, Dunn G, Fornells-Ambrojo M, Colbert S, Rahaman N, et al. Specialised care for early psychosis: symptoms, social functioning and patient satisfaction: randomised controlled trial. *British Journal of Psychiatry* 2006;**188**(1):37-45.

Garety PA, Craig TK, Dunn G, Fornells-Ambrojo M, Colbert S, Rahaman N, et al. Specialised care for early psychosis: symptoms, social functioning and patient satisfaction: randomised controlled trial: corrigenda. *British Journal of Psychiatry* 2006;**188**(3):295.

Power P, Craig T, Garety P, Rahaman N, Colbert S, Fornells-Ambrojo M. Lambeth early onset (LEO) trial: a randomised controlled trial of assertive community follow-up in early psychosis: initial 6 month data. Unknown Source. 1994.

Power P, Iacoponi E, Reynolds N, Fisher H, Russell M, Garety P, et al. The Lambeth Early Onset Crisis Assessment Team Study: general practitioner education and access to an early detection team in first-episode psychosis. *British Journal of Psychiatry. Supplements* 2007;**51**:s133-9.

Power P, McGuire P, Iacoponi E, Garety P, Morris E, Valmaggia L, et al. Lambeth early onset (LEO) and outreach & support in South London (OASIS) service. *Early Intervention in Psychiatry* 2007;**1**(1):97-103.

Tempier R, Balbuena L, Lepnurm M, Craig TK. Perceived emotional support in remission: results from an 18-month follow-up of patients with early episode psychosis. *Social Psychiatry and Psychiatric Epidemiology* 2013;**48**(12):1897-904.

**Leweke-Germany** {published data only}

DRKS00011151. Enhancing recovery in early schizophrenia a multi-center, two-arm, double-blind, randomised clinical trial investigating cannabidiol vs. placebo as an add-on to an individualised antipsychotic treatment using either amisulpride or quetiapine. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00011151 2016. [http://www.drks.de/DRKS00011151]

**Lewis-USA** {published data only}

Lewis L, Unkefer EP, O'Neal SK, Crith CJ, Fultz J. Cognitive rehabilitation with patients having persistent, severe

psychiatric disabilities. *Psychiatric Rehabilitation Journal* 2003;**26**(4):325-31.

**NEURAPRO-Q-Australia** {published data only}

McGorry P, Amminger P. A comparison study of quetiapine medication and psychological therapy versus placebo tablets and psychological therapy in patients who are deemed at risk of developing a psychotic disorder. Australian New Zealand Clinical Trials Registry 2010.

**O'Neill-UK** {published data only}

O'Neill A, Wilson R, Appiah-Kusi E, Bossong M, McGuire P, Bhattacharyya S. Effects of cannabidiol on mediotemporal and dorsostriatal activity during encoding and recall, in the at-risk mental state for psychosis. *Schizophrenia Bulletin* 2017;**43**:S187.

**OPUS-Denmark** {published data only}

Albert N, Jensen H, Melau M, Hjorthoj C, Nordentoft M. How long should a specialised assertive early intervention program last?. *Early Intervention in Psychiatry* 2014;**8**:10.

Bertelsen M, Jeppesen P, Petersen L, Thorup A, Ohlenschlaeger J, Le Quach P, et al. Course of illness in a sample of 265 patients with first-episode psychosis - five-year follow-up of the Danish OPUS trial. *Schizophrenia Research* 2009;**107**(2-3):173-8.

Bertelsen M, Jeppesen P, Petersen L, Thorup A, Ohlenschlaeger J, le Quach P, et al. First episode of psychosis intensive early intervention programme versus standard treatment - secondary publication. *Ugeskrift for Laeger* 2009;**171**(41):2992-5.

Bertelsen M, Jeppesen P, Petersen L, Thorup A, Ohlenschlaeger J, le Quach P, et al. Five-year follow-up of a randomised multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. *Archives of General Psychiatry* 2008;**65**(7):762-71.

Bertelsen M, Jeppesen P, Petersen L, Thorup A, Ohlenschlaeger J, le Quach P, et al. Suicidal behaviour and mortality in first-episode psychosis: the OPUS trial. *British Journal of Psychiatry. Supplements* 2007;**191**(Suppl 51):s140-6.

Ellersgaard D, Mors O, Thorup A, Jorgensen P, Jeppesen P, Nordentoft M. A prospective study of the course of delusional themes in first episode non-affective psychosis. *Early Intervention in Psychiatry* 2012;**6**:67.

Ellersgaard D, Mors O, Thorup A, Jorgensen P, Jeppesen P, Nordentoft M. Prospective study of the course of delusional themes in first-episode non-affective psychosis. *Early Intervention in Psychiatry* 2014;**8**(4):340-7.

Hastrup LH, Kronborg C, Bertelsen M, Jeppesen P, Jorgensen P, Petersen L, et al. Cost-effectiveness of early intervention in first-episode psychosis: economic evaluation of a randomised controlled trial (the opus study). *British Journal of Psychiatry* 2013;**202**(1):35-41.

Hastrup LH, Kronborg C, Nordentoft M, Simonsen E. Cost-effectiveness of a randomised multicenter trial in first-episode

psychosis (OPUS) in Denmark. *Journal of Mental Health Policy and Economics* 2011;**14**:S10.

Jeppesen P, Abel MB, Krarup G, Jorgensen P, Nordentoft M. Family burden and expressed emotion in first episode psychosis. The OPUS-trial. 3rd International Conference on Early Psychosis; 2002 Sep 25-28; Copenhagen, Denmark. 2002:59.

Jeppesen P, Hemmingsen R, Jørgensen P, Reisby N, Abel M-B, Nordentoft M. OPUS project: impact of mental disorder on caregivers. *11th World Congress of Psychiatry*; 1999 Aug 6-11; Hamburg, Germany 1999;**2**:157.

Jeppesen P, Hemmingsen R, Reisby N, Jørgensen P, Nordentoft M, Abel M-B. The impact of mental disorder on caregivers. *11th World Congress of Psychiatry*; 1999 Aug 6-11; Hamburg, Germany 1999;**2**:187.

Jeppesen P, Nordentoft M, Abel M, Hemmingsen RP, Joergensen, Kassow P. OPUS-project: a RCT of integrated psychiatric treatment for recent onset psychotic patients. *Schizophrenia Research* 2001;**49**(1-2):262.

Jeppesen P, Petersen L, Thorup A, Abel M-B, Oehlenschlaeger J, Christensen TO, et al. Integrated treatment of first-episode psychosis: effect of treatment on family burden: OPUS trial. *British Journal of Psychiatry* 2005;**48**(Suppl):s85-90.

Jeppesen P, Petersen L, Thorup A, Abel M-B, Oehlenschlaeger J, Christensen TO, et al. The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis. *Psychological Medicine* 2008;**38**(8):1157-66.

Jørgensen P, Jeppesen P, Abel MB, Kassow P, Krarup G, Hemmingsen R, et al. Early intervention in schizophrenia. *Nordic Journal of Psychiatry* 2002;**56**(2):8.

Jørgensen P, Nordentoft M, Abel MB, Gouliaev G, Jeppesen P, Kassow P. Early detection and assertive community treatment of young psychotics: the OPUS study rationale and design of the trial. *Social Psychiatry and Psychiatric Epidemiology* 2000;**35**(7):283-7.

Nordentoft M, Bertelsen M, Jeppesen P, Thorup A, Petersen L, Oehlenschlaeger J, et al. OPUS trial: a randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. *Nordic Journal of Psychiatry* 2007;**61**(6):488.

Nordentoft M, Bertelsen M, Thorup A, Jeppesen P, Petersen L. The OPUS-trial; a randomised multi-centre trial of integrated versus standard treatment for patients with a first episode of psychotic illness-five-years follow-up. 12th International Congress on Schizophrenia Research; 2009 Mar 28-Apr 1; San Diego, CA. San Diego, CA, USA: Oxford Univ Press, 2009:370.

Nordentoft M, Jeppesen P, Abel M, Kassow P, Petersen L, Thorup A, et al. OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis. One-year follow-up of a randomised controlled trial. *British Journal of Psychiatry. Supplements* 2002;**181**(Suppl 43):S98-106.

Nordentoft M, Jeppesen P, Abel M, Petersen L, Thorup A, Christensen T, et al. Opus-project: a randomised controlled trial of integrated psychiatric treatment in first-episode psychosis - clinical outcome improved. Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25-28; Copenhagen, Denmark. 2002:56.

Nordentoft M, Jeppesen P, Abel MB, Hemmingsen R, Reisby N. Can duration of untreated psychosis be shortened and does optimal treatment program improve outcome? A randomised controlled study. *Nordisk Psykiatrisk Tidsskrift* 1998;**52**(41):76.

Nordentoft M, Jeppesen P, Jorgensen P, Abel M, Kassow P, Reisby N, et al. OPUS-project: a randomised controlled trial of first episode psychotic patients: better compliance. *Schizophrenia Research* 2000;**41**(1):B145.

Nordentoft M, Jeppesen P, Jørgensen P, Abel MB, Kassow P, Reisby N, et al. OPUS - project: a randomised controlled trial of first episode psychotic patients better compliance. 2nd International Conference on Early Psychosis; 2000 Mar 31 - Apr 2; New York, New York, USA. 2000.

Nordentoft M, Jeppesen P, Kassow P, Abel M, Petersen L, Thorup A, et al. OPUS-project: a randomised controlled trial of integrated psychiatric treatment in first-episode psychosis-clinical outcome improved. *Schizophrenia Research* 2002;**53**(3 Suppl 1):51.

Nordentoft M, Jeppesen P, Kassow P, et al. OPUS project: a randomised controlled trial of integrated psychiatric treatment in first episode psychosis - clinical outcome improved. *Schizophrenia Research* 2002;**53**(Suppl. 1):51.

Nordentoft M, Jeppesen P, Petersen L, Thorup A, Abel M, Oehlenschlaeger JK, et al. OPUS project: a randomised controlled trial of integrated psychiatric treatment in first episode psychosis. *Schizophrenia Research* 2003;**60**:297.

Nordentoft M, Jeppesen P, Petersen L, Thorup A, Jorgensen P. Duration of untreated psychosis predicts psychotic symptoms but not negative symptoms. *Schizophrenia Bulletin* 2005;**31**:234.

Nordentoft M, Jeppesen P, Petersen L, Thorup A, Oehlenschlaeger J, Christensen T, et al. The OPUS trial: a randomised multi-centre trial of integrated versus standard treatment for 547 first-episode psychotic patients. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland. 2004.

Nordentoft M, Jeppesen P, Petersen L, Thorup a, Krarup G, Abel M, et al. The Danish OPUS-trial: a randomised controlled trial of integrated treatment among 547 first-episode psychotic patients. One and two years follow-up. *Schizophrenia Research* 2004;**67**(1):35-6.

Nordentoft M, Jeppesen P, Ventegodt AT, Joergensen P, Abel M, Petersen L, et al. OPUS-project: a randomised controlled trial of first episode psychotic patients: patient satisfaction, depression and suicidal behaviour. *Schizophrenia Research* 2001;**49**(1-2):265.

Nordentoft M, Jorgensen P, Jeppesen P, Kassow P, Abel MB, Resiby N, et al. OPUS-project: differences in clinical and social

outcome of a randomised controlled trial of integrated care of first-episode psychotic patients. *Schizophrenia Research* 1999;**36**(1-3):330.

Nordentoft M, Melau M, Iversen T, Petersen L, Jeppesen P, Thorup A, et al. From research to practice: How OPUS treatment was accepted and implemented throughout Denmark. *Early Intervention in Psychiatry* 2015;**9**(2):156-62.

Nordentoft M, Melau M, Jeppesen P, Petersen L, Thorup A, Ohlenschlaeger J, et al. The OPUS-trial; a randomised single-blinded trial of integrated versus standard treatment for patients with a first episode of psychotic illness - results of five-years follow-up and presentation of a new trial. *Schizophrenia Research* 2010;**117**(2-3):116.

Nordentoft M, Ohlenschlaeger J, Thorup A, Petersen L, Jeppesen P, Bertelsen M. Deinstitutionalization revisited: a 5-year follow-up of a randomised clinical trial of hospital-based rehabilitation versus specialised assertive intervention (OPUS) versus standard treatment for patients with first-episode schizophrenia spectrum disorders. *Psychological Medicine* 2010;**40**(10):1619-26.

Nordentoft M, Petersen L, Jeppesen P, Thorup AA, Abel MB, Ohlenschlaeger J, et al. OPUS: a randomised, multicenter clinical trial of integrated treatment compared with standard treatment before the first episode psychosis - secondary publication. *Ugeskrift for Laeger* 2006;**168**(4):381-4.

Nordentoft M, Reisby N, Jeppesen P, Abel M-B, Kassow P, Jørgensen P. OPUS-project: differences in treatment outcome of a randomised controlled trial of integrated psychiatric treatment of first-episode psychotic patients. 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999; Vol. 2:165.

Nordentoft M, Secher G, Bertelsen M, Thorup A, Austin S, Albert N, et al. Opus: concept and recent findings. *European Archives of Psychiatry and Clinical Neuroscience* 2011;**261**:S37-S8.

Nordentoft M, Secher G, Hjorthoj CR, Austin S, Thorup A, Jeppesen P, et al. Ten-year follow-up of the OPUS specialised early intervention trial for patients with a first episode of psychosis. *Schizophrenia Bulletin* 2015;**41**:S149.

Nordentoft M, Thorup A, Petersen L, Jeppesen P, Krarup G, Christensen T, et al. The OPUS trial: a randomised multi-centre trial of integrated versus standard treatment for 547 first-episode psychotic patients. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:8.

Petersen L, Jeppesen P, Thorup A, Abel MB, Ohlenschlaeger J, Christensen TO, et al. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. *BMJ* 2005;**331**(7517):602-8.

Petersen L, Jeppesen P, Thorup A, Ohlenschlaeger J, Christensen T, Krarup G, et al. Substance abuse in first-episode schizophrenia-spectrum disorders. *Schizophrenia Research* 2006;**86**(Suppl 1):S44.

Petersen L, Nordentoft M, Jeppesen P, Ohlenschlaeger J, Thorup A, Christensen TO, et al. Improving 1-year outcome in first-episode psychosis: OPUS trial. *British Journal of Psychiatry* 2005;**48**(Suppl):s98-103.

Petersen L, Nordentoft M, Thorup A, Ohlenschlaeger J, Jeppesen P, Christensen T, et al. The OPUS trial: a randomised multi-centre trial of integrated versus standard treatment for 547 first-episode psychotic patients. *Schizophrenia Bulletin* 2005;**31**:531.

Secher RG, Austin SF, Ole Mors NP, Nordentoft M. The OPUS-trial: Intensive, early, psycho-social intervention versus treatment as usual for first-episode psychosis patients. Results from the 10-year follow-up. *European Archives of Psychiatry and Clinical Neuroscience* 2011;**261**:S59.

Secher RG, Hjorthoj CR, Austin SF, Thorup A, Jeppesen P, Mors O, et al. Ten-Year Follow-up of the OPUS Specialised Early Intervention Trial for Patients With a First Episode of Psychosis. *Schizophrenia Bulletin* 2015;**41**(3):617-26.

Secher RG, Hjorthoj CR, Austin SF, Thorup A, Jeppesen P, Mors O, et al. Ten-year follow-up of the OPUS specialised early intervention trial for patients with a first episode of psychosis. *Schizophrenia Bulletin* 2015;**41**(3):617-26.

Stevens H, Agerbo E, Dean K, Mortensen PB, Nordentoft M. Reduction of crime in first-onset psychosis: a secondary analysis of the OPUS randomised trial. *Journal of Clinical Psychiatry* 2013;**74**(5):e439-44.

Thorup A. Gender differences in first-episode psychosis at five-year followup - results from the Danish OPUS study gender differences have been found. *Early Intervention in Psychiatry* 2010;**4**(Suppl 1):53.

Thorup A, Albert N, Bertelsen M, Petersen L, Jeppesen P, Le Quack P, et al. Gender differences in first-episode psychosis at 5-year follow-up - two different courses of disease? Results from the OPUS study at 5-year follow-up. *European Psychiatry* 2013;**29**(1):44-51.

Thorup A, Nordentoft M, Petersen L, Ohlenschlaeger J, Abel M, Jeppesen P, et al. The Danish OPUS-project: psychopathology and gender differences in first episode psychotic patients. 3rd International Conference on Early Psychosis; 2002 Sep 25-28; Copenhagen, Denmark. 2002:59.

Thorup A, Petersen L, Jeppesen P, Nordentoft M. The quality of life among first-episode psychotic patients in the OPUS trial. *Schizophrenia Research* 2010;**116**(1):27-34.

Thorup A, Petersen L, Jeppesen P, Ohlenschlaeger J, Christensen T, Krarup G, et al. Integrated treatment ameliorates negative symptoms in first episode psychosis - results from the Danish OPUS trial. *Schizophrenia Research* 2005;**79**(1):95-105.

Øhlenschläger J, Thorup A, Petersen L, Jeppesen P, Abel M, Nordentoft M. Coercion in first episode psychosis. 3rd International Conference on Early Psychosis; 2002 Sep 25-28; Copenhagen, Denmark. 2002:89-90.

**Piskulic-2-Canada** {published data only}

NCT02582528. Cognitive remediation in youth at risk of serious mental illness. *ClinicalTrials.gov/show/NCT02582528* 2015.

**RAISE-ETP-USA** {published data only}

Brunette MF. Facilitators and barriers to implementation of coordinated specialty care in U.S. community mental health clinic. *Schizophrenia Bulletin* 2015;**41**:S304.

Cadenhead K, Addington J, Bearden C, Cannon T, Cornblatt B, Mathalon D, et al. Metabolic abnormalities prior to the onset of psychosis: another risk factor for psychosis?. *Neuropsychopharmacology* 2015;**40**:S565.

Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. *JAMA Psychiatry* 2014;**71**(12):1350-63.

Glynn SM, Gingerich S, Mueser KT, Cather C, Penn D. The role of family intervention in coordinated specialty care for first episode psychosis. *Schizophrenia Bulletin* 2015;**41**:S173.

Kane J, Schooler N, Robinson D, Addington J, Kane JM. The NIMH RAISE ETP (Early Treatment Program): initial results. *Early Intervention in Psychiatry* 2014;**8**:1.

Kane JM. RAISE-ETP: NAVIGATE vs usual care - two year outcomes. *Schizophrenia Bulletin* 2015;**41**:S317.

Kane JM. The RAISE ETP study: initial results. *Early Intervention in Psychiatry* 2014;**8**:2.

Kane JM, Robinson DG, Schooler NR, Mueser KT, Penn DL, Rosenheck RA, et al. Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE early treatment program. *American Journal of Psychiatry* 2016;**173**:362-72.

Mueser KT. Description and implementation of the RAISE-ETP study psychosocial treatment model: the NAVIGATE program. *Schizophrenia Bulletin* 2015;**41**:S325-6.

Mueser KT, Penn DL, Addington J, Brunette MF, Gingerich S, Glynn SM, et al. The NAVIGATE Program for first-episode psychosis: rationale, overview, and description of psychosocial components. *Psychiatric Services* 2015;**66**(7):680-90.

Robinson DG, Schooler NR, John M, Correll CU, Marcy P, Addington J, et al. Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. *American Journal of Psychiatry* 2015;**172**(3):237-48.

Schooler N. RAISE-ETP study design, site selection and implementation model. *Early Intervention in Psychiatry* 2014;**8**:1.

Schooler NR. The RAISE-ETP study design, research and implementation model. *Schizophrenia Bulletin* 2015;**41**:S332-3.

**Ramsay-USA** {published data only}

Ramsay I, Fryer S, Boos A, Roach BJ, Fisher M, Loewy R, et al. Targeted cognitive training is neuroprotective against thalamic

volume loss in early schizophrenia. *Schizophrenia Bulletin* 2017;**43**:S49.

**RAP-USA** {published data only}

Cornblatt B. Risperidone vs sertraline for prodromal schizophrenia. Stanley Foundation Research Programs 2009.

NCT00169988. Sertraline alone vs in combination with risperidone in the treatment of attenuated positive and negative symptoms. [www.ClinicalTrials.gov/ct/show/](http://www.ClinicalTrials.gov/ct/show/) 2005.

**Schmechtig-USA** {published data only}

Schmechtig A, Dourish C, Craig K, Dawson GR, Williams S, Deakin W, et al. Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by high schizotypy. *Pharmacopsychiatry* 2011;**21**:A99.

Schmechtig A, Lees J, Dawson G, Dourish C, Craig K, Deakin B, et al. Effects of high schizotypy on control of eye movements: Modulation by antipsychotic drugs and nicotine. *Neuropsychopharmacology* 2010;**35**:S389.

Schmechtig A, Lees J, Dawson G, Dourish C, Craig K, Deakin B, et al. Effects of high schizotypy on control of eye movements: modulation by antipsychotic drugs and nicotine. 49th Annual Meeting of the American College of Neuropsychopharmacology; 2010 Dec 5-9; Miami, Florida. 2010.

Schmechtig A, Lees J, Dawson GR, Dourish CT, Craig KJ, Deakin JF, et al. Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy. *Pharmacopsychiatry*. 2011:306.

**Uher-Canada** {published data only}

Uher R, Cumby J, MacKenzie LE, Morash-Conway J, Glover JM, Aylott A, et al. A familial risk enriched cohort as a platform for testing early interventions to prevent severe mental illness. *BMC Psychiatry* 2014;**14**:344.

Uher R, Cumby J, McKenzie L, Morash J, Bagnell A, Propper L, et al. Families overcoming risks and building opportunities for wellbeing (FORBOW): a high-risk cohort multiple randomised controlled trial. *Early Intervention in Psychiatry* 2014;**8**:6.

**Vadhan-USA** {published data only}

Vadhan NP, Corcoran CM, Bedi GI, Lieberman JG, Haney M. Marijuana smokers at clinical high-risk for schizophrenia exhibit an enhanced subjective, behavioral and physiological response to smoked marijuana. *Comprehensive Psychiatry* 2013;**54**(8):e37.

**Woods-2-USA** {published data only}

NCT00268749. Glycine treatment of prodromal symptoms. [www.ClinicalTrials.gov/ct/show/](http://www.ClinicalTrials.gov/ct/show/) 2005.

Woods S. A 12-week open label trial of glycine treatment of prodromal symptoms of schizophrenia in 25 patients. Glycine is an amino acid that stimulates the NMDA receptor. Some theories of schizophrenia posit that NMDA receptors may be hypoactive. Stanley Foundation Research Programs 2002.

## References to studies awaiting assessment

### Armando-Italy {published data only}

Armando M, De Crescenzo F, Vicari S, Digilio MC, Pontillo M, Papaleo F, et al. Indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11DS genetically at high risk for psychosis. Protocol of a randomised, double-blind, placebo-controlled treatment trial. *Early Intervention in Psychiatry* 2014;**10**(5):390-6. [DOI: [10.1111/eip.12197](https://doi.org/10.1111/eip.12197)]

### Goie-Norway {published data only}

NCT03048695. Goal management training for patients with schizophrenia or high risk for schizophrenia. [ClinicalTrials.gov/show/NCT03048695](https://clinicaltrials.gov/show/NCT03048695) 2017.

### Langer-Chile {published data only}

ISRCTN24327446. The effect of mindfulness based intervention in cognitive functions and psychological well-being applied as an early intervention in schizophrenia and high risk mental state. [www.isrctn.com/ISRCTN24327446](http://www.isrctn.com/ISRCTN24327446) 2016.

Langer AI, Schmidt C, Mayol R, Diaz M, Lecaros J, Krogh E, et al. The effect of a mindfulness-based intervention in cognitive functions and psychological well-being applied as an early intervention in schizophrenia and high-risk mental state in a Chilean sample: study protocol for a randomised controlled trial. *Trials* 2017;**18**(1):233.

### Nemoto-Japan {published data only}

Nemoto T, Takeshi K, Niimura H, Tobe M, Ito R, Saito H, et al. Phase-specific cognitive remediation in the early course of schizophrenia. *Early Intervention in Psychiatry* 2014;**8**:42.

### OMEGA3-NAPLS-USA {published data only}

Cadenhead K, Addington J, Bearden CE, Cannon T, Cornblatt B, Mathalon D, et al. Metabolic parameters prior to the onset of psychosis in the North American Prodrome Longitudinal Studies (NAPLS) consortium. *Schizophrenia Bulletin* 2015;**41**:S124.

Cadenhead K, Addington J, Cannon T, Cornblatt B, Mathalon D, McGlashan T, et al. Omega-3 fatty acid versus placebo in a clinical high-risk sample from the North American Prodrome Longitudinal studies (NAPLS) consortium. *Schizophrenia Bulletin* 2017;**43**:S16.

Kelsven S, Addington J, Bearden C, Cannon T, Cornblatt B, Mathalon D, et al. Metabolic abnormalities and omega-3 fatty acids in Latinos at clinical high risk for psychosis. *Schizophrenia Bulletin* 2017;**43**:S14-5.

### POP-Norway {published data only}

ISRCTN20328848. Primary prevention of psychosis through interventions in the prodromal phase. [www.isrctn.com/ISRCTN20328848](http://www.isrctn.com/ISRCTN20328848) 2014.

Joia I, Gisselgard J, Bronnick K, McGlashan T, Johannessen JO. Primary prevention of psychosis through interventions in the symptomatic prodromal phase, a pragmatic Norwegian ultra high risk study. *BMC Psychiatry* 2015;**15**:89.

### Woods-3-USA {published data only}

Woods S, Saksa J, Compton M, Daley M, Rajarethinam R, Graham K, et al. Effects of ziprasidone versus placebo in patients at clinical high risk for psychosis. *Schizophrenia Bulletin* 2017;**43**:S58.

## References to ongoing studies

### ChiCTR-INR-16009566 {published data only}

ChiCTR-INR-16009566. Personalised strategy for non-invasive early intervention on clinical high-risk subjects for psychosis. [apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-INR-16009566](https://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-INR-16009566) 2016.

### Deyoe-USA/Mexico {published data only}

Deyoe J, Kelsven S, Robles-Guerrero C, Mirzakhani H, Perez G, Reyes-Madriral F, et al. Compensatory cognitive training in high-risk Latino youth. *Schizophrenia Bulletin* 2017;**43**:S150-1.

NCT02245607. Compensatory cognitive training in clinical high risk Latino youth. [ClinicalTrials.gov/show/NCT02245607](https://clinicaltrials.gov/show/NCT02245607) 2014.

### ESPRIT B1-Germany {published data only}

Falkai P, Leweke FM, Ruhrmann S, Woelwer W. Enhancing schizophrenia prevention and recovery through innovative treatments - a new network approach in Germany. *Early Intervention in Psychiatry* 2014;**8**:20.

NCT03149107. Multimodal prevention of psychosis - a randomised trial investigating the efficacy of N-acetylcysteine (NAC) and integrated preventive psychological intervention (IPPI) in subjects clinically at high risk for psychosis. [ClinicalTrials.gov/show/NCT03149107](https://clinicaltrials.gov/show/NCT03149107) 2017.

Ruhrmann S, Hellmich M, Hurlmann R, Maier W, Klosterkötter J. N-acetylcysteine (NAC) and integrated preventive psychological intervention (IPPI) in subjects clinically at high risk for psychosis. *Early Intervention in Psychiatry* 2014;**8**:20.

### FOCUS-Denmark {published data only}

Glenthøj LB, Fagerlund B, Randers L, Hjorthøj CR, Wenneberg C, Krakauer K, et al. The FOCUS trial: an RCT evaluating the effectiveness of cognitive remediation therapy for patients at ultra-high risk of psychosis. *Early Intervention in Psychiatry* 2014;**8**:109.

Glenthøj LB, Fagerlund B, Randers L, Hjorthøj CR, Wenneberg C, Krakauer K, et al. The FOCUS trial: cognitive remediation plus standard treatment versus standard treatment for patients at ultra-high risk for psychosis: study protocol for a randomised controlled trial. *Trials* 2015;**16**(1):25.

NCT02098408. Effects of neurocognitive and social cognitive remediation in patients at ultra-high risk of psychosis [A randomised clinical trial examining cognitive remediation plus standard treatment versus standard treatment in participants at ultra-high risk of psychosis. - effect on cognitive functioning, functional outcome and symptomatology. Mental health services in the capital region, Denmark]. [Clinicaltrials.gov/show/NCT02098408](https://clinicaltrials.gov/show/NCT02098408). Denmark, 2014.



Wenneberg C, Nordentoft M, Glenthøj BY, Rostrup E, Glenthøj LB, Krakauer K, et al. Glutamatergic disturbances in subjects at ultra-high risk of psychosis and the effect of cognitive remediation therapy. *Early Intervention in Psychiatry* 2014;**8**:168.

**ISRCTN42478021** {published data only}

ISRCTN42478021. Combined individual and family cognitive behavioural therapy compared with treatment as usual. [www.isrctn.com/](http://www.isrctn.com/) 2016.

**NCT02047539** {published data only}

NCT02047539. Randomised controlled trial of aspirin vs placebo in the treatment of pre-psychosis [Randomised controlled trial of aspirin vs placebo in the treatment of patients with the clinical risk syndrome for psychosis]. [ClinicalTrials.gov/show/NCT02047539](http://ClinicalTrials.gov/show/NCT02047539). USA, 2014.

**NCT02155699** {published data only}

NCT02155699. Exercise and markers of medial temporal health in youth at ultra high-risk for psychosis. [ClinicalTrials.gov/show/NCT02155699](http://ClinicalTrials.gov/show/NCT02155699) 2014.

**NCT02234258** {published data only}

NCT02234258. Cognitive behavioral social skills training for youth at risk of psychosis. [ClinicalTrials.gov/show/NCT02234258](http://ClinicalTrials.gov/show/NCT02234258) 2015.

**NCT02404194** {published data only}

NCT02404194. Targeted cognitive training in clinical high risk (CHR) for psychosis. [www.ClinicalTrials.gov/ct/show/](http://www.ClinicalTrials.gov/ct/show/) 2015.

**NCT02557945** {published data only}

NCT02557945. Gabapentin in patients at clinical risk for psychosis. [ClinicalTrials.gov/show/NCT02557945](http://ClinicalTrials.gov/show/NCT02557945) 2015.

**NCT02751632** {published data only}

ACTRN1261600098437. Staged Treatment in Early Psychosis (STEP): a sequential multistage randomised clinical trial (SMART) of interventions for ultra high risk (UHR) of psychosis patients. [apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN1261600098437](http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN1261600098437) 2016.

NCT02751632. The staged treatment in early psychosis study. [ClinicalTrials.gov/show/NCT02751632](http://ClinicalTrials.gov/show/NCT02751632) 2016.

**NCT02951208** {published data only}

NCT02951208. tDCS coupled with virtual rehabilitation for negative symptoms in at-risk youth. [ClinicalTrials.gov/show/NCT02951208](http://ClinicalTrials.gov/show/NCT02951208) 2016.

**NCT02960451** {published data only}

NCT02960451. PRIME vs usual care for clinical high risk. [ClinicalTrials.gov/show/NCT02960451](http://ClinicalTrials.gov/show/NCT02960451) 2016.

**OMEGA3-Ireland** {published data only}

NCT02848469. Irish omega-3 study. [ClinicalTrials.gov/show/NCT02848469](http://ClinicalTrials.gov/show/NCT02848469) 2016.

**PREVENT-Germany** {published data only}

Bechdolf A, Mueller H, Stuetzer H, Wagner M, Maier W, Lautenschlager M, et al. Rationale and baseline characteristics of prevent: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis valuating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis. *Schizophrenia Bulletin* 2011;**37**(Suppl 2):111-21.

Bechdolf A, Muller H, Stutzer H, Lambert M, Karow A, Zink M, et al. PREVENT: a randomised controlled trial for the prevention of first-episode psychosis comparing cognitive-behavior therapy (CBT), clinical management, and aripiprazole combined and clinical management and placebo combined. *Schizophrenia Bulletin* 2017;**43**:S56-7.

Bechdolf A, Muller H, Stutzer H, Wagner M, Maier W, Lautenschlager M, et al. Rationale and baseline characteristics of prevent: a second generation intervention trial in subjects at-risk (prodromal) of developing first episode psychosis evaluating cognitive behaviour therapy, aripiprazole and placebo for the prevention of psychosis. *Schizophrenia Research* 2012;**136**:S18.

Bechdolf A, Veith V, Vogeley K, Brockhaus-Dumke A, Ruhrmann S, Schultze-Lutter F, et al. PREVENT: a second generation intervention trial in subjects at risk of developing first episode psychosis evaluating CBT, aripiprazole and placebo for the prevention of psychosis. *Early Intervention in Psychiatry* 2008;**2**(Suppl 1):A11.

Bechdolf A, Wessels H, Wagner M, Kuhr K, Berning J, Putzfeld V, et al. Predictors of treatment response to psychosocial interventions in people at risk. *European Archives of Psychiatry and Clinical Neuroscience* 2015;**1**:S9.

Klosterkötter J. Secondary prevention of schizophrenia: a randomised controlled trial. [www.controlled-trials.com](http://www.controlled-trials.com) 2007.

**Quarashi-Pakistan** {published data only}

NCT02569307. Pilot study of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk mental states. [ClinicalTrials.gov/show/NCT02569307](http://ClinicalTrials.gov/show/NCT02569307) 2015.

Qurashi I, Chaudhry IB, Khoso AB, Farooque S, Lane S, Husain MO, et al. A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol. *Trials* 2017;**18**(1):524. [doi: 10.1186/s13063-017-2275-y]

**Ruhrman-USA/UK** {published data only}

Keefe R, Woods S, Cannon T, Ruhrmann S, Mathalon D, McGuire P, et al. Early intervention in attenuated psychosis syndrome: a phase II study evaluating efficacy, safety, and tolerability of oral BI 409306. *Schizophrenia Bulletin* 2017;**43**:S216.

## Additional references

### Abi-Dargham 2004

Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. *International Journal of Neuropsychopharmacology* 2004;**7**(Suppl 1):S1-5.

### Addington 1990

Addington D, Addington J, Maticka-Tyndale E. Specificity of the Calgary Depression Scale for schizophrenics. *Schizophrenia Research* 1994;**11**:239-44.

### Addington 2017

Addington J, Addington D, Abidi S, Raedler T, Remington G. Canadian treatment guidelines for individuals at clinical high risk of psychosis. *Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie* 2017;**62**(9):656-61.

### Ainsworth 2007

Ainsworth J, Harper R. The PsyGrid Experience: Using Web Services in the Study of Schizophrenia. *International Journal of Healthcare Information Systems and Informatics* 2007;**2**(2):1-20.

### Allen 2012

Allen P, Chaddock CA, Howes OD, Egerton A, Seal ML, Fusar-Poli P, et al. Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis. *Schizophrenia Bulletin* 2012;**38**(5):1040-9. [DOI: [10.1093/schbul/sbr017](https://doi.org/10.1093/schbul/sbr017)]

### Altman 1996

Altman DG, Bland JM. Detecting skewness from summary information. *BMJ* 1996;**313**(7066):1200.

### Amminger 2010

Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo-controlled trial. *Archives of General Psychiatry* 2010;**67**(2):146-54.

### Anderson 2015

Anderson K, Laxhman N, Priebe S. Can mental health interventions change social networks? A systematic review. *BMC Psychiatry* 2015;**15**:297. [DOI: [10.1186/s12888-015-0684-6](https://doi.org/10.1186/s12888-015-0684-6)]

### Andreasen 1983

Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa, 1983.

### Andreasen 1984

Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa, 1984.

### Andreasen 2013

Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. *American Journal of Psychiatry* 2013;**170**(6):609-15.

### Andrew 1979

Andrew DM, Paterson DG, Longstaff HP. Minnesota Clerical Test Manual. 2nd Edition. San Antonio: Harcourt Assessment Company, Psychological Corporation, 1979.

### Anticevic 2015

Anticevic A, Haut K, Murray JD, Repovs G, Yang GJ, Diehl C, et al. Association of thalamic dysconnectivity and conversion to psychosis in youth and young adults at elevated clinical risk. *JAMA Psychiatry* 2015;**72**(9):882-91. [DOI: [10.1001/jamapsychiatry.2015.0566](https://doi.org/10.1001/jamapsychiatry.2015.0566)]

### APA 1994

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition. 4th Edition. Washington: American Psychiatric Association, 1994.

### APA 2013

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. 5th Edition. Arlington: American Psychiatric Association, 2013.

### Barnes 1989

Barnes TR. A rating scale for drug-induced akathisia. *British Journal of Psychiatry* 1989;**154**:672-6.

### Beck 1961

Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. *Archives of General Psychiatry* 1961;**4**:561-71.

### Beck 1996

Beck AT, Steer RA, Brown GK. Beck Depression Inventory-II. San Antonio: Psychological Corporation, 1996.

### Berger 2012

Berger GE, Wood SJ, Ross M, Hamer CA, Wellard RM, Pell G, et al. Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study. *Current Pharmaceutical Design* 2012;**18**(4):570-5.

### Bergman 2017

Bergman H, Walker DM, Nikolakopoulou A, Soares-Weiser K, Adams CE. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. *Health Technology Assessment (Winchester, England)* 2017;**21**(43):1-218. [PUBMED: 28812541]

### Birchwood 1990

Birchwood M, Smith J, Cochrane R, Wetton S, Copstake S. The Social Functioning Scale: the development and validation of a new scale adjustment for use in family intervention programmes with schizophrenic patients. *British Journal of Psychiatry* 1990;**157**:853-9.

### Birchwood 1993

Birchwood M, Mason R, MacMillan F, Healy J. Depression, demoralisation and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis. *Psychological Medicine* 1993;**23**:387-95. [DOI: [10.1017/s0033291700028488](https://doi.org/10.1017/s0033291700028488)]

**Birchwood 2012**

Birchwood M, Jackson Ch, Brunet K, Holden J, Barton K. Personal beliefs about illness questionnaire-revised (PBIQ-R): reliability and validation in a first episode sample. *British Journal of Clinical Psychology* 2012;**51**:448-58.

**Bland 1997**

Bland JM. Statistics notes. Trials randomised in clusters. *BMJ* 1997;**315**:600.

**Boissel 1999**

Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Aperçu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. *Therapie* 1999;**54**(4):405-11. [PUBMED: 10667106]

**Broome 2005**

Broome MR, Woolley JB, Johns LC, Valmaggia LR, Tabraham P, Gafoor R, et al. Outreach and support in south London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. *European Psychiatry* 2005;**20**(5-6):372-8.

**Cai 2015**

Cai Y, Zhu Y, Zhang W, Wang Y, Zhang C. Comprehensive family therapy: an effective approach for cognitive rehabilitation in schizophrenia. *Neuropsychiatric Disease and Treatment* 2015;**11**:1247-53.

**Cannon 2008**

Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. *Archives of General Psychiatry* 2008;**65**(1):28-37.

**Chouinard 1980**

Chouinard G, Ross-Chouinard A, Annable L, Jones B. The extrapyramidal symptom rating scale. *Canadian Journal of Neurological Sciences* 1980;**7**(3):233.

**Chung 2015**

Chung Y, Jacobson A, He G, Van Erp TG, McEwen S, Addington J, et al. Prodromal symptom severity predicts accelerated gray matter reduction and third ventricle expansion among clinically high risk youth developing psychotic disorders. *Molecular Neuropsychiatry* 2015;**1**(1):13-22.

**Cornblatt 2002**

Cornblatt B, Lencz T, Obuchowski M. The schizophrenia prodrome: treatment and high-risk perspectives. *Schizophrenia Research* 2002;**54**(1-2):177-86.

**Cornblatt 2007a**

Cornblatt BA, Lencz T, Smith CW, Olsen R, Auther AM, Nakayama E, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. *Journal of Clinical Psychiatry* 2007;**68**(4):546-57.

**Cornblatt 2007b**

Cornblatt BA, Auther AM, Niendam T, Smith CH, Zinberg J, Bearden CE, et al. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. *Schizophrenia Bulletin* 2007;**33**(3):688-702.

**Davies 2018a**

Davies C, Radua J, Cipriani A, Stahl D, Provenzani U, McGuire P, et al. Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: a network meta-analysis. *Frontiers in Psychiatry / Frontiers Research Foundation* 2018;**9**:187.

**Davies 2018b**

Davies C, Cipriani A, Ioannidis JP, Radua J, Stahl D, Provenzani U, et al. Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. *World Psychiatry* 2018;**17**(2):196-209. [DOI: [10.1002/wps.20526](https://doi.org/10.1002/wps.20526)]

**Deeks 2000**

Deeks J. Issues in the selection for meta-analyses of binary data. 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.

**Deeks 2017**

Deeks JJ, Higgins JP, Altman DG (editors), on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), *Cochrane Handbook for Systematic Reviews of Interventions* version 5.2.0 (updated June 2017), Cochrane, 2017. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).

**Derogatis 1995**

Derogatis L. Brief Symptom Inventory. Baltimore: Research, CP, 1995.

**Devoe 2018a**

Devoe DJ, Peterson A, Addington J. Negative symptom interventions in youth at risk of psychosis: a systematic review and network meta-analysis. *Schizophrenia Bulletin* 2018;**44**(4):807-23. [DOI: [10.1093/schbul/sbx139](https://doi.org/10.1093/schbul/sbx139); PUBMED: 29069511]

**Devoe 2018b**

Devoe DJ, Farris MS, Townes P, Addington J. Interventions and social functioning in youth at risk of psychosis: a systematic review and meta-analysis. *Early Intervention in Psychiatry* 2018;**13**(2):169-180. [DOI: [10.1111/eip.12689](https://doi.org/10.1111/eip.12689)]

**Devoe 2018c**

Devoe DJ, Farris MS, Townes P, Addington J. Attenuated psychotic symptom interventions in youth at risk of psychosis: a systematic review and meta-analysis. *Early Intervention in Psychiatry* 2018;**13**(1):3-17. [DOI: [10.1111/eip.12677](https://doi.org/10.1111/eip.12677)]

**Divine 1992**

Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. *Journal of General Internal Medicine* 1992;**7**(6):623-9.

**Dolder 2003**

Dolder CR, Lacro JP, Leckband S, Jeste DV. Interventions to improve antipsychotic medication adherence: review of recent literature. *Journal of Clinical Psychopharmacology* 2003;**23**(4):389–99.

**Donner 2002**

Donner A, Klar N. Issues in the meta-analysis of cluster randomised trials. *Statistics in Medicine* 2002;**21**(19):2971–80.

**Durham 2005**

Durham RC, Chambers JA, Power KG, Sharp DM, Macdonald RR, Major KA, et al. Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland. *Health Technology Assessment* 2005;**9**(42):1–174.

**Egger 1997**

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**:629–34.

**Elbourne 2002**

Elbourne DR, Altman DG, Higgins JP, Curtina F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. *International Journal of Epidemiology* 2002;**31**(1):140–9.

**Emsley 2013**

Emsley R, Chiliza B, Asmal R, Harvey BH. The nature of relapse in schizophrenia. *BMC Psychiatry* 2013;**13**:50.

**Falloon 1985**

Falloon IR, Boyd JL, McGill CW, Williamson M, Razani J, Moss HB, et al. Family management in the prevention of morbidity of schizophrenia. Clinical outcome of a two-year longitudinal study. *Archives of General Psychiatry* 1985;**42**(9):887–96.

**Furukawa 2006**

Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. *Journal of Clinical Epidemiology* 2006;**59**(7):7–10.

**Fusar-Poli 2007**

Fusar-Poli P, Valmaggia L, McGuire P. Can antidepressants prevent psychosis?. *Lancet* 2007;**370**(9601):1746–8.

**Fusar-Poli 2016**

Fusar-Poli P, Schultze-Lutter F, Cappucciati M, Rutigliano G, Bonoldi I, Stahl D, et al. The dark side of the moon: meta-analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. *Schizophrenia Bulletin* 2016;**42**(3):732–43.

**Glasziou 2018**

Glasziou P, Chalmers I. Research waste is still a scandal - an essay by Paul Glasziou and Iain Chalmers. *BMJ (Clinical Research Ed.)* 2018;**363**:k4645. [PubMed: 30420358]

**Gold 1997**

Gold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR. Auditory working memory and Wisconsin Card Sorting Test

performance in schizophrenia. *Archives of General Psychiatry* 1997;**54**:159–65.

**Golden 1978**

Golden C. Stroop Color and Word Test: Manual for Clinical and Experimental Uses. Chicago: Stoelting, 1978.

**Goldman 1992**

Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM- IV: a review of measures of social functioning. *American Journal of Psychiatry* 1992;**149**(9):1148–56.

**GRADEpro GDT [Computer program]**

McMaster University (developed by Evidence Prime). GRADEpro GDT. Version 19 September 2019. Hamilton (ON): McMaster University (developed by Evidence Prime).

**Gulliford 1999**

Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. *American Journal of Epidemiology* 1999;**149**(9):876–3.

**Guy 1976**

Guy W (editor). ECDEU Assessment Manual for Psychopharmacology. Rockville: US Department of Health, Education, and Welfare, 1976.

**Guy 1976b**

Guy W. ECDEU Assessment Manual for Psychopharmacology (DOTES: Dosage Record and Treatment Emergent Symptom Scale). Rockville: National Institute of Mental Health, 1976.

**Hamilton 1959**

Hamilton M. The assessment of anxiety states by rating. *British Journal of Medical Psychology* 1959;**32**:50–5.

**Hamilton 1960**

Hamilton, M. A rating scale for depression. *Journal of Neurology, Neurosurgery, and Psychiatry* 1960;**23**:56–62.

**Heaton 1993**

Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtis G. Wisconsin Card Sorting Test, Manual. Odessa: Psychological Assessment Resources, 1993.

**Heinrichs 1984**

Heinrichs DW, Hanlon TE, Carpenter WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. *Schizophrenia Bulletin* 1984;**10**(3):388.

**Higgins 2003**

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557–60.

**Higgins 2011a**

Higgins JP, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), *Cochrane Handbook for Systematic Reviews of Interventions*. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [www.cochrane-handbook.org](http://www.cochrane-handbook.org).

### Higgins 2011b

Higgins JP, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions*. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [handbook.cochrane.org](http://handbook.cochrane.org).

### Higgins 2017

Higgins JP, Altman DG, Sterne JA (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), *Cochrane Handbook for Systematic Reviews of Interventions* version 5.2.0 (updated June 2017), Cochrane, 2017. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).

### Hogarty 1991

Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, Greenwald DP, Ulrich RF, et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. II. Two-year effects of a controlled study on relapse and adjustment. *Archives of General Psychiatry* 1991;**48**(4):340–7.

### Howes 2012

Howes OD, Fusar-Poli P, Bloomfield M, Selvaraj S, McGuire P. From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments. *Current Pharmaceutical Design* 2012;**18**(4):459–65.

### Häfner 1992

Häfner H, Riecher-Rössler A, Hambrecht M, Maurer K, Meissner S, Schmidtke A, et al. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. *Schizophrenia Research* 1992;**6**:209–23.

### Jaaskelainen 2013

Jaaskelainen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, et al. A systematic review and meta-analysis of recovery in schizophrenia. *Schizophrenia Bulletin* 2013;**39**(6):1296–306.

### Jauhar 2014

Jauhar S, McKenna PJ, Radau J, Fung E, Salvador R, Laws KR. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. *British Journal of Psychiatry* 2014;**204**(1):20–9. [DOI: [10.1192/bjp.bp.112.116285](https://doi.org/10.1192/bjp.bp.112.116285)]

### Job 2006

Job DE, Whalley HC, McIntosh AM, Johnstone EC, Lawrie SM. Grey matter changes can improve the prediction of schizophrenia in subjects at high risk. *BMC Psychiatry* 2006;**4**:29.

### Kantrowitz 2015

Kantrowitz JT, Woods SW, Petkova E, Cornblatt B, Corcoran CM, Chen H, et al. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. *Lancet Psychiatry* 2015;**2**(5):403–12. [DOI: [10.1016/S2215-0366\(15\)00098-X](https://doi.org/10.1016/S2215-0366(15)00098-X)]

### Kay 1987

Kay SR, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. *Schizophrenia Bulletin* 1987;**13**(2):261–76. [PUBMED: 3616518]

### La Greca 1993

La Greca AM, Stone WL. Social anxiety scale for children revised: factor structure and concurrent validity. *Journal of Clinical Child Psychology* 1993;**22**:17–27. [DOI: [10.1207/s15374424jccp2201\\_2](https://doi.org/10.1207/s15374424jccp2201_2)]

### Leon 2006

Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomised controlled clinical trials: methodological issues in psychopharmacology. *Biological Psychiatry* 2006;**59**(11):1001–5. [PUBMED: 16905632]

### Leucht 2005a

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. *British Journal of Psychiatry* 2005;**187**:366–71. [PUBMED: 16199797]

### Leucht 2005b

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. *Schizophrenia Research* 2005;**79**(2-3):231–8. [PUBMED: 15982856]

### Levine 1986

Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. *Psychopharmacology Bulletin* 1986;**22**(2):343–81.

### Lingjærde 1987

Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. *Acta Psychiatrica Scandinavica* 1987;**76**:Suppl 334.

### Marshall 2000

Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. *British Journal of Psychiatry* 2000;**176**:249–52.

### Mattick 1998

Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. *Behaviour Research and Therapy* 1998;**36**:455–70.

### Maurer 2004

Maurer K, Horrmann F, Schmidt G, Trendler G, Häfner H. The early recognition inventory ERIraos: a two-step procedure for detection of “at-risk mental states”. *Schizophrenia Research* 2004;**70** (suppl):s76.

### McAusland 2015

McAusland L, Buchy L, Cadenhead KS, Cannon TD, Cornblatt BA, Heinsen R, et al. Anxiety in youth at clinical high risk for psychosis. *Early Intervention in Psychiatry* 2017; Vol. 11, issue 6:480–487. [DOI: [10.1111/eip.12274](https://doi.org/10.1111/eip.12274)]

**Miller 1999**

Miller TJ, McGlashan TH, Woods SW, Stein K, Driesen N, Corcoran CM, et al. Symptom assessment in schizophrenic prodromal states. *Psychiatric Quarterly* 1999;**70**:273-87.

**Miller 2003**

Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. *Schizophrenia Bulletin* 2003;**29**(4):703-15.

**Montgomery 1979**

Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *British Journal of Psychiatry* 1979;**134**:382-9.

**Morrison 2004**

Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk randomised controlled trial. *British Journal of Psychiatry* 2004;**185**(4):291-7.

**Neuchterlein 2008**

Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. *American Journal of Psychiatry* 2008;**165**:203-13.

**Overall 1962**

Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. *Psychological Reports* 1962;**10**:799-812.

**Priebe 1999**

Priebe S, Huxley P, Knight S, Evans S. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). *International Journal of Social Psychiatry* 1999;**45**:7-12.

**Pyle 2015**

Pyle M, Stewart SL, French P, Byrne R, Patterson P, Gumley A, et al. Internalised stigma, emotional dysfunction and unusual experiences in young people at risk of psychosis. *Early Intervention in Psychiatry* 2015;**9**:133-40. [DOI: [10.1111/eip.12098](https://doi.org/10.1111/eip.12098)]

**Reitan 1985**

Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tuscon: Neuropsychology Press, 1985.

**Review Manager 2014 [Computer program]**

Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

**Rey 1964**

Rey RA. L'examen clinique en psychologique, Vol. Paris: Presses Universitaires de France, 1964.

**Ruggeri 2015**

Ruggeri M, Bonetto C, Lasalvia A, Fioritti A, de Girolamo G, Santonastaso P, et al. Feasibility and effectiveness of a multi-element psychosocial intervention for first- episode psychosis: results from the cluster-randomised controlled GET UP PIANO trial in a catchment area of 10 million inhabitants. *Schizophrenia Bulletin* 2015;**41**(5):1192-203.

**Schmidt 2015**

Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, Maric NP, Salokangas RK, Riecher-Rössler A, et al. EPA guidance on the early intervention in clinical high risk states of psychoses. *European Psychiatry* 2015;**30**(3):388-404. [DOI: [10.1016/j.eurpsy.2015.01.013](https://doi.org/10.1016/j.eurpsy.2015.01.013)]

**Schooler 1979**

Schooler N, Hogarty G, Weissman MM. Social Adjustment Scale II (SAS II). In: Hargreaves WA, Attkisson CC, Sorenson JE editor(s). Resource Materials for Community Mental Health Program Evaluators, publication No. (ADM) 79-328. US Department of Health, Education, and Welfare, 1979:290-330.

**Schultze-Lutter 2009**

Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. *Schizophrenia Bulletin* 2009;**35**(1):5-8.

**Schünemann 2017**

Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al. on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).

**Simpson 1970**

Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. *Acta Psychiatrica Scandinavica* 1970;**212**:11-19.

**Sommer 2014**

Sommer IE, Van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. *Schizophrenia Bulletin* 2014;**40**(1):181-91. [DOI: [10.1093/schbul/sbt139](https://doi.org/10.1093/schbul/sbt139)]

**Spreen 1969**

Spreen O, Benton AL. Neurosensory Center Comprehensive Examination for Aphasia (NCCEA). Victoria: University of Victoria Neuropsychology Laboratory, 1969.

**Spreen 1998**

Spreen O, Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 2nd Edition. New York: Oxford, 1998.

**Sterne 2017**

Sterne JA, Egger M, Moher D, Boutron I (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill

R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).

#### Stone 2010

Stone JM, Howes OD, Egerton A, Kambeitz J, Allen P, Lythgoe DJ, et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. *Biological Psychiatry* 2010;**68**(7):599–602. [DOI: [10.1016/j.biopsych.2010.05.034](https://doi.org/10.1016/j.biopsych.2010.05.034)]

#### Streiner 1990

Streiner DL. Sample size and power in psychiatric research. *Canadian Journal of Psychiatry* 1990;**35**:616–20.

#### Ukoumunne 1999

Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. *Health Technology Assessment* 1999;**3**(5):iii-92.

#### Van der Does 2002

Van der Does JW. The Dutch version of the Beck Depression Inventory- (BDI-IINL). 2nd Edition. Lisse: Swets Test Publishers, 2002.

#### Velligan 2008

Velligan DI, Diamond PM, Maples NJ, Mintz J, Li X, Glahn DC, et al. Comparing the efficacy of interventions that use environmental supports to improve outcomes in patients with schizophrenia. *Schizophrenia Research* 2008;**102**(1-3):312–9.

#### Wechsler 1999

Wechsler D. Wechsler abbreviated scale of intelligence (WASI-III) manual. San Antonio: Psychological Corporation, 1999.

#### Weissman 1976

Weissman MM, Bothwell S. Assessment of social adjustment by patient self report. *Archives of General Psychiatry* 1976;**33**:1111–15.

#### WHO 2010

WHO. International Statistical Classification of Diseases and Related Health Problems, 10th revision. Geneva: World Health Organization, 2010.

#### Wiersma 1998

Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. *Schizophrenia Bulletin* 1998;**24**(1):75–85.

#### Winter 1999

Winter LB, Steer R, Jones-Hicks L, Beck AT. Screening for major depressive disorder in adolescent medical outpatients with the Beck Depression Inventory for Primary Care. *Journal of Adolescent Health* 1999;**24**:389–94.

#### Wittchen 2011

Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. *European Neuropsychopharmacology* 2011;**21**(9):655–79.

#### Wunderink 2013

Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy long-term follow-up of a 2-year randomised clinical trial. *JAMA Psychiatry* 2013;**70**(9):913-20. [DOI: [10.1001/jamapsychiatry.2013.19](https://doi.org/10.1001/jamapsychiatry.2013.19)]

#### Xia 2009

Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. *Psychiatric Bulletin* 2009;**33**(7):254-7.

#### Xu 2015

Xu XJ, Jiang GS. Niacin-respondent subset of schizophrenia – a therapeutic review. *European Review for Medical and Pharmacological Sciences* 2015;**19**(6):988-97.

#### Young 1978

Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. *British Journal of Psychiatry* 1978;**133**:429-35.

#### Yung 1998

Yung AR, Phillips LJ, McGorry PD, McFarlane CA, Francey S, Harrigan S, et al. Prediction of psychosis: a step towards indicated prevention of schizophrenia. *British Journal of Psychiatry* 1998;**172** (Suppl. 33):14–20.

#### Yung 2004

Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. *Schizophrenia Research* 2004;**67**(2-3):131-42.

#### Yung 2005

Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell'Olio M, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. *Australian & New Zealand Journal of Psychiatry* 2005;**39**(11-12):964-71.

### References to other published versions of this review

#### Bošnjak 2016

Bošnjak D, Kekin I, Hew J, Kuzman MR. Early interventions for prodromal stage of psychosis. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2016, issue 6. [DOI: [10.1002/14651858.CD012236](https://doi.org/10.1002/14651858.CD012236)]

\* Indicates the major publication for the study

## CHARACTERISTICS OF STUDIES

### Characteristics of included studies [ordered by study ID]

#### ADAPT-Canada

Methods	<p>Allocation: randomised</p> <p>Blinding: single</p> <p>Setting: community</p> <p>Duration: 18 months (6 months treatment, 12 months follow-up)</p> <p>Recruitment and ascertainment: included advertisement on radio, public transit and local newspaper</p> <p>Inclusion criteria: clinical high-risk participants (COPS, from SIPS; <a href="#">Miller 1999</a>).</p> <p>Exclusion criteria: any Axis I psychotic disorder, prior antipsychotic treatment, IQ &lt; 70, history of clinically significant central nervous system disorder</p>
Participants	<p>Diagnosis: people at high risk of developing psychosis</p> <p>N = 51</p> <p>Sex: 36 male, 15 female</p> <p>Age: 14-30 years, mean <math>\sim 21 \pm 5</math> years</p>
Interventions	<p>1. CBT: manualised problem-focused, time-limited treatment of up to 26 sessions within 6 months, mean 12 sessions. N = 27</p> <p>2. Standard care: an active psychological treatment directly assisting individuals to cope with current problems. N = 24</p>
Outcomes	<p>Transition to psychosis: POPS criteria</p> <p>Leaving the study early</p> <p>Mental state: SOPS, CDSS, SPS, SIAS</p> <p>Functioning: SFS, GAF</p> <p>Unable to use:</p> <p>Satisfaction with treatment: WAI-SF (no usable data)</p> <p>Mental state: BAS, SPAI2 (no data)</p> <p>Physical: CMRS, GHQ2 (no data)</p> <p>Economics: cost-effectiveness (no data)</p>
Notes	<p>Funding: grant from Ontario Mental Health Research Foundation, Ontario Canada</p> <p>Power, sample size calculation: "In designing this study sample size calculations were based on current reported rates in the literature. We expected a transition rate of 40% in the control group with a 50% reduction in transition for the active treatment group, i.e. a reduction of transition rate from 40% to 20%, a difference which would be clinically significant. Using a formula based on comparing the proportions of subjects in two groups who exhibit an outcome (40% to 20%) (<a href="#">Streiner 1990</a>) sample size estimates for two-tailed tests with a significance level of 0.05 and a power of 80% were 83 per group."</p> <p>Adherence: see <a href="#">Table 1</a>.</p>

#### Risk of bias

#### Interventions for prodromal stage of psychosis (Review)



**ADAPT-Canada** (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised immediately after the baseline assessment using concealed stratified randomisation with minimisation. Participants stratified by sex and severity of the prodromal symptoms
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	Single-blind (clinical raters and attending psychiatrists blinded, participants not blinded)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Clinical raters and attending psychiatrists were blinded
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Out of 51 randomised, 23 dropped out before the 24- month assessment (attrition 45%). Attrition rate CBT group was 44% (N = 12) and 46% in the supportive therapy group (N = 11). The reasons for study discontinuation were reported.
Selective reporting (reporting bias)	Unclear risk	BAS, SPAI2, CMRS, GHQ2, as well as cost-effectiveness not reported. We contacted the corresponding author for clarification and received this response: "cost effectiveness was never done and some of those measures were not used or completed."  SAS and SIAS reported in manuscript, but not in the published protocol on ClinicalTrials.gov ( <a href="https://clinicaltrials.gov/ct2/show/study/NCT00260273">NCT00260273</a> ). We contacted the corresponding author for clarification, who responded that she can not explain this discrepancy because "this was registered by my study coordinator who may have forgotten".
Other bias	Low risk	We did not identify any other sources of bias

**Amminger-Austria**

Methods	Allocation: randomised Blinding: double-blind (participant, care provider, investigator, outcomes assessor)  Setting: Vienna, Austria; the major referral source was the outpatient service (52, 64.2%). Also derived from psychiatrists and psychologists from the department, other youth services or adult mental health services and private mental health professionals  Duration: 12 months (12 weeks intervention + 36 weeks monitoring). Thereafter 7-year follow-up
Participants	Diagnosis: people at high risk of developing psychosis  N = 81  Sex: men and women  Age: 13-25 years
Interventions	1. omega-3 fatty acids: dose 4 capsules daily – each containing 700 mg of eicosapentaenoic acid, 500 mg of docosahexaenoic acid and 10 mg of Vitamin E. N = 41  2. Placebo (coconut oil capsules matched with appearance and taste). N = 40

**Amminger-Austria** (Continued)

Concomitant medication use after randomisation was allowed: antidepressants and benzodiazepines. Existing medication was re-evaluated at baseline and continued in case of clinical indication. Psychological and psychosocial interventions as well as additional appointments for crisis management were provided.

Outcomes	Transition to PANSS-defined first episode psychosis  Leaving the study early  Mental state: PANSS, MADRS  Functioning: GAF  Adverse effects: UKU  Global state: prescription of antipsychotic medication (assumed to represent the severity of psychotic phenomena)  Additional outcomes:  physiological: neuroinflammation biomarkers, EEG activity, phospholipid metabolism, erythrocyte membrane fatty acid composition and intracellular phospholipase A2 activity
Notes	Cut-off points on PANSS subscales, ( $\geq 4$ hallucinations, $\geq 4$ delusions, and $\geq 5$ conceptual disorganisation).  Funding: Grant 03T-315 from the Stanley Medical Research Institute.  Power, sample size calculation: "The study was powered to detect a 50% reduction in the expected transition rate, corresponding to a transition rate of 20% in the -3 group and an anticipated rate of 40% in the placebo group. Power analysis indicated that 75 subjects would provide a 70% chance of detecting such an effect (2-sided level of .05). Allowing for a 5% to 10% dropout rate, we sought to recruit at least 80 participants."  Adherence: see <a href="#">Table 1</a>

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated random sequence based on a block-randomised design. Stratified according to MADRS. Two strata with block size of 4 within each stratum.
Allocation concealment (selection bias)	Unclear risk	Quote: "Randomisation kept in a remote secure location and administered by an independent third party until all study data were collected and verified."  Comment: precise method of allocation concealment not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Participants, parents, and those involved in administering interventions, assessing outcomes, data entry, and/or data analyses were blind to group assignments.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants, parents, and those involved in administering interventions, assessing outcomes, data entry, and/or data analyses were blind to group assignments.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Out of 81 randomised participants, 5 discontinued the study before 12 months' follow-up (attrition 6%). Attrition rate was 8% in the omega-3 fatty acids group (N = 3: 1 participant/parent decision, 1 physician decision, partic-

**Amminger-Austria** (Continued)

		ipant moved out of the country) and 7% in the placebo group (N = 2: 2 participant/parent decisions)
Selective reporting (reporting bias)	Low risk	All outcomes mentioned in registered protocol (NCT00396643) and publications' methods reported
Other bias	Low risk	We did not identify any other sources of bias

**Choi-USA**

Methods	Allocation: randomised (no details)  Blinding: double-blind (participants, assessors)  Setting: New York, USA  Duration: 4 months (2 months of treatment + 2 months' follow-up)
Participants	Diagnosis: people at high risk of developing psychosis  N = 62  Sex: men and women (~50% M:F)  Age: 16-24 years, mean ~18 SD 4 years  Inclusion criteria: SIPS/SOPS criteria (Miller 1999), English-speaking, age 16-30, processing speed at least 0.5 SD below the norm  Exclusion criteria: prior diagnosis of Axis I psychotic disorder, major medical or neurological disorder, IQ < 70, attenuated positive symptoms occurring solely in the context of substance use or withdrawal, risk for suicide or violence not commensurate with outpatient treatment, substance abuse diagnosis in past 3 months
Interventions	1. PST: cognitive training using pupillometric neurofeedback techniques to adjust training parameters in real time, groups of 2 or 3 participants on tablets for approximately 30 h over the course of 2 months (about 3.5 to 4.0 h per week). N = 30  2. Active control group: commercially available tablet games in same format and duration as PST. N = 32  Participants continued with their regular treatment while participating in the study.
Outcomes	Leaving the study at 2 months (post-intervention assessment)  Mental state: BDI-II, WAIS-III (digit symbol-coding subtest), MCT, SAS-A  Functioning: SAS-SR  Unable to use:  Leaving the study at 2-month follow-up (data unclear)  Cognition: CPT-IP, WMI (data not reported)
Notes	Funding: in part by a Brain & Behavior Research Foundation Grant (CU-17748) and NIMH K23. K23MH086755-05 to Jimmy Choi  Power, sample size calculation: not reported

**Choi-USA** (Continued)

 Adherence: see [Table 1](#)
**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation method not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind study (adequacy of blinding assessed in study)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "All assessments were conducted by a graduate-level research assistant blind to randomisation status, while the intervention was conducted by a different graduate-level research assistant. The participants and research assistant conducting assessments completed a best guess rating form at 2 month follow-up to assess adequacy of the blind (adequate blind defined as rate of correct guessing $\leq$ 50%)."
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Out of 62 randomised participants, 4 did not complete the 2-month intervention (attrition 6%) and additional 2 did not complete 2-month post-treatment follow-up (attrition 10%). Attrition rate across treatment groups is not clearly described. Study authors stated that there was attrition rate of 10% (N = 3) at the end of treatment. As there is no data about dropouts from the active control group at both assessments nor data about dropouts from PST group at 2-month follow-up, it remains unclear whether the additional 2 dropouts at 2-month follow-up are from PST or active control group.
Selective reporting (reporting bias)	Unclear risk	All outcomes mentioned in the publication methods were reported except the CPT-IP, WMI
Other bias	Low risk	We did not identify any other sources of bias

**DEPTh-Australia**

Methods	Allocation: randomised  Blinding: double-blind  Setting: Newcastle and New South Wales, Australia  Inclusion criteria: age 14-30 years, resided within the boundaries of one of the relevant Health Services, met criteria for UHR status defined by the CAARMS ( <a href="#">Yung 2005</a> ).  Exclusion criteria: DSM-IV psychotic disorder, previously prescribed antipsychotic medication, organic mental disorder or intellectual disability, serious suicidal/homicidal risk, inadequate English  Duration: 18 months (6 months of treatment + 12 months of follow-up)
Participants	Diagnosis: people at high risk of developing psychosis  N = 57

**DEPTh-Australia** (Continued)

Sex: men and women, ~40:60% M:F

Age: average ~16 years SD 3

History: participants reimbursed AUD 20 for time and travel at each assessment occasion

Interventions	<p>1. CBT, problem-oriented, time-limited, educational, manualised model: average 9.2 sessions during 6 months. N = 30</p> <p>2. NDRL, manualised person-centred counselling: average 10.1 sessions during 6 months. N = 27</p> <p>All participants offered casework and non-structured family education and supports.</p>
Outcomes	<p>Transition to psychosis: 6 months: CAARMS</p> <p>Leaving the study: 12 months</p> <p>Mental state: CAARMS, BSI, 6 months</p> <p>Functioning: GAF, SOFAS, 6 months</p> <p>Quality of life: QLS, 6 months</p> <p>Unable to use:</p> <p>Transition to psychosis: CAARMS, BSI – 12 months (&gt; 50% attrition rate)</p> <p>Functioning: SOFAS, GAF – 12 months (&gt; 50% attrition rate)</p> <p>Quality of life: QOL – 12 months (&gt; 50% attrition rate)</p> <p>Self-esteem: Rosenberg Self Esteem Scale, Meta-cognitions Questionnaire (data not reported)</p> <p>Additional outcomes:</p> <p>Addiction: OTI, Alcohol Use Disorders Identification Test, Cannabis Use Disorders Identification Test, Severity of Dependence Scale (Cannabis)</p>
Notes	<p>1 participant re-randomised, after breaking the blinding (after the initial assessment, but prior to commencing therapy)</p> <p>Funding: National Health and Medical Research Council, NHMRC (Grant number: 401230)</p> <p>Power, sample size calculation: "Based on an effect size of XX, as found in the EDIE trial (<a href="#">Morrison 2004</a>) for those making a transition to psychosis within six months, the sample required to have 80% power with 5% significance for a two-tailed test of differences in proportions was 39 in each treatment arm. Consistent with other studies of UHR young people, there were difficulties recruiting to the trial with 25% fewer participants than planned and thus the trial was underpowered. The recruitment phase was funded for two years only and thus we were unable to continue to recruit beyond this time."</p> <p>Adherence: see <a href="#">Table 1</a></p>

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated block randomisation, stratified by site and antidepressant medication
Allocation concealment (selection bias)	Unclear risk	<p>Quote: "The allocation list was kept in a secure location by an independent clerical worker, not accessible by the research team."</p> <p>Comment: precise method of allocation concealment was not described</p>

### DEPTh-Australia (Continued)

Blinding of participants and personnel (performance bias) All outcomes	High risk	Participants not blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Research assistants who completed assessments remained blind to randomisation. Extensive steps taken to maintain blindness of raters. Therapist and raters did not discuss details of individual participants. Blinding was broken in one case, after the initial assessment, but prior to commencing therapy. In this case, the participant was re-randomised.
Incomplete outcome data (attrition bias) All outcomes	High risk	Out of 57 participants, 27 discontinued the study before 12 month follow-up assessment (attrition 53%). Attrition rate was 60% in the CBT (N = 18) and 56% in the NDRL group (N = 12). No details for study discontinuation reported
Selective reporting (reporting bias)	Low risk	All outcomes mentioned in the registered protocol (ACTRN12606000101583) and in the publications' methods were reported in the manuscript.
Other bias	Low risk	We did not identify any other sources of bias.

### EDIE-2-UK

Methods	<p>Allocation: randomised</p> <p>Blinding: single (raters)</p> <p>Setting: Manchester, Birmingham, Worcestershire, Glasgow, Cambridgeshire, Norfolk, UK</p> <p>Inclusion criteria: CAARMS (Yung 2005), age 14-35 years, seeking help for symptoms</p> <p>Exclusion criteria: current or previous receipt of antipsychotic medication &gt; 2 days, moderate-severe learning disability, organic impairment, non-English speaking</p> <p>Duration: 24 months (6 months' treatment + 18 months' post-treatment follow-up)</p>
Participants	<p>Diagnosis: people at high risk for developing psychosis (Yung 2005)</p> <p>N = 288</p> <p>Sex: men and women, ~60:40% M:F</p> <p>Age: 14-34 years, average 21 SD 4, median 19</p>
Interventions	<p>1. Cognitive therapy: up to 25 weekly, 1-h sessions plus up to 4 booster sessions (average 9.1) + monitoring. N = 144</p> <p>2. Monitoring: N = 144</p> <p>All participants monitored by monthly assessment for first 6 months, then every 3 months for up to 2 years</p>
Outcomes	<p>Leaving the study early</p> <p>Transition to psychosis: 12 months, follow-up (CAARMS, Yung 2005)</p> <p>Mental state: CAARMS, BDI-PC, SIAS, 12 months follow-up.</p> <p>Functioning: GAF, 12 months follow-up.</p> <p>Global state: PBEQ, 12 months' follow-up</p>

### Interventions for prodromal stage of psychosis (Review)

**EDIE-2-UK** (Continued)

Unable to use:

Transition to psychosis: 24 months' follow-up (CAARMS) (high attrition)

Mental state: CAARMS, BDI-PC, SIAS, 24 months' follow-up (high attrition)

Functioning: GAF, 24 months' follow-up (high attrition)

Global state: PBEQ, 24 months' follow-up (high attrition)

Quality of life: MANSA, EQ-5D (lack of participants)

Economic: incremental cost effectiveness ratio and associated net benefit statistic and probability of cost effectiveness derived from the cost-effectiveness acceptability analysis (no data)

Insight: Metacognitions Questionnaire (short form), Beliefs About Paranoia Scale, Persecution and Derservedness Scale, Brief Core Schema Scales, Interpretations of Voices Inventory, California Psychotherapy Alliance Scales (no data)

**Notes**

Funding: Medical Research Council (G0500264) and the Department of Health.

Power, sample size calculation: Quote: "Power calculations showed that 242 participants (121 in each group) would be required based on assuming a 15% transition rate in the CBT group and a 30% transition rate in the control group. To allow for a dropout rate of up to 25%, we set our recruitment goal at 320 (80 each at Manchester, Birmingham and Glasgow, and 40 each at Cambridge and Norfolk)."

 Adherence: see [Table 1](#)
**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants randomised electronically using Open CDMS ( <a href="#">Ainsworth 2007</a> ). Independent computer randomisation, blocks of 6 or 8 and stratified by site and gender, results concealed from the assessors.
Allocation concealment (selection bias)	Unclear risk	Quote: "Following the second baseline assessment, participants are randomised electronically within two working days using OpenCDMS23 University of Manchester, Manchester, UK). The randomisation algorithm uses blocks of six or eight and stratifies by site and gender. OpenCDMS then sends out an email notification of the allocation to the therapists and study manager. Thus, the results of the randomisation are concealed from the assessors and randomisation is independent."  Comment: list concealed from assessors
Blinding of participants and personnel (performance bias) All outcomes	High risk	Participants not blinded
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "Assessors were blind to treatment condition but 67 blind breaks were reported (22.2% of participants), 15 in the Monitoring group and 52 in CBT + monitoring group. Hence, blinding was successfully maintained for 78.8% of participants. In cases where blinding was broken, another rater assessed the patient for all subsequent assessments or the ratings were discussed with a blind rater and consensus reached (the latter was only carried out if there was a clinical justification not to switch, such as risk considerations or tentative engagement with the trial)."
Incomplete outcome data (attrition bias)	High risk	Out of 288 randomised participants, only 65 were assessed at 24 months' follow-up meaning that attrition was 77% (N = 223). In the cognitive therapy +

### EDIE-2-UK (Continued)

All outcomes		monitoring group attrition rate was 76% (N = 110) and in the monitoring group 78% (N = 113).
Selective reporting (reporting bias)	Unclear risk	All outcomes mentioned in protocol (ISRCTN56283883) were reported in the manuscript, but more outcomes were mentioned in the publications' methods.  These are listed above (outcomes) and but no data for them were reported.
Other bias	Low risk	We did not identify any other sources of bias.

### EDIE-NL

Methods	<p>Allocation: randomised</p> <p>Blinding: single blind (assessors)</p> <p>Setting: The Hague, Rivierduinen (Leiden and surroundings); Friesland, Netherlands</p> <p>Inclusion criteria: age 14-35 years, genetic risk or CAARMS scores in range of At Risk Mental State (Miller 1999), impairment in social functioning, SOFAS score of <math>\leq 50</math> and/or drop in SOFAS score of 30% (Goldman 1992)</p> <p>Exclusion criteria: usage of antipsychotic medication <math>\geq 15</math> mg haloperidol equivalent, severe learning impairment, problems due to organic condition, insufficient competence in Dutch, history of psychosis</p> <p>Duration: initially 18 months (6 months' treatment, 12 months' post-treatment follow-up); additional 4-year data reported</p>
Participants	<p>Diagnosis: UHR for developing psychosis</p> <p>N = 201</p> <p>Sex: men and women, ~50:50 M:F</p> <p>Age: range 14-35 years, average ~23 SD 6</p> <p>History: patients diagnosed by routine psychiatric diagnostic procedures of mental health services (anxiety disorders (N = 53), depression (N = 52), mixed anxiety and depression (N = 10), personality disorders (N = 15), attention deficit hyperactivity disorder (N = 13), addiction problems (N = 12), eating disorders (N = 11), post-traumatic stress disorder (N = 10), oppositional defiant disorder (N = 6), Asperger syndrome (N = 5), relationship problems (DSM-V) (N = 5), and other problems (N = 9)</p>
Interventions	<p>1. CBT: manualised protocol of maximum of 25 sessions, average 10 + TAU. N = 97 (94 analysed)*.</p> <p>2. TAU: N = 104 (102 analysed)*</p>
Outcomes	<p>Transition to psychosis (CAARMS), at planned and additional follow-up</p> <p>Leaving the study, at planned and additional follow-up</p> <p>Mental state: CAARMS**, BDI- II- NL**, CDSS**, SIAS**, MANSA**</p> <p>Functioning: SOFAS**.</p> <p>Global state: PBIQ- R**</p> <p>Economics: cost-effectiveness, at planned and additional follow-up</p> <p>Unable to use:</p>



**EDIE-NL** (Continued)

QOL: EQ-5D (baseline values but used to calculate QALYs gained – not reported)

Mental state: CAARMS, BDI- II- NL, CDS, SIAS, MANSA (at additional follow-up data, results not presented for each group separately)

Functioning: SOFAS (at additional follow-up data, results not presented for each group separately).

Global state: PBIQ- R (at additional follow-up data, results not presented for each group separately)

Cognitive function: verbal fluency test (animal naming) (no data reported)

Additional outcomes:

Drug and alcohol use: CIDI

**Notes**

\*During the study, 5 participants were removed. 2 of them (1 in the CBT and 1 in the TAU group) were already psychotic at baseline (they had dissimulated their symptom levels with the purpose of being enrolled in the study). 3 of them revealed that they had antipsychotic treatment before for psychotic disorder (2 were in the CBT and 1 in the TAU group). These 5 participants were removed from the trial because they fulfilled the exclusion criteria, the decisions were made by the assessors who were blind to randomisation.

\*\*All secondary outcomes measures analyses based on participants who did not make a transition to psychosis.

Funding: ZON-MW, The Netherlands Organization for Health Research; Sponsor/Initiator: VU University Medical Center, Department of Clinical Psychology

Power, sample size calculation: quote: "We calculated power on an expected transition rate of 35 percent over eighteen months with a 50 percent reduction of transitions in the CBT-group. The sample we need for a 2-tailed test of the proportions with an alpha of 0.05 and a power of.80 is 2 × 93 for the reduction of the transition to psychosis and 2 × 82 for the persistence of ARMS and 2 × 91 for the transition into psychosis. A conservative estimate of the drop-out rate is twenty percent per year in schizophrenia research [24]. With an estimated 30 percent drop-out over 18 months, we decided to include 240 persons in the trial."

Adherence: see [Table 1](#)

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random allocation lists were generated by a web-based automated randomisation system
Allocation concealment (selection bias)	Unclear risk	Quote: "The allocation list was kept in a remote secure location, and an independent person randomly allocated the included patients after they signed informed consent."  Comment: precise method of allocation concealment not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	Participants not blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Those who performed research assessments kept blind to randomisation
Incomplete outcome data (attrition bias)	Low risk	Out of 201 randomised participants, 32 dropped out of the study (attrition 16%). Attrition rate in the CBT + TAU group was 18% (N = 17, 3 excluded from

**EDIE-NL** (Continued)

All outcomes		the analysis, 2 moved, 12 withdrew consent) and 14% in the TAU group (N = 15, 2 excluded from the analysis, 2 moved, 11 withdrew).
Selective reporting (reporting bias)	Unclear risk	Most of the outcomes mentioned in registered protocol (ISRCTN21353122) and publications' methods were reported except verbal fluency test (animal naming). Data for EQ-5D were not usable for analysis as well as data for mental and global state, QOL and functioning at 4 years' additional follow-up (see Outcomes section in table above).
Other bias	Low risk	We did not identify any other sources of bias.

**EDIE-UK**

Methods	Allocation: randomised Blinding: single (raters) Setting: Salford and Manchester, UK (community) Inclusion criteria: met adapted criteria by <a href="#">Yung 1998</a> , age range 16-36 years Exclusion criteria: < 16 or > 36 years, receipt of antipsychotic medication. Duration: 36 months (6 months of treatment + 30 months of post-treatment follow-up)
Participants	Diagnosis: people at high risk of developing psychosis N = 60 Sex: men and women, 70:30% M:F Age: range 16–36 years, average ~22 SD 5 History: recruitment from primary care teams, student counselling services, accident and emergency departments, specialist services, and voluntary sector agencies
Interventions	1. Cognitive therapy (manualised, problem oriented, time-limited, educational intervention: up to 26 sessions + monitoring. N = 37* 2. Monitoring. N = 23 Both groups incorporated elements of case management for resolving crises regarding social issues and mental health risks. Medication not prescribed as part of study protocol
Outcomes	Transition to psychosis (according to cut-off points on PANSS ( <a href="#">Kay 1987</a> )), at 12 months' follow-up 2. Leaving the study Unable to use: Transition to psychosis – 3 years (no mean, SD; 55% lost to follow-up) Mental state: PANSS – 3 years (no mean, SD; 55% lost to follow-up) Global state: GAF, GHQ – 3 years (no mean, SD; 55% lost to follow-up) Functioning: Sociotropy-Autonomy Scale – 3 years (no mean, SD; 55% lost to follow-up) Cognitive function: Meta-Cognitions Questionnaire – 3 years (no mean, SD; 55% lost to follow-up) Satisfaction: OLIFE – 3 years (no mean, SD; 55% lost to follow-up)

**EDIE-UK** (Continued)

## Notes

Funding: North-West NHS Executive

Power, sample size calculation: not reported

\*37 in cognitive therapy + monitoring and 23 in monitoring group), 2 participants from cognitive therapy + monitoring group excluded from analysis due to developed psychosis meeting PANSS criteria at first assessment after randomisation and also reported having concealed psychotic symptoms during their initial assessment.

 Adherence: see [Table 1](#)
**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Stratified random assignment by independent clerical worker." Stratified according to gender and genetic risk (independent clerical worker, sealed envelopes).  Comment: precise randomisation method not described
Allocation concealment (selection bias)	Unclear risk	Quote: "The sequence of randomisation was concealed until treatment had been allocated."  Comment: precise allocation concealment method not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	Participants not blind. Rater intended to be blind, but was difficult in practice
Blinding of outcome assessment (detection bias) All outcomes	High risk	Rater intended to be blind, but participants divulged information
Incomplete outcome data (attrition bias) All outcomes	High risk	Out of 60 participants, 33 dropped out (attrition 55%) at 3-year follow-up. Attrition rate was 54% (N = 20) in the cognitive therapy + monitoring group and 57% (N = 13) in the monitoring group. 2 participants from cognitive therapy + monitoring group excluded from analysis due to developed psychosis at first assessment after randomisation when they reported having concealed psychotic symptoms during their initial assessment. No details published for reasons of discontinuation at this time point  We did not use results at 3-year follow-up due to high attrition rate (55%) at that time point.  At 12 months, attrition rate in the cognitive therapy + monitoring group was 30% (N = 11, 2 excluded from analysis due to developed psychosis at baseline, 4 lost to follow-up of which 3 moved, 3 withdrew from therapy and 2 would not engage) and in the monitoring group 30% (N = 7, 4 lost to follow-up of which 2 moved out of the area, 3 discontinued monitoring).
Selective reporting (reporting bias)	Low risk	All outcomes mentioned in study protocol and publications' methods reported in the manuscript.
Other bias	Low risk	We did not identify any other sources of bias.

**EDIP-USA**

Methods	<p>Allocation: randomised (no details)</p> <p>Blinding: single (outcomes assessor)</p> <p>Setting: Maine, USA</p> <p>Inclusion criteria: prodromal psychotic symptoms, age 12-35 years</p> <p>Exclusion criteria: psychotic episode, IQ &lt; 70, outside catchment area, toxic psychosis</p> <p>Duration: 24 months</p> <p>History: participants identified via community education about attenuated psychotic symptoms, targeting school counsellors, paediatricians, and mental health professionals</p>
Participants	<p>Diagnosis: prodromal psychotic disorders</p> <p>N = 100</p> <p>Age: range 12-35 years, average 16 SD 3</p> <p>Sex: male and female</p>
Interventions	<p>1. FACT: combination of family psychoeducation, assertive community treatment, supported education/employment, psychotropic medication. N = 50</p> <p>2. EST: psychotropic drugs, individual case management, family education and crisis intervention. N = 50</p>
Outcomes	<p>Onset of psychosis: rating of 6 on &gt; 1 SIPS P-scale item</p> <p>Leaving the study early</p> <p>Functioning: GAF</p> <p>Adverse effects</p>
Notes	<p>Discrepancy observed between data published in a journal manuscript and data posted on ClinicalTrials.gov. After communicating with the authors and checking which data were correct, we included data posted on ClinicalTrials.gov.</p> <p>Funding: Part of PIER under foundation of NIH and Center for Mental Health Services sponsorship.</p> <p>Power analysis, sample size calculation: not reported</p> <p>Adherence: see <a href="#">Table 1</a></p>

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Stated randomised, but no details described
Allocation concealment (selection bias)	Unclear risk	Method of allocation concealment not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	Single-blinded study (only outcomes assessors)

**EDIP-USA** (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcomes assessors blinded
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Out of 100 participants, 31 discontinued the study (attrition 31%). In the FACT group 15 participants dropped out (attrition rate 30%) and in the EST group 16 participants dropped out (32%). The reasons for study discontinuation were not reported
Selective reporting (reporting bias)	Unclear risk	All outcomes mentioned in registered protocol (NCT01597141) and publications' methods were reported for 24 months, but with discrepancies in published data (please see section Notes). Additionally, on clinicaltrials.gov it is stated that the primary outcome (onset of psychosis) will be assessed at up to 60 months, which was not reported.
Other bias	Low risk	We did not identify any other sources of bias.

**EIPS-Germany**

Methods	Allocation: randomised  Blinding: not stated*  Setting: Cologne, Bonn, Dusseldorf, Munich, Germany  Inclusion criteria: ERlraos criteria, 18-36 years  Exclusion criteria: < 18 years and > 36 years, treatment with antipsychotics, history of psychotic episode, refusing enrolment in research studies, refusing psychopharmacological treatment, living out of area, moving out of area, delirium, dementia, amnesic or other cognitive disorder, mental retardation, psychiatric disorders due to somatic factor or related to psychotropic substances, alcohol or drug misuse in last 3 months, diseases of central nervous system (inflammatory, traumatic, epilepsy etc.)**  Duration: 36 months (12 months' treatment + 24 months' follow-up)
Participants	Diagnosis: risk for developing psychosis  N = 128  Sex: men and women, ~60:40% M:F  Age: 18-36 years, average ~26, SD 6 years  History: not reported
Interventions	1. IPI: individual CBT, group skills training, cognitive remediation and multifamily psychoeducation, up to 30 sessions. N = 63***  2. Supportive counselling: support, psychoeducation and counselling, up to 30 sessions. N = 65***
Outcomes	Transition to psychosis: ERlraos, PANSS  Leaving the study  Functioning: GAF, SAS-II****  Mental state: PANSS (total, positive and negative score), MADRS
Notes	*Raters could have been aware of the treatment allocation.

**Interventions for prodromal stage of psychosis (Review)**

**EIPS-Germany** (Continued)

\*\*Presence of inclusion criteria for the **LIPS-Germany** was additional exit criteria from **EIPS-Germany** study

\*\*\*After randomisation, 2 in IPI group and 1 in supportive counselling group failed to attend any treatment sessions.

\*\*\*\*15 participants not accounted for

\*\*\*\*\*37 participants not accounted for

Funding: German Federal Ministry of Education and Research

Power analysis, sample size calculation: not reported

Adherence: see [Table 1](#)

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised by computer-generated, by block, results placed in sealed envelopes and only opened at the time of treatment allocation
Allocation concealment (selection bias)	Unclear risk	Quote: "Using sealed envelopes."  Comment: allocation concealment method insufficiently described; it is unclear whether envelopes were sequentially numbered and opaque.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not reported in any of the manuscripts where this study was described. In the study protocol (NCT00204087) it was indicated: "Masking: None (open label)"
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote: "as well as in most trials involving psychosocial interventions it was extremely difficult to make assessments that are totally blind to the treatment condition. Although ratings were mainly carried out by people, who were not involved in treatment, raters could have been aware of the treatment allocation, which raises the possibility that rating bias could have influenced the results."  Comment: high possibility that raters may not have been blinded.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Out of 128 randomised participants, 47 dropped out of the trial before its completion (attrition 37%). In the IPI group, attrition rate was 37% (N = 23, 1 withdrawn from intervention because of suspicion of organic brain disease and 22 lost to follow-up: 3 moved, 19 did not return). In the supportive counselling group, attrition rate was 37% (N = 24, 24 lost to follow-up: 7 moved, 17 did not return).
Selective reporting (reporting bias)	Low risk	All outcomes mentioned in registered protocol (NCT00204087) and publications' methods reported in the manuscript
Other bias	Low risk	We did not identify any other sources of bias.

**Kantrowitz-USA**

Methods	Allocation: randomised  Blinding: double-blind (participants, study team)
---------	---

**Interventions for prodromal stage of psychosis (Review)**

**Kantrowitz-USA** (Continued)

Setting: USA (multisite, clinical high-risk treatment clinics and local physicians)

Inclusion criteria: aged 13–35 years, total score of > 20 SOPS, interest in participation in study, no psychotropic medication changes within 4 weeks

Exclusion criteria: history of supra-threshold psychosis or clinical judgment that the SOPS symptoms were accounted for by another disorder (e.g. depression), unstable medical illness or renal impairment (glomerular filtration rate < 60), alcohol or substance misuse in past month or dependence within past 6 months, EPS (Simpson Angus Scale total  $\geq$  12, depression (CDS total > 10), or suicidal ideation

Duration: 16 weeks

**Participants**

Diagnosis: UHR for developing psychosis

N = 44

Sex: men and women, ~60:40% M:F

Age: range 13-35 years, average ~20 SD 4

History: included if met criteria for either attenuated positive symptoms (positive clinical high risk, defined by rating of 3–5 on  $\geq$  1 of 5 SOPS positive items or negative symptoms (negative clinical high risk, defined by rating  $\geq$  3 on 2 of 6 negative symptom items, even in the absence of positive symptoms

**Interventions**

1. D-serine: 60 mg/kg/day, average 4.2 g/day, oral, 2 doses a day: N = 20

2. Placebo: 60 mg/kg/day: N = 24

Some continued taking other medications prescribed previous to the study (e.g. antidepressants, anti-anxiety medications); > 60% not receiving other psychotropic medications during study

Participants removed if transition of diagnosis to psychosis, repeated non-compliance, out of range renal values (e.g. increased urinary protein to creatinine ratio or abnormal urine analysis)

**Outcomes**

1. Transition to psychosis

2. Leaving the study early

3. Suicidal thoughts

Unable to use:

Mental state: SOPS (high attrition rate)

Neurocognitive symptoms: MATRICS (high attrition rate)

Adverse effects: Simpson Angus Scale, AIMS, the Systematic Assessment for Treatment Emergent Events (high attrition rate)

Sleep: PSQI (high attrition rate)

Physiological: interleukin-6 (IL-6) levels, liver function tests, complete blood count, general chemistry (not listed in review protocol)

**Notes**

Funding: National Institutes of Mental Health Cooperative Drug Development, grant number U01 MH074356, to DCJ. Cytokine analyses were supported by the National Center for Advancing Translational Sciences, National Institutes of Health, grant number UL1 TR000040.

Power, sample size calculation: "Power calculations for this study were based on a study with glycine in participants (24) at clinical high risk that showed an effect size of  $d = 1.15$  for The Scale of Prodromal Symptoms (SOPS) change scores during glycine treatment versus a typical placebo response rate of  $d = 0.27$ . Although we originally specified a sample size of 72 participants to provide additional power, we regarded  $N = 44$  as the minimum sample size necessary to detect significant  $p < 0.05$  treatment-related change in the primary endpoint."

**Kantrowitz-USA** (Continued)

 Adherence: see [Table 1](#)
**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Randomisation lists for each site, block-randomised using blocks of 4. Participants were stratified by type (high or negative high clinical risk)."  Comment: precise randomisation method not described
Allocation concealment (selection bias)	Low risk	Quote: "Only the central data management group and a study pharmacist at each site were aware of group assignments. Sealed unmasking envelopes were used."  Comment: precise allocation concealment method not described; it is unclear whether envelopes were sequentially numbered and opaque
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind (participants, study team)  D-serine and placebo treatment bottles were matched and identical looking.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	High risk	Out of 44 participants, 23 discontinued the study before its completion (attrition 52%). Participants who completed the study did not differ from other participants in baseline characteristics and symptoms. Attrition rate in D-serine group was 50% (N = 10, 5 did not complete at least one post-baseline efficacy evaluation: 1 withdrew consent, 2 protocol error, 2 renal laboratory abnormality) and in the placebo group 54% (N = 13; 4 did not complete at least one post-baseline efficacy evaluation, 9 discontinued intervention after first post-baseline efficacy evaluation: 2 lost to follow-up, 5 withdrew consent, 2 psychosis transition for < 16 weeks).
Selective reporting (reporting bias)	Low risk	All outcomes mentioned in the registered protocol (NCT00826202) and in the publications' methods reported. Due to high attrition rate at follow-up assessments, we did not use results for mental scales and neurocognitive symptoms, nor adverse effects and PSQI in our analysis.
Other bias	Low risk	We did not identify any other sources of bias.

**LIPS-Germany**

Methods	Allocation: randomised (no details)  Blinding: open-label  Setting: Cologne, Bonn, Dusseldorf and Munich, Germany  Inclusion criteria: adapted version ERIraos, 18–36 years of age  Exclusion criteria: any DSM-IV diagnosis of schizophrenia, bipolar disorder, brief psychotic episode (with duration > 1 week), delirium, dementia (and other cognitive disorders), mental retardation, mental disorders due to a general medical condition or mental disturbances due to psychotropic substances, alcohol abuse or drugs in past 3 months.
---------	--



**LIPS-Germany** (Continued)

Duration: 12 weeks of intervention + up to 2 years of observation period

Participants	Diagnosis: late prodromal state (presence of attenuated positive symptoms and/or brief limited intermittent positive symptoms in 3 months preceding study)  N = 124*  Sex: men and women, ~ 50:50% M:F  History: no details
Interventions	1. Amisulpride: average dose 118 mg/day, range 50–800 mg/day + NFI). N = 65.  2. NFI: psychoeducation, crisis intervention, family counselling and assistance with education or work-related difficulties. N = 59  SSRIs prescribed in 7 in each group; benzodiazepines prescribed for 6 (5 in amisulpiride group), 1 in each group took chloral hydrate for sleep disturbances
Outcomes	Leaving the study early  Mental state: PANSS, MADRS, ERIraos – 3 months post-treatment  Functioning: GAF – 3 months post-treatment  Adverse effects: ESRS (only akathisia subscore), UKU, prolactin levels – 3 months post-treatment  Unable to use:  Adverse effects: ESRS (other subscores), cardiovascular adverse effects, BMI (reported only as range, or results of statistical tests, but without summary outcome data per group)  Functioning: SAS-II (no data)  Mental state: PANSS, MADRS, ERIraos, 24 months (no data)  Functioning: GAF, 24 months (no data)  Adverse effects: ESRS (only akathisia subscore), UKU, prolactin levels, 24 months (no data).
Notes	*18 left before baseline assessments (4 in NFI + amisulpiride group and 14 in NFI); 3 in amisulpiride group excluded from analysis as treatment had started before baseline assessment; 1 participant in NFI group had severe, unstable endocrinological dysfunction (not detectable by routine laboratory measurement). Hence, 102 participants (58 in amisulpiride group and 44 NFI) included in analysis ("ITT" sample).  Results presented for 12 weeks' intervention period  Funding: German Federal Ministry for Education and Research BMBF (grant 01 GI 9935) and Sanofi Synthelabo, Germany  Power, sample size calculation: not reported; quote: "A sample size of N = 130 cases is planned"  Adherence: see <a href="#">Table 1</a>

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described.

**LIPS-Germany** (Continued)

Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not blinded (open-label)
Blinding of outcome assessment (detection bias) All outcomes	High risk	Rater not blinded
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition 39% (amisulpiride + NFI group 29%, NFI 49%. Early dropouts (N = 18) did not differ from the remaining sample (N = 106) nor when comparisons were made separately for the 2 treatment groups in any of measured variables, however, reasons for discontinuation are unknown in most cases as these participants had not returned.
Selective reporting (reporting bias)	Unclear risk	Most outcome measures mentioned in the registered protocol (NCT00204061) and publications' methods reported for post-treatment point, except SAS-II. Results for observation period of 24 months were not reported. Data for ESRS subscores besides akathisia, cardiovascular effects and BMI were not usable for our analysis.
Other bias	Low risk	We did not identify any other sources of bias.

**Miklowitz-USA**

Methods	<p>Allocation: randomised</p> <p>Blinding: single (assessors)</p> <p>Setting: Emory University, Harvard University, University of Calgary, University of California Los Angeles, University of California San Diego, University of North Carolina, Yale University and Zucker Hillside Hospital, USA</p> <p>Inclusion criteria: age 12-35 years, speaking and writing English, meet SIPS/SOPS criteria</p> <p>Exclusion criteria: diagnosis of schizophrenia or schizoaffective disorder (DSM- IV-TR), pervasive developmental disorders, current substance or alcohol dependence, neurological disorders</p> <p>Duration: 18 months (6 months of treatment, 12 months of follow-up)</p>
Participants	<p>Diagnosis: high risk for developing psychosis</p> <p>N = 129</p> <p>Sex: men and women, ~60:40% M:F</p> <p>Age: 12-35 years, average 17 SD 4</p> <p>History: no details</p>
Interventions	<p>1. FFT: 18 sessions of psychoeducation, communication enhancement training and problem-solving skills training in 6 months, average 11 sessions SD 7: N = 66</p> <p>2. Enhanced care: 3-session family psychoeducational therapy, average 2.4 sessions SD 1.2: N = 63</p>

**Miklowitz-USA** (Continued)

Drug treatment not requirement of study. When participants were taking medications, their pharmacotherapy was managed by a study psychiatrist, unless they wished to consult a community provider. 27 (20.9%) were taking antipsychotic medications at randomisation

Outcomes	<p>Transition to psychosis</p> <p>Leaving the study early</p> <p>Mental state: SOPS (positive), at 6 months post-treatment</p> <p>Prescription of antipsychotics, by 6 months</p> <p>Unable to use:</p> <p>Mental state: SOPS (negative symptoms) (no usable data), SOPS – at 1 year (no data)</p> <p>Functioning: GAF, GFR, GFS (no usable data)</p> <p>Additional outcomes:</p> <p>Family interactions (e.g. perceived criticism): PCPW, CBQ- mother report, 10-min problem-solving family interaction task</p>
Notes	<p>Funding: National Institute of Mental Health (NIMH) grants 1RC1MH088546 (TDC, DJM), and R01MH093676 (DJM), and a grant from the Stanley Family Foundation (TDC).</p> <p>Power, sample size calculation: quote: "Power for the study's repeated measure design, calculated prior to the study based on an expectation of 120 participants and 20% attrition, was 80% to detect a medium-sized (0.50 SD) group difference in symptoms (alpha = 0.05, two-tailed). Our study design had 95% power to detect a three-way interaction between treatment, age group, and time with a medium effect size (f = 0.25) (p&lt;0.05)."</p> <p>Adherence: see <a href="#">Table 1</a></p>

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Lead study investigator who was neither involved in the provision of treatments nor the follow-up evaluations conducted the random assignments to groups, with 50% of participants allocated to each condition, allocations, performed using Efron's biased coin toss were stratified by site and whether or not the participant was prescribed an antipsychotic medication at baseline, allocation results were sent by email to each site's principal investigator.
Allocation concealment (selection bias)	Unclear risk	See above
Blinding of participants and personnel (performance bias) All outcomes	High risk	Participants not blinded
Blinding of outcome assessment (detection bias) All outcomes	High risk	Although this was an RCT with 'blind' evaluations of clinical outcome, the clinical supervisors knew whether they were rating FFT or enhanced care sessions
Incomplete outcome data (attrition bias) All outcomes	Low risk	Out of 129 randomised participants, 27 discontinued the study before 6-month assessment (attrition 21%). In the FFT group attrition rate was 17% (N = 11) and in the enhanced care group 25% (N = 16). The reasons for dropping out of the study were classified as "withdrew or missed assessment" in both groups.

**Miklowitz-USA** (Continued)

In the FFT group, 11 participants withdrew prior to first session and in the enhanced care group 10 withdrew prior to first session.

Selective reporting (reporting bias)	Unclear risk	All outcomes mentioned in registered protocol (NCT01907282) and publications' methods reported for post-treatment point (6 months), but some of the data were only partially reported, unusable figures or reported per age groups, and not per randomised groups. Data for 1-year follow-up not reported
Other bias	Low risk	We did not identify any other sources of bias.

**NEURAPRO-AAE**

Methods	<p>Allocation: randomised</p> <p>Blinding: double-blind (participants, people administering treatment, assessors)</p> <p>Inclusion criteria: ability to give informed consent, age 13-40 years, meet criteria for 'at-risk' groups: Trait and State Risk Factor, APS, BLIPS</p> <p>Exclusion criteria: history of psychotic episode of <math>\geq 1</math> week, organic and inflammatory brain disease, abnormal coagulation profile parameters for thyroid function test results <math>&gt; 10\%</math> above/below limits of normal, any physical illness with psychotropic effect, unstable current treatment with lithium, methylphenidate or ketamine or recreational use of ketamine, past antipsychotic exposure (<math>\sim</math> total lifetime haloperidol dose of <math>&gt; 50</math> mg), serious developmental disorder, IQ <math>&lt; 70</math>, developmental delay or intellectual disability, current aggression/dangerous behaviour, current suicidality/self-harm, current pregnancy, current attenuated symptoms explained by acute intoxication (e.g. LSD), <math>&gt; 4</math> weeks of regular omega-3 supplementation (<math>&gt; 2</math> capsules standard strength providing <math>&gt; 600</math> mg combined eicosapentaenoic acid/docosahexaenoic acid (DHA)) within the last 6 months</p> <p>Setting: multicentre, North America, Europe and Australia</p> <p>Duration: 24 months</p>
Participants	<p>Diagnosis: people at high risk for developing psychosis</p> <p>N = 304</p> <p>Sex: men and women, 46:54% M:F</p> <p>Age: range 13-40 years, average <math>\sim 19</math> SD 5</p>
Interventions	<p>1. Omega-3 fatty acids: 2.8 g of marine fish oil <math>\sim 1.4</math> g eicosapentaenoic acid/DHA in 4 x 0.700 g capsules, oral, daily for 6 months + cognitive behavioural case management: 6-20 sessions in first 6 months, depending on needs (weekly sessions recommended), then further sessions on an 'as needs' basis for up to 12 months (from entry), each session <math>\sim 30-60</math> min duration: N = 153</p> <p>2. Placebo: 4 x 0.700 g matched capsules, oral, daily for 6 months (contained paraffin/coconut oil, tocopherols to match the content in the active ingredient and a small proportion of the fish oil to ensure the placebo capsules have the same odour as the active capsules) + cognitive behavioural case management: N = 151</p> <p>For the first 12 months of the study SSRIs permitted for moderate-severe depression (MADRS <math>\geq 21</math> for <math>&gt; 2</math> consecutive weeks), benzodiazepines permitted for anxiety. Antipsychotics/mood stabilisers not permitted unless participant withdrawn before 12 months</p>
Outcomes	<p>Transition to psychosis: measured by CAARMS</p> <p>Leaving the study</p> <p>Mental state: SANS, BPRS, YMS, MADRS</p>

**NEURAPRO-AAE** (Continued)

Functioning: SOFAS, GFS, GFR

Adverse effects: UKU

Unable to use:

Mental state: SANS subscores, BPRS psychotic subscale (presented as "Month 12 Minus Baseline", no baseline data)

## Notes

Funding: Grant 07TGF-1102 from the Stanley Medical Research Institute, grant 566529 from the NHMRC Australia Program (Drs McGorry, Hickie, and Yung, and Amminger), and a grant from the Colonial Foundation.

 Adherence: see [Table 1](#)
**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated via an online electronic data management system, stratified by site and the moderate to severe major depression (MADRS) total score
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "All participants and clinicians involved in delivering interventions, assessing outcomes, and data entry were blind to group assignment. The trial statistician (HPY) was unblinded at the analysis stage. Appearance, size and 'taste' of the placebo capsules are matched with the fish oil capsules)"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "All participants and clinicians involved in delivering interventions, assessing outcomes, and data entry were blind to group assignment. The trial statistician (H.P.Y.) was unblinded at the analysis stage."
Incomplete outcome data (attrition bias) All outcomes	Low risk	Out of 304 randomised participants, 79 dropped out before end of the study (attrition 26%). Attrition rate in omega-3 fatty acids group was 25% (N = 39: 24 withdrew, 14 unable to contact, 1 pregnant) and in placebo group was 26% (N = 40: 18 withdrew, 22 unable to contact).
Selective reporting (reporting bias)	Low risk	All outcomes mentioned in registered protocol (ACTRN12608000475347) and publications' methods were reported
Other bias	Low risk	We did not identify any other sources of bias.

**Nordentoft-Denmark**

## Methods

Allocation: randomised

Blinding: not blinded (independent assessors aware of treatment allocation)

Setting: Copenhagen and Aarhus County, Denmark (inpatient and outpatient mental health services)

Inclusion criteria: met criteria for schizotypal disorder (ICD-10)

Exclusion criteria: antipsychotic medication for &gt;12 weeks, psychiatric symptoms due to organic condition

Duration: 24 months

**Nordentoft-Denmark** (Continued)

Participants	Diagnosis: schizotypal disorder (ICD-10)  N = 79  Sex: men and women, ~70:30% M:F  Age: average ~25 SD 5 years  History: no details
Interventions	1. Integrated treatment: modified Assertive Community Treatment model with case load and home visits, group or individual social skills training, psycho-education in multiple-family groups: N = 42  2. Standard treatment: standard mental health service routines in Copenhagen and Aarhus: N = 37  There were no specific guidelines for providing antipsychotic medication to patients with schizotypal disorder, medication was prescribed by psychiatrist responsible for treatment
Outcomes	Transition to psychosis (ICD- 10)  Leaving the study early  Mental state: SAPS, SANS
Notes	Funding: Danish Ministry of Health (jr.nr. 96-0770-71), The Danish Ministry of Social Affairs, The University of Copenhagen, The Copenhagen Hospital Corporation, The Danish Medical Research Council (jr.nr. 9601612 and 9900734), and Slagtermester Wørzners Foundation.  Power, sample size calculation: Quote: "Using Pocock's formula (Pocock, 1996), we calculated that 39 patients were required for each study group to show a difference in transition rate of 10% compared with 40%. Thus, the study only has statistical power to detect large differences in transition rate".  Adherence: see <a href="#">Table 1</a>

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Randomisation will be centralised and computerised with concealed randomisation sequence carried out by the Copenhagen Trial Unit (CTU)."
Allocation concealment (selection bias)	Unclear risk	Quote: "Randomisation will be centralised and computerised with concealed randomisation sequence carried out by the Copenhagen Trial Unit (CTU)."  Ratio of 1:1 in blocks of 6, and stratified for each centre.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "The allocations concealment is ensured by the investigators call to the randomisation unit, CTU, after completing the collection of baseline data and data needed for the randomisation."  Comment: precise method of allocation concealment was not described.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Not blinded
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Assessors not blinded for treatment allocation

**Nordentoft-Denmark** (Continued)

Selective reporting (reporting bias)	Unclear risk	Out of 79 randomised participants, 14 discontinued the study (attrition 18%). Attrition rates per group were 14% (N = 6) in integrated treatment group and 22% (N = 8) in standard treatment group. While treatment group, treatment site, gender, age, abuse of alcohol or drugs, psychotic, negative or disorganised symptoms at entry were not associated with study discontinuation, there was a significant association within participants who reported use of cannabis at least monthly at entry compared to those who reported no or less frequent use (37.5% versus 12.7%, P = 0.02). No details for study discontinuation reported.
Other bias	Low risk	All outcomes mentioned in publication methods reported. However, compared to registered protocol for the OPUS study, most of the outcomes relevant for this population of participants were reported except: suicidal behaviour, user satisfaction, adherence to treatment, compliance with medication.

**PACE-Australia**

Methods	Allocation: randomised Blinding: not blinded Setting: Melbourne, Australia Inclusion criteria: age 14-30 years, living in Melbourne metropolitan area, meeting criteria for $\geq 1$ of 3 operationally defined UHR groups (Yung 2005). Exclusion criteria: previous psychotic/manic episode, previous treatment with antipsychotic/mood stabilising agent, substance-induced psychotic disorder, IQ < 70, inadequate English Duration: initially 12 months (6 months of treatment, 6 months of follow-up); 4 years thereafter
Participants	Diagnosis: people at UHR for developing psychosis N = 59 Sex: men and women, ~60:40% M:F Age: range 14-28 years, average 20 SD 4 History: no details
Interventions	1. SPI: NBI, low-dose risperidone therapy (average 1.3 mg/daily), CBT. N = 31 2. NBI: supportive psychotherapy focusing on social relationships and vocational and family issues: N = 28 Both groups received case management and medication when needed (sertraline for depression, benzodiazepines for insomnia, usually temazepam)
Outcomes	Progression to psychosis Leaving the study early Mental state: BPRS, SANS, HRSD, HRSA, YMS Quality of life: QLS Functioning: GAF Economics: costs

**PACE-Australia** (Continued)

Notes Funding: Commonwealth Government of Australia Research and Development Grants Advisory Committee, and Janssen-Cilag Pharmaceuticals; Australian Rotary Health Research Fund grant

Power, sample size calculation: not reported

Adherence: see [Table 1](#)

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Simple randomisation by trial coordinator." Comment: precise method of randomisation not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	Treating clinicians, research staff or participants and their families were not blind to the randomisation procedure
Blinding of outcome assessment (detection bias) All outcomes	High risk	Two intervention groups treated by different clinicians, which was difficult to conceal from raters
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts in SPI nor NBI group
Selective reporting (reporting bias)	Low risk	Study was not registered. All outcome measures mentioned in publication methods reported
Other bias	Low risk	We did not identify any other sources of bias.

**Piskulic-Canada**

Methods Allocation: randomised

Blinding: single (cognitive and symptom raters)

Setting: Calgary, Australia

Inclusion criteria: age 15-35 years, SIPS prodromal criteria, written informed consent

Exclusion criteria: IQ < 75, organic central nervous system disorder (e.g. epilepsy, traumatic brain injury), substance dependence

Duration: 9 months (10-12 weeks of treatment followed by 6 months of follow-up)

Participants Diagnosis: people at UHR for developing psychosis

N = 32

Sex: men and women, 21:11 M:F

Age: range 14-35 years, average ~19 SD 5



**Piskulic-Canada** (Continued)

History: recruited as part of multisite North American Prodrome Longitudinal Study (NAPLS2) from the Calgary site. All received monetary reimbursement for Internet usage if training from home, or for travel following each training session.

Interventions	<p>1. Post Science Brain Fitness: cognitive remediation therapy involving auditory training exercises: 4 days/week, 1 h/day, 10–12 weeks. N = 18</p> <p>2. Control treatment: commercial video games: 4–5 games/training day, same hours as participants in treatment group. N = 14</p>
Outcomes	<p>Leaving the study</p> <p>Mental state: MCCB (apart from the Mayer–Salovey Emotional Intelligence Test (MSCEIT)), at 3 months</p> <p>Functioning: GFS, GFR, at 3 months.</p> <p>Unable to use:</p> <p>Mental state: MCCB, at 9 months (high attrition)</p> <p>Functioning: GFS, GFR, at 9 months (high attrition)</p>
Notes	<p>Funding: The Brain and Behaviour Research Fund Young Investigator Award 17369 to D. Piskulic and National Institute of mental Health (NIMH) grant U01MH08984 to J. Addington and the Alberta Centennial Mental Health Research Chairs Program</p> <p>Power, sample size calculation: not reported</p> <p>Adherence: see <a href="#">Table 1</a></p>

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Described as randomised. Method of randomisation not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	Single-blinded (participants were not blind to group allocation, only cognitive and symptom raters)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All cognitive and symptom raters were blinded to group allocation
Incomplete outcome data (attrition bias) All outcomes	High risk	<p>21% of participants in the intervention group and 30% in the control group withdrew from the study after randomisation, prior to commencement. Of those randomised that started treatment, 38% participants from the intervention and 14% from the control group discontinued by after-treatment assessment and 61% of the Post Science Brain Fitness group and 50% of the control treatment group discontinued the study by the 9-month follow-up.</p> <p>Reasons for attrition:</p> <p>Participants who discontinued from the study (N = 18) were significantly more educated (M = 11.44, SD = 2.7) than those who remained in the study (N = 14, M = 9.57, SD = 2.12) (T (30) = 2.11, P &lt; 0.05). There were no other significant group differences on demographic, symptom, functioning or cognitive variables. Ad-</p>

**Interventions for prodromal stage of psychosis (Review)**

**Piskulic-Canada** (Continued)

ditionally, the main reasons for attrition rates across both groups were loss of interest in training (N = 10), lack of time (N = 4), problems with either Internet connection or personal computers at home (N = 3) for those who opted for home training and moving provinces (N = 1). For participants who were allocated to either treatment group but withdrew prior to study commencement, the main reasons were lack of interest (N = 5), lack of time (N = 5) and transition to psychosis (N = 1). The participant who converted to psychosis was initially consented and randomised into the Control treatment group but subsequently discontinued from the study prior to commencement of training as a result of the transition.

Selective reporting (reporting bias)	Low risk	All outcome measures mentioned in study protocol (NCT01619319) and publication's methods reported.  Results for MCCB and functioning scales at 9 months' follow-up not used in our analysis due to high attrition rate resulting in small number of participants.
Other bias	Low risk	We did not identify any other sources of bias.

**PRIME-USA**

Methods	<p>Allocation: randomised</p> <p>Blinding: double-blind (participants, investigators, dispensers)</p> <p>Setting: New Haven and North Carolina, USA; Calgary and Toronto, Canada (outpatient clinic)</p> <p>Inclusion criteria: treatment-seeking outpatients, age 12-45 years, met SIPS criteria, possessed a level of understanding sufficient to communicate with investigator and to understand nature of study, agreed to study and signed informed consent or assent (if a minor)</p> <p>Exclusion criteria: psychotic disorder, psychiatric disorder that could account for the prodromal symptoms, suicidal or homicidal behaviour, symptoms due to drug or alcohol use, IQ &lt; 80, seizure disorder without clear aetiology, pregnancy and lactation (not pregnant or lactating women had to be using medically accepted means of contraception), taking non-allowed antipsychotic, anticonvulsant, mood stabilising, and most anti-anxiety medications.</p> <p>Patients on antidepressant medication included and allowed to continue taking the antidepressant medication, but efforts made to reduce dosage or stop. If antidepressant indicated for study-active people not already on antidepressants, participant dropped from study and referred for disorder-specific treatment</p> <p>Duration: 2 years (1-year medication with 1-year follow-up without medication)</p>
Participants	<p>Diagnosis: UHR for psychosis</p> <p>N = 60</p> <p>Sex: men and women, 65:35% M:F</p> <p>Age: range 12-45 years, average 18 SD 5</p> <p>History: no details</p>
Interventions	<p>1. Olanzapine: 5-15 mg/day, average 8 mg/day, 1-3 tablets, clinician's judgement. N = 31</p> <p>2. Placebo: N = 29</p> <p>Individual and family psychosocial interventions available for both interventions. Lorazepam (max 8 mg/day) diazepam (max 40 mg/day) and chloral hydrate (max 100 mg/day) used for agitation and/or</p>

**PRIME-USA** (Continued)

insomnia. Bzotropine mesylate or biperiden up to 6 mg/day allowed to treat EPS. Nizatidine 300-600 mg/day for weight gain, beginning towards the end of the study.

Outcomes	<p>Transition to psychosis</p> <p>Leaving the study early</p> <p>Mental state: SOPS, PANSS, MADRS, YMS, 12 months</p> <p>Global state: CGI</p> <p>Functioning: GAF, 12 months</p> <p>Adverse effects: Simpson Angus Scale, AIMS, Barnes Akathisia Scale, weight gain, cardiovascular adverse effects, 12 months</p> <p>Unable to use:</p> <p>Neurocognitive measures: (no usable data)*</p> <p>Mental state, global state, functioning and adverse effects outcomes at 12 months' follow-up (&gt; 50% attrition rate)</p> <p>Quality of life: QLS (no data reported)</p>	
Notes	<p>*Text reported results of statistical tests, not data per group; results figures impossible to extract. Study authors did not respond to repeated requests for data.</p> <p>We used results for 12 months (after treatment point) for all outcomes, because study authors stated that they did not perform analysis for follow-up data due to lack of participants.</p> <p>Funding: investigator-initiated grant from Eli Lilly and Company. Other support came from NIMH grants K05 MH-01654 (Dr. McGlashan), R02 MH-50557 and R01 MH-67073 (Dr. Hoffman), R24 MH54446 (Dr. Woods), and 1K23 MH-01905 (Dr. Perkins) and the Tapscott Chair in Schizophrenia Trials at the University of Toronto (Dr. Zipursky).</p> <p>Power, sample size calculation: under-powered study. Power analysis suggested 180 participants (80% power) or 80 participants (50% power), but due to difficulties with recruitment, it was stopped after 3.5 years at 60 participants, which corresponded to 39% power for testing treatment effects on transition to psychosis and on prodromal symptom severity).</p> <p>Adherence: see <a href="#">Table 1</a></p>	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Study described as randomised, but randomisation method not described
Allocation concealment (selection bias)	Unclear risk	Quote: "Pills dispensed in prepackaged packs, pre-labelled by site number and sequential subject number within site." Comment: precise allocation concealment method not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Participants, investigators and dispensers to group assignment blinded; pills dispensed in pre-packaged packs, pre-labelled by site number and sequential subject number within site
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants, investigators and dispensers to group assignment blinded

**PRIME-USA** (Continued)

Incomplete outcome data (attrition bias) All outcomes	High risk	Out of 60 participants, 27 dropped out before the end of treatment phase (attrition 45%). However, attrition was higher than 50% when calculated for each group separately. Attrition rate in olanzapine group was 55% (N = 17) and in placebo group 53% (N = 10); although dropout rate for reasons other than transition to psychosis was higher for the olanzapine group, there was no statistically significant difference between groups, including discontinuation of the study due to adverse events. During the follow-up period, there were no discontinuations due to any reasons other than transition to psychosis in either treatment group. Because of the low number of participants due to dropout and transition to psychosis (9 participants in olanzapine and 8 in placebo group), no statistical analysis was performed to assess treatment differences in this study period.
Selective reporting (reporting bias)	Unclear risk	Most of the outcome measures mentioned in publications' methods reported, except QOL. Statistical analysis was not performed for follow-up period for mental state, global state, functioning and adverse effects outcomes due to lack of participants.
Other bias	Low risk	We did not identify any other sources of bias.

**Vinogradov-USA**

Methods	Allocation: randomised  Blinding: double-blind (participant, care provider, assessor)  Setting: San Francisco, USA  Inclusion criteria: good physical health, age 12-30 years, fluent English, IQ $\geq$ 70, no neurological disorder, no past (year) or current substance dependence, SIPS criteria  Duration: 24 months (8 weeks of treatment + follow-up)
Participants	Diagnosis: people at high risk for developing psychosis  N: 83  Sex: men and women, 50:50% M:F  Age: range 12-30 years, average $\sim$ 18 SD 4  History: recruited via community clinicians, schools, family members, and self-referred from seeing information on internet
Interventions	1. AT: computerised exercises designed to improve speed and accuracy of auditory information processing while engaging auditory and verbal working memory: in each session 4 of 6 exercises (15 min/exercise)/day, 5 days/week, 8 weeks, coaching (goal-setting, discussion of scheduling, setting an alarm and using reminders) provided if difficulty in completing hours. N = 50  2. Control Group: series of 16 different commercially available games. N = 33  At a "check-in" in-person appointment after every 10 sessions completed, coaching provided and participants paid USD 5/completed h, USD 20/10 sessions, and USD 30 after 40 h, USD 20/assessment appointment.  Participants received treatment by outside providers or clinic personnel not involved in the study (psychoeducation, psychotherapy, medications as clinically indicated)
Outcomes	Mental state: SOPS

**Vinogradov-USA** (Continued)

Leaving the study

Functioning: GFR, GFS

Unable to use:

Neurocognitive tasks: abbreviated version MATRICS (z scores only)

Notes

Funding: The National Institutes of Health (grant number MH081051).

Power, sample size calculation: Not reported

Adherence: see [Table 1](#)

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "CHR subjects were stratified by age, IQ, symptom severity and gender and randomly assigned to auditory training or to the CG control condition."  Comment: precise randomisation method not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind (participant, care provider, outcomes assessor)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind (participant, care provider, outcomes assessor)
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Out of 83 randomised participants, 35 dropped out before the training was completed (attrition 42%). In AT group, attrition rate was 38% (N = 19). In control group, attrition rate was 48% (N = 16). Reasons for dropping out of the study were not reported. However, there were no significant differences in demographic variables, cognition, symptom severity, or functioning between those who completed the study and those who dropped out.
Selective reporting (reporting bias)	Low risk	All outcome measures mentioned in registered protocol (NCT00655239) and publications methods reported.
Other bias	Low risk	We did not identify any other sources of bias.

**Woods-1-USA**

Methods

Allocation: randomised

Blinding: double-blind

Setting: New Haven, USA

Inclusion criteria: met COPS criteria,  $\geq 20$  on SOPS

Exclusion criteria: DSM-IV any lifetime psychotic disorder or psychiatric disorder, inclusion symptoms due to drug/alcohol use, alcohol or drug abuse or dependence in past 3 months, antipsychotic medica-

**Woods-1-USA** (Continued)

tion in the past 3 months, dose change of antidepressant, anxiolytic, psychostimulant or mood stabiliser medication in past 8 weeks

Duration: 24 weeks (12 weeks of RCT and 12 weeks open-label administration)\*

Participants	Diagnosis: people at high risk for developing psychosis  N = 8  Sex: men and women, 75:25% M:F  Age: average ~16 SD 1  History: not reported
Interventions	1. Glycine: 0.2 g/kg during the first 7 days, then 0.4 g/kg until end. N = 4  2. Placebo (sucrose). N = 4
Outcomes	Transition to psychosis: SOPS  Leaving the study early  Mental state: SOPS, MADRS  Cognitive functioning: Trails A, Stroop color word, AVLT, semantic (category) fluency, FAS, test of phonemic fluency, letter-number sequencing, Trails B.  Adverse effects: treatment-emergent adverse effects, weight, cardiovascular (blood pressure, pulse)  Unable to use:  Cognitive functioning: WCS, CPT (identical pairs version), N-back (available for 1 participant only)
Notes	*Results for 8 weeks  Funding: NARSAD Distinguished Investigator Award, a research grant from Glytech Inc., the Donaghue Foundation Early Schizophrenia Initiative and National Institutes of Health Grant U01MH74356.  Power, sample size calculation: not reported  Adherence: see <a href="#">Table 1</a>

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Study was double-blind, placebo taste-matched
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described

**Woods-1-USA** (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	2 participants out of 8 did not complete the study (attrition 25%). In the glycine group, 1 participant was withdrawn at week 5 due to non-adherence (attrition rate 25%), and in the placebo group, 1 participant was withdrawn at week 3 due to transition to psychosis
Selective reporting (reporting bias)	Unclear risk	All the outcome measures mentioned in the registered protocol (NCT00291226) and publication methods reported. Data for some of the cognitive tasks were not used in our analyses as they were available for 1 participant only.
Other bias	Low risk	We did not identify any other sources of bias.

**Yung-Australia**

Methods	<p>Allocation: randomised</p> <p>Blinding: double-blind (participants, staff administering the treatment(s), assessing the outcomes and analysing the results/data)</p> <p>Setting: Personal Assessment and Crisis Evaluation (PACE) Clinic, Melbourne, Australia (a clinical service for young people at UHR of developing a psychotic disorder)</p> <p>Inclusion criteria: met CAARMS criteria, not previously psychotic, IQ &gt; 70, adequate English skills, living in Melbourne metro area</p> <p>Exclusion criteria: history of previous psychotic/manic episode, history of medical condition that may account for symptoms leading to initial referral, clinically relevant neurologic, biochemical, or haematologic abnormalities, serious coexisting illnesses, lifetime antipsychotic dose of <math>\geq 15</math> mg of haloperidol (or equivalent), previous or current use of mood stabilising medication, history of severe drug allergy, IQ &lt; 70, women who were pregnant or lactating</p> <p>Duration: 24 months (12 months' treatment, 12 months' follow-up)</p>
Participants	<p>Diagnosis: people at UHR for developing psychosis</p> <p>N = 115</p> <p>Sex: men and women</p> <p>Age: range 14-30 years, average 18</p> <p>History: no details</p>
Interventions	<ol style="list-style-type: none"> <li>1. Risperidone + CBT: dose 0.5-2.0 mg/day. N = 43</li> <li>2. Placebo and CBT. N = 44</li> <li>3. Placebo and supportive therapy. N = 28</li> </ol>
Outcomes	<p>Transition to psychotic disorder: CAARMS</p> <p>Leaving the study early</p> <p>Mental state: BPRS, SANS</p> <p>Functioning: GAF</p> <p>Quality of life: QLS</p> <p>Adverse effects: UKU (number reporting adverse effects and number assessed to have adverse effects)</p>

**Yung-Australia** (Continued)

Unable to use:

Mental state: HRSD (high loss to follow-up)

Additional outcomes:

Substance misuse: SUQ

**Notes**

Funding: major investigator-initiated grant from Janssen-Cilag Pharmaceuticals (RIS-AUS-9). Alison Yung, Lisa Phillips and Patrick McGorry have received investigator-initiated funding from Janssen Pharmaceuticals. Patrick McGorry has received investigator-initiated funding from Astra-Zeneca.

Power, sample size calculation: underpowered study (for a significance level of 0.05 and a power of 0.7, a sample of 75 was required in risperidone and cognitive therapy and in placebo and cognitive therapy groups, and 50 in group with placebo and supportive therapy (3:3:2 randomisation ratio)).

 Adherence: see [Table 1](#)
**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	<p>Quote: "The randomisation sequence was created by an independent statistician, who created sealed envelopes containing the medication number and the group assignment code."</p> <p>Web-based automated randomisation system, stratified by site, in random permuted blocks of 10, allocation list kept in a remote secure location, independent person randomly allocated participants</p> <p>Comment: good description</p>
Allocation concealment (selection bias)	Unclear risk	<p>Quote: "Sealed envelopes."</p> <p>Comment: precise allocation concealment method not described; it is unclear whether envelopes were sequentially numbered and opaque.</p> <p>Quote from the manuscript: "Medication packaged by automated process, codes stored in locked cabinet and not revealed until trial completed."</p> <p>Comment: it is unclear from this description who prepared packaging and held allocation list.</p>
Blinding of participants and personnel (performance bias) All outcomes	Low risk	<p>Double-blind (participants, staff administering the treatment(s), assessing the outcomes and analysing the results/data)</p> <p>Psychiatrists were blind to the treatment allocation, but therapists knew which psychological treatment to provide. Therapists, therefore, also knew that, when participants allocated to supportive therapy, they were also receiving placebo. However, psychologists were blind to medication allocation for those participants receiving cognitive therapy.</p>
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Staff assessing outcomes blinded
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Of 115 randomised participants, 75 completed 12 months' assessment (attrition 35%). In risperidone and cognitive therapy group, attrition was 37% (N = 16, 3 became psychotic, 1 withdrew consent, 5 refused medication, 1 moved interstate, 6 dropped out without specifying a reason). In placebo and cognitive therapy group, attrition was 34% (N = 15, 4 became psychotic, 2 withdrew consent, 2 refused medication, 2 withdrew due to work or study commit-



**Yung-Australia** (Continued)

ments, 5 dropped out without specifying a reason). In placebo and supportive therapy group, attrition was 32% (N = 9, 3 became psychotic, 1 withdrew consent, 5 dropped out without specifying a reason).

Selective reporting (reporting bias)	Low risk	All outcome measures mentioned in registered protocol (AC-TRN12605000247673) and publications were reported.  Results for HRSD were not used in our analysis due to lack of baseline and follow-up data for participants (see section Outcomes in the above table for detailed description)
Other bias	Low risk	We did not identify any other sources of bias.

**AIMS:** Abnormal Involuntary Movement Scale; **APS:** Attenuated Psychotic Symptoms; **AT:** auditory training; **AVLT:** Auditory Verbal Learning Task; **BDI-II:** Beck Depression Inventory-II; **BDI-PC:** Beck Depression Inventory; **BAS:** Behavioral Activation System; **BLIPS:** Brief Limited Intermittent Psychotic Symptoms; **BMI:** body-mass index; **BPRS:** Brief Psychiatric Rating Scale; **BSI:** Brief Symptom Inventory; **CAARMS:** Comprehensive Assessment of At Risk Mental States; **CBQ:** Conflict Behavior Questionnaire; **CBT:** cognitive behavioral therapy; **CDS:** Calgary Depression Scale; **CDSS:** Calgary Depression Scale for Schizophrenia; **CGI:** Clinical Global Impression-Severity of Illness Scale; **CIDI:** Composite International Diagnostic Interview; **CMRS:** Cardio-metabolic risk factors; **COPS:** Criteria of Prodromal States; **CPT:** Continuous Performance Task; **CPT-IP:** Continuous Performance Test: Identical Pairs; **DSM-IV:** Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; **DSM-IV-TR:** Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision; **DSM-V:** Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; **EEG:** electroencephalogram; **EPS:** extrapyramidal symptoms; **ERIRaos:** Early Recognition Inventory; **EST:** Enhanced standard treatment; **EQ-5D:** European Quality of Life; **ESRS:** Extrapyramidal Symptom Rating Scale; **FACT:** Family-aided Assertive Community Treatment; **FAS:** Controlled Oral Word Association **FFT:** family-focused treatment; **GAF:** Global Assessment of Functioning; **GFR:** Global Functioning-Role; **GFS:** Global Functioning-Social; **GHQ2:** General Health Questionnaire; **HRSA:** Hamilton Rating Scale for Anxiety; **HRSD:** Hamilton Rating scale for Depression; **ICD-10:** International Classification of Diseases 10th revision; **IPI:** Integrated psychological intervention; **IQ:** intelligence quotient; **ITT:** intention-to-treat; **MADRS:** Montgomery-Asberg Depression Rating Scale; **MANSA:** Montgomery-Asberg Depression Rating Scale; **MATRICES:** Measurement and Treatment Research to Improve Cognition in Schizophrenia; **MCCB:** Measurement and Treatment Research to Improve Cognition in Schizophrenia consensus cognitive battery; **MCT:** Minnesota Clerical Test; **MSCEIT:** Mayer-Salovey Emotional Intelligence Test; **NBI:** needs-based intervention; **NFI:** needs-focused intervention; **NDRL:** Non Directive Reflective Listening; **OLIFE:** Oxford-Liverpool Inventory of Feelings and Experiences; **OpenCDMS:** data collection system; **OTI:** Opiate Treatment Index; **PANSS:** Positive and Negative Syndrome Scale; **PBEQ:** Personal Beliefs about Experiences Questionnaire; **PBIQ-R:** Personal Beliefs on Illness Questionnaire-Revised; **PCPW:** Perceived Criticism and Perceived Warmth Scales; **PIER:** Portland Identification and Early Referral; **POPS:** Presence of Psychotic Symptoms; **PSQI:** Pittsburgh Sleep Quality Index; **PST:** Processing speed training; **QALYs:** Quality-adjusted life years; **QLS:** Quality of Life Scale; **QOL:** quality of life; **SANS:** Scale for Assessment of Negative Symptoms; **SAPS:** Scale for Assessment of Positive Symptoms; **SAS-A:** Social Anxiety Scale for Adolescents; **SAS-II:** Social Adjustment Scale-II; **SAS-SR:** Social Adjustment Scale-Self Report; **SD:** standard deviation; **SFS:** Social Functioning Scale; **SIAS:** Social Interaction and Anxiety Scale; **SIPS:** Structured Interview for Prodromal Symptoms; **SOFA:** Social and Occupational Functioning Assessment Scale; **SOPS:** Scale of Prodromal Symptoms; **SPA12:** Social Phobia and Anxiety Inventory; **SPI:** Specific preventive intervention; **SPS:** Social Phobia Scale; **SSRI:** Selective serotonin reuptake inhibitors; **SUQ:** Substance Use Questionnaire; **TAU:** Treatment as usual; **UKU:** Udvalg for Kliniske Undersøgelser Adverse Effects Scale  
**UHR:** ultra high risk; **WAI-SF:** Working Alliance Inventory-Short Form; **WAIS-III:** Wechsler Adult Intelligence Scale-Third Edition; **WCS:** Wisconsin Card Sort Test; **WMI:** Working Memory Index; **YMS:** Young Mania Rating Scale

**Characteristics of excluded studies** [ordered by study ID]

Study	Reason for exclusion
Berger-Australia	Allocation: not randomised, open-label study
Berry-USA	Allocation: randomised  Participants: participants with recent onset of non-affective psychosis and cannabis dependence or abuse
Biagianti-USA	Allocation: randomised  Participants: participants in the early course of schizophrenia-spectrum illness

Study	Reason for exclusion
Capra-Australia	Allocation: randomised Participants: not-help seeking young participants with psychosis-like experiences
CHANGSHA-USA	Allocation: randomised Participants: adult Chinese participants who met study's criteria for schizotaxia
Chien-Hong Kong	Allocation: randomised Participants: family caregivers of people with recent-onset psychosis
Cordes-Germany	Allocation: randomised Participants: participants with schizophrenia
EDIPP-USA	Allocation: not randomised, cutoff, regression discontinuity design
EPIP-Singapore	Allocation: not randomised, prospective assessment
Heresco-Levy-Israel	Allocation: randomised Participants: UHR ((COPS) derived using the SIPS/SOPS scales) Intervention: sarcosine versus placebo Outcomes: no data; this study has been withdrawn prior to enrolment due to lack of participants (0 participants enrolled as stated on Clinicaltrials.gov for NCT00276263)
Holzer-Switzerland	Allocation: randomised Participants: adolescent participants with psychosis or at high risk for psychosis. Results for UHR participants not separated from the whole sample
Keri-Hungary	Allocation: not randomised, prospective study
Koren-Israel	Allocation: randomised Participants: adults from the community Intervention: 1 of 2 vignettes depicting an at-risk adolescent Outcomes: degree to which that adolescent is likely to seek help for and to feel stigmatised and hopeless because of his/her symptoms
LEGS-USA	Allocation: randomised Participants: primary care practitioners
LEO CAT-UK	Allocation: randomised Participants: participants with first episode of psychosis
LEO-UK	Allocation: randomised Participants: participants with non-affective psychosis presenting to mental health services for the first time.
Leweke-Germany	Allocation: randomised

Study	Reason for exclusion
	Participants: participants with early schizophrenia
Lewis-USA	Allocation: not randomised (participants assigned to intervention or control using method of minimisation to equate group membership on risk factors).  Participants: people with schizophrenia or schizoaffective disorder
NEURAPRO-Q-Australia	Allocation: randomised  Participants: UHR participants  Intervention: quetiapine and placebo  Outcomes: no data, study was terminated in July 2011 due to feasibility reasons, recruitment of participants never commenced (as stated on ANZCTR.org for ACTRN12610000244000)
O'Neill-UK	Allocation: randomised  Participants: participants with ARMS for psychosis  Interventions: cannabidiol and placebo  Outcomes: neuroimaging study (block design fMRI while performing a verbal paired associate learning task) with different types of outcomes, not included in our protocol (activation of different brain areas).
OPUS-Denmark	Allocation: randomised  Participants: participants with first-episode of psychosis
Piskulic-2-Canada	Allocation: randomised  Participants: participants at risk for serious mental disorders (inclusion criteria: subthreshold mood and psychotic symptoms)  Intervention: cognitive remediation and motivational interviewing  Outcomes: no data, terminated due to recruitment difficulties (actual enrollment of 12 participants according to Clinicaltrials.gov for NCT02582528)
RAISE-ETP-USA	Allocation: randomised  Participants: participants with first episode of psychosis
Ramsay-USA	Allocation: randomised  Participants: participants with early schizophrenia
RAP-USA	Allocation: randomised  Participants: prodromal schizophrenia  Intervention: sertraline and risperidone  Outcomes: no data, "Terminated by the principal investigator, as a sufficient number of subjects could not be enrolled." (actual enrollment of 8 participants as stated on Clinicaltrials.gov for NCT00169988)
Schmechtig-USA	Allocation: randomised  Participants: participants with high and average schizotypy

Study	Reason for exclusion
	Intervention: 4 drug groups (nicotine, risperidone, amisulpiride, placebo)  Outcomes: performance of prosaccade (PS), antisaccade (AS) and smooth pursuit eye movement (SPEM) tasks
Uher-Canada	Allocation: randomised  Participants: high-risk offspring of parents with schizophrenia, bipolar disorder and severe recurrent depression from age of 3-21 years
Vadhan-USA	Allocation: not randomised  Participants: marijuana users at clinical high risk for schizophrenia (CHR) and healthy marijuana-using controls  Intervention: marijuana
Woods-2-USA	Allocation: not randomised, open-label study

**ARMS:** At-Risk Mental State; **COPS:** Criteria of Prodromal Syndromes; **fMRI:** functional magnetic resonance imaging; **SIPS:** Structured Interview for Prodromal Symptoms; **SOPS:** Scale of Prodromal Symptoms; **UHR:** ultra high risk;

### Characteristics of studies awaiting assessment [ordered by study ID]

#### Armando-Italy

Methods	Allocation: randomised  Blindness: double-blind  Inclusion criteria: written informed consent (for > 18 written informed consent of parents), age 12-26 years, UHR as classified by the CAARMS (Yung 2005), genetic diagnosis of 22q11DS.  Exclusion criteria: acute suicidal behaviour (6 on CAARMS item 7.3) or aggressive behaviour (6 on CAARMS item 5.4), drug abuse that contributed decisively to presentation of index episode, dependency on morphine, cocaine, amphetamine (not THC), alcohol abuse if considered major problem, epilepsy, IQ < 70, pregnancy and lactation  Duration: 12 weeks
Participants	Diagnosis: people with 22q11DS and UHR criteria for psychosis  N = 80 planned  Age: range 12-26 years  Sex: men and women
Interventions	1. Omega-3 PUFAs + standard care (omega-3 PUFA + non-neuroleptic, standard therapy in those with 22q11DS and UHR criteria for psychosis)  2. Placebo + standard care (placebo + non-neuroleptic, standard therapy in those with 22q11DS and UHR criteria for psychosis)
Outcomes	1. Transition to psychosis rate measured by the CAARMS 2. Mental status: PANSS, MADRS, WAIS-R, WMS-R, WCST, Trail Making Test-Part A and B, CPT, Finger Tapping Test: (right and left)  3. Functioning: GAF 4. Adverse effects: UKU

### Armando-Italy (Continued)

Notes We contacted study authors regarding the status of this study via email, but they did not respond.  
Protocol registration: ClinicalTrials.gov ID NCT02070211

### Goie-Norway

Methods Allocation: randomised  
Blindness: single-blind (outcomes assessor)  
Inclusion criteria: DSMIV schizophrenia, schizophreniform disorder and schizoaffective disorder or high risk for psychosis or being treated for psychotic disorder > 5 years, reporting executive problems through structured interview or selfreport, i.e. BRIEF scale Tscore < 55  
Exclusion criteria: ongoing alcohol or substance abuse, premorbid neurological disease or insult and/or comorbid neurological disease, severe cognitive problems interfering with the capacity to participate, IQ > 70  
Duration: not provided

Participants Diagnosis: people with schizophrenia spectrum disorders or high-risk individuals with executive deficits  
N = 100  
Age: 16-67 years  
Sex: men and women

Interventions 1. Goal Management Training  
2. Cognitive Rehabilitation Therapy

Outcomes Mental state: Hopkins Symptom Checklist 10, PANSS.  
Functioning: GAF, everyday functioning from NORMENT, SFS  
Cognition: BRIEF, CPT-III, Hotel Task, DKEFS, digit span and letter-number sequencing, Iowa gambling task, dysexecutive questionnaire (self + informant), Cognitive Failures Questionnaire, Goal Attainment Scaling  
Self-esteem: General Perceived Self-Efficacy Scale, Rosenberg self-esteem scale.  
Quality of life: Perceived Quality of Life Scale

Notes Protocol registration: ClinicalTrials.gov ID NCT03048695

### Langer-Chile

Methods Allocation: randomised  
Blindness: double-blind  
Setting: Chile  
Inclusion criteria: FES or at high risk of psychosis, age 15-35 years, clinical stability defined by medical and psychometric criteria (e.g. PANSS)

### Langer-Chile *(Continued)*

Exclusion criteria: risk of suicide, severe intellectual disability (mental retardation), medical illness inconsistent with the intervention, substance abuse or dependence in past 6 months

Duration: 8 weeks + 3 months' follow-up

Participants	<p>Diagnosis: FES and high-risk of psychosis</p> <p>N = 48 FES, 48 high risk mental state</p> <p>Age: 15-35 years</p> <p>Sex: men and women</p>
Interventions	<p>1. MBI + TAU. N = 48 (24 FES)</p> <p>2. TAU: standard care, pharmacology and psychosocial intervention under clinical guidelines</p>
Outcomes	<p>Mental state: MATRICS</p> <p>Psychological well-being: Psychological well-being scale, Rosenberg Self-esteem scale, Five Facet Mindfulness Questionnaire, PANAS, PSWQ-11, DASS-21</p>
Notes	<p>Protocol registration: ISRCTN24327446</p>

### Nemoto-Japan

Methods	<p>Allocation: randomised</p> <p>Setting: Japan</p> <p>Duration: 24 weeks of treatment + 1 year follow-up</p>
Participants	<p>Diagnosis: schizophrenia (within 5 years of onset), chronic schizophrenia, or ARMS for psychosis</p> <p>N = 94</p> <p>Sex: 50 men, 44 women</p>
Interventions	<p>1. Cognitive training programme for divergent thinking (DT)</p> <p>2. Cognitive training programme for convergent thinking (CT)</p> <p>Both training programmes administered as homework for 24 weeks</p>
Outcomes	<p>Clinical assessments and neurocognitive tests (not specified)</p>
Notes	<p>Based on the abstract, participants could potentially be eligible for this review, but the abstract did not provide sufficient information about participants or any data for analysis. Study authors did not respond to e-mail request for clarifications.</p>

### OMEGA3-NAPLS-USA

Methods	<p>Allocation: randomised</p> <p>Blindness: double-blind</p> <p>Setting: North America</p> <p>Inclusion criteria: SIPS criteria</p>
---------	---

### Interventions for prodromal stage of psychosis (Review)

**OMEGA3-NAPLS-USA** (Continued)

	<p>Exclusion criteria: antipsychotic medication or history of diabetes</p> <p>Duration: 24 weeks</p>
Participants	<p>Diagnosis: CHR people from NAPLS consortium</p> <p>N = 127 CHR participants (118 completed baseline assessment, 70 completed study)</p> <p>Race: 82.5% Latino, 66.7% white</p> <p>Age: range 12–30 years, average 18.5 SD 5</p> <p>Sex: men and women, ~ 60:40 M:F</p>
Interventions	<p>1. Omega-3: dose 740 mg/day, etyl-eicosapentaenoic acid/400 mg/day DHA</p> <p>2. Placebo</p> <p>Baseline diet characterisation assessed using a systematic checklist that includes Omega-3 fatty acid foods</p>
Outcomes	<p>Transition to psychosis</p> <p>Leaving the study early</p> <p>Mental state: change in symptoms and functioning</p> <p>Physiological: fasting erythrocyte fatty acid composition</p> <p>Adverse effects</p>
Notes	<p>Published data not usable for analysis</p> <p>Protocol registration: ClinicalTrials.gov ID NCT01429454</p>

**POP-Norway**

Methods	<p>Allocation: randomised</p> <p>Blindness: single (study personnel)</p> <p>Setting: Norway</p> <p>Inclusion criteria: listed in national register, residing in the catchment areas (Stavanger and Fonna), 13-65 years, meet SIPS criteria, does not meet current or life-time criteria for any psychotic disorder, symptoms not better accounted for by Axis I/II or substance use disorder (exception, schizotypal personality disorder), not used antipsychotic medication for &gt; 4 weeks, no neurological/endocrine disorders that may cause presenting psychotic symptoms, IQ &gt; 70, understand and speak Norwegian, understand and sign an informed consent or assent for minors document</p> <p>Duration: 2 years</p>
Participants	<p>Diagnosis: UHR state</p> <p>N = 240 (target)</p> <p>Sex: men and women</p> <p>History: recruited through information campaigns and assessed by low-threshold detection teams</p>

**POP-Norway** (Continued)

Interventions	<p>1. Prodromal treatment package: 1-1 monitoring of clinical status (symptom levels (prodromal and psychotic), risk profiles (suicidality, dangerousness), instrumental and social functioning), 1-1 case management (to help deal with clinical, familial, social and vocational crises, needs and deficits), omega-3 fatty acids (2 g of fish oils containing approx. 1.5 g eicosapentaenoic acid/DHA + 80 mg Vitamin E/day for 12 weeks), individual CBT, to deal with social/cognitive distortions and deficits and to maintain real world investment, 26 sessions of CBT within a 6-month period), individuals that experience functional loss will in addition receive single-family psycho-education (to inform participants and families about current problems, how to understand and cope with them, especially within the family).</p> <p>Anti-anxiety agents and anti-depressants will be available if the participant is so symptomatic that they otherwise would be prescribed these agents by their general doctors. Antipsychotic medication will be available if the participant either enters the study with any SIPS positive symptom score at the level of 5, or if any positive prodromal symptom score(s) moves from a level of 3 or 4 to a 5, open-label use based on the participant's symptom profile</p>
Outcomes	<p>Mental state: transition to psychosis (SCID, PANSS), time to transition</p> <p>Neuroimaging and cognition: fMRI + working memory task, resting state task, dichotic listening task</p>
Notes	<p>We contacted study authors via email regarding study status, but they did not respond.</p> <p>Protocol registration: ISRCTN20328848</p>

**Woods-3-USA**

Methods	<p>Allocation: randomised</p> <p>Blindness: quadruple (participant, care provider, investigator, outcomes assessor).</p> <p>Setting: multisite study, USA</p> <p>Inclusion criteria: treatment-seeking patients meeting SIPS criteria for psychosis prodrome, clinically referred, age range 16-40 years</p> <p>Exclusion criteria: use of antipsychotic medication in last 3 months, initiation/increase in dosage of antidepressant within 6 weeks, medical contraindications to taking ziprasidone (QTcF <math>\geq</math> 450 msec at screening or baseline, history of arrhythmia or QTc prolongation or syncope, family history of QTc prolongation, current receipt of medication known to prolong QTc, or K<sup>+</sup>, Mg<sup>++</sup>, or Ca<sup>++</sup> below the normal range</p> <p>Duration: 24 weeks</p>
Participants	<p>Diagnosis: people at UHR for psychosis</p> <p>N = 51</p> <p>Age: 16-40 years</p> <p>Sex: men and women</p> <p>History: no details</p>
Interventions	<p>1. Ziprasidone: dose 20-160 mg/day in 2 doses. N = 24</p> <p>2. Placebo: matched with ziprasidone. N = 27</p> <p>Each participant offered Supportive Interpersonal Therapy session at each visit</p>



**Woods-3-USA** (Continued)

Outcomes	Mental state: transition to psychosis (SIPS), SOPS
Notes	<p>Due to insufficient information regarding the study and data presentation, published data were not usable for analysis.</p> <p>We contacted study authors via e-mail three times, but they did not respond.</p> <p>Protocol registration: ClinicalTrials.gov ID NCT00635700</p>

**BRIEF:** Behaviour Rating Inventory for Executive Functions; **CAARMS:** Comprehensive Assessment of At Risk Mental States; **CBT:** cognitive behavioural therapy; **CHR:** clinical high risk; **PANSS:** Positive and Negative Syndrome Scale; **CPT:** Continuous Performance Task; **DASS-21:** Depression, Anxiety and Stress Scale; **DHA:** docosahexaenoic acid; **DKEFS:** Delis Kaplan Executive Function System; **DSM-IV:** Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; **FES:** first episode schizophrenia; **GAF:** Global Assessment of Functioning Scale; **IQ:** intelligence quotient; **MADRS:** Montgomery-Asberg Depression Rating Scale; **MATRICES:** Measurement and Treatment Research to Improve Cognition in Schizophrenia; **MBI:** Mindfulness-based intervention; **NORMENT:** Norwegian Centre for Mental Disorders Research; **PANAS:** Positive and Negative Affect Schedule; **PSWQ-11:** Penn State Worry Questionnaire; **PUFA:** Polyunsaturated fatty acid; **SCID:** Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders; **SFS:** Social Functioning Scale; **SIPS:** Structured Interview for Prodromal Symptoms; **SOPS:** Scale of Prodromal Symptoms; **TAU:** treatment as usual; **THC:** tetrahydrocannabinol; **UHR:** ultra high risk; **UKU:** Udvalg for Kliniske Undersøgelser side effect rating scale; **WAIS-R:** Wechsler Adult Intelligence Scales-Revised; **WCST:** Wisconsin Card Sort Test; **WMS-R:** Wechsler Memory Scale-Revised

**Characteristics of ongoing studies** [ordered by study ID]

**ChiCTR-INR-16009566**

Trial name or title	Personalised strategy for non-invasive early intervention on clinical high-risk subjects for psychosis
Methods	<p>Allocation: randomised</p> <p>Blindness: unclear</p> <p>Setting: China</p> <p>Inclusion criteria: 1. UHR (SIPS and SOPS criteria), 15-45 years, IQ &gt; 69, no substance or alcohol abuse within 3 months, no DSM-V axis I disorders, no prior psychopharmacological treatment; 2. FES (DSM-V), 15-45 years, IQ &gt; 69; PANSS ≥ 60, CGI ≥ 4, no other DSM-V axis I disorders; no prior psychopharmacological treatment; 3. healthy controls: no mental disorders screened (SIPS/SOPS and SCID), 15-45 years, IQ &gt; 69, no history or family history of mental disorders, no substance or alcohol abuse</p> <p>Exclusion criteria: sensory/motion disorders (e.g. hearing disorders, blindness), neurological illness (brain injury, epilepsy), or other severe somatic illness which can lead to CHR symptoms, claustrophobia, with metallic objects in their head or any type of stimulator in their body</p>
Participants	<p>Diagnosis: UHR for psychosis, first episode of psychosis</p> <p>N: not provided</p> <p>Age: 15-45 years (mean 23 years)</p> <p>Sex: men and women</p>
Interventions	<ol style="list-style-type: none"> <li>1. Real rTMS</li> <li>2. Sham rTMS</li> <li>3. No intervention</li> </ol>
Outcomes	Mental state: CHR SIPS/SOPS, PANSS

**ChiCTR-INR-16009566** (Continued)

	Cognition: MCCB, social cognitive function
Starting date	January 2017
Contact information	<a href="mailto:jjunwang27@163.com">jjunwang27@163.com</a>
Notes	Protocol registration: <a href="#">ChiCTR-INR-16009566</a>

**Deyoe-USA/Mexico**

Trial name or title	Compensatory cognitive training in clinical high risk Latino youth
Methods	<p>Allocation: randomised</p> <p>Blindness: single</p> <p>Setting: USA</p> <p>Inclusion criteria: meet clinical high-risk criteria, Latino descent, speak Spanish as preferred language</p> <p>Exclusion criteria: concomitant medical/neurological illness, brain injury with loss of consciousness &gt; 30 min, current substance abuse (excluding nicotine), IQ &lt; 80, high suicidal risk</p> <p>Duration: 12 weeks + 12 weeks' follow-up</p>
Participants	<p>Diagnosis: UHR for psychosis</p> <p>N = 120</p> <p>Age: 12-30 years</p> <p>Sex: men and women</p>
Interventions	<p>1. Compensatory cognitive training</p> <p>2. Behavioral: recreational therapy</p>
Outcomes	<p>Neurocognition: Global Cognitive Index</p> <p>Functional capacity: UPSA/UPSA-A</p> <p>Self-reported functioning: SLoF</p> <p>Mental state: SOPS</p>
Starting date	September 2016
Contact information	<a href="mailto:kcadenhead@ucsd.edu">kcadenhead@ucsd.edu</a>
Notes	Protocol registration: <a href="#">ClinicalTrials.gov ID NCT02245607</a>

**ESPRIT B1-Germany**

Trial name or title	Multimodal prevention of psychosis - a randomised trial investigating the efficacy of n-acetylcysteine (NAC) and integrated preventive psychological intervention (IPPI) in subjects clinically at high risk for psychosis (ESPRIT B1)
Methods	<p>Allocation: randomised</p> <p>Blindness: double</p> <p>Setting: Germany</p> <p>Inclusion criteria: age 18-40 years, people with ability to follow study instructions, likely to attend and complete all required visits, written informed consent, ability to speak, write and understand German, meet Clinical High Risk Criteria (ESPRIT ultra high risk criteria) and/or Basic Symptom Criterion 'Cognitive Disturbances, COGDIS' (2/9 cognitive-perceptive basic symptoms; assessed by SPIA)</p> <p>Duration: 26 months (26 weeks of treatment + 78 weeks' follow-up)</p>
Participants	<p>Diagnosis: UHR for psychosis</p> <p>N = 200</p> <p>Age: 18-40 years</p> <p>Sex: men and women</p>
Interventions	<ol style="list-style-type: none"> <li>1. Acetylcysteine: dose 2000 mg/day orally, 2 doses, continuously over 26 weeks parallel to the psychological intervention (IPPI or psychological stress management (PSM))</li> <li>2. Placebo: orally for 26 weeks parallel to the psychological intervention (IPPI or PSM).</li> <li>3. Integrated preventive psychological intervention, IPPI: 21 sessions, 1-20 weekly, last session 2 weeks later</li> <li>4. Psychological stress management (PSM): 11 sessions; 1-10 biweekly, last session 2 weeks later</li> </ol>
Outcomes	<p>Mental state: transition to psychosis (SIPS), symptom remission (APS/BLIPS and/or COGIDS), SIPS, BNSS.</p> <p>Psychosocial functioning: SOFAS, FROGS.</p> <p>Cognition: COGDIS, SPIA, UHR (SPIA); SATMC I &amp; II, PoFA</p> <p>Adverse effects: weight, UKU</p> <p>Laboratory assessments</p>
Starting date	September 2016
Contact information	Not provided
Notes	Protocol registration: ClinicalTrials.gov ID NCT03149107

**FOCUS-Denmark**

Trial name or title	A randomised clinical trial examining cognitive remediation plus standard treatment versus standard treatment in participants at ultra high risk psychosis- effect on cognitive functioning, functional outcome and symptomatology
Methods	Allocation: randomised

**Interventions for prodromal stage of psychosis (Review)**

**FOCUS-Denmark** (Continued)

	Blindness: double
	Setting: Denmark
	Inclusion criteria: age 18-40 years, meet criteria for UHR of psychosis ( $\geq 1$ vulnerability, attenuated psychotic symptoms, brief limited intermittent psychotic symptoms, informed consent)
	Exclusion criteria: history of psychotic episode of $\geq 1$ week's duration, psychiatric symptoms explained by physical illness with psychotropic effect or acute intoxication, serious developmental disorder, currently receiving treatment with methylphenidate, rejection of informed consent
	Duration: 24 weeks
Participants	Diagnosis: UHR for psychosis N = 126 Age: 18-40 years Sex: men and women
Interventions	1. Cognitive remediation + standard care 2. Standard care
Outcomes	Mental state: BACS, MADRS, BPRS-E, SCoRS, SANS, SPPI-A, BRIEF-A, CAARMS, ERT, SCSQ Global state: PSP, GAF, SFS, TASIT, SRS, HiSoC 3. Quality of life: QLS 4. Adverse events
Starting date	March 2014
Contact information	merete.nordentoft@dadlnet.dk
Notes	Protocol registration: ClinicalTrials.gov ID NCT02098408

**ISRCTN42478021**

Trial name or title	Combined individual and family cognitive behavioural therapy compared with treatment as usual
Methods	Allocation: randomised (using secure telephone, 1:1 ratio) Blinding: double Setting: UK Inclusion criteria: aged 16-35 years, screen positive on CAARMS for at-risk mental state, living with at least one member of their family, help seeking Exclusion criteria: receipt of antipsychotic drugs, moderate-severe learning disability, organic impairment, insufficient fluency in English Duration: 12 months
Participants	Diagnosis: UHR for psychosis N = 76

**ISRCTN42478021** (Continued)

	Age: 16-35 years
	Sex: men and women
Interventions	<p>1. Individual + family therapy: maximum 25 individual therapy sessions, ~1/week, 1 h, over 6 months, (focusing on whatever most concerned participant) + 4-6 sessions of CBT with key family members or family support members (focusing on making sense of experiences, communication styles, problem solving and goal setting) + TAU, routine care from their care team or GP</p> <p>2. TAU</p>
Outcomes	<p>Mental state: transition to psychosis (CAARMS defined), BDI, SIAS</p> <p>Health and social care: adapted EPQ, EQ-5D</p>
Starting date	March 2016
Contact information	Greater Manchester West Mental Health NHS Foundation Trust Psychosis Research Unit, Rico House, Harrop House, Bury New Road
Notes	Protocol registration: <a href="#">ISRCTN42478021</a>

**NCT02047539**

Trial name or title	Randomised controlled trial of aspirin vs placebo in the treatment of patients with the clinical risk syndrome for psychosis
Methods	<p>Allocation: randomised</p> <p>Blindness: double</p> <p>Setting: USA</p> <p>Inclusion criteria: age 19-35 years, &gt; 1 of 3 CHR syndromes (SIPS), adequate decisional capacity</p> <p>Exclusion criteria: &lt; 19 years old, pre-existing gastrointestinal disease, heart disease, kidney disease, taking non-steroidal anti-inflammatory medications, hypersensitivity to NSAID, coexisting unstable major medical illness, pregnancy or breastfeeding, consumption &gt; 2 drinks of alcohol/day, blood clotting disorder, taking ACE inhibitors, acetazolamide, anticoagulants, anticonvulsants, beta blockers, diuretics, methotrexate, oral hypoglycaemic or uricosuric agents, history of substance abuse in past 3 months or dependence in past 6 months.</p> <p>Duration: 12 weeks</p>
Participants	<p>Diagnosis: UHR</p> <p>N = 40</p> <p>Age: 19-35 years</p> <p>Sex: men and women</p>
Interventions	<p>1. Aspirin: 100 mg/day</p> <p>2. Placebo</p>
Outcomes	Mental state: SOPS
Starting date	March 2014

**Interventions for prodromal stage of psychosis (Review)**

**NCT02047539** (Continued)

Contact information	scott.woods@yale.edu
Notes	Protocol registration: ClinicalTrials.gov ID <a href="#">NCT02047539</a>

**NCT02155699**

Trial name or title	Exercise and markers of medial temporal health in youth at risk for psychosis
Methods	<p>Allocation: randomised</p> <p>Blindness: single</p> <p>Setting: USA</p> <p>Inclusion criteria: age 16-24, no history of brain injury or neurological disease, no contraindications to exercise training, no history or current treatment with antipsychotic, no contraindications for being in MRI scanner, meet criteria for a prodromal syndrome based on SIPS</p> <p>Exclusion criteria: extremely claustrophobic, significant head injury, other physical disorder that could affect brain functioning, mental retardation, substance use disorder within 6 months, psychotic disorder and/or serious self-harm behaviours, pregnancy, contraindications to MRI, inability of participant or their parent/guardian to understand informed consent document, meeting criteria for an Axis I psychotic disorder</p> <p>Duration: 12 weeks + 24 months' follow-up</p>
Participants	<p>Diagnosis: UHR for psychosis</p> <p>N = 45</p> <p>Age: 16-24 years</p> <p>Sex: men and women</p>
Interventions	<p>1. Exercise 1: 65% of vo2max 2 sessions/week</p> <p>2. Exercise 2: 85% intensity 3 sessions/week</p>
Outcomes	<p>Physiological: brain volume</p> <p>Cognition: MATRICS, relational and item-specific coding and retrieval task (RISE)</p> <p>Mental state: attenuated symptoms</p> <p>Functioning: social role functioning</p>
Starting date	July 2016
Contact information	viyaj.mittal@colorado.edu
Notes	Protocol registration: ClinicalTrials.gov ID <a href="#">NCT02155699</a>

**NCT02234258**

Trial name or title	Cognitive behavioral social skills training for youth at risk of psychosis
Methods	Allocation: randomised

**Interventions for prodromal stage of psychosis (Review)**

**NCT02234258** (Continued)

	Blindness: single
	Setting: USA
	Inclusion criteria: prodromal criteria in past 4 years, 1 attenuated psychotic symptom $\leq 3$ , social functioning $< 6$
	Exclusion criteria: meet criteria for psychotic/neurological disorder, IQ $< 70$
	Duration: 12 months (6 months + 6 months' follow-up)
Participants	Diagnosis: UHR for psychosis
	N = 225
	Age: 14-30 years
	Sex: men and women
Interventions	1. Cognitive behavioral social skills (CBSST): 18-week group comprised of 3 modules (cognitive skills, social skills, problem solving)
	2. Psychoeducation support group
Outcomes	Functioning: GFS
	Insight: defeatist beliefs
Starting date	January 2015
Contact information	<a href="mailto:jmadding@ucalgary.ca">jmadding@ucalgary.ca</a>
Notes	Protocol registration: ClinicalTrials.gov ID <a href="https://clinicaltrials.gov/ct2/show/study/NCT02234258">NCT02234258</a>

**NCT02404194**

Trial name or title	Optimizing cognitive training to improve functional outcome in clinical high risk (CHR)
Methods	Allocation: randomised
	Blindness: double
	Setting: USA
	Inclusion criteria: English speaking, $\geq 1$ psychosis-risk syndromes (SIPS)
	Exclusion criteria: IQ $< 70$ , major medical illness or neurological disorder, history of Axis I psychotic disorder and/or clear evidence that psychosis risk syndrome is due to non-schizophrenia-spectrum Axis I or Axis II disorder
	Duration: 10 weeks + 9 months' follow-up
Participants	Diagnosis: UHR for psychosis
	N = 76
	Age: 15-30 years
	Sex: men and women
Interventions	1. Targeted cognitive training: 40 h computerised cognitive training

**Interventions for prodromal stage of psychosis (Review)**

**NCT02404194** (Continued)

	2. Computer games: 40 h of computer games
Outcomes	Cognition: MATRICS, behavioural assessment of cognition Global Functioning: Social and Role Scales, behavioural assessment of daily functioning
Starting date	March 2015
Contact information	braintrainingstudy@gmail.com
Notes	Protocol registration: ClinicalTrials.gov ID <a href="#">NCT02404194</a>

**NCT02557945**

Trial name or title	Gabapentin in patients at clinical risk for psychosis
Methods	Allocation: randomised Blindness: double Setting: USA Inclusion criteria: COPE patient, age 18-30, capacity to give informed consent, currently using a reliable method of birth control (female) Exclusion criteria: metal implants in body or history of metal working, or more than one past MRI scan with gadolinium, asthmatic symptoms in past 3 years or known sensitivity to contrast agents, diagnosis of renal failure/disease, acute neurological, neuroendocrine, or medical disorder including renal insufficiency, lifetime diagnosis of hypertension or diabetes, IQ < 70, acute risk for suicide and/or violence, pregnancy, lactation, current abuse of substances (alcohol, cocaine, stimulants, cannabis, opiates, sedative hypnotics), current use or anticipated need for antipsychotics or mood stabilisers (all antipsychotics, also Depakote, lithium, lamotrigine, pregabalin or any medication with a mechanism of action like gabapentin), improvement in CGI score during study $\geq 6$ Duration: 6 weeks
Participants	Diagnosis: UHR for psychosis N = 48 Age: 18-30 years Sex: men and women
Interventions	1. Gabapentin: up to 3600 mg/day (9 tablets, 3 times/day) 2. Placebo: up to 9 tablets (3 times/day)
Outcomes	Physiological: left CA1 cerebral blood volume (MRI measure) Mental state: SIPS, SOPS Cognitive function: hippocampal-dependent verbal memory (CLVT-II)
Starting date	August 2015
Contact information	gb2428@columbia.edu
Notes	Protocol registration: ClinicalTrials.gov ID <a href="#">NCT02557945</a>



**NCT02751632**

Trial name or title	The staged treatment in early psychosis study (STEP): a sequential multistage randomised clinical trial (SMART) of interventions for ultra high risk (UHR) of psychosis patients
Methods	<p>Allocation: randomised</p> <p>Blindness: double</p> <p>Setting: Australia</p> <p>Inclusion criteria: age 12-25 years, ability to speak adequate English and to provide informed consent, meet <math>\geq 1</math> UHR for psychosis groups: vulnerability (trait and state risk factor) group, APS group, BLIPS group with symptoms present during past year and associated with a significant reduction in or sustained low functioning</p> <p>Exclusion criteria: past psychotic episode of <math>\geq 1</math> week, attenuated psychotic symptoms only present during acute intoxication, organic brain disease known to cause psychotic symptoms, any metabolic, endocrine or other physical illness with known neuropsychiatric consequences, diagnosis of a serious developmental disorder, IQ &lt; 70, history of developmental delay or intellectual disability</p> <p>Duration: 6 weeks (Step 1) + 18 weeks (Step 2) + 6 months (Step 3)</p>
Participants	<p>Diagnosis: UHR for psychosis</p> <p>N = 120</p> <p>Age: 12-30 years</p> <p>Sex: men and women</p>
Interventions	<p>SPS treatment: administered by allied health professionals on a 1-1 basis, providing participants with emotional support and help with resolving problems in day-to-day life during 3-6 sessions over 6 weeks, each session 30-50 min</p> <p>The study treatment sequence involves 3 steps, without any break between them.</p> <p>Initially all participants receive SPS treatment (Step 1)</p> <p>A. Participants who improve with the SPS treatment:</p> <ol style="list-style-type: none"> <li>1. SPS: sessions for up to 1 year</li> <li>2. simple monitoring: 3-monthly intervals for 1 year</li> </ol> <p>B. Participants who do not improve with the initial SPS treatment (proceed to Step 2)</p> <ol style="list-style-type: none"> <li>1. SPS: 18 weeks, 1-1 basis, frequency of sessions depending on clinical need and participant preference (&gt; 6 sessions)</li> <li>2. CBCM: strategies to help stress management (targets thinking and behavioural patterns), practical assistance, as well as yoga and mindfulness (similar intensity of treatment sessions as above)</li> </ol> <p>C. At the end of Step 2</p> <p>C.i. Participants who improve</p> <ol style="list-style-type: none"> <li>1. SPS: monthly sessions for further 6 months.</li> <li>2. Simple monitoring: at 3-monthly intervals for further 6 months.</li> </ol> <p>C.ii Participants who do not improve proceed to Step 3</p>

**NCT02751632** (Continued)

1. CBCM + fluoxetine: dose 20 mg/day titrated at 6 weeks to 40 mg/day, 6 months

2. CBCM + placebo: 6 months

If no improvement/deterioration by 12 weeks in Step 3, option to continue with treatment, increase dose, start new medication. Upon choosing, medication may either be an antipsychotic (quetiapine) or omega-3 fatty acids ('fish oil'), taken in addition to the other treatment components of Step 3

Outcomes	Functioning: GAF, SFS Global state: relapse Mental state: transition to psychotic disorder (CAARMS), BPRS, SANS, MADRS
Starting date	April 2016
Contact information	barnaby.nelson@orygen.org.au
Notes	Protocol registration: ClinicalTrials.gov ID <a href="#">NCT02751632</a>

**NCT02951208**

Trial name or title	Transcranial direct current stimulation coupled with virtual rehabilitation for negative symptoms in atrisk youth
Methods	Allocation: randomised Blindness: double Setting: Canada Inclusion criteria: age 16-30 years, meet CHR criteria for a psychosis risk syndrome (SIPS), SOPS (negative subscale) score of > 11, > 1 negative symptom of severity ≥ 3 Exclusion criteria: psychotic disorder, IQ < 70, seizures or clinically significant neurological disorder that may contribute to prodromal symptoms, involvement in another treatment study in past 4 weeks Duration: 4 weeks
Participants	Diagnosis: people with CHR for psychosis N = 22 Age: 16-30 years Sex: men and women
Interventions	1. Active anodal tDCS*: over left DLPFC, for 30 minutes, 3/week for 4 weeks 2. Sham anodal tDCS**: over left DLPFC, for 30 minutes, 3/week for 4 weeks
Outcomes	Mental state: SOPS (negative and positive subscale), BSS, CDSS, MCCB, RAD, RMET, TASIT, ER40, IRI, SSQ Functioning: GAF, SFS Functional brain imaging: change in regional brain activity; structural brain imaging changes in brain structure (e.g. white matter tract integrity, measured with structural MRI)

**NCT02951208** (Continued)

Starting date	October 2016
Contact information	george.foussias@camh.ca
Notes	<p>*Other name: Active Transcranial Direct Current Stimulation Behavioral: Active VR Motivation Training.</p> <p>**Other Name: Sham Transcranial Direct Current Stimulation Behavioral: Sham VR Motivation Training</p> <p>Protocol registration: ClinicalTrials.gov ID <a href="#">NCT02951208</a></p>

**NCT02960451**

Trial name or title	Randomised trial of usual care vs. specialised, phase specific care for youth at risk for psychosis
Methods	<p>Allocation: randomised</p> <p>Blindness: open</p> <p>Setting: USA</p> <p>Inclusion criteria: 12-30 years old, understand and sign an informed consent (or assent for minors) document in English, meet diagnostic criteria for prodromal syndrome COPS criteria</p> <p>Exclusion criteria: diagnosis of Axis I psychotic disorder, including mood disorder with psychotic symptoms, IQ &lt; 70, clinically significant central nervous system disorder that may contribute to prodromal symptoms or confound their assessment, alcohol or substance dependence in the past 6 months.</p> <p>Duration: 24 months</p>
Participants	<p>Diagnosis: UHR for psychosis</p> <p>N = 128</p> <p>Age: 12-30 years</p> <p>Sex: men and women</p>
Interventions	<p>1. PRIME care: specialist medication, cognitive behaviour therapy, family focused therapy</p> <p>2. Usual care: education and psychotherapy as available form community providers</p>
Outcomes	<p>Functioning: GAF</p> <p>Service utilisation: hospitalisation and emergency room use</p>
Starting date	January 2015
Contact information	barbara.walsh@yale.edu
Notes	Protocol registration: ClinicalTrials.gov ID <a href="#">NCT02960451</a>

## OMEGA3-Ireland

Trial name or title	Randomised control trial of omega3 fatty acids compared to placebo in the prevention of psychosis in very high risk individuals
Methods	<p>Allocation: randomised</p> <p>Blindness: double</p> <p>Setting: Ireland</p> <p>Inclusion criteria: 13-50 years, written informed consent, UHR (SIPS)</p> <p>Exclusion criteria: previous psychotic episode &gt; 1 week's duration, previous manic episode &gt; 1 week's duration, acute suicidal or aggressive behaviour, substance dependence, lactose intolerance/milk allergy, intellectual disability, previous treatment with antipsychotic or mood stabiliser for psychiatric indication &gt; 2 weeks in past 3 months, consumption of over the counter or prescribed Omega3 fatty acids supplements within 12 weeks of entering study, pregnancy/breastfeeding, severe intercurrent illness that could affect ability of participant to take part in study</p> <p>Duration: 6 months</p>
Participants	<p>Diagnosis: UHR for psychosis</p> <p>N = 150</p> <p>Age: 13-45 years</p> <p>Sex: men and women</p>
Interventions	<p>1. Omega3 fatty acids: 200 mL juice drinks, containing 1000 mg of eicosapentaenoic acid and 1000 mg docosahexaenoic acid – across 6 months</p> <p>2. Placebo: matched with intervention, 200 mL juice drinks – across 6 months</p>
Outcomes	<p>Mental state: transition to psychosis (SIPS)</p> <p>Physiological: blood omega3:omega6 ratio</p>
Starting date	September 2013
Contact information	<a href="mailto:damianodriscoll@ucc.ie">damianodriscoll@ucc.ie</a>
Notes	Protocol registration: ClinicalTrials.gov ID NCT02848469

## PREVENT-Germany

Trial name or title	Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behaviour therapy, aripiprazole, and placebo for the prevention of psychosis
Methods	<p>Allocation: randomised (computer-generated, restricted block randomisation, stratified by MADRS score, kept in a remote secure location and administered by an independent third party until all study data are collected and verified).</p> <p>Blindness: double</p> <p>Setting: Germany</p> <p>Inclusion criteria: Inclusion Criteria Checklist, SIPS/SOPS criteria</p>

**PREVENT-Germany** (Continued)

Exclusion criteria: current or past antipsychotic treatment > 1 week, previous psychotic episode > 1 week, current suicidality or dangerous behaviour, alcohol or substance dependence, organic brain disease, IQ < 70, living out of area, other medical reasons like current or intended pregnancy, lactation or missing reliable method of contraception, taking drugs with anticipated interactions, etc.

Duration: 12 months

Participants	Diagnosis: UHR for psychosis (APS, BLIPS, BS, family risk plus reduced functioning)  N = 156  Age: 18-40 years, average 23 years  Sex: men and women
Interventions	1. Aripiprazole + clinical management: dose range 5-15 mg/day, 20 manualised sessions (1-4 weekly sessions, then biweekly, 3 months, then monthly, following 8 months); initial session 45-60 min, with other sessions of 20-30 min.  2. CBT: 30 individual, 50-min CBT sessions over 12-months (weekly month 1-4, then biweekly, 6 months, then monthly, the last 2 months)  3. Placebo + clinical management: tablets identical to aripiprazole
Outcomes	Mental state: transition to psychosis ( $\geq 1$ of 5 SOPS-positive items rated $\geq 6$ longer than 7 days), time to transition, SIPS/SOPS, SPIA, PANSS, MADRS, BDI, STAI  Quality of life: Modular System for Quality of Life  Functioning: SOFAS, SAS.  Adverse effects: UKU, EPSR
Starting date	April 2008
Contact information	joachim.klosterkoetter@uk-koeln.de
Notes	Protocol registration: ISRCTN: 02658871

**Quarashi-Pakistan**

Trial name or title	Pilot study of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk mental states (NAYAB)
Methods	Allocation: randomised  Blindness: double  Setting: Pakistan  Inclusion criteria: help-seeking individuals, 16-35 years, > 1 ARMS criteria, competent to provide informed consent  Exclusion criteria: history of previously experiencing a psychotic illness, IQ < 70 and/or history of learning disability, pre-existing inflammatory conditions, organic brain disease, treatment with an antipsychotic or mood-stabilising agent, prior history of intolerance or serious adverse effects (hepatotoxicity, photosensitivity, blood dyscrasias) to any of the tetracyclines or omega-3 fatty acids, concomitant penicillin therapy or concomitant anticoagulant therapy, active substance abuse (except nicotine or caffeine) or dependence within 3 months (DSM-V), treatment with warfarin or lamotrigine, current or previous treatment with tetracycline antibiotics or omega-3 fatty acids in the

**Quarashi-Pakistan** (Continued)

preceding 3 months before study entry, current treatment with any anti-inflammatory medication, treatment with electroconvulsive therapy within 12 weeks preceding study, active expression of suicidal ideation (CAARMS item 7.3 severity score 6) or current aggression/dangerous behaviour (CAARMS item 5.4 severity score 6), relevant current or past haematologic, hepatic, renal, neurological or other medical disorder that in the opinion of the principal investigator may interfere with the study, pregnancy or breastfeeding women

Duration: unclear

Participants	Diagnosis: UHR for psychosis N = 320 Age: 16-35 years Sex: men and women
Interventions	1. Minocycline + TAU: dose 200 mg/day 2. Omega-3 fatty acids + TAU: dose 1.2 g/day 3. Minocycline + omega-3 fatty acids + TAU: doses as above 4. Placebo + TAU
Outcomes	Mental state: transition to psychotic disorder, severity of at-risk mental state (CAARMS)
Starting date	October 2015
Contact information	ibchaudhry@btinternet.com
Notes	Protocol registration: ClinicalTrials.gov ID NCT02569307

**Rurhman-USA/UK**

Trial name or title	Early intervention in attenuated psychosis syndrome: a phase II study evaluating efficacy, safety, and tolerability of oral BI 409306
Methods	Allocation: randomised (secure telephone, 1:1 ratio) Blindness: double Setting: USA, UK Inclusion criteria: 16-30 years, patients with APS (SIPS), with a screening risk profile based on NAPLS algorithm Exclusion criteria: unclear Duration: 52 weeks + 4 weeks' follow-up
Participants	Diagnosis: UHR for psychosis N = 300 Age: 16-30 years Sex: men and women
Interventions	1. Oral BI 409306

**Interventions for prodromal stage of psychosis (Review)**

**Rurhman-USA/UK** (Continued)

## 2. Placebo

Outcomes	Global state: CGI-S, PGI-I Mental state: transition to psychosis (SOPS), time to transition (PANSS) Cognition: SCoRS, MATRICS, MCCB Physiological: EEG, event-related potentials, and visual-evoked potentials
Starting date	Q2 2017
Contact information	Not provided
Notes	Protocol registration: ClinicalTrials.gov ID NCT01892384

**ACE:** angiotensin-converting-enzyme; **APS:** attenuated psychotic symptoms; **ARMS:** at risk mental state; **BACS:** Brief Assessment of Cognition in Schizophrenia; **BDI:** Beck Depression Inventory; **BLIPS:** Brief Limited Intermittent Psychotic Symptoms Group; **BNSS:** Brief Negative Symptom Scale; **BPRS:** Brief Psychiatric Rating Scale; **BPRS-E:** Brief Psychiatric Rating Scale Expanded Version; **BRIEF-A:** Behavior Rating Inventory of Executive Function, Adult Version; **BS:** basic symptoms; **BSS:** Beck Scale for Suicidal Ideation; **CAARMS:** Comprehensive Assessment of At Risk Mental States; **CBCM:** Cognitive Behavioural Case Management; **CBT:** cognitive behavioural therapy; **CDSS:** Calgary Depression Scale for Schizophrenia; **CGI:** Clinical Global Impression; **CGI-S:** Clinical Global Impression - Severity; **CHR:** clinical high risk; **CLVT-II:** California Verbal Learning Test-Second Edition; **COGDIS:** conceptual disorganization and cognitive basic symptoms; **COPS:** Criteria of Prodromal States; **DLPFC:** dorsolateral prefrontal cortex; **DSM-V:** Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; **EEG:** electroencephalography; **EPQ:** Eysenck Personality Questionnaire; **EPSR:** Extrapyrimal Symptom Rating Scale; **EQ-5D:** EuroQol 5D instrument; **ER40:** Emotion Recognition 40; **ERT:** Emotion Recognition Task; **FES:** first episode schizophrenia; **FROGS:** Functional Remission of General Schizophrenia; **GAF:** Global Assessment of Functioning  
**GFS:** Global Functioning Scale; **HiSoC:** High Risk Social Challenge; **IQ:** intelligence quotient; **IRI:** Interpersonal Reactivity Index; **MADRS:** Montgomery Asberg Depression Rating Scale; **MATRICES:** Measurement and Treatment Research to Improve Cognition in Schizophrenia; **MCCB:** Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery; **MRI:** magnetic resonance imaging; **NAPLS:** North American Prodrome Longitudinal Study; **NSAID:** nonsteroidal anti-inflammatory drug; **PANSS:** Positive and Negative Syndrome Scale; **PGI-I:** Patient Global Impressions-Improvements; **PoFA:** Pictures of Facial Affect; **PSP:** Personal and Social Performance Scale; **QLS:** Quality of Life Scale; **RAD:** Relationships Across Domains; **RMET:** Reading the Mind in the Eyes Task; **rTMS:** repetitive transcranial magnetic stimulation; **SANS:** Scale for the Assessment of Negative Symptoms  
**SAS:** Social Adjustment Scale; **SATMC I & II:** Social Attribution Task-Multiple Choice; **SCID:** Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM); **SCoRS:** Schizophrenia Cognitive Rating Scale; **SCSQ:** Social Cognition Screening Questionnaire; **SFS:** Social Functioning Scale; **SIAS:** Social Interaction Anxiety Scale; **SIPS:** Structured Interview for Prodromal Symptoms; **SLoF:** Specific Level of Functioning Scale; **SOFAS:** Social and Occupational Functioning Assessment Scale; **SOPS:** Scale of Prodromal Symptoms; **SPIA:** Schizophrenia Proneness Instrument - Adult Version; **SPPI-A:** Schizophrenia Prediction Proneness Instrument - Adult Version; **SPS:** support and problem solving; **SRS:** Social Responsiveness Scale; **SSQ:** Simulator Sickness Questionnaire; **STAI:** State Trait Anxiety Inventory; **TASIT:** Awareness of Social Inferences Test; **TAU:** treatment as usual; **UHR:** ultra high risk; **UKU:** Udvalg for Kliniske Undersøgelser side effect rating scale

**DATA AND ANALYSES**
**Comparison 1. Group A: amino acids vs placebo**


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Prodromal symptoms: transition to psychosis, endpoint data	2	52	Risk Ratio (M-H, Random, 95% CI)	0.48 [0.08, 2.98]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2 Mental state 1: specific, psychosis risk symptoms, average total score, short-term (at 8 weeks), SOPS (higher score = worse)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.1 Total score	1	8	Mean Difference (IV, Fixed, 95% CI)	-10.00 [-22.38, 2.38]
2.2 Positive score	1	8	Mean Difference (IV, Fixed, 95% CI)	-2.5 [-7.86, 2.86]
2.3 Negative score	1	8	Mean Difference (IV, Fixed, 95% CI)	-1.80 [-4.88, 1.28]
2.4 Disorganisation score	1	8	Mean Difference (IV, Fixed, 95% CI)	1.0 [-1.57, 3.57]
2.5 General score	1	8	Mean Difference (IV, Fixed, 95% CI)	-6.80 [-9.47, -4.13]
3 Mental state 2 specific: depression, average total score, short-term (at 8 weeks), MADRS (higher score = worse), skewed data			Other data	No numeric data
4 Mental state 3a specific: cognitive symptoms, average total score, short-term (at 12 weeks), various tests (higher score = better)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.1 Immediate verbal memory (AVLT immediate trials sum)	1	5	Mean Difference (IV, Random, 95% CI)	6.5 [-2.15, 15.15]
4.2 Delayed verbal memory (AVLT delay trial)	1	5	Mean Difference (IV, Random, 95% CI)	0.50 [-1.17, 2.17]
4.3 Executive functioning (semantic fluency test)	1	4	Mean Difference (IV, Random, 95% CI)	-0.5 [-10.53, 9.53]
4.4 Executive functioning (phonemic fluency test)	1	4	Mean Difference (IV, Random, 95% CI)	-1.00 [-20.38, 14.38]
4.5 Attention and working memory (letter number sequencing)	1	5	Mean Difference (IV, Random, 95% CI)	4.5 [2.04, 6.96]
5 Mental state 3b specific: cognitive symptoms, average total score, short-term (at 12 weeks), various tests (higher score = worse)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
5.1 Processing speed (Trails A)	1	4	Mean Difference (IV, Random, 95% CI)	8.8 [-8.57, 26.17]
5.2 Attention and working memory (Trails B)	1	4	Mean Difference (IV, Random, 95% CI)	-2.80 [-48.70, 43.10]
5.3 Processing speed (Stroop words)	1	4	Mean Difference (IV, Random, 95% CI)	-11.5 [-27.49, 4.49]
5.4 Processing speed (Stroop colors)	1	4	Mean Difference (IV, Random, 95% CI)	-6.60 [-17.45, 4.25]
5.5 Processing speed (Stroop color-words)	1	4	Mean Difference (IV, Random, 95% CI)	-6.0 [-9.50, -2.50]




Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5.6 Executive functioning (WCS perseverative errors)	1	5	Mean Difference (IV, Random, 95% CI)	9.7 [4.16, 15.24]
6 Adverse effects 1 specific: treatment-emergent adverse effects, short-term (by 8 weeks)	1		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
6.1 Psychological: irritability	1	8	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.02, 6.37]
6.2 Psychological: mentation impaired	1	8	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.02, 6.37]
6.3 Psychological: hallucinations	1	8	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.02, 6.37]
6.4 Arousal: sedation	1	8	Risk Ratio (M-H, Random, 95% CI)	0.2 [0.01, 3.20]
6.5 Arousal: disturbed sleep	1	8	Risk Ratio (M-H, Random, 95% CI)	0.2 [0.01, 3.20]
6.6 Arousal: malaise	1	8	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.02, 6.37]
6.7 Sexual: orgasm dysfunction	1	8	Risk Ratio (M-H, Random, 95% CI)	3.00 [0.16, 57.36]
6.8 Gastrointestinal: stomach discomfort	1	8	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.02, 6.37]
7 Adverse effects 2 specific: cardiovascular, average total score, short-term (by 8 weeks), blood pressure and pulse rate (higher score = worse)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
7.1 Systolic blood pressure	1	8	Mean Difference (IV, Random, 95% CI)	6.0 [-8.70, 20.70]
7.2 Diastolic blood pressure	1	8	Mean Difference (IV, Random, 95% CI)	2.0 [-12.03, 16.03]
7.3 Pulse	1	8	Mean Difference (IV, Random, 95% CI)	-20.0 [-41.76, 1.76]
8 Adverse effects 3 specific: weight, average total change score, short-term (by 8 weeks), kg gained (higher score = worse)	1	8	Std. Mean Difference (IV, Random, 95% CI)	-0.67 [-2.13, 0.79]
9 Adverse effects 4 specific: suicidal thoughts, short-term (by 16 weeks)	1	44	Risk Ratio (M-H, Random, 95% CI)	3.57 [0.15, 83.14]
10 Satisfaction with treatment: leaving the study early - end point data	2	52	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.55, 1.69]

**Analysis 1.1. Comparison 1 Group A: amino acids vs placebo, Outcome 1 Prodromal symptoms: transition to psychosis, endpoint data.**



**Analysis 1.2. Comparison 1 Group A: amino acids vs placebo, Outcome 2 Mental state 1: specific, psychosis risk symptoms, average total score, short-term (at 8 weeks), SOPS (higher score = worse).**




**Analysis 1.3. Comparison 1 Group A: amino acids vs placebo, Outcome 3 Mental state 2 specific: depression, average total score, short-term (at 8 weeks), MADRS (higher score = worse), skewed data.**


Mental state 2 specific: depression, average total score, short-term (at 8 weeks), MADRS (higher score = worse), skewed data

Study	Intervention	Mean	SD	N	Note
Woods-1-USA	Amino acids	7.2	4	4	
Woods-1-USA	Placebo	14	4.9	3	


**Analysis 1.4. Comparison 1 Group A: amino acids vs placebo, Outcome 4 Mental state 3a specific: cognitive symptoms, average total score, short-term (at 12 weeks), various tests (higher score = better).**




**Analysis 1.5. Comparison 1 Group A: amino acids vs placebo, Outcome 5 Mental state 3b specific: cognitive symptoms, average total score, short-term (at 12 weeks), various tests (higher score = worse).**




**Analysis 1.6. Comparison 1 Group A: amino acids vs placebo, Outcome 6 Adverse effects 1 specific: treatment-emergent adverse effects, short-term (by 8 weeks).**







**Analysis 1.7. Comparison 1 Group A: amino acids vs placebo, Outcome 7 Adverse effects 2 specific: cardiovascular, average total score, short-term (by 8 weeks), blood pressure and pulse rate (higher score = worse).**




**Analysis 1.8. Comparison 1 Group A: amino acids vs placebo, Outcome 8 Adverse effects 3 specific: weight, average total change score, short-term (by 8 weeks), kg gained (higher score = worse).**




**Analysis 1.9. Comparison 1 Group A: amino acids vs placebo, Outcome 9 Adverse effects 4 specific: suicidal thoughts, short-term (by 16 weeks).**





**Analysis 1.10. Comparison 1 Group A: amino acids vs placebo, Outcome 10 Satisfaction with treatment: leaving the study early - end point data.**



**Comparison 2. Group A: omega-3 fatty acids vs placebo**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
<a href="#">1 Prodromal symptoms: transition to psychosis</a>	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Medium-term (at 12 months)	2	385	Risk Ratio (M-H, Random, 95% CI)	0.50 [0.08, 3.08]
1.2 Long-term (at 7 years)	1	81	Risk Ratio (M-H, Random, 95% CI)	0.24 [0.09, 0.67]
<a href="#">2 Global state: antipsychotic prescription, long-term (at 7 years' follow-up)</a>	1	69	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.30, 0.99]
<a href="#">3 Mental state 1a specific: psychotic symptoms, average total score, PANSS (higher score = worse)</a>	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
3.1 General: medium-term (at 12 months)	1	81	Mean Difference (IV, Random, 95% CI)	-3.90 [-8.06, 0.26]
3.2 General: long-term (up to 7 years)	1	81	Mean Difference (IV, Random, 95% CI)	-4.70 [-9.69, 0.29]
3.3 Negative: medium-term (at 12 months)	1	81	Mean Difference (IV, Random, 95% CI)	-2.60 [-5.09, -0.11]
3.4 Negative: long-term (up to 7 years)	1	81	Mean Difference (IV, Random, 95% CI)	-3.10 [-6.15, -0.05]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.5 Positive: medium-term (at 12 months)	1	81	Mean Difference (IV, Random, 95% CI)	-2.10 [-4.32, 0.12]
3.6 Positive: long-term (up to 7 years)	1	81	Mean Difference (IV, Random, 95% CI)	-3.50 [-5.99, -1.01]
3.7 Total: medium-term (at 12 months)	1	81	Mean Difference (IV, Random, 95% CI)	-8.60 [-16.36, -0.84]
3.8 Total: long-term (up to 7 years)	1	81	Mean Difference (IV, Random, 95% CI)	-11.40 [-20.55, -2.25]
4 Mental state 1b specific: negative symptoms, average total score, medium-term (at 12 months), SANS (higher score = worse)	1	225	Mean Difference (IV, Random, 95% CI)	0.5 [-2.56, 3.56]
5 Mental state 2 specific: depression, average total score, medium-term (at 12 months), MADRS (higher score = worse), skewed data	1	225	Mean Difference (IV, Random, 95% CI)	-0.30 [-2.78, 2.18]
6 Mental state 3 specific: mania, average total score, medium-term (at 12 months), YMS (higher score = worse)	1	225	Mean Difference (IV, Random, 95% CI)	0.40 [-0.35, 1.15]
7 Mental state 4 specific: average total scores, various scales (higher score = worse), skewed data			Other data	No numeric data
7.1 Psychotic symptoms: positive (average total score), long-term (by up to 7 years) PANSS			Other data	No numeric data
7.2 Psychotic symptoms: negative (average total score), medium-term (at 12 months) PANSS			Other data	No numeric data
7.3 Psychotic symptoms: negative (average total score), long-term (by up to 7 years) PANSS			Other data	No numeric data
7.4 Depression: average total score, medium-term (at 12 months), MADRS			Other data	No numeric data
7.5 Depression: average total score, long-term (by up to 7 years) MADRS			Other data	No numeric data
8 Functioning 1 global: average total score, GAF (higher score = better)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
8.1 Medium-term (at 12 months)	1	81	Mean Difference (IV, Random, 95% CI)	11.5 [5.12, 17.88]
8.2 Long-term (at up to 7 years)	1	81	Mean Difference (IV, Random, 95% CI)	9.5 [2.02, 16.98]




Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
9 Functioning 2 specific: role functioning, average total score, medium-term (at 12 months), GFR (higher score = better)	1	225	Mean Difference (IV, Random, 95% CI)	0.0 [-0.49, 0.49]
10 Functioning 3a specific: social functioning, average total score, medium-term (at 12 months), GFS (higher score = better)	1	225	Mean Difference (IV, Random, 95% CI)	-0.20 [-0.59, 0.19]
11 Functioning 3b specific: social functioning, average total score, medium-term (at 12 months), SOFAS (higher score = better)	1	225	Mean Difference (IV, Random, 95% CI)	0.10 [-4.60, 4.80]
12 Adverse effects, specific: medium-term (by 12 months), UKU checklist	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
12.1 Arousal: concentration difficulties	1	81	Risk Ratio (M-H, Random, 95% CI)	0.20 [0.02, 1.60]
12.2 Arousal: increased fatigability	1	81	Risk Ratio (M-H, Random, 95% CI)	1.46 [0.26, 8.30]
12.3 Arousal: sleep - reduced duration of sleep	1	81	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.21, 4.55]
12.4 Arousal: sleep-related - unspecified	1	304	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.49, 1.42]
12.5 Autonomic nervous system: orthostatic dizziness	1	81	Risk Ratio (M-H, Random, 95% CI)	0.20 [0.01, 3.94]
12.6 Autonomic nervous system: sweating increase	1	81	Risk Ratio (M-H, Random, 95% CI)	0.20 [0.01, 3.94]
12.7 Autonomic nervous system: unspecified	1	304	Risk Ratio (M-H, Random, 95% CI)	1.56 [0.79, 3.11]
12.8 Gastrointestinal: diarrhoea	1	81	Risk Ratio (M-H, Random, 95% CI)	0.24 [0.03, 2.09]
12.9 Gastrointestinal: nausea/ vomiting	1	81	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.21, 4.55]
12.10 Gastrointestinal: unspecified	1	304	Risk Ratio (M-H, Random, 95% CI)	1.28 [0.91, 1.79]
12.11 Haematological: increased bleeding	1	304	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.01, 8.01]
12.12 Hormonal: unspecified	1	304	Risk Ratio (M-H, Random, 95% CI)	0.61 [0.26, 1.42]
12.13 Neurological: extrapyramidal	1	304	Risk Ratio (M-H, Random, 95% CI)	2.57 [0.94, 7.02]
12.14 Neurological: failing memory	1	81	Risk Ratio (M-H, Random, 95% CI)	0.20 [0.01, 3.94]
12.15 Neurological: tension headache	1	81	Risk Ratio (M-H, Random, 95% CI)	0.24 [0.03, 2.09]
12.16 Neurological: unspecified	1	304	Risk Ratio (M-H, Random, 95% CI)	1.85 [0.81, 4.24]
12.17 Psychological: depression	1	81	Risk Ratio (M-H, Random, 95% CI)	0.39 [0.08, 1.90]
12.18 Psychological: emotional indifference	1	81	Risk Ratio (M-H, Random, 95% CI)	0.49 [0.09, 2.52]
12.19 Psychological: tension/inner unrest	1	81	Risk Ratio (M-H, Random, 95% CI)	0.78 [0.23, 2.70]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
12.20 Psychological: unspecified	1	304	Risk Ratio (M-H, Random, 95% CI)	1.32 [0.70, 2.47]
12.21 Sexual: unspecified	1	304	Risk Ratio (M-H, Random, 95% CI)	6.91 [0.86, 55.48]
12.22 Skin: unspecified	1	304	Risk Ratio (M-H, Random, 95% CI)	0.70 [0.23, 2.17]
12.23 Other: unspecified	1	304	Risk Ratio (M-H, Random, 95% CI)	1.12 [0.66, 1.90]
<b>13 Satisfaction with treatment: leaving the study early</b>	<b>2</b>		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
13.1 Medium-term (by 12 months), endpoint	2	385	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.68, 1.42]
13.2 Long-term (by 7 years), additional follow-up	1	81	Risk Ratio (M-H, Random, 95% CI)	1.46 [0.45, 4.80]

**Analysis 2.1. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 1 Prodromal symptoms: transition to psychosis.**





**Analysis 2.2. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 2 Global state: antipsychotic prescription, long-term (at 7 years' follow-up).**






**Analysis 2.3. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 3 Mental state 1a specific: psychotic symptoms, average total score, PANSS (higher score = worse).**







**Analysis 2.4. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 4 Mental state 1b specific: negative symptoms, average total score, medium-term (at 12 months), SANS (higher score = worse).**




**Analysis 2.5. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 5 Mental state 2 specific: depression, average total score, medium-term (at 12 months), MADRS (higher score = worse), skewed data.**



**Analysis 2.6. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 6 Mental state 3 specific: mania, average total score, medium-term (at 12 months), YMS (higher score = worse).**







**Analysis 2.7. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 7 Mental state 4 specific: average total scores, various scales (higher score = worse), skewed data.**

Study	Mental state 4 specific: average total scores, various scales (higher score = worse), skewed data			
	Intervention	Mean	SD	N
<b>Psychotic symptoms: positive (average total score), long-term (by up to 7 years) PANSS</b>				
Amminger-Austria	Omega-3 fatty acids	9.9	5.76	41
Amminger-Austria	Placebo	13.4	5.69	40
<b>Psychotic symptoms: negative (average total score), medium-term (at 12 months) PANSS</b>				
Amminger-Austria	Omega-3 fatty acids	10.2	5.76	41
Amminger-Austria	Placebo	12.8	5.69	40
<b>Psychotic symptoms: negative (average total score), long-term (by up to 7 years) PANSS</b>				
Amminger-Austria	Omega-3 fatty acids	10.9	7.04	41
Amminger-Austria	Placebo	14.0	6.96	40
<b>Depression: average total score, medium-term (at 12 months), MADRS</b>				
Amminger-Austria	Omega-3 fatty acids	9.4	12.17	41
Amminger-Austria	Placebo	13.5	12.02	40
<b>Depression: average total score, long-term (by up to 7 years) MADRS</b>				
Amminger-Austria	Omega-3 fatty acids	10.3	12.81	41
Amminger-Austria	Placebo	16.1	12.65	40


**Analysis 2.8. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 8 Functioning 1 global: average total score, GAF (higher score = better).**




**Analysis 2.9. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 9 Functioning 2 specific: role functioning, average total score, medium-term (at 12 months), GFR (higher score = better).**




**Analysis 2.10. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 10 Functioning 3a specific: social functioning, average total score, medium-term (at 12 months), GFS (higher score = better).**





**Analysis 2.11. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 11 Functioning 3b specific: social functioning, average total score, medium-term (at 12 months), SOFAS (higher score = better).**




**Analysis 2.12. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 12 Adverse effects, specific: medium-term (by 12 months), UKU checklist.**















**Analysis 2.13. Comparison 2 Group A: omega-3 fatty acids vs placebo, Outcome 13 Satisfaction with treatment: leaving the study early.**



**Comparison 3. Group B: antipsychotic drugs, amisulpiride + needs-focused intervention (NFI) vs NFI**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mental state, specific: average endpoint scores, short-term (at 12 weeks), various scales (higher score = worse), skewed data			Other data	No numeric data
1.1 Psychotic symptoms: positive (endpoint score) PANSS			Other data	No numeric data
1.2 Psychotic symptoms: negative (endpoint score) PANSS			Other data	No numeric data
1.3 Psychotic symptoms: general (endpoint score) PANSS			Other data	No numeric data
1.4 Depression (endpoint score) MADRS			Other data	No numeric data

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2 Functioning, global: average endpoint score, short-term (at 12 weeks), GAF (higher score = better)	1	102	Mean Difference (IV, Random, 95% CI)	6.10 [0.44, 11.76]
3 Adverse effects 1a specific: akathisia, short-term (at 12 weeks), ESRS	1	104	Risk Ratio (M-H, Random, 95% CI)	2.82 [0.33, 24.36]
4 Adverse effects 1b specific: akathisia (average endpoint score), short-term (at 12 weeks), ESRS (higher score = worse), skewed data			Other data	No numeric data
5 Adverse effects 2 specific: increased prolactin levels, short-term (at 12 weeks)	1	78	Risk Ratio (M-H, Random, 95% CI)	3.97 [2.02, 7.80]
6 Adverse effects 3 specific: severity of at least moderate and a frequency of at least 5%, short-term (at 12 weeks), UKU	1		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
6.1 Psychological: concentration difficulties	1	101	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.78, 1.31]
6.2 Psychological: asthenia/lassitude/increased fatigability	1	101	Risk Ratio (M-H, Random, 95% CI)	1.64 [1.08, 2.50]
6.3 Psychological: failing memory	1	101	Risk Ratio (M-H, Random, 95% CI)	2.19 [1.17, 4.10]
6.4 Psychological: depression	1	101	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.82, 1.48]
6.5 Psychological: tension	1	101	Risk Ratio (M-H, Random, 95% CI)	1.17 [0.85, 1.61]
6.6 Arousal: sleepiness/sedation	1	101	Risk Ratio (M-H, Random, 95% CI)	1.48 [0.49, 4.47]
6.7 Arousal: increased duration of sleep	1	101	Risk Ratio (M-H, Random, 95% CI)	3.28 [1.37, 7.85]
6.8 Arousal: decreased duration of sleep	1	101	Risk Ratio (M-H, Random, 95% CI)	0.49 [0.23, 1.06]
6.9 Arousal: increased dream activity	1	101	Risk Ratio (M-H, Random, 95% CI)	21.82 [1.35, 353.77]
6.10 Gastrointestinal: nausea/vomiting	1	101	Risk Ratio (M-H, Random, 95% CI)	9.92 [0.58, 169.00]
6.11 Autonomic nervous system: orthostatic dizziness	1	101	Risk Ratio (M-H, Random, 95% CI)	5.95 [0.33, 107.62]
6.12 Autonomic nervous system: increased tendency to sweating	1	101	Risk Ratio (M-H, Random, 95% CI)	16.53 [1.01, 271.60]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6.13 Cardiological: palpitation/tachycardia	1	101	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.30, 3.27]
6.14 Neurological: headache	1	101	Risk Ratio (M-H, Random, 95% CI)	1.86 [0.80, 4.31]
6.15 Endocrinological: polyuria/polydipsia	1	101	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.30, 3.27]
6.16 Sexual: diminished sexual desire	1	101	Risk Ratio (M-H, Random, 95% CI)	3.44 [1.28, 9.28]
6.17 Sexual: orgasmic dysfunction	1	101	Risk Ratio (M-H, Random, 95% CI)	5.95 [0.33, 107.62]
7 Adverse effects 4 specific: suicidal thoughts	1	102	Risk Ratio (M-H, Random, 95% CI)	0.25 [0.01, 6.10]
8 Satisfaction with treatment: leaving the study early, end point data	1	124	Risk Ratio (M-H, Random, 95% CI)	0.59 [0.38, 0.94]

**Analysis 3.1. Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs-focused intervention (NFI) vs NFI, Outcome 1 Mental state, specific: average endpoint scores, short-term (at 12 weeks), various scales (higher score = worse), skewed data.**


Mental state, specific: average endpoint scores, short-term (at 12 weeks), various scales (higher score = worse), skewed data

Study	Intervention	Mean	SD	N	Note
<b>Psychotic symptoms: positive (endpoint score) PANSS</b>					
LIPS-Germany	Amisulpiride + Needs focused interventions	9.7	3.4	58	
LIPS-Germany	Needs focused interventions	11.8	4.5	44	
<b>Psychotic symptoms: negative (endpoint score) PANSS</b>					
LIPS-Germany	Amisulpiride + Needs focused interventions	12.2	5	58	
LIPS-Germany	Needs focused interventions	13.5	5	44	
<b>Psychotic symptoms: general (endpoint score) PANSS</b>					
LIPS-Germany	Amisulpiride + Needs focused interventions	25.8	8.7	58	
LIPS-Germany	Needs focused interventions	29.2	8.9	44	
<b>Depression (endpoint score) MADRS</b>					
LIPS-Germany	Amisulpiride + Needs focused interventions	11.8	9	58	
LIPS-Germany	Needs focused interventions	12.9	8.4	44	

**Analysis 3.2. Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs-focused intervention (NFI) vs NFI, Outcome 2 Functioning, global: average endpoint score, short-term (at 12 weeks), GAF (higher score = better).**



**Analysis 3.3. Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs-focused intervention (NFI) vs NFI, Outcome 3 Adverse effects 1a specific: akathisia, short-term (at 12 weeks), ESRS.**





**Analysis 3.4. Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs-focused intervention (NFI) vs NFI, Outcome 4 Adverse effects 1b specific: akathisia (average endpoint score), short-term (at 12 weeks), ESRS (higher score = worse), skewed data.**

Adverse effects 1b specific: akathisia (average endpoint score), short-term (at 12 weeks), ESRS (higher score = worse), skewed data


Study	Intervention	Mean	SD	N	Note
LIPS-Germany	Amisulpiride + Needs focused interventions	0.5	1.3	61	
LIPS-Germany	Needs focused interventions	0.2	0.8	43	


**Analysis 3.5. Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs-focused intervention (NFI) vs NFI, Outcome 5 Adverse effects 2 specific: increased prolactin levels, short-term (at 12 weeks).**






**Analysis 3.6. Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs-focused intervention (NFI) vs NFI, Outcome 6 Adverse effects 3 specific: severity of at least moderate and a frequency of at least 5%, short-term (at 12 weeks), UKU.**











**Analysis 3.7. Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs-focused intervention (NFI) vs NFI, Outcome 7 Adverse effects 4 specific: suicidal thoughts.**



**Analysis 3.8. Comparison 3 Group B: antipsychotic drugs, amisulpiride + needs-focused intervention (NFI) vs NFI, Outcome 8 Satisfaction with treatment: leaving the study early, end point data.**



**Comparison 4. Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention**


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Prodromal symptoms: transition to psychosis, end-point data, medium-term (by 12 months)	1	60	Risk Ratio (M-H, Random, 95% CI)	0.58 [0.28, 1.18]
2 Global state, global: illness severity, average total score, medium-term (at 12 months), CGI (higher score = worse)	1	59	Mean Difference (IV, Random, 95% CI)	-0.23 [-0.82, 0.36]
3 Mental state specific: average total scores, medium-term (at 12 months), various scales (higher score = worse), skewed data			Other data	No numeric data
3.1 Psychosis risk symptoms: total, average total change score, SOPS			Other data	No numeric data

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.2 Psychosis risk symptoms: positive, average total change score, SOPS			Other data	No numeric data
3.3 Psychosis risk symptoms: negative, average total change score, SOPS			Other data	No numeric data
3.4 Psychosis risk symptoms: disorganisation, average total change score, SOPS			Other data	No numeric data
3.5 Psychosis risk symptoms: general, average total change score, SOPS			Other data	No numeric data
3.6 Psychosis risk symptoms: total, average total change score, PANSS			Other data	No numeric data
3.7 Psychotic symptoms: positive, average total change score, PANSS			Other data	No numeric data
3.8 Psychotic symptoms: negative, average total change score, PANSS			Other data	No numeric data
3.9 Psychotic symptoms: general, average total change score, PANSS			Other data	No numeric data
3.10 Depression: average total change score, MADRS			Other data	No numeric data
3.11 Mania: average total change score, YMS			Other data	No numeric data
4 Functioning, global: average total score, medium-term (at 12 months), GAF (higher score = better)	1	59	Mean Difference (IV, Random, 95% CI)	2.43 [-4.77, 9.63]
5 Adverse effects 1 specific: average total score, short-term (at 8 weeks), various scales (higher score = worse), skewed data			Other data	No numeric data
5.1 Extrapyramidal symptoms: average total change score, Simpson-Angus scale			Other data	No numeric data
5.2 Akathisia: average total change score, Barnes akathisia scale			Other data	No numeric data
5.3 Abnormal involuntary movements: average total change score, AIMS			Other data	No numeric data
6 Adverse effects 2a specific: cardiovascular, average total change score, short-term (at 8 weeks), blood pressure and pulse rate (higher score = worse)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
6.1 Sitting systolic blood pressure	1	59	Mean Difference (IV, Random, 95% CI)	1.0 [-4.28, 6.28]
6.2 Sitting diastolic blood pressure	1	59	Mean Difference (IV, Random, 95% CI)	-2.3 [-7.43, 2.83]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6.3 Sitting pulse	1	59	Mean Difference (IV, Random, 95% CI)	8.2 [0.03, 16.37]
6.4 Standing systolic blood pressure	1	59	Mean Difference (IV, Random, 95% CI)	-1.80 [-8.18, 4.58]
6.5 Standing diastolic blood pressure	1	59	Mean Difference (IV, Random, 95% CI)	-1.80 [-6.96, 3.36]
6.6 Standing pulse	1	59	Mean Difference (IV, Random, 95% CI)	7.9 [-0.74, 16.54]
<b>7 Adverse effects 2b specific: cardiovascular, average total score, medium-term (at 12 months), pulse rate (higher score = worse)</b>	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
7.1 Sitting pulse	1	58	Mean Difference (IV, Random, 95% CI)	9.27 [1.49, 17.05]
7.2 Standing pulse	1	57	Mean Difference (IV, Random, 95% CI)	6.94 [-2.61, 16.49]
<b>8 Adverse effects 3 specific: treatment-emergent adverse effects, short-term (at 8 weeks)</b>	1		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
8.1 Arousal: somnolence	1	60	Risk Ratio (M-H, Random, 95% CI)	2.25 [0.90, 5.59]
8.2 Gastrointestinal: weight gain	1	60	Risk Ratio (M-H, Random, 95% CI)	10.29 [1.42, 74.79]
8.3 Gastrointestinal: increased appetite	1	60	Risk Ratio (M-H, Random, 95% CI)	1.87 [0.51, 6.80]
8.4 Psychological: anxiety	1	60	Risk Ratio (M-H, Random, 95% CI)	4.68 [0.58, 37.68]
8.5 Psychological: nervousness	1	60	Risk Ratio (M-H, Random, 95% CI)	1.87 [0.37, 9.46]
8.6 Psychological: asthenia	1	60	Risk Ratio (M-H, Random, 95% CI)	3.74 [0.44, 31.55]
8.7 Psychological: abnormal thoughts	1	60	Risk Ratio (M-H, Random, 95% CI)	1.40 [0.25, 7.81]
8.8 Musculoskeletal: joint disorder	1	60	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.20, 4.27]
<b>9 Adverse effects 4a specific: weight, average total weight change, kg gained (higher scores = worse)</b>	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
9.1 Short-term (by 8 weeks)	1	59	Mean Difference (IV, Random, 95% CI)	4.58 [2.02, 7.14]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
9.2 Medium-term (by 12 months)	1	59	Mean Difference (IV, Random, 95% CI)	8.49 [4.90, 12.08]
10 Adverse effects 4b specific: weight gain, medium-term (at 12 months)	1	60	Risk Ratio (M-H, Random, 95% CI)	3.55 [1.53, 8.28]
11 Adverse effects 5 specific: fatigue, medium-term (at 12 months)	1	60	Risk Ratio (M-H, Random, 95% CI)	8.42 [1.14, 62.40]
12 Satisfaction with treatment: leaving the study early, endpoint data, medium-term (by 12 months)	1	60	Risk Ratio (M-H, Random, 95% CI)	1.59 [0.88, 2.88]

**Analysis 4.1. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 1 Prodromal symptoms: transition to psychosis, endpoint data, medium-term (by 12 months).**



**Analysis 4.2. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 2 Global state, global: illness severity, average total score, medium-term (at 12 months), CGI (higher score = worse).**




### Analysis 4.3. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 3 Mental state specific: average total scores, medium-term (at 12 months), various scales (higher score = worse), skewed data.

Mental state specific: average total scores, medium-term (at 12 months), various scales (higher score = worse), skewed data

Study	Intervention	Mean	SD	N	Note
<b>Psychosis risk symptoms: total, average total change score, SOPS</b>					
PRIME-USA	Olanzapine + Supportive intervention	33.8	17.17	30	
PRIME-USA	Placebo + Supportive intervention	36.56	19.08	29	
<b>Psychosis risk symptoms: positive, average total change score, SOPS</b>					
PRIME-USA	Olanzapine + Supportive intervention	7.2	5.78	30	
PRIME-USA	Placebo + Supportive intervention	9.93	7.6	29	
<b>Psychosis risk symptoms: negative, average total change score, SOPS</b>					
PRIME-USA	Olanzapine + Supportive intervention	13.8	6.38	30	
PRIME-USA	Placebo + Supportive intervention	13.52	6.54	29	
<b>Psychosis risk symptoms: disorganisation, average total change score, SOPS</b>					
PRIME-USA	Olanzapine + Supportive intervention	6	4.05	30	
PRIME-USA	Placebo + Supportive intervention	6.49	4.54	29	
<b>Psychosis risk symptoms: general, average total change score, SOPS</b>					
PRIME-USA	Olanzapine + Supportive intervention	6.8	3.66	30	
PRIME-USA	Placebo + Supportive intervention	6.62	4.21	29	
<b>Psychosis risk symptoms: total, average total change score, PANSS</b>					
PRIME-USA	Olanzapine + Supportive intervention	61.93	22.12	30	
PRIME-USA	Placebo + Supportive intervention	61.45	21.65	29	
<b>Psychotic symptoms: positive, average total change score, PANSS</b>					
PRIME-USA	Olanzapine + Supportive intervention	13.6	5.65	30	
PRIME-USA	Placebo + Supportive intervention	14.17	6.74	29	
<b>Psychotic symptoms: negative, average total change score, PANSS</b>					
PRIME-USA	Olanzapine + Supportive intervention	16.97	6.55	30	
PRIME-USA	Placebo + Supportive intervention	16.45	5.66	29	
<b>Psychotic symptoms: general, average total change score, PANSS</b>					
PRIME-USA	Olanzapine + Supportive intervention	31.37	12.07	30	
PRIME-USA	Placebo + Supportive intervention	30.83	11.35	29	
<b>Depression: average total change score, MADRS</b>					
PRIME-USA	Olanzapine + Supportive intervention	12.57	9.01	30	
PRIME-USA	Placebo + Supportive intervention	11.89	8.6	29	
<b>Mania: average total change score, YMS</b>					
PRIME-USA	Olanzapine + Supportive intervention	4.54	5.74	30	
PRIME-USA	Placebo + Supportive intervention	5.45	5.48	29	

**Analysis 4.4. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 4 Functioning, global: average total score, medium-term (at 12 months), GAF (higher score = better).**





**Analysis 4.5. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 5 Adverse effects 1 specific: average total score, short-term (at 8 weeks), various scales (higher score = worse), skewed data.**

Adverse effects 1 specific: average total score, short-term (at 8 weeks), various scales (higher score = worse), skewed data


Study	Intervention	Mean	SD	N	Note
<b>Extrapyramidal symptoms: average total change score, Simpson-Angus scale</b>					
PRIME-USA	Olanzapine + Supportive intervention	1	1.32	30	
PRIME-USA	Placebo + Supportive intervention	0.9	1.39	29	
<b>Akathisia: average total change score, Barnes akathisia scale</b>					
PRIME-USA	Olanzapine + Supportive intervention	0.9	2.3	30	
PRIME-USA	Placebo + Supportive intervention	0.4	1.92	29	
<b>Abnormal involuntary movements: average total change score, AIMS</b>					
PRIME-USA	Olanzapine + Supportive intervention	0.9	2.4	30	
PRIME-USA	Placebo + Supportive intervention	0.3	1.05	29	


**Analysis 4.6. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 6 Adverse effects 2a specific: cardiovascular, average total change score, short-term (at 8 weeks), blood pressure and pulse rate (higher score = worse).**






**Analysis 4.7. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 7 Adverse effects 2b specific: cardiovascular, average total score, medium-term (at 12 months), pulse rate (higher score = worse).**







**Analysis 4.8. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 8 Adverse effects 3 specific: treatment-emergent adverse effects, short-term (at 8 weeks).**









**Analysis 4.9. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 9 Adverse effects 4a specific: weight, average total weight change, kg gained (higher scores = worse).**




**Analysis 4.10. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 10 Adverse effects 4b specific: weight gain, medium-term (at 12 months).**



**Analysis 4.11. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 11 Adverse effects 5 specific: fatigue, medium-term (at 12 months).**



**Analysis 4.12. Comparison 4 Group B: antipsychotic drugs, olanzapine + supportive intervention vs placebo + supportive intervention, Outcome 12 Satisfaction with treatment: leaving the study early, endpoint data, medium-term (by 12 months).**




**Comparison 5. Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy**


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Prodomal symptoms: transition to psychosis	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Medium-term (by 12 months)	5	728	Risk Ratio (M-H, Random, 95% CI)	0.47 [0.29, 0.76]
1.2 Long-term (by 18 months)	2	252	Risk Ratio (M-H, Random, 95% CI)	0.45 [0.23, 0.89]
1.3 Long-term (by 24 months)	1	128	Risk Ratio (M-H, Random, 95% CI)	0.32 [0.11, 0.92]
1.4 Long-term (by 4 years' additional follow-up)	1	201	Risk Ratio (M-H, Random, 95% CI)	0.58 [0.31, 1.12]
2 Global state specific: personal beliefs, average scores, long-term (at 18 months), PBIQ- R (higher score = worse)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
2.1 Control	1	140	Mean Difference (IV, Random, 95% CI)	-0.70 [-1.79, 0.39]
2.2 Entrapment	1	140	Mean Difference (IV, Random, 95% CI)	-0.5 [-1.91, 0.91]
2.3 Loss	1	140	Mean Difference (IV, Random, 95% CI)	-0.90 [-2.37, 0.57]
2.4 Participation	1	140	Mean Difference (IV, Random, 95% CI)	-0.40 [-1.48, 0.68]
2.5 Shame	1	140	Mean Difference (IV, Random, 95% CI)	-0.40 [-1.68, 0.88]
3 Mental state 1 specific: social anxiety, average total score, long-term (at 18 months), SAS (higher score = worse)	1	28	Mean Difference (IV, Random, 95% CI)	-3.60 [-12.34, 5.14]
4 Mental state 2 specific: average scores, various scales, higher score = worse, skewed data)			Other data	No numeric data
4.1 Psychotic symptoms: total, average total score, medium-term (at 12 months), PANSS			Other data	No numeric data
4.2 Depression, average total score, medium-term (at 12 months), BDI-PC			Other data	No numeric data
4.3 Depression, average total score, medium-term (at 12 months), MADRS			Other data	No numeric data
4.4 Depression, average total score, long-term (at 18 months), BDI-II			Other data	No numeric data

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.5 Depression, average total score, long-term (at 18 months), CDSS			Other data	No numeric data
4.6 Psychotic symptoms: positive, average total score, medium-term (at 12 months), PANSS			Other data	No numeric data
4.7 Psychotic symptoms: negative, average total score, medium-term (at 12 months), PANSS			Other data	No numeric data
4.8 Psychosis risk symptoms: positive, average total score, long-term (at 18 months), SOPS			Other data	No numeric data
4.9 Psychosis risk symptoms: negative, average total score, long-term (at 18 months), SOPS			Other data	No numeric data
4.10 Social interaction and anxiety: average total score, medium-term (at 12 months), SIAS			Other data	No numeric data
4.11 Social interaction and anxiety: average total score, long-term (at 18 months), SIAS			Other data	No numeric data
<b>5 Functioning 1 global: average total score, GAF, (higher score = better)</b>	<b>3</b>		Mean Difference (IV, Random, 95% CI)	Subtotals only
5.1 Medium-term (at 12 months)	2	294	Mean Difference (IV, Random, 95% CI)	5.97 [-1.33, 13.27]
5.2 long-term (at 18 months)	1	28	Mean Difference (IV, Random, 95% CI)	-3.20 [-14.05, 7.65]
<b>6 Functioning 2.a specific: social functioning, average total score, medium-term (at 12 months), SAS II (higher score = worse)</b>	<b>1</b>	<b>67</b>	Mean Difference (IV, Random, 95% CI)	0.40 [-0.07, 0.87]
<b>7 Functioning 2.b.i. specific: social functioning, average total score, long-term (at 18 months), SFS (higher score = better)</b>	<b>1</b>	<b>28</b>	Mean Difference (IV, Random, 95% CI)	9.10 [-5.65, 23.85]
<b>8 Functioning 2.b.ii. specific: social functioning, average total score, medium-term (at 18 months), SOFAS (higher score = better)</b>	<b>1</b>	<b>140</b>	Mean Difference (IV, Random, 95% CI)	2.0 [-2.39, 6.39]
<b>9 Quality of life: average total score, long-term (at 18 months), MANSA (higher score = better)</b>	<b>1</b>	<b>140</b>	Mean Difference (IV, Random, 95% CI)	1.5 [-2.93, 5.93]
<b>10 Cost: cumulative, USD, skewed data</b>			Other data	No numeric data
10.1 Antipsychotic medication: 0-18 months			Other data	No numeric data
10.2 Antipsychotic medication: by 4 years			Other data	No numeric data
10.3 Productivity costs: 0-18 months			Other data	No numeric data
10.4 Service use: 0-18 months			Other data	No numeric data


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
10.5 Service use: by 4 years			Other data	No numeric data
10.6 Travel: 0-18 months			Other data	No numeric data
10.7 Travel: by 4 years			Other data	No numeric data
10.8 Total: 0-18 months			Other data	No numeric data
10.9 Total: by 4 years			Other data	No numeric data
<b>11 Satisfaction with treatment: leaving the study early, end point data</b>	<b>5</b>		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
11.1 By between > 1 year to 2 years	4	668	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.87, 1.10]
11.2 By between > 2 years to 4 years (additional follow-up)	2	261	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.74, 1.24]

**Analysis 5.1. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 1 Prodromal symptoms: transition to psychosis.**






**Analysis 5.2. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 2 Global state specific: personal beliefs, average scores, long-term (at 18 months), PBIQ- R (higher score = worse).**



**Analysis 5.3. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 3 Mental state 1 specific: social anxiety, average total score, long-term (at 18 months), SAS (higher score = worse).**




**Analysis 5.4. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 4 Mental state 2 specific: average scores, various scales, higher score = worse, skewed data).**


Mental state 2 specific: average scores, various scales, higher score = worse, skewed data					
Study	Intervention	Mean	SD	N	Note
<b>Psychotic symptoms: total, average total score, medium-term (at 12 months), PANSS</b>					
EIPS-Germany	CBT + Supportive therapy	39.4	10.2	33	
EIPS-Germany	Supportive therapy	39.1	9.9	35	
<b>Depression, average total score, medium-term (at 12 months), BDI-PC</b>					
EDIE-2-UK	CBT + Supportive therapy	5.41	5.12	93	
EDIE-2-UK	Supportive therapy	5.72	4.92	90	
<b>Depression, average total score, medium-term (at 12 months), MADRS</b>					
EIPS-Germany	CBT + Supportive therapy	10.3	8.8	32	
EIPS-Germany	Supportive therapy	10.5	8.4	32	
<b>Depression, average total score, long-term (at 18 months), BDI-II</b>					
EDIE-NL	CBT + Supportive therapy	9.6	9.4	71	
EDIE-NL	Supportive therapy	11.3	11.1	69	
<b>Depression, average total score, long-term (at 18 months), CDSS</b>					
ADAPT-Canada	CBT + Supportive therapy	2.6	3.5	15	
ADAPT-Canada	Supportive therapy	1.9	4.2	13	
EDIE-NL	CBT + Supportive therapy	2.6	3.7	71	
EDIE-NL	Supportive therapy	3.3	4.4	69	
<b>Psychotic symptoms: positive, average total score, medium-term (at 12 months), PANSS</b>					
EIPS-Germany	CBT + Supportive therapy	8.03	2.21	53	
EIPS-Germany	Supportive therapy	7.67	1.33	52	
<b>Psychotic symptoms: negative, average total score, medium-term (at 12 months), PANSS</b>					
EIPS-Germany	CBT + Supportive therapy	8.19	1.7	53	
EIPS-Germany	Supportive therapy	8.33	1.97	52	
<b>Psychosis risk symptoms: positive, average total score, long-term (at 18 months), SOPS</b>					
ADAPT-Canada	CBT + Supportive therapy	4.6	4.6	15	
ADAPT-Canada	Supportive therapy	4.5	4.1	13	
<b>Psychosis risk symptoms: negative, average total score, long-term (at 18 months), SOPS</b>					

Mental state 2 specific: average scores, various scales, higher score = worse, skewed data)					
Study	Intervention	Mean	SD	N	Note
ADAPT-Canada	CBT + Supportive therapy	4.4	4.3	15	
ADAPT-Canada	Supportive therapy	4.9	5.3	13	
Social interaction and anxiety: average total score, medium-term (at 12 months), SIAS					
EDIE-2-UK	CBT + Supportive therapy	32.51	17.08	91	
EDIE-2-UK	Supportive therapy	29.99	16.6	87	
Social interaction and anxiety: average total score, long-term (at 18 months), SIAS					
ADAPT-Canada	CBT + Supportive therapy	26.6	15.9	15	
ADAPT-Canada	Supportive therapy	29.1	18.6	13	
EDIE-NL	CBT + Supportive therapy	22.2	13.8	71	
EDIE-NL	Supportive therapy	20.3	15.2	69	

**Analysis 5.5. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 5 Functioning 1 global: average total score, GAF, (higher score = better).**




**Analysis 5.6. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 6 Functioning 2.a specific: social functioning, average total score, medium-term (at 12 months), SAS II (higher score = worse).**







**Analysis 5.7. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 7 Functioning 2.b.i. specific: social functioning, average total score, long-term (at 18 months), SFS (higher score = better).**



**Analysis 5.8. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 8 Functioning 2.b.ii. specific: social functioning, average total score, medium-term (at 18 months), SOFAS (higher score = better).**



**Analysis 5.9. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 9 Quality of life: average total score, long-term (at 18 months), MANSA (higher score = better).**




**Analysis 5.10. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 10 Cost: cumulative, USD, skewed data.**

Study	Intervention	Cost: cumulative, USD, skewed data		N	Notes
		Mean	SD		
<b>Antipsychotic medication: 0-18 months</b>					
EDIE-NL	CBT + supportive therapy	3.2	15.12	95	
EDIE-NL	Supportive therapy	5.11	15.17	101	

Study	Intervention	Cost: cumulative, USD, skewed data		N	Notes
		Mean	SD		
<b>Antipsychotic medication: by 4 years</b>					
EDIE-NL	CBT + supportive therapy	35.86	96.21	95	
EDIE-NL	Supportive therapy	48.28	111.91	101	
<b>Productivity costs: 0-18 months</b>					
EDIE-NL	CBT + supportive therapy	-27.56	3936.82	95	
EDIE-NL	Supportive therapy	-843.49	3947.99	101	
<b>Service use: 0-18 months</b>					
EDIE-NL	CBT + supportive therapy	5829.76	10093.17	95	
EDIE-NL	Supportive therapy	9505.17	16187.02	101	
<b>Service use: by 4 years</b>					
EDIE-NL	CBT + supportive therapy	16506.54	24362.36	95	
EDIE-NL	Supportive therapy	24452.73	40552.75	101	
<b>Travel: 0-18 months</b>					
EDIE-NL	CBT + supportive therapy	179.51	163.05	95	
EDIE-NL	Supportive therapy	185.07	244.46	101	
<b>Travel: by 4 years</b>					
EDIE-NL	CBT + supportive therapy	312.85	265.89	95	
EDIE-NL	Supportive therapy	397.46	411.31	101	
<b>Total: 0-18 months</b>					
EDIE-NL	CBT + supportive therapy	8007.44	11225.57	95	
EDIE-NL	Supportive therapy	8851.86	17179.7	101	
<b>Total: by 4 years</b>					
EDIE-NL	CBT + supportive therapy	19121.35	24507.61	95	
EDIE-NL	Supportive therapy	24898.47	40936.54	101	


**Analysis 5.11. Comparison 5 Group B: cognitive behavioural therapy (CBT), CBT + supportive therapy vs supportive therapy, Outcome 11 Satisfaction with treatment: leaving the study early, end point data.**



**Comparison 6. Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Prodromal symptoms: transition to psychosis, end point data	1	87	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.39, 2.67]
2 Mental state specific: average end point scores, medium-term (at 12 months), various scales (higher score = worse), skewed data			Other data	No numeric data
2.1 Psychopathology: total, end point data, BPRS			Other data	No numeric data
2.2 Negative symptoms: attention, end point data, SANS			Other data	No numeric data
2.3 Negative symptoms: total, end point data, SANS			Other data	No numeric data
3 Functioning global: average end point score, medium-term (at 12 months), GAF (higher score = better)	1	52	Mean Difference (IV, Random, 95% CI)	-2.0 [-6.55, 2.55]
4 Adverse effects 1 specific: doctors' assessment of adverse effects, medium-term (at 12 months), UKU	1	65	Risk Ratio (M-H, Random, 95% CI)	1.03 [0.55, 1.91]
5 Adverse effects 2 specific: adverse effects reported by participants, medium-term (at 12 months), UKU	1	65	Risk Ratio (M-H, Random, 95% CI)	2.01 [0.90, 4.53]
6 Quality of life: average end point score, medium-term (at 12 months), QLS (higher score = better)	1	51	Mean Difference (IV, Random, 95% CI)	5.70 [-7.86, 19.26]
7 Satisfaction with treatment: leaving the study early, end point data	1	87	Risk Ratio (M-H, Random, 95% CI)	1.09 [0.62, 1.92]

**Analysis 6.1. Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 1 Prodromal symptoms: transition to psychosis, end point data.**




**Analysis 6.2. Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 2 Mental state specific: average end point scores, medium-term (at 12 months), various scales (higher score = worse), skewed data.**


Mental state specific: average end point scores, medium-term (at 12 months), various scales (higher score = worse), skewed data

Study	Intervention	Mean	SD	N	Note
<b>Psychopathology: total, end point data, BPRS</b>					
Yung-Australia	Risperidone + CBT	14	9.3	24	
Yung-Australia	Placebo + CBT	16.5	11.1	27	
<b>Negative symptoms: attention, end point data, SANS</b>					
Yung-Australia	Risperidone + CBT	1.7	1.6	24	
Yung-Australia	Placebo + CBT	1.8	1.9	27	
<b>Negative symptoms: total, end point data, SANS</b>					
Yung-Australia	Risperidone + CBT	17.8	13.8	24	
Yung-Australia	Placebo + CBT	16.3	11.6	27	


**Analysis 6.3. Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 3 Functioning global: average end point score, medium-term (at 12 months), GAF (higher score = better).**




**Analysis 6.4. Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 4 Adverse effects 1 specific: doctors' assessment of adverse effects, medium-term (at 12 months), UKU.**




**Analysis 6.5. Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 5 Adverse effects 2 specific: adverse effects reported by participants, medium-term (at 12 months), UKU.**



**Analysis 6.6. Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 6 Quality of life: average end point score, medium-term (at 12 months), QLS (higher score = better).**



**Analysis 6.7. Comparison 6 Group B: cognitive behavioural therapy (CBT), CBT + risperidone vs CBT + placebo, Outcome 7 Satisfaction with treatment: leaving the study early, end point data.**




**Comparison 7. Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs-based intervention (NBI) + risperidone vs NBI**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Prodromal symptoms: transition to psychosis, end point data	1		Risk Ratio (M-H, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size	
1.1 Medium-term (at 12 months)	1	59	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.23, 1.30]	
1.2 Long-term (up to 4 years)	1	59	Risk Ratio (M-H, Random, 95% CI)	0.75 [0.39, 1.46]	
<b>2 Mental state specific: average end point scores, various scales (high score = worse), skewed data</b>			Other data	No numeric data	
2.1 Anxiety: immediately post-treatment, HRSA			Other data	No numeric data	
2.2 Anxiety: medium-term (at 12 months), HRSA			Other data	No numeric data	
2.3 Anxiety: long-term (at 4 years), HRSA			Other data	No numeric data	
2.4 Depression: immediately post-treatment, HRSD			Other data	No numeric data	
2.5 Depression: medium-term (at 12 months), HRSD			Other data	No numeric data	
2.6 Depression: long-term (at 4 years), HRSD			Other data	No numeric data	
2.7 Mania: immediately post-treatment, YMS			Other data	No numeric data	
2.8 Mania: medium-term (at 12 months), YMS			Other data	No numeric data	
2.9 Mania: long-term (at 4 years), YMS			Other data	No numeric data	
2.10 Negative symptoms: immediately post-treatment, SANS			Other data	No numeric data	
2.11 Negative symptoms: medium-term (at 12 months), SANS			Other data	No numeric data	
2.12 Negative symptoms: long-term (at 4 years), SANS			Other data	No numeric data	
2.13 Psychopathology: total, immediately post-treatment, BPRS			Other data	No numeric data	
2.14 Psychopathology: total, medium-term (at 12 months), BPRS			Other data	No numeric data	
2.15 Psychopathology: total, long-term (at 4 years), BPRS			Other data	No numeric data	
<b>3 Functioning global: average end point score, GAF (higher score = better)</b>		1	Mean Difference (IV, Random, 95% CI)	Subtotals only	
3.1 Medium-term (at 12 months)		1	40	Mean Difference (IV, Random, 95% CI)	-0.62 [-5.81, 4.57]
3.2 Long-term (up to 4 years)		1	40	Mean Difference (IV, Random, 95% CI)	-2.40 [-12.32, 7.52]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
<b>4 Quality of life: average end point score, QLS (higher score = better)</b>	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.1 Immediately post-treatment	1	40	Mean Difference (IV, Random, 95% CI)	2.83 [-13.07, 18.73]
4.2 Medium-term (at 12 months)	1	40	Mean Difference (IV, Random, 95% CI)	-2.12 [-15.43, 11.19]
4.3 Long-term (up to 4 years)	1	40	Mean Difference (IV, Random, 95% CI)	-2.03 [-16.90, 12.84]
<b>5 Cost: average cost of treatment, AUD, skewed data</b>			Other data	No numeric data
5.1 Inpatient costs: post-treatment			Other data	No numeric data
5.2 Inpatient costs: medium-term (at 12 months)			Other data	No numeric data
5.3 Inpatient costs: long-term (at 36 months)			Other data	No numeric data
5.4 Outpatient costs: post-treatment			Other data	No numeric data
5.5 Outpatient costs: medium-term (at 12 months)			Other data	No numeric data
5.6 Pharmacology costs: post-treatment			Other data	No numeric data
5.7 Outpatient costs: long-term (at 36 months)			Other data	No numeric data
5.8 Pharmacology costs: medium-term (at 12 months)			Other data	No numeric data
5.9 Pharmacology costs: long-term (at 36 months)			Other data	No numeric data
5.10 Total costs: post-treatment			Other data	No numeric data
5.11 Total costs: medium-term (at 12 months)			Other data	No numeric data
5.12 Total costs: long-term (at 36 months)			Other data	No numeric data
<b>6 Satisfaction with treatment: leaving the study early</b>	1		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
6.1 Medium-term (at 12 months)	1	59	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
6.2 Long-term (up to 4 years)	1	59	Risk Ratio (M-H, Random, 95% CI)	0.57 [0.26, 1.28]

**Analysis 7.1. Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs-based intervention (NBI) + risperidone vs NBI, Outcome 1 Prodromal symptoms: transition to psychosis, end point data.**




**Analysis 7.2. Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs-based intervention (NBI) + risperidone vs NBI, Outcome 2 Mental state specific: average end point scores, various scales (high score = worse), skewed data.**

Mental state specific: average end point scores, various scales (high score = worse), skewed data				
Study	Intervention	Mean	SD	N
<b>Anxiety: immediately post-treatment, HRSA</b>				
PACE-Australia	Specific treatment intervention (SPI)	10.73	5.67	23
PACE-Australia	Needs-based intervention (NBI)	11.41	9.92	17
<b>Anxiety: medium-term (at 12 months), HRSA</b>				
PACE-Australia	Specific treatment intervention (SPI)	11.59	9.73	23
PACE-Australia	Needs-based intervention (NBI)	12.57	10.68	17
<b>Anxiety: long-term (at 4 years), HRSA</b>				
PACE-Australia	Specific treatment intervention (SPI)	17.52	8.78	23
PACE-Australia	Needs-based intervention (NBI)	18.82	10.29	17
<b>Depression: immediately post-treatment, HRSD</b>				
PACE-Australia	Specific treatment intervention (SPI)	14.55	8.6	23
PACE-Australia	Needs-based intervention (NBI)	14.65	10.58	17
<b>Depression: medium-term (at 12 months), HRSD</b>				
PACE-Australia	Specific treatment intervention (SPI)	12.5	9.08	23
PACE-Australia	Needs-based intervention (NBI)	13.14	9.2	17
<b>Depression: long-term (at 4 years), HRSD</b>				




<b>Mental state specific: average end point scores, various scales (high score = worse), skewed data</b>				
<b>Study</b>	<b>Intervention</b>	<b>Mean</b>	<b>SD</b>	<b>N</b>
PACE-Australia	Specific treatment intervention (SPI)	22.91	11.25	23
PACE-Australia	Needs-based intervention (NBI)	25.82	13.42	17
<b>Mania: immediately post-treatment, YMS</b>				
PACE-Australia	Specific treatment intervention (SPI)	3.32	8.25	23
PACE-Australia	Needs-based intervention (NBI)	2.29	4.58	17
<b>Mania: medium-term (at 12 months), YMS</b>				
PACE-Australia	Specific treatment intervention (SPI)	1.19	3.01	23
PACE-Australia	Needs-based intervention (NBI)	1.64	3.37	17
<b>Mania: long-term (at 4 years), YMS</b>				
PACE-Australia	Specific treatment intervention (SPI)	10.43	9.13	23
PACE-Australia	Needs-based intervention (NBI)	8.55	7.18	17
<b>Negative symptoms: immediately post-treatment, SANS</b>				
PACE-Australia	Specific treatment intervention (SPI)	20.59	14.68	23
PACE-Australia	Needs-based intervention (NBI)	25.76	25.95	17
<b>Negative symptoms: medium-term (at 12 months), SANS</b>				
PACE-Australia	Specific treatment intervention (SPI)	23.05	19.95	23
PACE-Australia	Needs-based intervention (NBI)	22.5	16.02	17
<b>Negative symptoms: long-term (at 4 years), SANS</b>				
PACE-Australia	Specific treatment intervention (SPI)	31.74	16.25	23
PACE-Australia	Needs-based intervention (NBI)	27.0	22.84	17
<b>Psychopathology: total, immediately post-treatment, BPRS</b>				
PACE-Australia	Specific treatment intervention (SPI)	15.86	8.36	23
PACE-Australia	Needs-based intervention (NBI)	16.35	11.64	17
<b>Psychopathology: total, medium-term (at 12 months), BPRS</b>				
PACE-Australia	Specific treatment intervention (SPI)	17.77	9.01	23
PACE-Australia	Needs-based intervention (NBI)	17.07	10.51	17
<b>Psychopathology: total, long-term (at 4 years), BPRS</b>				
PACE-Australia	Specific treatment intervention (SPI)	26.33	11.39	23
PACE-Australia	Needs-based intervention (NBI)	22.47	11.28	17

**Analysis 7.3. Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs-based intervention (NBI) + risperidone vs NBI, Outcome 3 Functioning global: average end point score, GAF (higher score = better).**



**Analysis 7.4. Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs-based intervention (NBI) + risperidone vs NBI, Outcome 4 Quality of life: average end point score, QLS (higher score = better).**




**Analysis 7.5. Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs-based intervention (NBI) + risperidone vs NBI, Outcome 5 Cost: average cost of treatment, AUD, skewed data.**

Cost: average cost of treatment, AUD, skewed data				
Study	Intervention	Mean	SD	N
<b>Inpatient costs: post-treatment</b>				
PACE-Australia	SPI	367.6	1109.8	31
PACE-Australia	NPI	1235.9	3477.9	28
<b>Inpatient costs: medium-term (at 12 months)</b>				
PACE-Australia	SPI	272.3	977.9	31
PACE-Australia	NPI	226.1	847.8	28
<b>Inpatient costs: long-term (at 36 months)</b>				
PACE-Australia	SPI	757.1	3078.3	31
PACE-Australia	NPI	866.6	2353.2	28
<b>Outpatient costs: post-treatment</b>				
PACE-Australia	SPI	2584.8	2522.4	25
PACE-Australia	NPI	1084.0	940.0	27
<b>Outpatient costs: medium-term (at 12 months)</b>				
PACE-Australia	SPI	1328.8	1795.7	24
PACE-Australia	NPI	1039.5	1384.8	23
<b>Pharmacology costs: post-treatment</b>				
PACE-Australia	SPI	223.3	235.4	25
PACE-Australia	NPI	122.0	140.4	27
<b>Outpatient costs: long-term (at 36 months)</b>				
PACE-Australia	SPI	4101.6	8334.0	24
PACE-Australia	NPI	10423.1	25277.3	17
<b>Pharmacology costs: medium-term (at 12 months)</b>				
PACE-Australia	SPI	119.8	300.6	24
PACE-Australia	NPI	114.1	156.0	23
<b>Pharmacology costs: long-term (at 36 months)</b>				
PACE-Australia	SPI	588.2	1011.0	24
PACE-Australia	NPI	446.6	883.2	17
<b>Total costs: post-treatment</b>				
PACE-Australia	SPI	3087.1	2926.2	25
PACE-Australia	NPI	2487.6	3754.0	27
<b>Total costs: medium-term (at 12 months)</b>				
PACE-Australia	SPI	1800.3	2234.0	24
PACE-Australia	NPI	1428.8	2330.3	23
<b>Total costs: long-term (at 36 months)</b>				
PACE-Australia	SPI	5667.6	11432.8	24
PACE-Australia	NPI	11613.8	27120.7	17

**Analysis 7.6. Comparison 7 Group B: cognitive behavioural therapy (CBT), CBT (specific preventive intervention (SPI) + needs-based intervention (NBI) + risperidone vs NBI, Outcome 6 Satisfaction with treatment: leaving the study early.**

Study or subgroup	Specific treatment intervention (SPI)	Needs-based intervention (NBI)	Risk Ratio		Weight	Risk Ratio
	n/N	n/N	M-H, Random, 95% CI			M-H, Random, 95% CI
<b>7.6.1 Medium-term (at 12 months)</b>						
PACE-Australia	0/31	0/28				Not estimable
<b>Subtotal (95% CI)</b>	<b>31</b>	<b>28</b>				<b>Not estimable</b>


Favours SPECIFIC TREATMENT INTERVENTION      0.001      0.1      1      10      1000      Favours NEEDS BASED INTERVENTION



**Comparison 8. Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Prodromal symptoms: transition to psychosis, end point data	1	72	Risk Ratio (M-H, Random, 95% CI)	0.74 [0.28, 1.98]
2 Mental state specific: average end point scores, medium-term (at 12 months), various scales (higher score = worse), skewed data			Other data	No numeric data
2.1 Psychopathology: total, end point data, BPRS			Other data	No numeric data
2.2 Negative symptoms: attention, end-point data, SANS			Other data	No numeric data
2.3 Negative symptoms: total, end point data, SANS			Other data	No numeric data
3 Functioning global: average end point scores, medium-term (at 12 months), GAF (higher score = better)	1	45	Mean Difference (IV, Random, 95% CI)	2.20 [-4.59, 8.99]
4 Adverse effects 1 specific: doctors' assessment of adverse effects, medium-term (at 12 months), UKU	1	51	Risk Ratio (M-H, Random, 95% CI)	1.39 [0.61, 3.18]
5 Adverse effects 2 specific: adverse effects reported by participants, medium-term (at 12 months), UKU	1	51	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.32, 2.60]
6 Quality of life: average end point scores, medium-term (at 12 months), QLS (higher score = better)	1	44	Mean Difference (IV, Random, 95% CI)	-3.30 [-18.76, 12.16]
7 Satisfaction with treatment: leaving the study early, end point data	1	72	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.54, 2.09]

**Analysis 8.1. Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 1 Prodromal symptoms: transition to psychosis, end point data.**




**Analysis 8.2. Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 2 Mental state specific: average end point scores, medium-term (at 12 months), various scales (higher score = worse), skewed data.**


Mental state specific: average end point scores, medium-term (at 12 months), various scales (higher score = worse), skewed data

Study	Intervention	Mean	SD	N	Note
<b>Psychopathology: total, end point data, BPRS</b>					
Yung-Australia	Placebo + CBT	16.5	11.1	27	
Yung-Australia	Placebo + Supportive therapy	15.3	10.1	18	
<b>Negative symptoms: attention, end-point data, SANS</b>					
Yung-Australia	Placebo + CBT	1.8	1.9	27	
Yung-Australia	Placebo + Supportive therapy	1.4	1.9	18	
<b>Negative symptoms: total, end point data, SANS</b>					
Yung-Australia	Placebo + CBT	16.3	11.6	27	
Yung-Australia	Placebo + Supportive therapy	13.9	13.9	18	


**Analysis 8.3. Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 3 Functioning global: average end point scores, medium-term (at 12 months), GAF (higher score = better).**




**Analysis 8.4. Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 4 Adverse effects 1 specific: doctors' assessment of adverse effects, medium-term (at 12 months), UKU.**




**Analysis 8.5. Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 5 Adverse effects 2 specific: adverse effects reported by participants, medium-term (at 12 months), UKU.**



**Analysis 8.6. Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 6 Quality of life: average end point scores, medium-term (at 12 months), QLS (higher score = better).**




**Analysis 8.7. Comparison 8 Group C: cognitive behavioural therapy (CBT), CBT + placebo vs supportive therapy + placebo, Outcome 7 Satisfaction with treatment: leaving the study early, end point data.**




**Comparison 9. Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non-directive reflective listening + supportive intervention**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Prodromal symptoms: transition to psychosis, end point data	1	57	Risk Ratio (M-H, Random, 95% CI)	6.32 [0.34, 117.09]
2 Functioning 1 global: average total score, short-term (at 6 months), GAF (higher score = better)	1	34	Mean Difference (IV, Random, 95% CI)	-4.48 [-12.81, 3.85]
3 Functioning 2 specific: social functioning, average total score, short-term (at 6 months), SOFAS (higher score = better)	1	34	Mean Difference (IV, Random, 95% CI)	-6.47 [-15.30, 2.36]
4 Satisfaction with treatment: leaving the study early, end point data	1	57	Risk Ratio (M-H, Random, 95% CI)	1.35 [0.81, 2.25]


**Analysis 9.1. Comparison 9 Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non-directive reflective listening + supportive intervention, Outcome 1 Prodromal symptoms: transition to psychosis, end point data.**




**Analysis 9.2. Comparison 9 Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non-directive reflective listening + supportive intervention, Outcome 2 Functioning 1 global: average total score, short-term (at 6 months), GAF (higher score = better).**



**Analysis 9.3. Comparison 9 Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non-directive reflective listening + supportive intervention, Outcome 3 Functioning 2 specific: social functioning, average total score, short-term (at 6 months), SOFAS (higher score = better).**



**Analysis 9.4. Comparison 9 Group C: cognitive behavioural therapy (CBT), CBT + supportive intervention vs non-directive reflective listening + supportive intervention, Outcome 4 Satisfaction with treatment: leaving the study early, end point data.**






**Comparison 10. Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Prodromal symptoms: transition to psychosis, end point data	1	71	Risk Ratio (M-H, Random, 95% CI)	0.76 [0.28, 2.03]
2 Mental state specific: average end point scores, medium-term (at 12 months), various scales (higher score = worse), skewed data			Other data	No numeric data
2.1 Psychopathology: total, end point data, BPRS			Other data	No numeric data
2.2 Negative symptoms: attention, end point data, SANS			Other data	No numeric data
2.3 Negative symptoms: total, end point data, SANS			Other data	No numeric data
3 Functioning global: average end point score, medium-term (at 12 months), GAF (higher score = better)	1	45	Mean Difference (IV, Random, 95% CI)	0.20 [-6.83, 7.23]
4 Adverse effects 1 specific: doctors' assessment of adverse effects, medium-term (at 12 months), UKU	1	58	Risk Ratio (M-H, Random, 95% CI)	1.43 [0.64, 3.16]
5 Adverse effects 2 specific: adverse effects reported by participants, medium-term (at 12 months), UKU	1	58	Risk Ratio (M-H, Random, 95% CI)	1.83 [0.77, 4.34]
6 Quality of life: average end point scores, medium-term (at 12 months), QLS (higher score = better)	1	43	Mean Difference (IV, Random, 95% CI)	2.40 [-9.91, 14.71]
7 Satisfaction with treatment: leaving the study early, end point data	1	71	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.60, 2.25]

**Analysis 10.1. Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 1 Prodromal symptoms: transition to psychosis, end point data.**




**Analysis 10.2. Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 2 Mental state specific: average end point scores, medium-term (at 12 months), various scales (higher score = worse), skewed data.**


Mental state specific: average end point scores, medium-term (at 12 months), various scales (higher score = worse), skewed data

Study	Intervention	Mean	SD	N	Note
<b>Psychopathology: total, end point data, BPRS</b>					
Yung-Australia	Risperidone + CBT	14	9.3	24	
Yung-Australia	Placebo + Supportive therapy	15.3	10.1	18	
<b>Negative symptoms: attention, end point data, SANS</b>					
Yung-Australia	Risperidone + CBT	1.7	1.6	24	
Yung-Australia	Placebo + Supportive therapy	1.4	1.9	18	
<b>Negative symptoms: total, end point data, SANS</b>					
Yung-Australia	Risperidone + CBT	17.8	13.8	24	
Yung-Australia	Placebo + Supportive therapy	13.9	13.9	18	


**Analysis 10.3. Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 3 Functioning global: average end point score, medium-term (at 12 months), GAF (higher score = better).**




**Analysis 10.4. Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 4 Adverse effects 1 specific: doctors' assessment of adverse effects, medium-term (at 12 months), UKU.**




**Analysis 10.5. Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 5 Adverse effects 2 specific: adverse effects reported by participants, medium-term (at 12 months), UKU.**



**Analysis 10.6. Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 6 Quality of life: average end point scores, medium-term (at 12 months), QLS (higher score = better).**



**Analysis 10.7. Comparison 10 Group C: cognitive behavioural therapy (CBT), CBT + risperidone vs supportive therapy + placebo, Outcome 7 Satisfaction with treatment: leaving the study early, end point data.**



**Comparison 11. Group C: other, cognitive training vs active control (tablet games)**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mental state 1 specific: average total scores, various scales (higher score = worse), skewed data			Other data	No numeric data
1.1 Psychosis risk symptoms: total, average total score, long-term (at 24 months), SOPS			Other data	No numeric data
1.2 Psychosis risk symptoms: negative, average total score, long-term (at 24 months), SOPS			Other data	No numeric data
1.3 Psychosis risk symptoms: disorganised, average total score, long-term (at 24 months), SOPS			Other data	No numeric data
1.4 Psychosis risk symptoms: general, average total score, long-term (at 24 months), SOPS			Other data	No numeric data
1.5 Social anxiety: fear of negative evaluation, average end point score, short-term (at 4 months), SAS-A			Other data	No numeric data
1.6 Social anxiety: avoidance/distress in new situations, average end point score, short-term (at 4 months), SAS-A			Other data	No numeric data
1.7 Social anxiety: social avoidance and distress, average end point score, short-term (at 4 months), SAS-A			Other data	No numeric data
2 Mental state 2 specific: depression, average end point score, short-term (at 4 months), BDI-II (higher score = worse)	1	62	Mean Difference (IV, Random, 95% CI)	0.99 [-1.72, 3.70]
3 Mental state 3.a specific: cognitive, average end point score, short-term (at 4 months)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
3.1 Processing speed (Minnesota Clerical Test, T score, higher score = better)	1	62	Mean Difference (IV, Random, 95% CI)	6.25 [1.70, 10.80]
3.2 Processing speed (Digit Symbol Coding, higher score = better)	1	62	Mean Difference (IV, Random, 95% CI)	1.69 [0.69, 2.69]
4 Mental state 3.b specific: cognitive, average total score (presented as LSM = least square means estimated by the generalised linear mixed models), short-term (at 3 months), MATRICS, higher score = better)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.1 Attention/vigilance	1	25	Mean Difference (IV, Random, 95% CI)	-3.12 [-11.48, 5.24]
4.2 Speed of processing	1	25	Mean Difference (IV, Random, 95% CI)	-2.58 [-9.72, 4.56]
4.3 Reasoning and problem solving	1	25	Mean Difference (IV, Random, 95% CI)	-1.84 [-8.32, 4.64]
4.4 Verbal learning	1	25	Mean Difference (IV, Random, 95% CI)	-0.19 [-5.00, 6.62]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.5 Visual learning	1	25	Mean Difference (IV, Random, 95% CI)	-4.39 [-11.10, 2.32]
4.6 Working memory	1	25	Mean Difference (IV, Random, 95% CI)	3.56 [-4.88, 12.00]
5 Functioning 1 global: average total score, long-term (at 24 months), GAF (higher score = better)	1	83	Mean Difference (IV, Random, 95% CI)	0.36 [-5.34, 6.06]
6 Functioning 2 specific: role functioning, GFR (higher score = better)	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
6.1 Role functioning: average total score (presented as LSM = least square means estimated by the generalised linear mixed models), short-term (at 3 months)	1	25	Mean Difference (IV, Random, 95% CI)	-1.27 [-1.84, -0.70]
6.2 Role functioning: average total score, long-term (at 24 months)	1	83	Mean Difference (IV, Random, 95% CI)	-0.23 [-1.37, 0.91]
7 Functioning 3.a specific: social functioning, GFS (higher score = better)	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
7.1 Social functioning: average total score (presented as LSM = least square means estimated by the generalised linear mixed models), short-term (at 3 months)	1	25	Mean Difference (IV, Random, 95% CI)	-0.68 [-2.12, 0.76]
7.2 Social functioning: average total score, long-term (at 24 months)	1	83	Mean Difference (IV, Random, 95% CI)	0.26 [-0.52, 1.04]
8 Functioning 3.b specific: social functioning, average end point score, short-term (at 4 months), SAS-SR (higher score = worse)	1	62	Mean Difference (IV, Random, 95% CI)	-0.64 [-0.94, -0.34]
9 Satisfaction with treatment: leaving the study early, end point data	3	177	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.82, 1.05]
9.1 Short-term (by 2 months), PST	1	62	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.81, 1.06]
9.2 Medium-term (by 9 months), AT	1	32	Risk Ratio (M-H, Random, 95% CI)	1.22 [0.64, 2.32]
9.3 Long-term (by 24 months), AT	1	83	Risk Ratio (M-H, Random, 95% CI)	0.78 [0.48, 1.29]

**Analysis 11.1. Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 1 Mental state 1 specific: average total scores, various scales (higher score = worse), skewed data.**


Mental state 1 specific: average total scores, various scales (higher score = worse), skewed data					
Study	Intervention	Mean	SD	N	Note
Psychosis risk symptoms: total, average total score, long-term (at 24 months), SOPS					
Vinogradov-USA	Cognitive training	33.9	16.4	50	


Mental state 1 specific: average total scores, various scales (higher score = worse), skewed data					
Study	Intervention	Mean	SD	N	Note
Vinogradov-USA	Tablet games	25.49	17.23	33	
Psychosis risk symptoms: negative, average total score, long-term (at 24 months), SOPS					
Vinogradov-USA	Cognitive training	8.75	5.16	50	
Vinogradov-USA	Tablet games	6.63	5.4	33	
Psychosis risk symptoms: disorganised, average total score, long-term (at 24 months), SOPS					
Vinogradov-USA	Cognitive training	11.03	8.13	50	
Vinogradov-USA	Tablet games	9.38	4.65	33	
Psychosis risk symptoms: general, average total score, long-term (at 24 months), SOPS					
Vinogradov-USA	Cognitive training	7.83	5.37	50	
Vinogradov-USA	Tablet games	6.02	5.63	33	
Social anxiety: fear of negative evaluation, average end point score, short-term (at 4 months), SAS-A					
Choi-USA	Cognitive training	19.43	11.42	30	
Choi-USA	Tablet games	18.78	11.73	32	
Social anxiety: avoidance/distress in new situations, average end point score, short-term (at 4 months), SAS-A					
Choi-USA	Cognitive training	12.18	5.35	30	
Choi-USA	Tablet games	15.73	8.24	32	
Social anxiety: social avoidance and distress, average end point score, short-term (at 4 months), SAS-A					
Choi-USA	Cognitive training	8.87	4.03	30	
Choi-USA	Tablet games	8.41	4.68	32	

**Analysis 11.2. Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 2 Mental state 2 specific: depression, average end point score, short-term (at 4 months), BDI-II (higher score = worse).**




**Analysis 11.3. Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 3 Mental state 3.a specific: cognitive, average end point score, short-term (at 4 months).**







**Analysis 11.4. Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 4 Mental state 3.b specific: cognitive, average total score (presented as LSM = least square means estimated by the generalised linear mixed models), short-term (at 3 months), MATRICS, higher score = better).**




**Analysis 11.5. Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 5 Functioning 1 global: average total score, long-term (at 24 months), GAF (higher score = better).**




**Analysis 11.6. Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 6 Functioning 2 specific: role functioning, GFR (higher score = better).**




**Analysis 11.7. Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 7 Functioning 3.a specific: social functioning, GFS (higher score = better).**









**Analysis 11.8. Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 8 Functioning 3.b specific: social functioning, average end point score, short-term (at 4 months), SAS-SR (higher score = worse).**



**Analysis 11.9. Comparison 11 Group C: other, cognitive training vs active control (tablet games), Outcome 9 Satisfaction with treatment: leaving the study early, end point data.**







**Comparison 12. Group C: other, family treatment vs enhanced care**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Prodromal symptoms: transition to psychosis	2	229	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.18, 1.59]
1.1 Short-term (6 months), FFT	1	129	Risk Ratio (M-H, Random, 95% CI)	0.19 [0.02, 1.59]
1.2 Long-term (24 months), FACT	1	100	Risk Ratio (M-H, Random, 95% CI)	0.71 [0.35, 1.45]
2 Global state: antipsychotic prescription, short-term (by 6 months)	1	129	Risk Ratio (M-H, Random, 95% CI)	1.18 [0.69, 2.02]
3 Mental state specific: psychosis risk positive symptoms, average total score, short-term (at 6 months), SOPS positive (higher score = worse)	1	102	Mean Difference (IV, Random, 95% CI)	-2.01 [-3.87, -0.15]
4 Functioning global: average total score, long-term (at 24 months), GAF (higher score = better)	1	69	Mean Difference (IV, Fixed, 95% CI)	5.15 [-1.90, 12.20]
5 Adverse events 1.a specific: suicide, long-term (by 24 months), events	1	100	Risk Ratio (M-H, Random, 95% CI)	1.0 [0.06, 15.55]
6 Adverse events 1.b specific: suicide, long-term (by 24 months), participants affected/at risk	1	100	Risk Ratio (M-H, Random, 95% CI)	1.0 [0.06, 15.55]
7 Satisfaction with treatment: leaving the study early	2	229	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.52, 1.26]
7.1 Short-term (6 months), FFT	1	129	Risk Ratio (M-H, Random, 95% CI)	0.66 [0.33, 1.30]
7.2 Long-term (24 months), FACT)	1	100	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.52, 1.68]


**Analysis 12.1. Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 1 Prodromal symptoms: transition to psychosis.**




**Analysis 12.2. Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 2 Global state: antipsychotic prescription, short-term (by 6 months).**




**Analysis 12.3. Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 3 Mental state specific: psychosis risk positive symptoms, average total score, short-term (at 6 months), SOPS positive (higher score = worse).**







**Analysis 12.4. Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 4 Functioning global: average total score, long-term (at 24 months), GAF (higher score = better).**




**Analysis 12.5. Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 5 Adverse events 1.a specific: suicide, long-term (by 24 months), events.**



**Analysis 12.6. Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 6 Adverse events 1.b specific: suicide, long-term (by 24 months), participants affected/at risk.**




**Analysis 12.7. Comparison 12 Group C: other, family treatment vs enhanced care, Outcome 7 Satisfaction with treatment: leaving the study early.**



**Comparison 13. Group C: other, integrated treatment vs standard treatment**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Prodromal symptoms: transition to psychosis, end point data, long-term (by 2 years)	1	79	Risk Ratio (M-H, Random, 95% CI)	0.57 [0.28, 1.15]
2 Mental state specific: average total score, long-term (at 2 years), various scales (higher score = worse), skewed data			Other data	No numeric data
2.1 Negative symptoms: total average score, SANS			Other data	No numeric data
3 Satisfaction with treatment: leaving the study early, end point data	1	79	Risk Ratio (M-H, Random, 95% CI)	0.66 [0.25, 1.73]


**Analysis 13.1. Comparison 13 Group C: other, integrated treatment vs standard treatment, Outcome 1 Prodromal symptoms: transition to psychosis, end point data, long-term (by 2 years).**



**Analysis 13.2. Comparison 13 Group C: other, integrated treatment vs standard treatment, Outcome 2 Mental state specific: average total score, long-term (at 2 years), various scales (higher score = worse), skewed data.**

Mental state specific: average total score, long-term (at 2 years), various scales (higher score = worse), skewed data					
Study	Intervention	Mean	SD	N	Note
<b>Negative symptoms: total average score, SANS</b>					
Nordentoft-Denmark	Integrated treatment	1.34	1.33	32	
Nordentoft-Denmark	Standard treatment	1.7	1.23	25	

**Analysis 13.3. Comparison 13 Group C: other, integrated treatment vs standard treatment, Outcome 3 Satisfaction with treatment: leaving the study early, end point data.**



**ADDITIONAL TABLES**

**Table 1. Adherence table**

ADAPT-Canada	Overall the mean number of sessions was 12 (SD = 6.2, range 1–26). 31% (N = 16) received < 7 sessions. Those who left before the 6-month follow-up had significantly fewer sessions (5 vs 13.4; T = 7.1, P < 0.0001).
Amminger-Austria	The mean rate for adherence with study medication, based on pill count and self-report, was 81.4% (SD, 17.7%) in the omega-3 group and 75.4% (SD, 17.8%) in the placebo group (P = 0.13).
Choi-USA	There was no significant difference in the dosage of training between groups as participants in PST completed 30.32 (SD = 0.92) h versus 30.11 (SD = 0.84) h for ACG (T = 0.94, P = 0.353). As expected, given the structured nature of the programmes at both sites (participants were coming in for a regimen of treatments, usually 2 days/week), treatment intensity between groups was also not significantly different (PST, 3.37 h/week, SD 1.03; ACG, 3.52 h/week, SD 0.94; T 0.60, p. 558).
DEPTH-Australia	The mean number of sessions completed was 9.2 for CBT (3% had no sessions, 17% had 1–5, 47% had 6–11, 30% had 12–26), and 10.1 for NDRL (4% had no sessions, 26% had 1–5, 37% had 6–11, 33% had 12–26).
EDIE-2-UK	Those allocated to cognitive therapy received a mean of 9.11 (SD 6.69; range 0–26) sessions, each lasting on average 1 h. Adherence to cognitive therapy was reasonably good, with only 9 of 144 (6.25%) participants not attending any sessions and 108 (75%) receiving at least ≥ 4 sessions. Fidelity to the therapy model was assessed using competency and adherence scales in relation to audio recordings of 80 therapy sessions. 90% of rated sessions scored over the threshold for competency and 93.3% met the criteria for therapy that adhered to the manual.
EDIE-NL	Not reported
EDIE-UK	Not reported
EDIP-USA	Not reported
EIPS-Germany	After randomisation, 2 participants from the IPI group and 1 from the SC group failed to attend any treatment sessions. In the IPI group 22 (33.8%) of participants received < 50% of treatment (< 20 sessions) and in the SC group 20 (31.7%) participants received < 50% of treatment (< 13 sessions), but there were no statistical differences between the number of these participants (Chi <sup>2</sup> = 0.003, P = 0.956). Mean number of sessions for the SC group was 15.8 ± 6.8 and for the IPI group 23.7 ± 13.1, therefore participants from the SC group received significantly less treatment (P < 0.001).
Kantrowitz-USA	Not reported
LIPS-Germany	Not reported
Miklowitz-USA	The average number of sessions in the FFT group was 11.0 ± 7.1 (range 0–19) sessions and 42 (63.6%) participants took part in at least 1 session of communication or problem-solving skills training. Out of 66 participants in this group, 18 received < 50% of sessions (9 sessions) and 37 > 9 sessions. The rest dropped out before the first session. In the enhanced care group, average number of sessions was 2.4 ± 1.2 sessions (range 0–4) and 50 (79.4%) took part in most or all (2–3 sessions) of the psychoeducational training. Out of 63 participants in this group, 5 received < 50% of sessions (1 session) and 48 received > 50% of sessions (2–3 sessions). Participants in both FFT and enhanced treatment groups were equally likely to obtain extra-protocol individual or group therapy sessions (34.5% and 36.2%; 2(1) = 0.3, P = 0.86).
NEURAPRO-AAE	There were 66 adherent participants (43.1%) in the omega-3 PUFA group and 62 in the placebo group (41.1%). Participants who had missing data for the capsule counts (N = 35 in omega-3 fatty acids group and 48 in placebo group) were considered as non-adherent. The overall median number of CBCM sessions attended was 8 (range, 1–35), in omega-3 fatty acids group 11.2 ± 6.4 and 10.3 ± 6.0 in placebo group. The transition rate was lower in the adherent participants, but without significant difference. There was no significant difference between groups in transition rates for those with a number of CBCM sessions ≤ median (P = 0.31), as well as for those > median (P = 0.50).

**Table 1. Adherence table** (Continued)

Nordentoft-Denmark	Not reported
PACE-Australia	Variable adherence to risperidone was reported; in the SPI group (N = 31), 13 participants were classified as nonadherent (< 50% doses taken), 4 as partially adherent, and 14 as fully adherent (almost 100% doses taken).
Piskulic-Canada	Half of all participants completed between 2 and 4 training sessions/week, the other half failed to reach the target, completing 42 sessions on any given week. On average, participants across both groups completed 20 training sessions (SD = 13.5 sessions) and 50% of all participants completed between 20 and 40 training sessions (N = 7 in Post Science Brain Fitness group and N = 9 in control treatment group) in 12 weeks.
PRIME-USA	Not reported
Vinogradov-USA	Not reported
Woods-1-USA	Quote: "Two placebo subjects missed one or more rating visits", no other data
Yung-Australia	Poor therapy adherence (only 2 participants (4.7%) had full adherence to risperidone).  Problems with therapy supervision (only 24 of 41 tapes from the cognitive therapy groups (58.5%) were classified as receiving cognitive therapy, 9 participants (22.0%) allocated to cognitive therapy were judged to be receiving supportive therapy, and, in a further 8 cases (19.5%), the nature of the psychological therapy was rated as not known).

**ACG:** active control group; **CBCM:** cognitive behavioural case management; **CBT:** cognitive behavioural therapy; **FFT:** family-focused treatment **IPI:** integrated psychological intervention; **NDRL:** non-directive reflective listening; **PST:** processing speed training; **SC:** supportive counselling; **SD:** standard deviation; **SPI:** specific preventive intervention

**Table 2. Suggested design for new study**

<b>Methods</b>	Allocation: randomised  Blinding: double-blind (participants and study team, treatment provider, investigator, outcomes assessor)  Duration: > 6 months of intervention period + > 12 months' follow-up period
<b>Participants</b>	Diagnosis: ultra high risk sample  N = 300*  Sex: men and women  Age: 14-30 years
<b>Interventions</b>	Stage 1  1. Low-dose antipsychotic + treatment as usual  2. Treatment as usual: psychosocial programme available in the setting  Stage 2  Comparison of different components of the psychosocial programme (compared components should follow similar rules in the duration, frequency and number of sessions)
<b>Outcomes</b>	Prodromal symptoms: transition to psychosis



**Table 2. Suggested design for new study** *(Continued)*

Global state: clinically important change in global state

Mental state: clinically important change in mental state

Functioning: clinically important change in functioning

Adverse effects: at least one serious adverse event

Quality of life: important change in quality of life

Satisfaction with treatment: leaving the study early

Economics: cost of care

**Notes**

\*Sample size suggested because at around 300 participants power to detect a difference in groups of 15% becomes realistic.

**APPENDICES**
**Appendix 1. Subscore data**

Outcome	Scale	Subscale	Study	Intervention	Mean	SD	N	
Mental state: specific, psychopathology	Brief Psychopathological Rating Scale (BPRS)	Comparison 1: CBT + placebo vs supportive therapy + placebo						
		Comparison 4: CBT + risperidone vs CBT + placebo						
		Comparison 5: CBT + risperidone vs supportive therapy + placebo						
		Medium-term (at 12 months)	Psychotic symptoms	Yung-Australia	Risperidone + CBT	2.6	2.5	24
					Placebo + CBT	2.8	2.9	27
					Placebo + supportive therapy	3.1	3	18
		Comparison 6: CBT (SPI) + NBI + risperidone vs NBI						
		Immediately post-treatment	Psychotic symptoms	PACE-Australia	SPI	3.19	3.23	23
					NBI	3.18	3.89	17
		Medium-term (at 12 months)		PACE-Australia	SPI	3.91	3.7	23
					NBI	3.0	2.96	17
		Long-term (at 4 years)		PACE-Australia	SPI	4.75	2.61	23
					NBI	4.65	2.67	17
Comparison 13: omega-3 fatty acids vs placebo								
Medium-term (at 12 months)	Psychotic symptoms	NEU-RAPRO-AAE	Omega-3 fatty acids	34.1	9.3	114		
			Placebo	32.9	8.4	111		
Mental state, specific: negative symptoms	Scale for Assessment of Negative Symptoms (SANS)	Comparison 1: CBT + placebo vs supportive therapy + placebo						
		Comparison 4: CBT + risperidone vs CBT + placebo						
		Comparison 5: CBT + risperidone vs supportive therapy + placebo						
		Medium-term (at 12 months)	Affective flattening	Yung-Australia	Risperidone + CBT	4.5	5.1	24
					Placebo + CBT	4.9	5.1	27

(Continued)

					Placebo + supportive therapy	3.3	4.4	18
			Alogia		Risperidone + CBT	2.7	2.8	24
					Placebo + CBT	2.6	2.6	27
					Placebo + supportive therapy	1.8	2.8	18
			Avolition		Risperidone + CBT	4.5	3.2	24
					Placebo + CBT	3.3	2.9	27
					Placebo + supportive therapy	2.7	3.3	18
			Anhedonia		Risperidone + CBT	4.4	4.3	24
					Placebo + CBT	3.7	3.5	27
					Placebo + supportive therapy	4.6	5	18
		Comparison 2: CBT + supportive intervention vs NDRL + supportive intervention						
Mental state, specific: psychotic symptoms	Brief Symptom Inventory (BSI)	Short-term (at 6 months)	Anxiety	DEPTh-Australia	CBT + supportive intervention	51.44	17.19	16
					NDRL + supportive intervention	54.47	11.34	15
			Depression	DEPTh-Australia	CBT + supportive intervention	52.13	13.97	16
					NDRL + supportive intervention	61.53	17.88	15
			Global severity of symptoms	DEPTh-Australia	CBT + supportive intervention	54.44	18.42	16
					NDRL + supportive intervention	57.27	12.31	15
		Comparison 2: CBT + supportive intervention vs NDRL + supportive intervention						
Quality of life	Quality of Life Scale (QLS)	Short-term (at 6 months)	Intrapsychic	DEPTh-Australia	CBT + supportive intervention	27.94	8.2	16
					NDRL + supportive intervention	31.18	6.17	17
			Intrapersonal	DEPTh-Australia	CBT + supportive intervention	29.4	12.56	15



(Continued)

	tionnaire (PBEQ)				Supportive therapy	19.78	5.04	81
		Social acceptability	EDIE-2-UK		CBT + supportive therapy	10.61	2.13	87
					Supportive therapy	10.49	2.38	82
		Comparison 3: CBT + supportive therapy vs supportive therapy						
Mental state, specific: social functioning	Social Functioning Scale II (SAS-II)	Medium-term (at 12 months)	Social activities	EIPS-Germany	CBT + supportive therapy	2.2	0.81	29
					Supportive therapy	2.1	0.74	38
			Well-being	EIPS-Germany	CBT + supportive therapy	1.5	0.76	29
					Supportive therapy	1.4	0.48	38
			Work	EIPS-Germany	CBT + supportive therapy	1.9	0.57	29
					Supportive therapy	2	0.58	38
		Comparison 9: integrated treatment vs standard treatment						
Mental state, specific: positive symptoms	Scale for the Assessment of Positive Symptoms (SAPS)	Long-term (at 2 years)	Psychotic	Nor-dentoft-Denmark	Integrated treatment	0.52	1.01	32
					Standard treatment	0.98	1.2	25
			Disorganised	Nor-dentoft-Denmark	Integrated treatment	0.52	0.61	32
					Standard treatment	0.43	0.65	25
		Comparison 10: amisulpiride + NFI vs NFI						
Mental state, specific: psychotic symptoms	Early Recognition Inventory based on IRAOS (ERIRAos)	Short-term (at 12 weeks)	ERI-BAP-PSS	LIPS-Germany	Amisulpiride + NFI	5.6	6.5	58
					NFI	7.9	8	44
			ERI-PPS	LIPS-Germany	Amisulpiride + NFI	1.8	2.6	58
					NFI	3.4	4.2	44
			ERI-BS	EIPS-Germany	Amisulpiride + NFI	3.8	4.8	58

	NFI	4.4	4.9	44
--	-----	-----	-----	----

---

**BAPSS:** Basic and Positive Psychotic Spectrum Symptoms score; **BS:** basic symptoms; **CBT:** cognitive behavioural therapy; **NBI:** needs-based intervention; **NDRL:** non-directive reflective listening; **NFI:** needs-focused intervention; **PPS:** psychotic positive symptoms; **SPI:** specific preventive intervention;

---

(Continued)

## CONTRIBUTIONS OF AUTHORS

Dina Bosnjak Kuharic: writing and development of the protocol, data extraction, data analysis, data interpretation, writing the review, editing the review, final approval of the review.

Ivana Kekin: data extraction, data analysis, data interpretation, writing the review, editing the review, final approval of the review.

Joanne Hew: writing and development of the protocol, data analysis, editing the review, final approval of the review.

Martina Rojnić Kuzman: writing and development of the protocol, editing the review, final approval of the review.

Livia Puljak: data analysis, data interpretation, writing the review, editing the review, final approval of the review.

## DECLARATIONS OF INTEREST

Dina Bošnjak: none

Ivana Kekin: none

Joanne Hew: none

Martina Rojnić Kuzman: none

## SOURCES OF SUPPORT

### Internal sources

- University Psychiatric Hospital, Zagreb, Croatia.  
Employs review author
- Clinical Hospital Centre Zagreb, Croatia.  
Employs review authors
- St Mary's Hospital, London, UK.

### External sources

- No external sources of support, Other.

## DIFFERENCES BETWEEN PROTOCOL AND REVIEW

Change in wording of outcomes: we have changed 'clinically important response' to 'clinically important change', and 'significant change' to 'clinically important change' in line with Cochrane Schizophrenia outcome names and to harmonise types of outcomes with 'Summary of findings' table outcomes. We clarified that outcomes in the 'Summary of findings' table should, ideally, be clinically important change.

We have updated some of the methods text to reflect latest changes in Cochrane Schizophrenia's methods template.

We have changed the title from 'Early interventions for prodromal stage of psychosis' to 'Interventions for prodromal stage of psychosis' as the interventions are not 'early' themselves, it is the stage of illness that is 'early'.